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Almost 25 years ago, the first mammalian transient receptor potential (TRP) channel, now named
TRPC1, was cloned and published (reviewed in [1]). Although the exact function of TRPC1 is still
elusive [1], TRP channels now represent an extended family of 28 members, fulfilling multiple roles in
the living organism [2]. Their identified functions include control of body temperature, transmitter
release, mineral homeostasis, chemical sensing, and survival mechanisms in a challenging environment.
The TRP channel superfamily covers six families: TRPC, with C for “canonical”; TRPA, with A
for “ankyrin”; TRPM, with M for “melastatin”; TRPML, with ML for “mucolipidin”; TRPP, with P
for “polycystin”; and TRPV, with V for “vanilloid” (see Figure 1). They all share a structure of six
transmembrane (TM) regions, with a pore domain between TM5 and 6 and cytoplasmic amino- and
carboxyl-termini. Functional nonselective, Ca2+ permeable TRP channels are tetramers, which consist
of the same or different TRP monomers preferentially from the same family [3].
Eleven mutant TRP channels cause a spectrum of 16 human diseases, additionally emphasizing
their essential role in vivo [2]. Moreover, TRP channels are important pharmacological targets for
specific novel therapeutic treatment options for patients. Along these lines, specific TRP modulators
have been identified in recent years and are now tested in vitro and in vivo against symptoms caused
by dysfunctional TRP proteins or pathophysiological processes (such as pain, chronic inflammation,
fibrosis, and edema), which occur if normal physiological responses are out of control [2,4].
Figure 1. Phylogenetic tree of the transient receptor potential (TRP) superfamily in vertebrates. Boxed
TRP channels are highlighted in the manuscripts of this special section. Stars (*) indicate the mutant
TRP channels that cause human diseases. Picture modified from [5].
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Over the last few years, new findings on TRP channels confirm their exceptional function as
cellular sensors and effectors. This special issue of Cells features a collection of eight reviews and
seven original articles summarizing the current state-of-the-art research on TRP channels, with a focus
on TRP channel activation, their physiological and pathophysiological function, and their roles as
pharmacological targets for future therapeutic options.
Returning to the roots of the mammalian TRP channel discovery, TRPC1 may preferentially
work as a regulator of heterotetrameric TRPC1/4/5 channels rather than of a homomeric TRPC1 ion
channel (reviewed in [1]). Dr. Minard and colleagues present an excellent overview on the function of
these heteromeric channel complexes in different tissues and pathologies, and they introduce specific
small molecular modulators that are important for future research and as therapeutic options in
pathophysiological processes [6].
Belonging to the same family of canonical TRPC channels, TRPC3 controls specific functions
in the cardiovascular system, the brain, the immune system, during cancer progression, and tissue
remodeling, which are summarized in the comprehensive review by Drs. Tiapko and Groschner. They
also present new therapeutic approaches, such as photopharmacology and optochemical genetics,
to manipulate the action of TRPC3 for the intervention of its tissue-specific tasks [7].
Along the same lines, Drs. Tian and Zhu present evidence in their original article for a specific and
exclusive role of TRPC3 for the metabotropic glutamate receptor 1 (mGluR1)-mediated augmentation
of slow excitatory postsynaptic currents (sEPSC) by type B γ-aminobutyric acid (GABAB) receptors in
the Purkinje cells of the cerebellum. This molecular mechanism is essential in long-term depression,
as well as synapse elimination, and may regulate motor coordination and learning [8].
A characteristic feature of TRPC3, TRPC6, and TRPC7 is their activation by diacylglycerol (DAG)
as a product of receptor-induced phospholipase-C activity (reviewed in [9]). Recent evidence, however,
suggests that TRPC4 and TRPC5 channels are also activated by DAG [10]. The much more complex
molecular mechanism includes the C-terminal interaction with the scaffolding proteins Na+/H+
exchange regulatory factors 1 and 2 (NHERF1 and NHERF2), which dynamically regulate the DAG
sensitivity of TRPC4 and TRPC5. These cellular events are summarized by Drs. Mederos y Schnitzler,
Gudermann, and Storch [11].
The role of ion channels and transporters, especially that of TRPC6 in inflammation, is the
topic of a review by Dr. Ramirez and colleagues. They present an overview on TRPC6 channel
activity in leucocytes, transendothelial migration, chemotaxis, phagocytosis, and cytokine release [12].
The importance of channel function is underlined by the very recent identification of a single nucleotide
polymorphism (SNP) in the TRPC6 gene in patients with the autoimmune disease lupus erythematosus
by the same authors [13].
TRPA1 is the only member of the TRPA family, carrying a higher amount of ankyrin repeats (16 for
human TRPA1) at the amino-terminus than other TRP proteins (usually four). Chemical modification
of its cysteine residues makes TRPA1 an attractive candidate as a toxicant sensor (reviewed in [14]).
Dr. Lüling and coauthors in their original article identified heat shock 70 kDa protein 6 as an effector
regulated by the activation of TRPA1 by sulfur mustard (SM), a chemical warfare agent used during the
civil war in Syria. The authors of this manuscript used a proteomic approach to identify differentially
regulated proteins in TRPA1-expressing HEK293 and A549 cells after SM treatment. The selective
TRPA1 inhibitor AP18 was used to distinguish the TRPA1-mediated effect from unspecific effects [15].
Moving to the TRPM family, Drs. Liu, Ong, and Ambudkar introduce an exciting role of TRPM2
in salivary glands. Xerostomia, also known as dry mouth, is an irreversible side effect after therapeutic
irradiation of head and neck cancers. TRPM2-deficient mice showed only a transient loss of salivary
gland exposure with more than 60% recovery after irradiation [16]. Moreover, there is evidence for
a role of this channel in inflammatory processes and inducing the autoimmune disease Sjögren’s
syndrome. The involvement of TRPM2 and other TRP channels in salivary gland excretion is discussed
in this comprehensive review [17].
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Patients carrying a mutation in their TRPM4 protein suffer from cardiac conduction disease,
emphasizing TRPM4’s key role in the heart [18]. Drs. Wang, Naruse, and Takahashi highlight the
functions of this channel in cardiovascular pathophysiology, e.g., ischemia-reperfusion injury causing
myocardial infarction [19].
The kinase-coupled TRPM7 channel is expressed in multiple cells of the immune system, such
as lymphocytes, mast cells, neutrophils, and macrophages. Recently, it was demonstrated that the
enzymatic activity of TRPM7 is required for the gut homing of intra-epithelial lymphocytes [20].
Mrs. Nadolni and Dr. Zierler shed light on how the TRPM7 channel, and/or kinase activity, is essential
for pathologies, such as allergic hypersensitivity, arterial thrombosis, and graft versus host disease [21].
Menthol, as a cooling compound from peppermint, has been used for hundreds of years without
the molecular basis of its action being revealed. Soon after cloning the eighth member—TRPM8—of
the melastatin family of TRP channels, several laboratories have reported that natural and synthetic
cooling mimetics, such as icilin, eucalyptol, and menthol, activate this channel (reviewed in [22]).
Dr. Khare and colleagues now provide evidence that the application of menthol may induce a so-called
“browning” effect in subcutaneous adipose tissue, although a direct involvement of TRPM8 has not
been identified yet [23].
Two original contributions analyze the distribution of TRPV channels in human tissues using
immunohistochemistry. Dr. Del Fiacco and colleagues present evidence for the expression of TRPV1
channels in a region of the human brain, which they name Locus Karalis (Locus K). Most interestingly,
TRPV1-like immunoreactivity partially overlaps with that of neuropeptides calcitonin gene-related
peptide (CGRP) and substance P [24].
Drs. Rizopoulos, Papadaki-Petrou, and Assimakopoulou analyze the expression of TRPV1, TRPV2,
TRPV3, and TRPV4 proteins in the mucosal epithelium of colitis ulcerosa patients in comparison to
healthy volunteers. In their research, they identified a decreased expression of TRPV1, while TRPV4
channels were found to be upregulated in tissues of patients. For TRPV2 and TRPV3, no changes in
expression levels were observed [25].
Many different TRP channel structures were recently resolved by cryo-electron microscopy
(reviewed in [26]). In each case a large amount of pure protein material is required, which cannot be
easily produced in E. coli, as eukaryotic post-translational processing is required for channel maturation.
Therefore, another cheap eukaryotic expression system for TRP channels is presented by Dr. Zhang
and colleagues. They recombinantly produced 11 human TRP members in the yeast Saccharomyces
cerevisiae and confirmed retained functionality for TRPM8 as the model target [27]. S. cerevisiae on its
own also expresses a TRP channel called TRPY1, which is activated by increased cytosolic levels of
Mn2+ in response to oxidative stress, as outlined in an original manuscript by Drs. Ruta, Nicolau,
Popa, and Farcasanu [28].
Last but not least, Dr. Steinritz and colleagues systematically screened available literature to
identify the role of TRP channels as chemical sensors in the human body. TRPA1, TRPM8, and TRPV1
proteins are coexpressed in many tissues and are most frequently associated with toxicity sensing.
TRPV4 channels are cited less often, with other TRP channels (TRPC1, TRPC4, and TRPM5) being
expressed to a lesser extent [29].
In summary, this special issue of Cells presents a comprehensive overview of the latest data on
four TRP channel families and will hopefully convince readers of the importance of these proteins for
human physiology and as drug targets for future therapeutics.
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Abstract: Proteins of the TRPC family can form many homo- and heterotetrameric cation channels
permeable to Na+, K+ and Ca2+. In this review, we focus on channels formed by the isoforms TRPC1,
TRPC4 and TRPC5. We review evidence for the formation of different TRPC1/4/5 tetramers, give an
overview of recently developed small-molecule TRPC1/4/5 activators and inhibitors, highlight
examples of biological roles of TRPC1/4/5 channels in different tissues and pathologies, and
discuss how high-quality chemical probes of TRPC1/4/5 modulators can be used to understand the
involvement of TRPC1/4/5 channels in physiological and pathophysiological processes.
Keywords: ion channel; TRPC; small molecules; calcium; chemical probes
1. Introduction
Transient Receptor Potential (TRP) proteins form tetrameric, non-selective ion channels permeable
to Na+, K+ and—in most instances—Ca2+ [1–4]. The 28 mammalian TRP homologues are divided
into six subclasses (TRPM, TRPV, TRPA, TRPP, TRPML and TRPC) according to distinctions at the
sequence level [3,5], while TRPN (NOMPC) proteins (present in, for example, fruit flies, nematodes
and zebrafish) have no mammalian homologues [3]. Four monomers are needed to form a functional
ion channel; more than 28 different mammalian TRP channels can form because channels may consist
of homomers or heteromers of subunits (Figure 1), each with their own characteristics and functions.
Although there is differential expression of TRPs in different cells, tissues, and in different pathologies,
most TRP proteins are broadly expressed in both excitable and non-excitable cells, where they enable
coupling of relatively slow chemical and physical events to cellular signalling, either directly or
indirectly [1,6,7]. The regulation of some TRP channels by many modulators has led to the idea that
the channels are complex integrators of multiple chemical and physical factors [1,8].
There are seven members of the TRPC subfamily, of which TRPC2 is not expressed in humans
and the great apes because it is encoded by a pseudogene in these species [9]. TRPC proteins are
especially prone to formation of heterotetrameric channels within subgroups (Figure 1), one consisting
of TRPC3, TRPC6 and TRPC7 and the other of TRPC1, TRPC4 and TRPC5 [5]. TRPC4 and TRPC5 are
the most closely related TRPC proteins [10], with 69% sequence identity (BLAST search [11]). TRPC1,
Cells 2018, 7, 52; doi:10.3390/cells7060052 www.mdpi.com/journal/cells6
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which can interact with proteins from other TRP channel families [12,13], may not form functional
homomeric channels, but is an important contributor to heteromeric channels with TRPC4 and/or
TRPC5 [1,14–18].
This review focuses on channels composed of TRPC1, TRPC4 and TRPC5 (Section 2), their
small-molecule modulators (Section 3) and their roles in health and disease (Section 4), to highlight
examples and opportunities for the use of small-molecule TRPC1/4/5 modulators to study the role
of these channels in physiology and disease. We have used the following notations (Figure 1B):
TRPC1, TRPC4 and TRPC5 (etc.) denote the different proteins or any channels incorporating them;
TRPC1/4/5 denotes channels composed of TRPC1, TRPC4 and/or TRPC5 (homo- or heteromeric; any
ratio); TRPC4:C4 and TRPC5:C5 (etc.) denote specific homomeric channels; TRPC1:C5, TRPC1:C4,
TRPC4:C5 and TRPC1:C4:C5 denote specific heteromeric channels (any ratio); and TRPC4–C1 and
TRPC5–C1 denote (channels composed of) recombinant, concatemeric proteins (fusions of TRPC1 at
the C-terminus of either TRPC4 or TRPC5 through a short linker) that have been developed in our
lab to control channel stoichiometry [15,19,20]. The majority of TRPC1/4/5 channels discussed in
this review are human and rodent homologues, and where relevant to the discussion, species have
been annotated.
Figure 1. (A) Formation of tetrameric TRPC1/4/5 cation channels by TRPC1/4/5 proteins and recently
discovered small-molecule modulators discussed in this review. Domains “A” are the ankyrin repeat
domains present in all TRPC proteins, and “P” is the PDZ binding domain present in TRPC4 and
TRPC5. (B) Composition of different TRPC1/4/5 channels discussed in this review. Native channels
are believed to exist predominantly as heteromers, but their exact compositions and stoichiometries are
often unknown (as depicted by white subunits, which may be TRPC1/4/5 proteins or other TRP(C)
proteins). Linked subunits depict recombinant TRPC4–C1 and TRPC5–C1 concatemeric proteins that
can be used to control channel stoichiometry.
2. Composition of TRPC1/4/5 Tetrameric Channels
The tetrameric nature of TRPC channels was originally predicted from their homology to
voltage-gated potassium channels such as KV1.2, for which a crystal structure is available [21]. Current
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data suggest that TRPC proteins form a variety of homo- and heterotetrameric channels (see below).
The recent “resolution revolution” in cryo-electron microscopy [22] has led to the determination of
a wide variety of high resolution ion channel structures, providing novel insights into ion channel
function. There are examples of TRP channel high resolution structures from each TRP subfamily,
which confirm their tetrameric structures [23–27]. Recently, cryo-EM structures of of several TRPC
channels, including human TRPC3:C3 [28], human TRPC6:C6 [29], mouse TRPC4:C4 [30] and zebrafish
TRPC4:C4 [31] have been reported. hTRPC3 and hTRPC6 share limited homology with hTRPC1,
hTRPC4 and hTRPC5 proteins (approximately 40% sequence identity). It is noteworthy that the
hTRPC6/C6 channel structure was determined in the presence of a small molecule inhibitor, BTDM,
which is bound at a similar position to resiniferatoxin and capsaicin in TRPV1 structures [32,33],
between the pore-forming region of one subunit and the voltage sensing-like domain (VSLD) of
another. mTRPC4 shares 97% sequence identity with hTRPC4, 70% identity with hTRPC5 and 48%
identity with hTRPC1 and so mTRPC4:C4 is the closest homologue to hTRPC1/4/5 channels that
has been structurally characterised. It is interesting that in both the mouse and zebrafish TRPC4:C4
structures, a disulfide bond is observed between Cys549 and Cys554 (numbered according to the
mouse gene); these disulfides have been previously implicated in channel gating in TRPC5 [34,35] and
are conserved only in TRPC1, TRPC4 and TRPC5. Both TRPC4:C4 structures were solved in their closed
state in the absence of modulators, so more structural information is required to understand the gating
mechanisms of these channels. Additionally, there are only three unique heteromeric structures of any
ion channels [36–38] and none of these contain TRP proteins. Therefore, to probe the heteromerisation
of TRPC channels, we must rely on indirect measurements of their interaction. In this section, we
describe evidence for the formation of different TRPC1/4/5 channels, in both overexpression systems
and as native channels.
2.1. Channels Formed by Overexpressed TRPC1/4/5 Proteins
There is some evidence to suggest that TRPC1, when overexpressed, is retained in the endoplasmic
reticulum (ER) but is found at the plasma membrane when co-expressed with TRPC4 or TRPC5 [39].
Förster Resonance Energy Transfer (FRET) experiments using TRPC1 labelled with Cyan Fluorescent
Protein (CFP) and Yellow Fluorescent Protein (YFP) suggest that there are at least two TRPC1 monomers
in the tetrameric complex at the ER. The authors suggest the formation of a homotetrameric TRPC1
channel; however, these data do not explicitly rule out a TRPC1 interaction with other natively
expressed ion channel monomers, such as Orai1, which has been implicated in the formation of
heteromeric channels with TRPC1 [40]. Additionally, it was observed that TRPC4 and TRPC5,
when co-expressed with TRPC1, showed different I–V relationships (for examples, see Figure 2),
a lower calcium flux, and increased selectivity to sodium ions compared with TRPC4:C4 or
TRPC5:C5 homomeric channels [41]. Another study, involving FRET and co-transfected HEK293
cells, demonstrated that TRPC1, TRPC4 and TRPC5 were able to form homomers, that TRPC1 could
interact with either TRPC4 or TRPC5, and that TRPC4 and TRPC5 could interact with each other. In this
study, co-immunoprecipitation also suggested each homomeric interaction and the same heteromeric
interactions between TRPC4 and TRPC5, and TRPC4 and TRPC1 [42]. However, these FRET and
co-immunoprecipitation data do not provide direct insight into stoichiometries of heteromeric channels.
In addition, stoichiometries may vary depending on expression levels of different TRPC proteins.
Atomic Force Microscopy (AFM) was used to probe TRPC1 tetrameric structure when
overexpressed in and purified from HEK293 cells [43]. The authors measured the angles between
antibodies binding to TRPC1 (approximately 90 and 180 degrees), which suggested that TRPC1
forms tetramers. Considering TRPC1 was transiently overexpressed, it is surprising that observed
tetramers were only seen with two or fewer antibodies bound, which could suggest the formation of
heterotetramers with other natively expressed channel proteins from the TRP and other families. The
majority of particle sizes were, however, consistent with monomeric TRPC1, suggesting that tetramers
8
Cells 2018, 7, 52
were broken up during purification in 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate
(CHAPS) detergent.
We have recently demonstrated that recombinant, concatemeric TRPC4–C1 or TRPC5–C1 proteins
can be overexpressed to form functional channels, the I–V relationships and reduced Ca2+ permeability
of which closely resemble those of native heteromeric TRPC1:C4 and TRPC1:C5 channels [15,19,20].
These concatemers allow the functional analysis of TRPC heterotetramers with fixed stoichiometry,
which will be critical to the development of small molecules specific to homo- or heterotetramers [20].
Figure 2. Example I–V plots of homomeric (left) and heteromeric/concatemeric (right) TRPC1/4/5
channels. Recordings from overexpressed TRPC4:C4 and TRPC1:C4 channels are shown. For examples
of native I–V plots, see references [14,16].
2.2. Native TRPC1/4/5 Channels
It has been observed that TRPC proteins show differential tissue expression [44]. Since TRPC1
is expressed in a wide variety of tissues and native I–V plots [14,16] resemble overexpressed
heteromeric or concatemeric channels (Figure 2), it is likely that TRPC1 is predominantly observed
in heterotetrameric channels in vivo. Additionally, there are several examples of detecting TRPC
heterotetramerisation ex vivo that largely agree with the above overexpression studies. For example,
TRPC1, TRPC4 or TRPC5 were purified from mouse hippocampal cells using antibodies specific to any
one isoform [18]. These data suggest the formation of a tetramer containing TRPC1, TRPC4 and TRPC5;
however, alternatively there could be populations of TRPC1/4, TRPC1/5 and TRPC4/5 channels,
which would result in similar co-immunoprecipitation results. In a second example, TRPC4 and
TRPC5, after formaldehyde crosslinking, were co-immunoprecipitated from bovine aortic endothelial
cells [45]. These results suggest that different tetrameric TRPC1/4/5 channels are formed in vivo.
Further complicating the field of TRPC heterotetramerisation is the existence of splice isoforms of
TRPC proteins; two have been reported for TRPC1 [46,47], and seven for TRPC4 [48,49]. Of the TRPC4
isoforms, TRPC4α and TRPC4β have been studied in most detail. TRPC4α and TRPC4β (which lacks
84 residues towards the C terminus) show differential tissue expression. TRPC4β:C4β channels no
longer respond to phosphatatidylinositol 4,5-bisphosphate [50], but are still activated by (−)-englerin
A [51]. These splice variants are likely to result in even more heterogeneity in TRPC1/4/5 channels.
In summary, there has been much progress in the field of TRPC1/4/5 heterotetramer
identification. It should be noted that interactions found in co-immunoprecipitation experiments with
detergent-solubilised TRPC1/4/5 proteins may not accurately reflect interactions in native membranes,
and even in experiments that involve formaldehyde crosslinking before cell lysis, it may be difficult
to exclude interactions between different homomeric channels during co-immunoprecipitations.
However, the combination of co-immunoprecipitation results and the fact that I–V plots of native
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channels closely resemble those of cells that either co-express TRPC4/5 and TRPC1, or express
TRPC4–C1 or TRPC5–C1 concatemers, strongly suggests that TRPC1, TRPC4 and TRPC5 form
functional heterotetrameric channels in different tissues. There is currently no firm evidence to
suggest the native stoichiometry—or, more probably, stoichiometries—of these multimers though.
3. Recent Progress with Small-Molecule Modulators of TRPC1/4/5 Channels
TRPC1/4/5 channels are modulated by a wide range of physiological factors, and physical
and chemical stimuli, including temperature, redox status, G-protein signalling, endogenous lipids,
heavy metal ions, dietary lipids, natural products and synthetic small molecules. We and others
have previously reviewed the development of small-molecule modulators of TRP(C) channels [1,52].
Traditionally, TRPC1/4/5 channels have often been activated with lanthanide ions (La3+, Gd3+), GPCR
agonists such as carbachol, or small molecules such as rosiglitazone (which is non-specific and has low
potency), and inhibited with the non-specific small molecules such as 2-APB or SFK96365. In addition,
for most traditional small-molecule TRPC1/4/5 modulators, little is known about their mode-of-action,
and cellular targets of these molecules are likely diverse. Although some TRPC1/4/5 modulators are
thought to bind directly to the channels, no small-molecule binding sites have been identified so far.
In 2011, Miller et al. reported ML204 (Figure 3) as a low micromolar inhibitor of TRPC4 and TRPC5
channels that did not inhibit other TRP channels and lacked binding to a panel of 68 receptors [53],
leading to use in several studies of the roles of TRPC1/4/5 channels (see Section 4). However, recent
studies suggest that ML204 is a relatively poor inhibitor of TRPC1:C4 and TRPC1:C5 channels, at least
when channels are activated by (−)-englerin A [16,19]. Because most native TRPC1/4/5 channels are
thought to be heteromeric, this needs to be taken into account when using ML204 for functional studies.
Figure 3. Structures of recently reported TRPC1/4/5 activators, the (−)EA metabolite (−)EB, and the
(−)EA antagonist A54.
Since 2013, remarkable progress has been made with the discovery and development of potent and
efficacious small-molecule modulators with unique selectivity profiles and improved pharmacological
properties. In this section, we highlight selected small-molecule TRPC1/4/5 modulators reported
since our previous review of the field [1].
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3.1. Activators
3.1.1. Englerins
Screening of organic extracts from the East African plant Phyllanthus engleri against the NCI
60 cancer cell panel, followed by bioactivity-guided fractionation, led to the identification of the
sequiterpene natural product (−)-englerin A ((−)EA; Figure 3) as a compound with highly selective
cytotoxicity against renal carcinoma cell lines [54,55]. Independent target identification approaches by
the groups of Waldmann, Christmann and Beech [14,15] and by Novartis [51] revealed that (−)EA is a
potent and efficacious activator (EC50 = 10 nM) of native TRPC1:C4 channels in A498 renal cancer cells
(see Section 4.3 for more detail about its relevance to cancer cell death).
Subsequent experiments revealed that (−)EA activates TRPC4:C4 and TRPC5:C5 channels with
low nanomolar EC50 values (11 and 7 nM, respectively) and a strong stimulatory effect on both
intracellular Ca2+ levels and TRPC4:C4 and TRPC5:C5 ionic currents [14]. (−)EA has similar activating
effects on heteromeric TRPC1:C4 and TRPC1:C5 channels, but TRPC6, TRPM2 and TRPV4 channels,
10 other ion channels, and 59 GPCRs lack responses to (−)EA [14,51]. (−)EA has been proposed to
affect protein kinase C isoform θ (PKCθ) [56] and L-type calcium channels as well [57], although at
higher concentrations (most experiments were done with 1–10 μM of (−)EA). Despite extensive target
identification campaigns, no further targets have been found [14,51]. This suggests that (−)EA is a
highly selective activator of TRPC1/4/5 channels.
The molecular mechanism by which (−)EA selectively activates TRPC1/4/5 channels is not
understood. Excised membrane patch recordings in the presence or absence of G protein blockade
suggest that (−)EA activates TRPC4/5 channels directly via a site exposed extracellularly or accessible
only via the external leaflet of the bilayer [12]. The recent identification of A54 (Figure 3), a competitive
antagonist of (−)EA-induced (but not Gd3+-induced) TRPC4/5 activation, suggests the presence of a
well-defined (−)EA binding site in TRPC4/5 channels [58]. Carson et al. found (−)EA to be stable in
human and canine plasma. However, in plasma from rats and mice, (−)EA converts to the inactive
metabolite (−)-englerin B ((−)EB; resulting from glycolate ester hydrolysis; Figure 3) [51]. These
effects were recapitulated in vivo upon oral dosing of 5 mg/kg in rodents: (−)EA blood levels did
not rise above 12 nM, but (−)EB levels of >50 nM were detected. (−)EB neither activates TRPC1/4/5
channels nor is a potent A498 killer and also glycolic acid is inactive [51,59]. (−)EA is acutely toxic to
rodents, although higher doses are tolerated upon intraperitoneal or subcutaneous injection than upon
intravenous administration and toxicity may depend on drug formulation [51,60]. In contrast, (−)EB
does not show toxicity to rodents [51].
3.1.2. BTD and Methylprednisolone
Through a screen of a ChemBioNet compound library against (mouse) TRPC5, Beckmann et
al. found two novel TRPC5 activators: the glucocorticoid methylprednisolone (EC50 = 12 μM) and
N-[3-(adamantan-2-yloxy)propyl]-3-(6-methyl-1,1-dioxo-2H-1λ6,2,4-benzothiadiazin-3-yl)propanamide
(BTD; EC50 = 1.4 μM) (Figure 3) [61]. The TRPC5 activation by these compounds is long-lasting,
reversible, and sensitive to the recently published TRPC5 inhibitor clemizole (see Section 3.2.2). The
more potent compound in this study, BTD, was studied in most detail. Although far less potent than
(−)EA, BTD has remarkable selectivity on TRPC1/4/5 channel subtypes: patch clamp recordings
revealed that BTD activates homomeric TRPC5:C5 channels as well as heteromeric TRPC1:C5 and
(putative) TRPC4:C5 channels, but not TRPC4:C4 and TRPC1:C4 channels. The fact that BTD does not
affect phospholipase C signalling, and activates TRPC5:C5 channels in inside-out excised membrane
patches when applied from the intracellular side, suggests that the compound has a direct effect on
TRPC5 channels. BTD has no effect on channels formed by TRPC3, TRPC6, TRPC7, TRPA1, TRPV1,
TRPV2, TRPV3, TRPV4, TRPM2 and TRPM3. Methylprednisolone also showed selectivity for TRPC5
channels over other TRP channels, but can potentiate carbachol-induced TRPC4 activation.
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3.1.3. Riluzole
Riluzole (Figure 3) is a marketed drug that delays the progression of amyotrophic lateral sclerosis
(ALS) [62], and it also has anti-depressant properties [63]. Its wide-ranging effects on neural activity—in
particular the neuromotor system—are thought to result from its effect on multiple ion channels; a
review of the neural mechanisms of action of riluzole in ALS has been published by Bellingham [64].
Through a medium-throughput screen on mTRPC5-expressing HEK293 cells, Richter et al. found that
riluzole activates TRPC5 channels with an EC50 of 9.2 μM [65]. Riluzole also activates overexpressed
heteromeric TRPC1:C5 channels and endogenous TRPC5 channels in the U-87 glioblastoma cell line.
The riluzole-induced TRPC5 activation is mechanistically different from La3+-mediated activation.
TRPC5 activation by riluzole is reversible upon washout, independent of G protein signalling and PLC
activity, and occurs in both inside-out and cell-attached patches. These data suggest a relatively direct
mechanism of action on TRPC5 channels.
3.2. Inhibitors
3.2.1. Xanthines
A patent by Hydra Biosciences and Boehringer-Ingelheim claims substituted xanthines and their
use as TRPC5 inhibitors [66]. Circa 20% of the 621 compounds therein were reported to have IC50
values <100 nM, and eight compounds were further tested in rodent models of anxiety/depression.
Studies from two different groups on the effects of the two most promising compounds in the patent
have now been published. Our lab reported Pico145 (later called HC-608 by its inventors; Figure 4)
as the most potent inhibitor of TRPC1/4/5 channels known to date [19,20]. In calcium recordings,
Pico145 inhibits TRPC4 and TRPC5 with IC50 values of 349 pM and 1.3 nM, respectively. However, the
highest potencies were measured against heteromeric channels (formed by TRPC4–C1 or TRPC5–C1
concatemers; IC50 values of 33 pM and 199 pM, respectively) and (−)EA-activated, endogenous
TRPC1:C4 channels in A498 renal carcinoma cells (IC50 = 49 pM). In whole-cell recordings, Pico145
inhibits both inward and outward currents of TRPC4–C1 with picomolar IC50 values, upon activation
with either (−)EA or the physiological TRPC4/C5 agonist sphingosine-1-phosphate (S1P). In contrast,
100 nM Pico145 does not affect activities of TRPC3, TRPC6, TRPV1, TRPV4, TRPA1, TRPM2, TRPM8
or store-operated Ca2+ entry mediated by Orai1.
Figure 4. Structures of ML204 and recently reported TRPC1/4/5 inhibitors.
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The molecular mechanism by which Pico145 selectively inhibits TRPC1/4/5 channels—and
distinguishes between specific tetramers—is not understood. Excised outside-out membrane patch
recordings suggest that Pico145 inhibits TRPC4 channels directly via a site exposed extracellularly or
accessible only via the external leaflet of the bilayer, in a manner independent of cellular signalling
mechanisms or Ca2+ concentrations, and that the potency of Pico145 depends partially on the
concentration of the agonist (−)EA [19]. In addition, the rather mild voltage-dependence of the
block does not support the idea of blockage deep inside the ion pore and electric field. Pico145 can
also inhibit TRPC4 channels activated with the direct agonist Gd3+, although at low concentrations
(10 pM), Pico145 can also potentiate Gd3+-induced currents mediated by TRPC4 [19]. These data, in
combination with the ability of Pico145 to distinguish between closely related channels, suggest that
Pico145 occupies a well-defined binding site essential to TRPC4/5 channel gating.
Recently, Just et al. reported the anxiolytic and antidepressant effects in mice of HC-070
(Figure 4), a close analogue of Pico145/HC-608 (for details, see Section 4.1.1) [67]. As part of this
study, the activities of HC-070 were tested against TRPC1/4/5 channels (including human, mouse
and rat versions) activated by La3+ or carbachol (the latter in combination with overexpression of
muscarinic receptors), giving IC50 values between 0.3 and 2 nM. In addition, both Pico145/HC-608
and HC-070 were subjected to substantial selectivity profiling against a large set of ion channels,
receptors, enzymes, kinases and transporters. At 1–2 μM (their solubility limit in Ringer’s buffer),
both compounds showed less than 50% inhibition of almost all tested targets. In addition, HC-070 [67]
and Pico145 [66] have suitable pharmacokinetic properties for oral dosing. The excellent potency
and selectivity of Pico145 and HC-070, in combination with their pharmacokinetic profiles and
ready availability—both compounds can be synthesised in three steps from commercially available
precursors—make these compounds highly suitable for functional studies of TRPC1/4/5 channels in
cells and animals. These data also suggest that small molecules can be pharmacologically distinctive
(by almost 40-fold for Pico145) for specific members of the TRPC1/4/5 subfamily, and that the
development of multimer-specific inhibitors may be feasible.
3.2.2. Benzimidazoles
Several derivatives of benzimidazole and 2-aminobenzimidazole have been reported as
TRPC1/4/5 inhibitors. Clemizole hydrochloride (Figure 4) was originally developed as a histamine
H1-receptor agonist [68]. However Richter et al. identified it as a novel inhibitor of (mouse) TRPC5:C5
channels with an IC50 of 1.1 μM [69]. Clemizole inhibits TRPC5:C5 channels reversibly and inhibition
is irrespective of activation mode. TRPC4β:C4β channels are also inhibited by clemizole with an IC50
of 6.4 μM. In whole-cell patch-clamp recordings, 10 μM clemizole inhibits heteromeric TRPC1:C5
channels, and 50 μM clemizole partially inhibits riluzole-activated currents in the U-87 glioblastoma
cell line. However, clemizole has limited selectivity, as it also inhibits channels formed by TRPC3
(IC50 = 9.1 μM), TRPC6 (IC50 = 11.3 μM) and TRPC7 (IC50 = 26.5 μM).
Following a high-throughput screen of 305,000 compounds (the same campaign that afforded the
TRPC4/5 inhibitor ML204), M084 (Figure 4) was identified as a reversible inhibitor of (mouse) TRPC4
and TRPC5 with better stability and inhibitory kinetics than ML204 [70]. Because of relatively low
potency of M084 against TRPC4:C4 (IC50 = 3.7–10.3 μM), TRPC5:C5 (IC50 = 8.2 μM) and TRPC1:C4
(IC50 = 8.3 μM), and its slight inhibition of TRPC3 (IC50 ~50 μM) and TRPC6 (IC50 ~60 μM), a series of
28 further 2-aminobenzimidazoles was generated and tested, suggesting that 2-aminobenzimidazoles
and 2-aminoquinolines (such as ML204) have similar structure-activity relationship (SAR) profiles,
and leading to three compounds (“9”, “13” and “28”; Figure 4) with slightly higher potency than M084
(IC50 values between 3.1 and 6.6 μM) that do not inhibit TRPC3 and TRPC6. At 30 μM, M084 and its
analogues “9”, “13” and “28” do not activate or inhibit Ca2+ influx mediated by TRPA1, TRPM8, TRPV1
or TRPV3. The compounds inhibit TRPC4-mediated currents when applied from the extracellular
side, and inhibition is not dependent on activation mode. In addition, at 30–100 μM, these compounds
block the plateau potential mediated by TRPC4-containing channels in mouse lateral septal neurons.
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A recent report on the use of small-molecule TRPC5 inhibitors to suppress progressive kidney
disease (see Section 4.2) included the identification of AC1903 (Figure 4) as a selective TRPC5
inhibitor [71]. AC1903 shares structural similarities with both clemizole and M084 (Figure 4), and is
equipotent to ML204 against riluzole-evoked TRPC5-mediated currents in whole-cell patch recordings
(IC50 values of 13.6 and 14.7 μM, respectively). AC1903 is a weak inhibitor of TRPC4 (IC50 > 100 μM)
and does not inhibit TRPC6 (no inhibition at 100 μM). In standard kinase profiling assays, AC1903 did
not show off-target effects. No further selectivity assays on ion channels and receptors were reported,
and it is not clear what the effect of AC1903 is on heteromeric TRPC1/4/5 channels.
3.2.3. Flavonols
Several dietary factors, including lipids and polyphenols, are known to inhibit TRPC channels [1].
More recently, we reported the identification of galangin (Figure 4), a natural product from
Alpinia officinarum and other members of the ginger family, as a TRPC5 inhibitor [72]. Galangin
inhibits homomeric TRPC5:C5 with an IC50 of 0.45 μM. In addition, galangin inhibits the basal (IC50
= 1.9 μM) and La3+-evoked (IC50 = 6.1 μM) Ca2+ responses of differentiated 3T3-L1 cells (a model of
mature adipocytes), which are thought to be mediated by heteromeric TRPC1:C5 channels. Subsequent
structure-activity relationship (SAR) studies of 48 natural and synthetic flavonols led to the discovery
of the more potent analogue AM12 (Figure 4), which inhibits TRPC5:C5 with an IC50 of 0.28 μM
but is a relatively weak inhibitor of TRPC1:C5 channels. AM12 has no significant inhibitory effect
on TRPC3, TRPV4, TRPM2 and store-operated Ca2+ release. The reversible inhibition by AM12 of
(−)EA-evoked currents of TRPC4:C4 and TRPC5:C5 in outside-out excised membrane patches suggest
a relatively direct effect on the channels. However, the effect of AM12 is dependent on the mode of
activation; AM12 potentiates TRPC5 when stimulated with S1P or lysophosphatidylcholine (LPC)
rather than (−)EA or Gd3+. The SAR of the flavonol series also revealed that subtle changes to the
flavonol structure can have major impacts on TRPC5 modulatory activity.
3.3. Choosing TRPC1/4/5 Modulators for Studies in Cells, Tissues and Animals
The effects of selected small-molecule TRPC1/4/5 modulators have been summarised in Tables 1
and 2. These compounds (and others described in this review) were profiled by different research
groups using a variety of assays (e.g., fluorometric Ca2+ and Tl+ measurements, calcium imaging,
whole-cell patch recordings, excised membrane patch recordings, single channel recordings) in a
variety of cell lines, and against TRPC1/4/5 channels from different species (usually the closely related
human or mouse homologues). In addition, in inhibition assays, a wide range of activation mechanisms
was used, including (−)EA, lanthanides, carbachol (often with overexpression of muscarinic receptors),
and riluzole. Such differences need to be taken into account during the design of studies in cells or
animals that make use of TRPC1/4/5 modulators.
Table 1. Overview of selected TRPC1/4/5 activators.
Compound Name Targets (EC50) Potential Off-Targets Comments References
(−)-englerin A TRPC1/4/5(1–10 nM)
PKCθ, CaV1.2 (μM
concentrations needed)









TRPM8 (EC50 = 20.6 μM)
No effect on TRPC4:C4,







Multiple ion channels Marketed drug [64,65]
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Table 2. Overview of selected TRPC1/4/5 inhibitors.
Compound Name Targets (IC50; Activator) Potential Off-Targets Comments References
Pico145/HC-608 TRPC1/4/5 (0.03–1.3 nM;(−)EA) Not known
Highly selective; suitable for
in vivo use [19,66,67]
HC-070
TRPC1/4/5 (0.3–2 nM; La3+
or carbachol/muscarinic
receptors)
Not known Highly selective; suitable forin vivo‘use [66,67]
AC1903 TRPC5:C5 (14.7 μM) Not known





Currently, the most promising TRPC1/4/5 activator for functional studies is (−)EA, which has
unrivalled potency, efficacy and selectivity, making it a valuable probe of TRPC1/4/5 in cellular
studies. However, its toxicity and instability in rodent serum and in the gastrointestinal (GI) tract limit
its use for in vivo studies. BTD has the advantage that it activates (mouse) TRPC5 channels selectively
with respect to TRPC4:C4 and TRPC1:C4 channels. It is selective against several other TRP channels,
but potential off-targets have not been profiled comprehensively yet. The marketed drug riluzole can
be used in vivo, but has relatively low potency and is thought to affect many ion channels [64].
The most promising TRPC1/4/5 inhibitors for functional studies are Pico145/HC-608 and HC-070.
These compounds inhibit TRPC1/4/5 channels at (sub)nM concentrations, while at concentrations
up to 1–2 μM, no significant effects on many other proteins have been found. Both compounds are
orally bioavailable and are suitable for in vivo studies. AC1903 is an interesting compound because it
can distinguish between TRPC5:C5 and TRPC4:C4 channels, while having no effect on TRPC6 or on a
panel of kinases. In addition, its pharmacokinetic profile is compatible with in vivo use. However, its
relatively low potency and unknown effects on different TRPC1/4/5 tetramers limit its current use as
a chemical probe.
4. Using Small Molecules to Unravel (Patho)physiological Roles of TRPC1/4/5 Channels
Although observational clinical studies and changes detected in genetically- or pharmacologically-
modified rodents and/or human tissue suggest multiple physiological roles of TRPC4/5 channels [1,73],
disruption of the Trpc4/5 genes [74] and global expression of a dominant-negative mutant TRPC5 [17] do
not cause catastrophic phenotypes. However, TRPC1/4/5 channels have been implicated in various human
diseases, including seizures (TRPC5 and TRPC1:C4) [75], fear-related behaviour (TRPC5) [76,77], severe
pulmonary arterial hypertension (TRPC4) [78–80], heart failure (TRPC1/C4) [81], and chemotherapeutic
resistance of cancers (TRPC5) [82,83]. This section contains a selection of recent studies on the roles of
TRPC1/4/5 channels in health and disease to highlight examples of, and opportunities for, the use of
small-molecule TRPC1/4/5 modulators to unravel TRPC1/4/5-mediated biological processes.
4.1. Roles of TRPC1/4/5 Channels in the Central Nervous System and Pain
4.1.1. Anxiety and Depression
One of the most researched areas of the role of TRPC1/4/5 channels is their potential involvement
in the treatment of anxiety and depression. Evidence for these roles comes from studies utilising both
transgenic mouse models and pharmacological modulators of these channels.
TRPC5 is expressed in brain regions associated with fear and anxiety, and Trpc5−/− mice show
decreased fear behaviour compared to wild-type mice in behavioural tests [76], which was attributed
to reduced potentiation of TRPC5 currents by Gq/11-coupled receptors, specifically those stimulated
by glutamate and cholecystokinin 2 [76]. A similar anxiolytic phenotype was seen in mice lacking the
TRPC4 subunit [84]. In addition, this study showed that TRPC4 protein knockdown limited to the
lateral amygdala region—a region of the brain implicated in anxiety—showed the same phenotype
as global Trpc4−/− mice. This suggests that both TRPC4 and TRPC5 channels in this specific area of
15
Cells 2018, 7, 52
the brain may be involved in the development of fear behaviours. It is not known if these TRPC4 and
TRPC5 channels are homomers or heteromers, and whether TRPC1 is involved as well.
This proposed role of TRPC4/5 channels in fear behaviour has led to TRPC1/4/5 modulators
being investigated as a possible treatment for anxiety. Indeed, the TRPC1/4/5 inhibitor M084 (see
Section 3.2.2) [85] has anxiolytic and antidepressant effects in mice [77]. However, it is unknown
whether this action of ML084 is due to its effects on homomeric or heteromeric channels, and whether
the effect is specifically due to inhibition of TRPC4/5 channels located in the amygdala.
The xanthine HC-070, a highly potent and selective inhibitor of both homo- and heteromeric
TRPC1/4/5 channels (see Section 3.2.1), reduces currents stimulated by CCK4 in basolateral amygdala
in brain slices, and additionally shows anxiolytic and antidepressant effects in mouse behavioural
studies, further confirming these channels as promising clinical targets in the treatment of anxiety and
depression [67].
4.1.2. Epilepsy
TRPC1/4/5 channels have also been implicated in epilepsy. TRPC5 channels are highly expressed
in rat hippocampal CA1 neurons, where they are thought to be involved in the formation of a
prolonged depolarisation, the so-called plateau potential, following cholinergic innervation [86]. Thus
far, inhibition of this process was only demonstrated with the non-specific compound 2-APB and with
intracellular ATP. The effects of newer pharmacological modulators that show increased potency and
selectivity are not known. Additionally, TRPC5 and TRPC1:4 channels are thought to be involved in
epileptogenesis in mice, but via distinct expression patterns and mechanisms [75].
Evidence from human studies is limited, however both TRPC1 and TRPC4 proteins are
upregulated in brain tissues of patients with focal cortical dysplasia, a common cause of refractory
epilepsy [87,88]. Additionally, TRPC4 channel variants have also been implicated in generalised
epilepsy [89]. Whether neuronal activity can be modulated by specific activators and inhibitors of
TRPC1/4/5 remains to be elucidated.
4.1.3. Pain
TRPC1/4/5 channels have also been implicated in different types of pain. Westlund et al.
investigated the role of TRPC4 channels in pain, using mice with a global knockout of the Trpc4
gene [90]. The Trpc4−/− mice showed a resistance to mustard-oil induced visceral pain, as well as
increased pain thresholds as compared to wild-type mice. In addition, animals treated with ML204
(0.5 and 1 mg/kg; orally administered) displayed reduced pain behaviours, similar to knockout mice.
Wei et al. also investigated the role of TRPC4/5 channels in a spared nerve injury model of neuropathic
pain with the TRPC4/5 inhibitor ML204 administered directly into the amygdala [91]. Administration
of 5–10 μg ML204 decreased pain behaviour and showed an anti-hypersensitivity effect, which was
not present when ML204 was injected into a control site.
4.1.4. Memory
Bröker-Lai et al. recently reported the presence of either TRPC1:C4:C5 channels or mixed
populations of TRPC1:C4, TRPC1:C5 and TRPC4:C5 channels in mouse hippocampal cells
(see Section 2.2) [18]. In this study, neurons and hippocampal slices from Trpc1/Trpc4/Trpc5 triple
knockout mice showed decreased (action potential-triggered) post-synaptic responses, while the
animals displayed impaired cross-frequency coupling in hippocampal networks and deficits in spatial
working memory and learning/adaptation. To date, the use of small-molecule TRPC1/4/5 modulators
in studies of working memory and learning has not been reported, and it would be important to study
whether TRPC1/4/5 inhibitors can have adverse effects on memory.
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4.2. Roles of TRPC1/4/5 Channels in Kidney Disease
A role for TRPC1/4/5 has been postulated in the kidney, specifically in the development of
kidney disease, however the literature provides conflicting findings in this field. TRPC5 channels
are expressed in kidney podocytes, specialised cells that form the kidney filter. The channels form a
molecular complex with the GTPase Rac1, and are involved in the regulation of cell migration and
actin remodelling downstream of angiotensin stimulation [92]. Trpc5 knockout protects mice from
kidney filter barrier damage and resultant albuminuria caused by lipopolysaccharide (LPS), as well
as protecting podocytes from barrier damage induced by protamine-sulfate. The same effects were
seen in wild-type animals treated with the TRPC4/5 inhibitor ML204 [93]. This was also supported
by in vitro data, showing an attenuation of cytoskeletal remodelling of podocytes, both after TRPC5
knockdown and pharmacological inhibition.
A role for TRPC5 in the development of focal segmental glomerusclerosis (FSGS), a leading cause
of kidney failure, was also suggested by Zhou et al., who used a transgenic rat with a podocyte-specific
overexpression of the angiotensin type 1 receptor (AT1R) [71]. These rats developed progressive
kidney disease, and treatment of these rats with the TRPC4/5 inhibitor ML204 prevented podocyte
death and attenuated the proteinuria caused by kidney damage. In addition, isolated cell studies
showed increased riluzole-mediated single channel currents in rat glomeruli from AT1R animals,
again inhibited by ML204. This study also introduced a novel TRPC5 inhibitor, named AC1903
(see Section 3.2.2), which showed similar effects to ML204 in suppressing proteinuria, in both
AT1R transgenic animals and a model of hypertension-induced FSGS. However, a role of TRPC5
in progressive kidney disease was not supported by a study with transgenic mice overexpressing
either wild-type TRPC5 or a dominant-negative TRPC5 mutant [94]. No difference in LPS-induced
kidney damage was seen between the different animal groups, and treatment with the inhibitor
ML204 (3 × 2 mg/kg) showed no effect on proteinuria in LPS-challenged animals. Treatment with the
TRPC1/4/5 activator (−)EA (3 mg/kg, 24 h apart, i.p.) had no adverse effects on proteinuria in mice.
However, as (−)EA displays poor stability in rodent plasma [51], it is debatable whether blood levels
of (−)EA would reach levels sufficient to activate kidney TRPC5 channels and cause kidney damage.
It is important to note, as stated by Van der Wijst and Bindels [95], that the two studies above used
different doses of ML204 and different dosing regimens, which could account for the different effects
seen. In addition, the exact identity of the TRPC1/4/5 channels expressed in the kidney is not known,
and neither is the exact role of TRPC6 in FSGS. The channels may contain TRPC1, and although ML204
has recently been found to be a weak inhibitor of (−)EA-activated TRPC1:C5 channels, it is unknown
how potent ML204 is against riluzole-activated channels. Overexpression of TRPC5 alone may not
lead to formation of more channels linked to the studied phenotype, and knockout of Trpc5 may lead
to changes in formation of tetrameric ion channels by non-affected proteins such as TRPC1.
4.3. Roles of TRPC1/4/5 Channels in Cancer
It is well established that intracellular Ca2+ homeostasis is altered in cancer and that dysregulation
of Ca2+ signalling is involved in tumour initiation, progression, metastasis, and angiogenesis. The roles
of TRPC4 and TRPC5 in migration/proliferation of cancer cells, angiogenesis, cancer cell multi-drug
resistance and (−)EA-induced renal cancer cell death have been reviewed in 2016 [96]. Here, we
highlight the use of small-molecule TRPC1/4/5 modulators in the study of specific vulnerabilities of
A498 renal carcinoma and SW982 synovial sarcoma cancer cells.
The discovery that the natural product (−)EA displays highly potent and selective cytotoxicity
against eight renal cancer cell lines (GI50 values of under 1–87 nM; >1000-fold selectivity over other
cell lines) led to target identification studies by several groups. PKCθ [56] and TRPC1:C4 channels
(see Section 3.1.1) [14,15,51] have been proposed as the relevant target of (−)EA in renal cancer cells,
and both proposals were based on extensive experimentation. A discussion of the evidence for these
proposed mechanisms-of-action was included in a recent review on the englerins by Wu et al. [55].
It is possible that activation of TRPC1:C4 and effects on PKCθ-mediated gene regulation are linked
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in some cancer cells. However, in A498 cells and SW982 cells, both the potency of (−)EA in cell
death assays (low nanomolar concentrations) and rapid onset of effects (minutes) are consistent with
activation of TRPC1:C4 channels in these cells (low nanomolar EC50 values; similar to the potency
in excised membrane patches from HEK293 cells containing TRPC1:C4 channels), but not with the
proposed direct effects on PKCθ (majority of effects reported with 1–10 μM of (−)EA) and (much
slower) downstream effects on gene transcription [14–16,51]. Furthermore, application of a PKCθ
inhibitor has no effect on A498 cell proliferation and does not protect the cells from (−)EA-induced
toxicity [51]. The analysis of >500 well characterized cancer cell lines revealed that TRPC4 mRNA
abundance is the feature best correlated with sensitivity to (−)EA [51]. Knockdown of either TRPC1
or TRPC4 protects A498 and SW982 cells against (−)EA [14–16], while the Na+/K+ ATPase inhibitor
ouabain increases the cytotoxic effect of (−)EA [15,16]. In addition, the well-characterised, highly
potent and selective TRPC1/4/5 inhibitor Pico145 (see Section 3.2.1) strongly inhibits the cytotoxicity
of (−)EA in SW982 cells [16], demonstrating the value of high-quality chemical probes in target
validation studies. Overall, these studies suggest that (−)EA achieves its effect in A498 and SW982
cells through induction of sustained Na+ entry through TRPC1:C4 channels, and that expression of
functional TRPC1:C4 channels is necessary for potent and rapid (−)EA-induced cytotoxicity in these
cell lines. In addition, Carson et al. demonstrated that overexpression of TRPC4 is sufficient to make
HEK293 cells sensitive to growth inhibition by nanomolar concentrations of (−)EA (IC50 = 28 nM) [51].
A recent report by Wei et al. suggests that the expression of TRPC4-containing channels in
medulloblastoma cells (which also express TRPC1 and TRPC5) promotes cell migration, contributing
to invasion/metastasis [97]. However, the exact composition of these channels is not known, and
inhibitory effects of (−)EA on migration of these cells are difficult to correlate with TRPC1/4/5
channel activity because the high concentration of (−)EA (10 μM) used in this study may affect
additional mechanisms.
4.4. Roles of TRPC1/4/5 Channels in the Cardiovascular System
Several members of the TRP channel family have been implicated in the cardiovascular system,
including TRPC1/4/5 (for reviews, see [98–101]). Here, we highlight a few recent examples. Based on
studies in mice and rats, a role of TRPC5 channels as baroreceptor mechanosensors that regulate blood
pressure has been suggested [73], although there was an error in the original published data and the
findings have been challenged [102,103], indicating that further studies are needed.
Camacho Londoño et al. found that a background Ca2+ entry pathway that fine-tunes Ca2+
cycling in cardiomyocytes critically depends on TRPC1 and TRPC4 proteins. Suppression of this
channel activity by Trpc1/Trpc4 double knockout protects against pathological cardiac remodelling in
mice, without affecting normal cardiac function [81].
TRPC4 channels have been studied in the development of pulmonary hypertension.
Alzoubi et al. reported that Trpc4 inactivation in rats confers a survival benefit in severe
pulmonary arterial hypertension [78]. This was attributed to decreased occlusive remodelling of
blood vessels in knockout animals. Recent reports suggest that TRPC4 channels are implicated
in (bacterial toxin-induced/aggravated) pulmonary arterial hypertension/stenosis by increasing
proliferation/permeability of endothelial and smooth muscle cells [79,80,104].
To date, no pharmacological modulators of TRPC1/4/5 have been reported in models of
pathological cardiac remodelling or pulmonary hypertension.
4.5. Additional Roles and Opportunities
Trpc5 knockout animals have been used in the study of hepatic dyslipidaemia by Alawi et al. [105].
The authors compared cholestasis-induced liver injury in wild-type compared to Trpc5 knockout mice,
and found significantly reduced injury in knockout animals, as well as reduced dyslipidaemia and
hypercholanemia, suggesting that TRPC5 channels could be involved in liver function.
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TRPC5 channels have also been implicated in arthritis, although their role is unclear. Human
fibroblast-like synoviocytes, the cells that secrete synovial fluid, express TRPC1 and TRPC5, and
blocking their activity using antibodies or siRNA increases the secretion of matrix metalloproteases
(MMPs), which is thought to lead to tissue remodelling and arthritis [34]. Additionally, TRPC5 channel
expression is increased in the synovium in a mouse model of arthritis, and genetic deletion of TRPC5
as well as pharmacological inhibition with ML204 exacerbate arthritis induced by injection of complete
Freud’s adjuvant [106]. Whether pharmacological activation of TRPC5 is beneficial in arthritis is as yet
unknown, but these results suggest a potentially protective role for TRPC5.
Mature adipocytes in murine and human perivascular fat express TRPC1 and TRPC5, and
contain constitutively active channels with an I–V profile consistent with TRPC1:C5 channels [17].
These mature adipocytes also suppress excretion of adiponectin, an adipokine known to have
anti-inflammatory, anti-atherosclerotic, and insulin-sensitising effects. Inhibition of TRPC1:C5 currents
by genetic methods (RNAi or over-expression of a dominant-negative TRPC5 ion pore mutant) led to
increased adiponectin secretion from adipocytes. The same effect was seen in vitro when TRPC1:C5
channels were blocked with a TRPC5 antibody or dietary fatty acids, revealing a potential mechanism
for cardioprotection by these fatty acids.
TRPC channels have been implicated in diabetes-associated complications [107], and a recent
study suggests that Ca2+-permeable channels containing TRPC1 inhibit exercise-induced protection
against high-fat diet-induced obesity and type II diabetes [108]. In addition, a recent study with
Trpc1/4/5/6−/− mice suggests that TRPC channels contribute to the development of diabetic retinopathy.
Knockout mice were protected from hyperglycaemia-evoked vasoregression and STZ-induced thinning
of the retinal layer. These effects may be due to a role of TRPC channels in the regulation of
expression/activity of glyoxalase 1 (GLO1), a key enzyme involved in the detoxification of the reactive
metabolite methylglyoxal [109]. The exact nature of the channels involved in this phenotype is not
known, and the effect of pharmacological TRPC1/4/5 modulators has not been reported yet.
5. Conclusions
Small-molecule modulators of TRPC1/4/5 channels can complement genetic approaches in
dissecting the different roles of specific TRPC1/4/5 channels across species, tissues, and pathologies
(see Section 4). Whereas genetic perturbation of TRPC proteins (overexpression, knockout/knockdown)
can be performed with high precision, it may lead to secondary effects caused by alterations in
native channel stoichiometries and protein–protein interactions, complicating data interpretation
(and potentially masking the full potential of the channels as therapeutic targets) [110]. In contrast,
chemical probes generally act quickly, acutely, reversibly, and can be used for experiments in cells,
tissues and animals [111–113]. High-quality chemical probes are powerful tools in target validation
studies, and can serve as useful starting points for drug development; however, their development is
often costly in terms of time and resources. In addition, even high-quality chemical probes are likely
to have off-targets, and potency and selectivity of a chemical probe may be dependent on cellular
context (expression levels and localisation of targets, post-translational modifications, protein–protein
interactions, presence of endogenous modulators, etc.). For these reasons, functional studies that
carefully combine genetic and pharmacological approaches—and take limitations of both into
account—are highly recommended for unravelling the biological roles of specific TRPC1/4/5 channels.
Traditionally, small-molecule modulation of TRPC1/4/5 channels has often relied on
small-molecule modulators with low potency/selectivity. The emergence of highly potent and highly
selective TRPC1/4/5 modulators such as (−)EA, Pico145 and HC-070 now offers unprecedented
opportunities for TRPC1/4/5 research, and especially Pico145 and HC-070 are suitable for in vivo
studies. The toxicity (depending on administration mode) [51,55,60] and instability of (−)EA in plasma
and the digestive system [51,60] may limit its use for such studies though, and other activators such as
BTD and riluzole have to be used at micromolar concentrations, increasing the chance of off-target
effects. Therefore, additional potent and selective TRPC1/4/5 activators are needed.
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The differentiation between different TRPC1/4/5 tetramers by compounds such as Pico145,
ML204 and AC1903 suggests that development of tetramer-specific modulators is possible, and
structural studies of TRPC1/4/5 channels may inform such developments. Such modulators could be
used to reveal the composition of TRPC1/4/5 channels implicated in different (patho)physiological
processes, which so far is often poorly understood (see Section 4). Studies of the roles of TRPC1/4/5
channels in anxiety, (−)EA-mediated cancer cell death and progressive kidney disease highlight the
necessity and usefulness of small-molecule TRPC1/4/5 modulators for biological research. In addition,
these studies show that it is essential to use carefully selected chemical probes and control compounds
(with different selectivity profiles), at concentrations that are sufficient (and not much higher than that)
to modulate the relevant TRPC1/4/5 channels under the tested conditions, and—where possible—to
test dose-dependence of effects. When used appropriately, TRPC1/4/5 modulators can transform the
understanding of TRPC1/4/5 channels in health and disease, and of the advantages and disadvantages
of TRPC1/4/5 channels as drug targets.
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Abstract: TRPC3 is one of the classical members of the mammalian transient receptor potential
(TRP) superfamily of ion channels. TRPC3 is a molecule with intriguing sensory features including
the direct recognition of and activation by diacylglycerols (DAG). Although TRPC3 channels are
ubiquitously expressed, they appear to control functions of the cardiovascular system and the brain
in a highly specific manner. Moreover, a role of TRPC3 in immunity, cancer, and tissue remodeling
has been proposed, generating much interest in TRPC3 as a target for pharmacological intervention.
Advances in the understanding of molecular architecture and structure-function relations of TRPC3
have been the foundations for novel therapeutic approaches, such as photopharmacology and
optochemical genetics of TRPC3. This review provides an account of advances in therapeutic
targeting of TRPC3 channels.
Keywords: transient receptor potential channels; TRPC3 pharmacology; channel structure; lipid
mediators; photochromic ligands
1. Introduction to TRPC3
Mammalian transient receptor potential (TRP) channels of the classical subfamily (TRPC) are
closely related to the founding member dTRP, which was discovered as a critical element in Drosophila
visual transduction [1]. In human tissues, TRPCs typically serve signal transduction pathways
downstream of G protein-coupled receptors [2]. All TRPCs are controlled by and able to sense
membrane lipids [3,4], where TRPC3/6/7 channels display a direct mechanism of activation via
diacylglycerols [5,6], which is generated in response to receptor-phospholipase C pathways. Like
all other TRPC channels, TRPC3 features six transmembrane spanning segments with nitrogen (N)
and carbon (C) termini residing in the cytoplasm. TRPC3 assembles into tetrameric complexes in
which the cytoplasmic termini interact to form an inverted bell-shaped cytoplasmic layer, as revealed
by single-particle cryo-electron microscopy (cryo-EM) [7,8]. The tetrameric assembly constitutes a
cation permeation path with a selectivity filter harboring negatively charged residues (E630 in the
848aa variant; isoform 3/Q13507-3 in UniProt) to determine calcium ion (Ca2+) transport within
the pore domains, connecting transmembrane domains 5 and 6 (TM5 and TM6) [7,9]. Multiple
cytoplasmic regulatory domains have been identified, including a highly conserved proline-rich and
calmodulin/IP3 receptor binding (CIRB) region in the C-terminus [10,11], which enable the channel
to serve multimodal signaling functions. Initially, the channel was implicated in store-operated Ca2+
entry processes [12,13] but later on, a consent was reached among researchers that the prominent
mechanism of TRPC3 activation and TRPC3-mediated Ca2+ signaling is based on a direct interaction
with diacylglycerol. This was found to occur within a lateral gating fenestration of the pore
domain [14]. Like its DAG-sensitive relatives TRPC6 and TRPC7, TRPC3 has been implicated in
a wide array of pathologies and disorders ranging from tumors to cardiac arrhythmias [15]. Notably,
expression of TRPC3 varies among tissues and their developmental state as well as cell phenotype.
A prominent functional role of TRPC3 has been detected in both proliferating cells, such a vascular
Cells 2018, 7, 83; doi:10.3390/cells7070083 www.mdpi.com/journal/cells26
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progenitors [16,17], but also in differentiated cell types [18,19]. Overall, pharmacological targeting
of TRPC3 with high specificity and spatiotemporal precision has become feasible and emerged as an
attractive perspective in TRPC pharmacology.
2. Potential Role of TRPC3 in Human Disease
Ca2+ influx is an essential determinant of cell function and fate, and TRPC3 serves to regulate
Ca2+ entry via its nonselective permeation pathway by multiple mechanisms, including functional
interaction with the sodium-calcium exchanger NCX1 [20–23]. TRPC3 mRNA was detected in both
excitable and non-excitable cells, and changes in expression levels are reportedly correlated with
pathological processes and organ disorders [24]. A gain in TRPC3 function was found to be associated
with pathologies of the cardiovascular system and brain. In the heart, TRPC3 channels were confirmed
as a major target of the angiotensin II- and noradrenaline-induced nuclear factor of activated T
cells (NFAT) activation involved in maladaptive cardiac remodeling and arrhythmias [20,22,25,26].
TRPC3 overexpression and/or gain-of-function depolarizes myocytes, promotes the calcineurin/NFAT
pathway, is involved in adverse mechanical stress responses, hypertrophy, and heart failure [25,26].
Importantly, NFAT signaling in myocytes has been linked to direct Ca2+ entry via TRPC3 channels [27].
Nonetheless, the pathophysiologicial role of TRPC3 in the heart appears, for a large part, to be based
on its expression and function in cardiac fibroblasts. TRPC3 was identified as a crucial player in the
proliferation and differentiation of fibroblasts in the myocardium and its activity was found to promote
fibrosis, structural remodeling and arrhythmias, specifically atrial fibrillation [28–30].
TRPC3 channels are also expressed in other cardiovascular cells, including vascular smooth
muscle and endothelial cells [31–33]. TRPC3 has been proposed to govern both the fate of
endothelial progenitor cells and functions in the mature endothelium specifically vasodilatory
responses [16]. TRPC3-mediated Ca2+ was reported to trigger NO-mediated [34] and NO-independent
vasodilation [33]. For vascular smooth muscle, Dietrich et al. showed that up-regulated expression
of TRPC3 channels, which features constitutive activity, is associated with high blood pressure in
TRPC6-deficient mice [35]. Similar to cardiac muscle, a role of TRPC3 in phenotype transitions and
vascular remodeling was suggested [36].
TRPC3 expression is detectable throughout the brain with prominent levels in cerebellar Purkinje
cells in the adult mouse brain [37]. Notably, up-regulation of the neuronal TRPC3 conductance by
the gain-of-function mutation T635A (moonwalker; Mwk) was shown to lead to Ca2+-dependent
degradation of Purkinje cells and, as a consequence, to impaired motor coordination [38,39]. In the
hippocampus, TRPC3 activity was found to be negatively correlated with contextual fear memory [40].
A role in non-excitable cell signaling was proposed for the immune system. TRPC3 was reported
to control Ca2+ waves and to facilitate the response to antigen stimulation [41]. Phillip et al. detected
defects in the TRPC3 gene of immune cell lines with impaired Ca2+ signaling, which were initially
described by Fanger et al. [42]. Phillip et al. were able to restore the Ca2+ influx and activation
of T-cells by overexpression of functional TRPC3 channels [43]. Hence, TRPC3 was suggested to
contribute to Ca2+ signaling in immune cells alongside the prominent players stromal interaction
molecule (STIM) and Orai, which constitute the classical calcium release-activated Ca2+ channel
(CRAC) conductance [44].
Growing consensus states that TRPC molecules impact on nearly all “cancer hallmarks” and drive
cancer progression [45]. In particular, TRPC3 was found as an ion channel that governs proliferation
and migration of a variety of tumor cells, including melanoma [46], lung [47], bladder [48], ovarian [49],
and breast [50] cancers.
Current knowledge on the role of TRPC3 in most investigated pathologies suggests that channel
blockers might be suitable for disease management. This has been suggested for cardiac fibrosis and
hypertrophy [29,51], coronary stenosis [36], and melanoma [46]. Nonetheless, for certain disorders,
selective block of TRPC3 channel functioning might not be a useful therapeutic strategy since the
protein’s cellular role is more complex, and TRPC3 function has also been assigned to beneficial
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effects, such as stabilization of cardiac contractility, and excitability and vasodilation or promotion of
immune responses. Not only should the expression levels and overall channel activity be considered,
but also the cell-type specific signaling signature of TRPC3 channels, which depends on factors like
subcellular localization, composition of pore complex, and input signaling pattern, and are likely
of relevance for disease etiology. The ability of TRPC proteins to assemble into specific heteromeric
complexes, for which stoichiometry is likely to determine signaling features as well as sensitivity to
pharmacological intervention, has long been recognized [52–54]. Moreover, native TRPC channels have
been shown to operate in cell-specifically organized signalplexes, which enable efficient interactions
with downstream signaling elements, such as CaN [27] or the electrogenic Ca2+ signaling partner
NCX1 [22]. Dynamic organization of TRPC3 into such cell-type specific signalplexes, along with the
TRPC channels cycling between activated, inactivated, and desensitized states, needs consideration as
a basis of cell-type specific signaling and therapeutic targeting of TRPC3. In this context, more refined
pharmacological interventions including also channel activators and modulators might be of value for
therapeutic applications.
3. Pharmacological Inhibitors
Early attempts to identify and characterize TRPC3 channel function were based on non-specific
channel blockers, such as the trivalent cations La3+ and Gd3+ [12,55,56], or commonly used
nonselective inhibitors of receptor-mediated Ca2+ entry, verapamil or SKF96365 [55]. Due to their
wide range of targets, these blockers were only of limited use for the characterization of TRPC3
in native tissues and not suitable for the development of therapeutic application. A first step
toward the more specific targeting of TRPC3 function was achieved by He et al., showing that the
3,5-bis(trifluoromethyl)pyrazole (YM-58483 or BTP2), which was initially described as an inhibitor of
T-lymphocytes store-operated Ca2+ entry (SOCE) [57,58], was inhibiting TRPC3 channel activity in
different cell types including DT40 B-lymphocytes [59]. Based on the observation of BTP2 inhibition
of TRPC3 conductance activated by carbachol (CCh) or oleoyl-acetyl glycerol (OAG; Figure 1) [59],
these authors clearly identified the pyrazole derivative as an inhibitor of TRPC3. Since BTP2 still
lacked appreciable selectivity among different Ca2+ entry pathways, Kiyonaka et al. synthesized and
characterized a series of pyrazole derivatives to discriminate between SOCE, TRPC,3 and other TRPC
isoforms. These authors reported a new pyrazole 3 (Pyr3) inhibitor of TRPC channels (Figure 1) with a
striking preference for TRPC3. Notably, 3 μM of Pyr3, which effectively inhibited TRPC3, failed to
suppress TRPC6, TRPM2, TRPM4, and TRPM7 channels overexpressed in HEK293 cells. Pyr3 was
suggested to inhibit TRPC3 channels from the extracellular side and photoaffinity labeling of Pyr3
showed a strong incorporation of the inhibitor into TRPC3 but not into TRPC6 channels [60]. The exact
site of molecular interaction has not been clearly defined, and even a principle blocking mechanism by
occluding the permeation pathway has not been conclusively delineated. Pyr3 certainly advanced the
field by enabling a pharmacological dissection of closely related TRPC channel subtypes. However,
later investigations on the selectivity of pyrazole inhibitors demonstrated that Pyr3 inhibits STIM/Orai
Ca2+ entry complexes [61]. The latter authors identified other pyrazole derivatives that are indeed able
to discriminate between TRPC3 and Orai-mediated SOCE, including an acceptably selective TRPC3
blocker (Pyr10). This pyrazole blocked recombinant, homomeric TRPC3 channels were highly potent
(IC50 > 0.72 μM) but affected SOCE only at concentrations more than one order of magnitude higher
(IC50 > 10 μM) [61].
28
Cells 2018, 7, 83
Figure 1. Chemical structures of prototypical antagonist and agonists of transient receptor potential
channel 3/6 (TRPC3/6): Pyrazole 3 (Pyr3) as a most commonly used pore blocker; GSK1702934A and
2-Acetyl-1-oleoyl-sn-glycerol (OAG) represent channel agonists (a synthetic, non-lipid activator, and a
diacylglycerol/lipid, respectively); OptoDArG as a photochromic agonist (photoswitchable lipid) and
a powerful tool for precise control of TRP channels (TRPC) activity.
Another screening study by Washburn et al. identified two potent and selective thiazole
inhibitors of TRPC channels. These compounds, assigned GSK2332255B (GSK255B) and GSK2833503A
(GSK503A), are anilino-thiazoles and feature a nanomolar potency for blocking TRPC6 and TRPC3
and reportedly lack significant effects on many other calcium-permeable channels [62]. Since TRPC3/6
channels were implicated in the pathogenesis of hypertension and hypertrophy, GSK255B and
GSK503A were tested in animal models of cardiac hypertrophy and remodeling. GSK255B and
GSK503A, most likely by a combined suppression of TRPC3 and TRPC6 conductance, reduced
hypertrophy and fibrosis induced by pressure overload in rodents [63].
Other TRPC3 blocking agents with ill-defined selectivity have been introduced, such
as norgestamate [64], HC-C3A [40], 4-({(1R,2R)-2-[(3R)-3-aminopiperidin-1-yl]-2,3-dihydro-1
H-inden-1-yl}oxy)-3-chlorobenzonitrile (SAR7334) [65], and 2-(benzo[d][1,3]dioxol-5-ylamino)thiazol-
4-yl)((3S,5R)-3,5-dimethylpiperidin-1-yl)methanone (BTDM) [8]. The latter compound (BTDM), albeit
incompletely characterized at the cellular and tissue level, was able to delineate TRPC6 and TRPC3
structure by cryo-EM [8]. Consequently, a BTDM binding site was localized within the TRPC6
tetrameric complex (Figure 1). Importantly, another study resolving the TRPC3 structure by cryo-EM [7]
identified a highly charged extracellular cavity with close structural relation to the pore domain,
therefore representing a potential interaction site for inhibitors and/or modulators of the channel.
Thus, the first high-resolution structural information on the drug binding site in the TRPC3 complex
has emerged, and this information will promote the development of therapeutic targeting of TRPC3
(Figure 1).
4. Endogenous and Synthetic Channel Activators
A hallmark of the cellular regulation of mammalian TRPC channels is the intimate linkage
between channel activity and membrane lipid composition. TRPC3 is, for a large part, governed
by its membrane lipid environment. Not only production of diacylglycerols (DAGs; Figure 1) in
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response to phospholipase C (PLC) activation activates the channel, but also phosphatidylinositol
4,5-bisphosphate PIP2 as a precursor of DAG formation, has been identified as a determinant of TRPC3
activity [66]. Both PIP2 and DAG appear to promote channel activity. Synthetic and photoswitchable
DAGs have been introduced as activators that enable optical control of TRPC3 activity. As a highly
active, unnatural lipid activator, a DAG with two arachidonyl-mimicking azobenzene moieties was
introduced (OptoDArG; Figure 1) [14]. In addition to glycerol derivatives, membrane cholesterol was
shown to initiate and enhance TRPC3 activity [67]. The effect of cholesterol was attributed in part by
enhanced recruitment of the channel into the plasma membrane. Importantly, two distinct regulation
mechanisms were reported for TRPC channels including TRPC3 in particular. This is, on the one
hand, an increase in the open probability in membrane resident channels, as shown at the level of
single TRPC3 channels for PLC-mediated activation, which is characterized by destabilized closed
channel conformations [14]. On the other hand, the recruitment of a vesicular pool of TRPC channels
into the plasma membrane was proposed. Through this mechanism, certain activating stimuli might
enhance channel availability, and thereby TRPC3 currents and downstream signaling [68]. In this
respect, TRPC3, in contrast to its close relative TRPC6, displays constitutive activity in resting cells,
at essentially low PLC activity. Suppressed basal activity in TRPC6 was found to be related to the
channel’s glycosylation pattern. Dual glycosylation at two asparagine residues was found to be crucial
for maintaining the basal activity of TRPC6 low compared to monoglycosylated TRPC3, which is
marginally permeable for ions in a resting state [69]. Constitutive gating activity appears largely
independent of basal levels of DAGs in the membrane, as a DAG-insensitive mutant (G652A) of
TRPC3 retained constitutive activity [14]. The same mutation also retained sensitivity to activation by
a synthetic activator GSK1702934A (GSK; Figure 1) that clearly acts in manner different from DAGs to
enhance the open probability of TRPC3 [14]. Xu et al. introduced this small and apparently selective
agonist of ligand-gated TRPC channels, which activated TRPC3/6 overexpressed in HEK293 cells
and increased the perfusion pressure of isolated rat heart and transiently increased blood pressure in
conscious Sprague Dawley rats [70]. Later, Qu et al. introduced a series of TRPC-selective agonists,
which lacked effects on other members of the TRP family (TRPA, TRPM, and TRPV). These agonists
were pyrazolopyrimidine-based and remarkably potent (EC50 in the nanomolar range) in the activation
of recombinant TRPC3, TRPC6, and TRPC7 channels [71]. These synthetic small molecule agonists
of TRPC channels (GSK-related and pyrazolopyrimidine-based structures) appear to bypass the PLC
pathway and the TRPC lipid-gating machinery. Importantly, GSK has been found to exert little to no
effect on membrane conductance of cardiomyocytes at an essentially low level of TRPC3 expression
in the murine heart, but induced TRPC3 currents when the channel was overexpressed in a genetic
mouse model [22]. This indicates a relatively high specificity of the GSK activator for TRPC3/6/7
channels, since none of the abundant voltage-gated cardiac conductances were affected [22]. For
pyrazolopyrimidine-based agonists, Qu et al. confirmed the selectivity and efficiency in stimulating
endogenous TRPC3/6 activity in rat primary glomerular mesangial cells by Ca2+ measurements [71].
Of note, limited therapeutic interest has been expressed as of yet for synthetic activators of TRPC3, since
most TRPC3-associated pathologies are related to either an enhanced expression or a gain in function
of phenotypes. Hence, drug development activities have focused primarily on selective antagonists
or blockers of the channel. Nonetheless, TRPC3 has been identified as promoting proliferative cell
phenotypes [16,29,36] and may be involved not only in maladaptive tissue remodeling but also in
tissue regeneration. Therefore, unconventional approaches that provide high spatial precision of
intervention, such as photopharmacology, may create the possibility of a therapeutic application for
TRPC3 activators.
5. New Insights into the Ligand Binding Domains in TRPC3
The delineation of TRPC3 and TRPC6 structures by cryo-EM microscopy approaches succeeded
in the localization of potential binding sites for blockers, modulators, as well as endogenous lipids.
Tang et al. presented the structure of homotetrameric TRPC3 complexes at 4.4 Å [7]. A resolution
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along with the structure of TRPC6 (3.8 Å resolution), in which binding of the high affinity inhibitor
BTDM was localized between the S1–S4 voltage sensor-like domain (VSLD) and the pore domain.
This is a position in which an interaction is likely to hinder gating movements (Figure 1). The BTDM
binding site is conserved between TRPC6 and TRPC3, and interaction of this potent inhibitor structure
with the channel appears not to overlap with lipid regulation, as some mutations that prevent BTDM
binding did not interfere with activation by DAGs. Tang et al. performed a structure analysis of
TRPC3 reconstituted into nanodiscs in the presence of the diacylglycerol activator OAG, but obtained
a closed channel conformation and could not discern the presence of the lipid activator [8]. Fan et al.
reported the structure of tetrameric TRPC3 complexes in a lipid-occupied closed state at a 3.3 Å
resolution and localized two lipid interaction sites without identifying the molecular nature of the
lipid species [7]. One lipid molecule occupied a position between a pre-S1 elbow-like structure and the
S4–S5 linker representing a pivotal element of TRPC gating. A second lipid-like density was found
within a lateral fenestration in the pore domain (Figure 2). This second and potentially lipid-interaction
site is close to the previously recognized critical LFW motif in the pore domain. It was identified
by our laboratory as a structure essential for DAG recognition and lipid gating in the channel using
homology modeling combined with structure-guided mutagenesis and a novel optical lipid-clamp
approach [14]. Observation of a closed channel state may reflect either a desensitized or inactivated
state of the channel or the presence of an inert, non-activating lipid species that occupies the channel
in its resting state.
 
Figure 2. Ligand-channel interactions and potential drug binding sites in TRPC3. (a) Schematic
illustration of the domain structure of one TRPC3 channel subunit according to information provided in
Fan et al. [7]. Lipid binding sites (green stars) are indicated with L1 (formed by LD9, pre-S1, S1, S4, and
S4–S5 linker) and L2 (between p-loop and S6 helix); potential modulator binding site (M) represented by
a cavity (extracellular domain) formed by the extended S3 helix, S1–S2 and S3–S4 linkers as previously
identified [7]. Proposed BTDM binding site formed by S3, S4–S5 linker, S4, S5, and S6 identified
by Tang et al. [8]. (b) Detailed view on postulated 2-(benzo[d][1,3]dioxol-5-ylamino)thiazol-4-yl)
((3S,5R)-3,5-dimethylpiperidin-1-yl)methanone (BTDM) binding site in TRPC3: amino acids in the
TRPC3 sequence, corresponding to the TRPC6 BTDM binding site are marked in red. The BTDM
molecule is only schematically introduced into the TRPC structure and not adjusted in size. The glycine
residue G652 (here G640, isoform 1/Q13507-1 in UniProt) identified as crucial for recognition and
accommodation of lipid activators is highlighted in blue [14]. The BTDM molecule is schematically
placed into the proposed binding site.
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Both natural as well as synthetic modulators are likely to occupy distinct binding pockets to
interfere with the gating machinery involving conformational changes in both the S1–S4 VSLD and
the pore domains. Fan et al. identified a charged extracellular cavity formed by an extended S3
helix and the S3–S4 linker. This extracellular domain connects to the pore domain via hydrophobic
interactions and represents a potential extracellular modulatory site for small molecules including
pyrazole inhibitors [7].
Importantly, these advances in TRPC3 structural biology have created a basis for further advances
with TRPC3 synthetic biology in terms of optogenetics and photopharmacology as outlined below.
Availability of structural information at the atomic level will allow for tethered ligand approaches and
optogating by crosslinking domains recognized as gating elements.
6. TRPC3 Photopharmacology—A Therapeutic Perspective
Therapeutic targeting of a multifunctional signaling molecule that is expressed in a wide range of
tissues, as is the case for TRPC3 [23], typically requires refined pharmacological strategies to obtain
sufficient tissue and/or cell-type specificity for clinically useful interventions. Of note, information
on the viability in a genetic mouse model, which lacks expression of all TRPC species [72], indicated
that the nonselective and simultaneous block of multiple TRPC conductances might not necessarily
generate severe side effects in healthy tissues and organs. It is tempting to speculate that the impact of
TRPC3 in organ dysfunction is based on either a certain expression profile of TRPC genes and/or a
certain cell- or phenotype-dependent signaling signature of TRPC3, along with its closer relatives in
diseased states. Hence, gaining understanding on the cell-type specific function of these channels in
normal and pathological states is important. Cell-type specific interventions might be achievable by
manipulating TRPC3 signaling in a spatiotemporally precise manner using photopharmacology.
Initial attempts adopted the caged ligand concept to gain optical control over TRPC channels [73].
This approach was based on the availability of caged lipid activators of TRPC3/6 channels. DAGs were
fused to coumarin and nitroveratroyl molecules to prevent immediate interaction with their biological
targets [74]. A significant increase in Ca2+ was generated in HeLa cells, which endogenously express
TRPC3 and TRPC6 channels upon photorelease of the active lipid mediator with ultraviolet (UV)-A
light. Notably, caged stearyl-arachinonyl-glycerol (SAG) was found to be the most potent agonist
amongst different DAGs, consistent with the initial characterization of lipid sensitivity by Hofmann et
al. [5]. Photoreleased SAG triggered the most sustained and largest increase in Ca2+ concentrations
compared with other lipid activators, such as stearyl-linoenyl- and 1,2-dioctanoyl-glycerol. NiCl2 and
TRPC non-selective blocker SKF-96365 almost completely suppressed response in HeLa cells to lipid
uncaging, suggesting a TRPC-dependent Ca2+ influx [74].
Disadvantages of the caged-lipid approach include the principle irreversibility of the chemical
switch and the unavoidable generation of a second molecular structure represented by the released
cage. Tiapko et al. clearly showed the undesirable off-target effect with the caged lipid strategy.
Photorelease of caged 1,2-DOG was found to generate an artifact caused by UV light application
in the presence of the generated free coumarin moiety, whereas the UV light itself did not affect
membrane conductance. Hence, off-target effects, due to the phototoxicity of the caging structure,
requires consideration and is expected to limit the therapeutic value of caged ligand strategies [75].
As an alternative approach, the photochromic ligand approach has been successfully adopted
for TRPC photopharmacology [14,76]. Herein, the structure and activity of the ligand was reversibly
controlled by light. As a conformation-flexible, light-sensing structure, azobenzene was introduced into
the DAG structure. The biological activity of these photochromic activators is controlled by cis-trans
photoisomerization of the azobenzene, which resides within the aliphatic side chains of the DAG.
Azobenzene-modified DAGs successfully served as tools for studying TRPC cell-specific functions as
well as ligand-protein interactions and channel activation-deactivation kinetics [14,76–78].
Initial characterization of different photochromic DAGs demonstrated precise and reversible
control of Ca2+ signals in HeLa cells, with probes designated as PhoDAGs. PhoDAG-1 resembles
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SAG with the arachidonyl side chain replaced by a corresponding structural element containing
the azobenzene moiety. Two other structurally related lipids were predicted to functionally mimic
1,2-DOG (PhoDAG-2 and PhoDAG-3). Typically, the trans-conformation exerted little or no effect on
intracellular Ca2+, whereas cis-adopted molecules efficiently triggering Ca2+ influx through the plasma
membrane. These actions were fully reversible and allowed for precise cyclic control of the signaling
function [78].
With these new tools, Leinders-Zufall et al. demonstrated manipulation of mTRPC2 channels,
endogenously expressed in neurons of murine sensory neurons from main olfactory and vomeronasal
epithelium. As localization of these channels is confined to certain cell types and cellular structures, the
spatial precision of the new technology provided important insight into DAG-sensitive TRPC2 function
in the mouse olfactory system [76]. In another study, a photochromic DAG, containing two arachidonic
acid-mimicking photochromic moieties, designated as OptoDArG, was introduced and successfully
used to investigate the lipid sensing machinery [14]. This study used the intriguing temporal precision
of the method and uncovered not only a structural element involved in lipid recognition by TRPC3,
but also a cooperative slow gating processes, residing in a subunit interface within the pore domain.
Such cooperative gating processes are potentially important determinants of frequency dependence
of signaling, thereby generating specific signaling signatures dependent on complex composition,
cellular localization of the complexes, or upstream signaling patterns. Detailed elucidation of cell-
and phenotype-specific TRPC3 signaling features appears to be an essential next step toward the
therapeutic targeting of this molecule.
7. Conclusions
Emerging technologies for precise spatiotemporal manipulation of the activity of TRPC channels
by light, along with an increase in available structural information on drug interaction sites and gating
processes in TRPC channels, are expected to promote the development of novel therapeutic concepts.
TRPC photopharmacology will advance the field by enabling exact control over gating pattern, the
option of spatially precise manipulation, as well as by providing a basis for efficient all-optical drug
screening. As such, cell-type and tissue-specific targeting of TRPC3 and respective interventions of
therapeutic value appear feasible and are awaited.
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Abstract: During strong parallel fiber stimulation, glutamate released at parallel fiber-Purkinje cell
synapses activates type-1 metabotropic glutamate receptor (mGluR1) to trigger a slow excitatory
postsynaptic current (sEPSC) in cerebellar Purkinje neurons. The sEPSC is mediated by transient
receptor potential canonical 3 (TRPC3) channels. Often co-localized with mGluR1 in Purkinje neuron
dendrites are type B γ-aminobutyric acid receptors (GABABRs) that respond to inhibitory synaptic
inputs from interneurons located in the molecular layer of cerebellar cortex. It has been shown that
activation of postsynaptic GABABRs potentiates mGluR1 activation-evoked sEPSC in Purkinje cells,
but the underlying molecular mechanism remains elusive. Here we report that the augmentation of
mGluR1-sEPSC by GABABR activation in Purkinje neurons is completely absent in TRPC3 knockout
mice, but totally intact in TRPC1-, TRPC4-, and TRPC1,4,5,6-knockout mice, suggesting that TRPC3
is the only TRPC isoform that mediates the potentiation. Moreover, our results indicate that the
potentiation reflects a postsynaptic mechanism that requires both GABABRs and mGluR1 because
it is unaffected by blocking neurotransmission with tetrodotoxin but blocked by inhibiting either
GABABRs or mGluR1. Furthermore, we show that the co-stimulation of GABABRs has an effect on
shaping the response of Purkinje cell firing to mGluR1-sEPSC, revealing a new function of inhibitory
input on excitatory neurotransmission. We conclude that postsynaptic GABABRs regulate Purkinje
cell responses to strong glutamatergic stimulation through modulation of mGluR1-TRPC3 coupling.
Since mGluR1-TRPC3 coupling is essential in cerebellar long-term depression, synapse elimination,
and motor coordination, our findings may have implications in essential cerebellar functions, such as
motor coordination and learning.
Keywords: transient receptor potential; TRPC3; mGluR1; GABAB; EPSC; Purkinje cell; cerebellum
1. Introduction
Purkinje cells in the cerebellum serve vital functions in motor coordination and motor learning.
These neurons receive glutamatergic inputs at their extremely elaborated dendrites from parallel fibers
at the molecular layer of cerebellar cortex and send outputs to deep cerebellar nuclei in the form of
γ-aminobutyric acid (GABA) [1,2]. The excitatory postsynaptic potentials or currents (EPSPs or EPSCs)
elicited by the glutamatergic inputs in Purkinje neurons include both fast and slow components,
which have been referred to as fast EPSC (fEPSC) and slow EPSC (sEPSC) in the case of voltage-clamp
recordings [3]. While fEPSC is mainly mediated by the ionotropic glutamate receptors, sEPSC is
triggered by the activation of metabotropic glutamate receptors (mGluRs), mainly the type 1 mGluR
(mGluR1) [4]. Importantly, sEPSC only develops when the Purkinje cell receives a strong glutamate
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input, which in experimental settings requires multiple pulses of high intensity and high frequency
electrical stimulations of the parallel fibers [3,5]. This reflects high levels of glutamate release at the
parallel fiber-Purkinje cell synapses, causing a spillover of the neurotransmitter from the synaptic clefts
to activate mGluR1 abundantly present at the extra-postsynaptic sites of these synapses [6]. mGluR1
is highly expressed in the brain, particularly Purkinje cells [7,8]. The mGluR1-mediated signaling
is essential for synaptic plasticity of Purkinje cells, such as cerebellar long-term depression (LTD),
the long-lasting reduction of transmission efficiency at the parallel fiber-Purkinje cell synapses [9].
The activation of mGluR1 triggers sEPSC, which is exclusively mediated by channels made of the
transient receptor potential canonical 3 (TRPC3) protein [3].
TRPC3 is a member of the TRPC subgroup of transient receptor potential (TRP) superfamily of
cation channels. The seven members of the TRPC subgroup (TRPC1-7) function as receptor-operated,
non-selective cation channels activated downstream from the stimulation of phospholipase C
(PLC) [10,11]. Since mGluR1 is coupled to Gq/11 proteins which exert effects through PLCβ isoforms,
it is natural for TRPC channels to be a part of signaling cascades associated with mGluR1 activation.
Among all TRPCs, TRPC3 exhibits the highest expression in cerebellum, particularly Purkinje
neurons [3,4], being most abundant in the somatodendritic compartment of these neurons [3].
Disruption of TRPC3 expression not only eliminated sEPSC in Purkinje neurons [3] but also impaired
the normal cerebellar LTD induction [12]. Moreover, multiple motor deficits were observed in mice
with an altered expression of TRPC3 or ablation of the Trpc3 gene [4]. Therefore, by mediating sEPSC
TRPC3 plays an important role in cerebellar function.
In addition to mGluR1, metabotropic GABAB receptors (GABABRs) are also abundantly expressed
at the extra-postsynaptic sites of the parallel fiber-Purkinje cell synapses [13–15]. It has been reported
that in the continued activation of GABABRs, mGluR1 agonist-evoked inward current, representing
sEPSC, in cerebellar Purkinje cells is augmented [5]. However, it is not known whether the enhanced
response to mGluR1 stimulation resulted from potentiation of the mGluR1-TRPC3 coupling or
recruitment of a new channel(s); especially given that unlike mGluR1, GABABRs are coupled to
Gi/o proteins. In the present study, we used whole-cell patch clamp recordings to examine the
receptors and ion channels that underlie the potentiation of mGluR1-sEPSC by GABABRs at the parallel
fiber-Purkinje cell synapses. We found that GABABR activation still converges on mGluR1-TRPC3
coupling to augment sEPSC and this modulation helps shape the Purkinje cell firing response to
mGluR1 activation.
2. Materials and Methods
2.1. Animals and Brain Slice Preparation
All animal procedures are approved by the Animal Welfare Committee of the University of
Texas Health Science Center at Houston in accordance with NIH guidelines. TRPC3 knockout mice
were generously provided by Dr. Oleh M. Pochynyuk at The University of Texas Health Science
Center at Houston. TRPC1 knockout mice and TRPC1,4,5,6 quadruple knockout mice were generously
offered by Dr. Lutz Birnbaumer at the National Institute of Environmental Health Sciences, USA.
TRPC4 knockout mice were generously provide by Dr. Marc Freichel at Saarland University, Germany.
The TRPC knockout mice are either in C57BL/6 background or mixed C57BL/6 × 129/Sv background.
The wild-type (C57BL/6) and TRPC knockout mice used in this study were between postnatal days
17–22. Both male and female mice were used and no sex differences were found in the results. Mice
were anesthetized by isoflurane before they were sacrificed. Whole cerebellum was excised quickly
and immediately immersed into ice-cold, oxygenated artificial cerebrospinal fluid (aCSF, in mM): 125
NaCl, 26 NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 1 MgCl2, 2 CaCl2, and 10 glucose, bubbled with 5% CO2
and 95% O2 (pH 7.4). Sagittal cerebellar slices of 300 μm thickness were prepared from vermis of the
cerebellum with a vibratome (VT1200S, Leica Biosystems, Wetzlar, Germany) in ice-cold, oxygenated
40
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aCSF. Slices were recovered at 35 ◦C for 1 h and then maintained at room temperature (22–24 ◦C) in
aCSF until use.
2.2. Drug Delivery
Each cerebellar slice placed in the recording chamber was continuously perfused with the
normal aCSF unless indicated otherwise. Drugs were diluted in aCSF and applied either through
whole-chamber perfusion or by pressure ejection via a drug-delivery glass pipette positioned about
300 μm away from the targeted cell in the molecular layer of the cerebellar cortex (Figure 1A).
The pressure ejections (puffs) were delivered by TooheySpritzer pressure system IIe (Toohey
Company, Fairfield, NJ, USA) with the trigger controlled via stimulation protocols programmed
using PatchMaster software (HEKA Instruments, Holliston, MA, USA). The puff duration was 100–200
ms and the air pressure ranged 5–20 psi. The recording chamber was continuously perfused with aCSF
during the drug ejection.
 
Figure 1. Activation of postsynaptic mGluR1 by a brief ejection of DHPG to dendrites triggers sEPSC
in cerebellar Purkinje neurons. (A) Fluorescent image of a Purkinje cell loaded with Lucifer Yellow
through the recording pipette placed at soma. The location of the puffing pipette for drug ejection is
shown on the top. Scale bar: 50 μm. (B–D) Consecutive recordings of sEPSCs evoked by DHPG (30
or 100 μM, shown as 30D or 100D, respectively) from individual Purkinje cells before (left) and after
(right) application of 1 μM TTX (B), 100 μM LY367385 (C), or 10 μM MPEP (D) through whole-chamber
perfusion. Representative of 2–4 cells with similar results. Arrows point to the time when DHPG was
ejected. Scale bars: 1 s, 100 pA.
2.3. Drugs
(S)-3,5-Dihydroxyphenylglycine (DHPG), LY367385, 2-methyl-6-(phenylethynyl)pyridine
hydrochloride (MPEP), (R)-baclofen and CGP 55845 were purchased from Abcam Biochemicals
(Cambridge, MA, USA). Tetrodotoxin (TTX) was purchased from Tocris Bioscience (Minneapolis,
MN, USA). GSK2293017A was a kind gift from Prof. Xuechuan Hong (Wuhan University, China).
2.4. Electrophysiology
Glass pipettes (Sutter Instrument, Novato, CA, USA) were pulled using a Narishige PC-10 puller
(Narishige International USA, Amityville, NY, USA). Whole-cell patch clamp recordings were made
using pipettes with tip resistance of 3–6 MΩ when filled with internal solution containing (in mM):
130 K-methanesulfonate, 7 KCl, 0.05 EGTA, 1 Na2-ATP, 3 Mg-ATP, 0.05 Na2-GTP and 10 HEPES, with
pH adjusted to 7.3 by KOH and osmolarity of 300 mOsm. Purkinje cells (lobules V-VII) were visualized
using a 60x water objective lens and infrared-differential interference contrast videomicroscopy
(Olympus BX51WI with OLY-150IR video camera, Olympus America, Center Valley, PA, USA). sEPSC
was recorded in voltage-clamp mode when the cell was held at −70 mV. Membrane potential and
41
Cells 2018, 7, 90
action potential firing were recorded in current-clamp mode. Immediately before switching to current
clamp, cells were held at −45 or −50 mV. After switching to current-clamp, a constant current based
on the value in voltage-clamp mode was injected to maintain the membrane potential at the set level.
Only Purkinje cells which showed tonic firing around −50 mV were included in the firing frequency
analysis. The temperature of the recording chamber was maintained at approximately 32 ◦C by passing
the perfusion solution (aCSF) through an in-line heater (Warner Instruments, Hamden, CT, USA) at
3 mL/min driven by a RabbitTM peristaltic pump (Mettler-Toledo Rainin, Oakland, CA, USA).
2.5. Data Acquisition and Analysis
Data were acquired using an EPC10 amplifier operated by PatchMaster software (both from HEKA
Instruments). Recordings were filtered at 2.9 kHz and digitized at 10 kHz. The amplitude of the sEPSC
was measured at the time point when the inward current reached the maximum. All measurements
were made off-line using the analysis function of the PatchMaster software. Data are presented as
means ± SEM. Bar graphs were produced in GraphPad Prism 6 software (GraphPad software, Inc.,
San Diego, CA, USA). Differences are considered statistically significant when P < 0.05.
3. Results
3.1. Stimulation of Dendritic mGluR1 Evokes an sEPSC-Like Inward Current in Cerebellar Purkinje Neurons
Previous studies have shown the critical involvement of TRPC3 in mediating sEPSC of cerebellar
Purkinje cells in response to stimulation of mGluR1 [3,4]. To confirm this in mouse brain slices, we used
a pressure-driven drug ejection (puffing) system to eject varying concentrations of the mGluR1 agonist,
(S)3,5-dihydroxyphenylglycine (DHPG), towards the molecular layer of cerebellum, which consists of
dendritic trees of Purkinje cells. The response of individual Purkinje cells to DHPG stimulation
was recorded by whole-cell patch clamp technique from the soma of each neuron (Figure 1A).
As shown in Figure 1B–D (left panel), with the cells held at −70 mV under voltage clamp, the ejection
of DHPG (30–100 μM, 100–200 ms) evoked inward currents that rose slowly and lasted for >1 s.
These represent sEPSC because of the much slower kinetics of onset and longer lasting duration than
fEPSCs typically mediated by ionotropic glutamate receptors [3]. The DHPG-elicited inward current
(herein referred to as sEPSC) is independent of neurotransmission, as it was not affected by blocking
neurotransmitter release with whole-chamber perfusion of 1 μM tetrodotoxin (TTX) (Figure 1B).
Supporting the involvement of mGluR1, but not mGluR5, the DHPG-elicited sEPSC was abolished
almost completely by LY367385 (100 μM), a specific mGluR1 antagonist (Figure 1C), but not MPEP
(10 μM), a specific mGluR5 antagonist (Figure 1D), both applied through whole-chamber perfusion.
These results suggest that postsynaptic mGluR1 expressed in the dendrites of cerebellar Purkinje
neurons mediated DHPG-evoked sEPSCs.
3.2. TRPC3 Mediates the mGluR1 Activation-Evoked sEPSC in Cerebellar Purkinje Neurons
While the DHPG-evoked sEPSC in cerebellar Purkinje cells of adult mice has been shown to be
mediated by TRPC3 [3], that in developing Purkinje neurons of young animals had been suggested
to also depend on TRPC1 [16]. Given that the Purkinje cells also express other TRPC isoforms, albeit
at lower levels than that of TRPC3 [4], we also evaluated the possible involvement of several TRPC
isoforms in DHPG-evoked sEPSC under our experimental setting using transgenic mice with selective
ablation of Trpc genes. With pressure ejection of 30 and 100 μM DHPG, we detected sEPSCs in
cerebellar Purkinje neurons from brain slices prepared from Trpc1 knockout (KO) mice, Trpc4 KO
mice, and Trpc1,4,5,6 quadruple KO mice, but not that from Trpc3 KO mice (Figure 2A,B), suggesting
that among the 5 TRPC isoforms tested, only TRPC3 is involved in DHPG-elicited sEPSC response.
For both DHPG concentrations, the mean amplitudes of the sEPSCs in all transgenic lines, except for
the Trpc3 KO mice, were not different from that of wild type mice (Figure 2B), confirming again the lack
of contribution of TRPC1, C4, C5, and C6 to this response. Consistent with the absolute dependence
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on TRPC3, the strong sEPSC elicited by 100 μM DHPG in wild type Purkinje cells was abolished by
whole-chamber perfusion of GSK2293017A (2 μM), a specific TRPC3/C6 antagonist [17] (Figure 2C).
Taken together, these results confirm that TRPC3 is the sole TRPC isoform involved in mediating
sEPSC in mouse cerebellar Purkinje neurons in response to DHPG stimulation of mGluR1 under our
experimental conditions.
Figure 2. TRPC3 mediates DHPG-evoked sEPSC in mouse cerebellar Purkinje cells. (A) Representative
current traces showing responses of cerebellar Purkinje cells in brain slices from different Trpc gene
knockout mice to 30 μM DHPG (30D). C1KO, Trpc1 knockout; C3KO, Trpc3 knockout; C4KO, Trpc4
knockout; C1456KO, Trpc1,4,5,6 quadruple knockout. Note, only C3KO exhibited no response to DHPG.
(B) Bar graph showing mean ± SEM of peak amplitudes of inward currents at −70 mV elicited by
DHPG (30 and 100 μM) in Purkinje cells from wild type (WT) and Trpc knockout mice. n = 3–14 for
each group. Two-way ANOVA analysis followed by Sidak post hoc test, * P < 0.05 between 30 and 100
μM in C4KO group, ** P < 0.01 for the factor of drug concentration, no significant difference for the
factor of genotype. (C) Consecutive recordings of sEPSCs evoked by 100 μM DHPG before (left) and
after (right) whole-chamber perfusion of 2 μM GSK2293017A in a Purkinje cell from wild type mouse.
Representative of two cells with similar results. Arrows point to the time when DHPG was ejected.
Scale bars: 1 s, 100 pA.
3.3. Stimulation of GABABR Potentiates mGluR1 Agonist-Evoked sEPSC in Cerebellar Purkinje Neurons via a
Postsynaptic Mechanism
Previously, the mGluR1 agonist-activated currents in Purkinje neurons were shown to be enhanced
following the activation of GABABRs [5]. Different from mGluR1, which is coupled to Gq/11-PLCβ
signaling, the GABABRs are known to be preferentially coupled to pertussis-toxin sensitive Gi and Go
proteins [18]. Therefore, the co-stimulation of mGluR1 and GABABRs represents co-incident Gq/11
and Gi/o signaling. To test if GABABR signaling also affects the DHPG-evoked sEPSCs under our
experimental setting, we used the GABABR agonist, baclofen. Pressure ejection of baclofen (10 μM)
alone onto the molecular layer of cerebellum in brain slices from wild type mice evoked a small
and slowly developing outward current (Figure 3A), consistent with the idea that GABABRs are
inhibitory because of their coupling to Gi/o proteins [18]. The baclofen-evoked outward current lasted
as long as the drug was present and persisted for seconds even after the drug had been washed out
(data not shown, but see [13]). In the continued presence of baclofen (1–10 μM, applied through
whole-chamber perfusion), the ejection of 30 μM DHPG evoked larger sEPSC than in the absence of
baclofen (Figure 3A,B), indicating that instead of being inhibitory, the activation of GABABR actually
enhances the excitatory response of mGluR1 activation by DHPG. On average, the whole-chamber
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perfusion of 1, 3, and 10 μM baclofen all potentiated sEPSC peak amplitude elicited by 30 μM
DHPG by about double (Figure 3B), suggesting that either the potentiation only requires very weak
GABABR activation or it is easily saturable. Thus, consistent with the previous study [5], the mGluR1
agonist-induced sEPSC in cerebellar Purkinje cells is potentiated by the co-activation of GABABRs.
Figure 3. Stimulation of GABABRs potentiates DHPG-evoked sEPSC in Purkinje neurons by a
postsynaptic mechanism. (A) Representative current traces showing responses of Purkinje cells
to pressure ejection of 10 μM baclofen (10B) or the ejection of 30 μM DHPG (30D) before (upper)
and after (lower) the application of 1, 3, and 10 μM baclofen (+1B, +3B, and +10B, respectively)
through whole-chamber perfusion. (B) Bar graph showing the potentiation of 30 μM DHPG-evoked
sEPSC by 1, 3 and 10 μM baclofen. Peak sEPSC amplitudes were normalized to that before baclofen
application (set as 100% and shown by the dotted line). Shown are individual data points and summary
(mean ± SEM). One-way ANOVA analysis followed by Sidak post hoc test, no significant differences
among three baclofen concentrations. (C–F) Receptor types and postsynaptic mechanism of GABABR
action. Representative current traces showing responses of individual Purkinje cells to pressure ejection
of 30 μM DHPG before and after application of 4 μM CPG55845 (C), 100 μM LY367385 (D), 10 μM
MPEP (E), and 1 μM TTX (F) in combination with either 3 or 10 μM baclofen as indicated through
whole-chamber perfusion. Representatives of 2–4 cells with similar results. For (A,C–F), arrows point
to the time when baclofen or DHPG was ejected. Scale bars: 1 s, 100 pA.
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To confirm that baclofen indeed acted at the GABABRs to cause sEPSC potentiation in Purkinje
neurons, we applied a specific GABABR antagonist, CGP55845, together with baclofen. In the presence
of 4 μM CPG55845, baclofen (10 μM) failed to enhance the DHPG-evoked sEPSC (Figure 3C). On the
other hand, the co-application of the mGluR1 antagonist LY367385 (100 μM), but not that of the
mGluR5 antagonist MPEP (10 μM), completely abolished the generation of sEPSC in response to 30 μM
DHPG even in the presence of 3 μM baclofen (Figure 3D–E), suggesting that baclofen did not recruit a
separate mGluR subtype(s) or another DHPG-sensitive receptor type(s) to trigger a new form of sEPSC.
Therefore, the co-activation of GABABRs enhanced sEPSC triggered by the stimulation of mGluR1 in
cerebellar Purkinje neurons.
Given that GABABRs are present at both the presynaptic and postsynaptic sides of parallel
fiber-Purkinje cell synapses [5,13–15,19,20], the potentiation action of GABABRs on the DHPG-evoked
sEPSC could arise either presynaptically or postsynaptically. To clarify these possibilities, we applied
TTX (1 μM) to the brain slices through whole chamber perfusion. By blocking synaptic transmission,
TTX should inhibit the presynaptic action of GABABRs on postsynaptic currents. However, in the
presence of TTX, baclofen (3 and 10 μM) still markedly enhanced the current evoked by pressure
ejection of 30 μM DHPG (Figure 3F), suggesting a postsynaptic mechanism for the potentiation of
DHPG-evoked sEPSC by GABABR activation in cerebellar Purkinje neurons.
3.4. TRPC3 Underlies the Potentiation of sEPSC by GABABR Stimulation
The potentiation of DHPG-evoked sEPSC by the postsynaptic GABABRs could arise either from
enhancing the activity of TRPC3, which underlies the DHPG-induced inward current in cerebellar
Purkinje neurons, as shown earlier in Figure 2, or by recruiting other channels that respond specifically
to mGluR1 and GABABR co-activation. To test these possibilities, we examined the effect of baclofen
on DHPG-evoked currents in Purkinje cells of brain slices prepared from Trpc gene KO mice. We found
that while neurons from Trpc1 KO, Trpc4 KO, and Trpc1,4,5,6 quadruple KO mice showed similar
responses as the wild type neurons to DHPG and the potentiation by baclofen, those from Trpc3 KO
animals failed to develop inward currents in response to DHPG (30 μM) either in the absence or
presence of baclofen applied through whole-chamber perfusion (Figure 4A,B). Furthermore, in wild
type Purkinje neurons, the TRPC3 blocker, GSK2293017A, not only inhibited the DHPG-elicited sEPSC
in the absence of baclofen (Figure 2C) but also abolished it in the presence of the GABABR agonist
(Figure 4C). Collectively, these results suggest an exclusive dependence on TRPC3 channels on not
only the generation of sEPSC by mGluR1 agonist, but also its potentiation by postsynaptic GABABR
activation in cerebellar Purkinje neurons.
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Figure 4. Baclofen potentiates TRPC3-mediated currents evoked by DHPG in cerebellar Purkinje
neurons. (A) Representative current traces showing responses of cerebellar Purkinje cells in brain slices
prepared from Trpc1 KO (C1KO), Trpc3 KO (C3KO), Trpc4 KO (C4KO), and Trpc1,4,5,6 quadruple KO
(C1456KO), to pressure ejection of 30 μM DHPG (30D) in the absence (upper) and presence of 10 μM
baclofen (10B) applied through whole-chamber perfusion. Only C3KO neurons failed to develop the
inward current in response to DHPG no matter baclofen was applied or not. (B) Bar graph showing the
effect of 10 μM baclofen on sEPSCs elicited by ejection of 30 μM DHPG in wild type (WT) and Trpc KO
Purkinje neurons. Peak sEPSC amplitudes were normalized to that before baclofen application (set as
100% and shown by the dotted line). The values for C3KO (n = 5) could not be calculated because the
sEPSC amplitudes are all 0. Shown are individual data points and summary (mean ± SEM). One-way
ANOVA analysis followed by Sidak post hoc test did not show significant differences among different
genotypes. (C) GSK2293017A strongly inhibited sEPSC evoked by ejection of DHPG (30 μM) in the
presence of baclofen (10 μM) in wild type Purkinje neurons. Representative current trace for three
neurons. For (A,C), arrows point to the time when DHPG was ejected. Scale bars: 1 s, 100 pA.
3.5. GABABR Co-Stimulation Reshapes mGluR1-mediated Increase of Purkinje Cell Firing
Like in most brain areas, GABA is commonly considered an inhibitory neurotransmitter in the
cerebellar cortex. Upon parallel fiber stimulation, GABA is released from interneurons that make
synaptic connections with Purkinje cells. This would suppress the excitatory action of glutamate
released by the parallel fiber at the parallel fiber-Purkinje cell synapse through activation of both
ionotropic GABAA receptors and metabotropic GABABRs. The GABABR action can be both pre- and
postsynaptic, as shown by the previous study [5]. Particularly, the presynaptic action of GABABRs
is purely inhibitory, resulting in reduced glutamate release and thereby inhibition of both fEPSC
and sEPSC. By contrast, at the postsynaptic level, GABABR activation can assume both inhibitory or
excitatory roles, with the latter being dependent on mGluR1 activation and the presence of TRPC3
channels. However, exactly how GABABR potentiation of the mGluR1 activation-induced TRPC3
inward cation currents might modulate Purkinje cell function remained mysterious, as the previous
study did not attempt to separate the pre- and post-synaptic functions of GABABRs by maintaining
the constant stimulation levels of mGluR1 [5].
TRPC3 exerts a prominent effect on tonic firing frequency of Purkinje neurons [21]. Therefore,
to address the functional significance of GABABR potentiation of TRPC3 activity, we used current
clamp recording to examine how Purkinje neuron firing is altered by activating TRPC3 through
stimulation of mGluR1 in the absence and presence of GABABR activation by baclofen. Purkinje
cells in brain slices were initially held close to −50 mV, which produced spontaneous firing. When
DHPG alone was applied by pressure ejection (100 ms), a significant increase of Purkinje cell firing was
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instantly initiated along with a small baseline membrane depolarization. It took about 1 s for the instant
firing frequency to reach to a peak before the frequency winded down slowly with a time constant
(Tau) of 2.5 s (Figure 5A,C). When DHPG was applied together with baclofen, increases in firing
frequency were also observed. However, it took about 1.5 s for the instant firing frequency to achieve
the maximum, which was less robust than that evoked by DHPG alone (Figure 5B,C). On the other
hand, the decay of the firing frequency after reaching the peak was faster with the DHPG and baclofen
co-stimulation, showing a time constant of 1.04 s. In appearance, such a negative impact of baclofen
on mGluR1-TRPC3 mediated firing increase would be inconsistent with the strong potentiation of
TRPC3 sEPSC by GABABR stimulation observed in voltage-clamp recordings. However, given that
the action potentials were recorded under the current-clamp configuration, in which voltage-gated
channels are allowed to be activated, it is reasonable to assume that the stronger activation of TRPC3
was also accompanied with greater activations of Ca2+-activation and/or voltage-sensitive K+ channels
that could more quickly dampen the depolarizing effect of TRPC3. Thus, these results suggest that
the activation of GABABRs exerts a pronounced effect on shaping the TRPC3-mediated response of
cerebellar Purkinje cells to mGluR1 activation.
Figure 5. GABABRs attenuate mGluR1-TRPC3-mediated firing increase and facilitate firing recovery in
Purkinje cell. Current-clamp recordings of membrane depolarization and action potential generation
(firing) in response to pressure ejection of 30 μM DHPG (30D) alone (A) or co-ejection of 30 μM DHPG
and 10 μM baclofen (30D + 10B) (B). Lower traces are expanded regions indicated between the two
short vertical lines from the top traces. The initial holding potentials were −50 mV (A) or −45 mV
(B). Arrows in the top traces point to the time when drugs were ejected. Horizontal bars in the lower
traces mark the time period when drugs were ejected. (C) Purkinje cell instant firing frequency changes
before and after drug treatments. Co-ejection of 10 μM baclofen significantly attenuated firing increase
evoked by 30 μM DHPG in Purkinje cells. It also significantly accelerated the recovery of the firing to
the original frequency. n = 6 for each group. Two-way ANOVA analysis followed by Holm-Sidak post
hoc test, ** P < 0.01 between the two drug treatments; ** P < 0.01, * P < 0.05 at individual time points
between two drug groups.
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4. Discussion
Increasing evidence has implicated the importance of TRPC3 in cerebellar Purkinje cell function
by mediating sEPSCs in response to stimulation of mGluR1 [3,4,12]. The TRPC3 activity accelerates the
firing rate of Purkinje neurons [21]. Given that TRPC channels are generally activated downstream from
receptors that signal through PLC [4], the functional coupling between mGluR1 and the TRPC3 channel
in Purkinje neurons is not surprising. However, it is not known that TRPC3 is also regulated by Gi/o
proteins although the Gi/o-dependence has been demonstrated for TRPC4/C5 [22–24]. The current
study suggests that endogenous TRPC3 channels in cerebellar Purkinje cells are regulated by Gi/o
protein signaling, stimulated by postsynaptic GABABRs in these neurons. Our data demonstrate
that GABABR activation alone is insufficient to stimulate TRPC3, but when combined with mGluR1
activation, the GABABR-evoked signaling not only markedly enhances TRPC3 currents, but also alters
the response of Purkinje cell firing to mGluR1 stimulation.
Previously, GABABR activation has been shown to enhance mGluR1 agonist-evoked inward
currents in cerebellar Purkinje neurons [5]. The mGluR1 agonist-evoked inward currents were later
determined to be exclusively dependent on TRPC3, but not other TRPC isoforms [3], a conclusion
supported by our current study (Figure 2). We further demonstrate that the GABABR potentiation
is also absolutely dependent on TRPC3 (Figure 4), ruling out the possibility that GABABRs recruit
additional channel types that only respond to the co-stimulation of both mGluR1 and GABABRs.
Thus, GABABRs exert their potentiation effect on sEPSC through TRPC3, the same channel that
responds to mGluR1 activation. The potentiation effect of GABABRs was shown to be dependent
on Gi/o signaling with the use of N-ethylmaleimide (NEM) in the previous study [5]. Surprisingly,
the same study also suggested that the Gi/o-dependent potentiation of the inward currents was
specific for GABABRs, as stimulation of other Gi/o-coupled receptors—such as acetylcholine,
serotonin, and adenosine receptors—failed to mimic the effect of the GABABR agonist [5]. Therefore,
Gi/o protein signaling appears to be necessary but not sufficient for the potentiation of TRPC3-mediated
sEPSC. It remains to be determined whether such specificity is a result of close colocalization
between mGluR1 and GABABRs at the peripheral of parallel fiber-Purkinje cell synapse [5] or
unique signaling pathway(s) activated by GABABRs but not other Gi/o-coupled receptors. In fact,
it has been reported that in cerebellar Purkinje cells, GABABRs constitutively enhance mGluR1
signaling in a manner that is dependent on the extracellular Ca2+ concentration, but independent of
GABABR-mediated cell signaling. This presumably occurs through a direct binding of extracellular
Ca2+ to GABABRs, which alters the conformation of GABABRs and further modifies the direct
interaction between GABABRs and mGluR1, leading to an enhanced function of mGluR1 [25].
Although co-immunoprecipitation experiments suggest that GABABRs and mGluR1 form physical
association at the dendritic synapses of Purkinje cells and both mGluRs and GABABRs are atypical
(Class C) G protein-coupled receptors that only work as dimers [26], to date, no evidence suggests that
GABABRs oligomerize with mGluR1. Even if they do oligomerize, the oligomerized receptor complex
would unlikely be responsive to the GABABR agonist, as baclofen alone did not induce any inward
current, meaning that without an mGluR1 agonist, the receptor complex could not trigger TRPC3
activation. It is possible that signaling pathway(s) downstream from GABABRs is involved, which
acts either at the level of mGluR1 or that of TRPC3 (Figure 6). Indeed, mGluR1 may be sensitized
by shifting to a high affinity binding state [27] and TRPC3 can be activated via binding of β-arrestin,
one of the signaling pathways associated with the activation of Gi/o-coupled receptors [28].
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Figure 6. Diagram of GABABR-mediated potentiation of mGluR1-TRPC3 signaling pathway in
cerebellar Purkinje cells. Stimulation of mGluR1 at the dendrites of Purkinje cells activates TRPC3
channels to evoke an excitatory postsynaptic current (EPSC). The EPSC is enhanced if GABABRs
expressed on the dendrites of the same Purkinje cell are activated at the same time. The enhanced
EPSC is still mediated by mGluR1-TRPC3 coupling, presumably through enhancing mGluR1 function
and/or increasing the sensitivity of TRPC3 to mGluR1 mediated signaling in Purkinje cells.
Our results indicate that TRPC3 expressed on Purkinje cell dendrites not only responds to
postsynaptic mGluR1 activation with an inward cation current that induces membrane depolarization
but also integrates the signals from Gi/o-coupled GABABRs to shape the overall response of the
Purkinje neuron to the co-transmission of the excitatory and inhibitory neurotransmitters, glutamate,
and GABA, respectively. For the TRP channel, this appears to strengthen the channel activity,
giving rise to potentiation of sEPSC; however, the net output of this integrated co-transmission
is a better controlled time window of excitatory effect of mGluR1 activation on Purkinje neuron
firing (Figure 5). The co-stimulation of GABABRs helps shape the mGluR1-mediated firing changes
in tonic firing Purkinje neurons, by slowing down and dampening the mGluR1-mediated firing
increase and accelerating the recovery of the augmented firing (Figure 5). These results appear to be
inconsistent with the voltage-clamp recording data showing that GABABRs potentiate TRPC3 current
(enhanced sEPSC). However, considering that membrane potentials are allowed to change freely under
current-clamp but not voltage-clamp, the opposite net outcomes under the two recording modes are
not unexpected. The voltage-gated K+ channels and Ca2+-activated and voltage-sensitive K+ channels,
such as the large conductance Ca2+-activated K+ channels, are likely activated subsequent to TRPC3
and voltage-gated Ca2+ channels during action potentials. The activation of K+ channels counters the
depolarization action of TRPC3. Depending on the types of K+ channels involved and their voltage
and Ca2+ sensitivities, the net effect of TRPC3 activation can be depolarizing or hyperpolarizing, but it
is predictable that when TRPC3 is strongly activated, more K+ channels will be recruited due to the
very strong depolarization and Ca2+ influx, which will bring down the membrane potential. Therefore,
TRPC3 plays a central role in mGluR1-mediated synaptic responses, which are further modulated by
GABA input through GABABRs to shape Purkinje cell firing in the cerebellum.
It is particularly worth noting that GABABR co-stimulation with mGluR1 accelerated the recovery
of Purkinje cell firing to the original frequency (Figure 5). Such a modification may be functionally
relevant. Because of the slow development of sEPSC, as opposed to fEPSC mediated by ionotropic
glutamate receptors, the termination of sEPSC is also slow, leading to slow recovery of the tonic
firing to the original rate. This may be undesirable for the neuron as the sluggish recovery interferes
with subsequent neurotransmission. Thus, the co-activation of GABABRs helps shut off the mGluR1
effect properly in Purkinje neurons. It remains to be clarified if this effect on termination is due to
the hyperpolarization action of GABABRs through stimulating K+ channels or it is a result of TRPC3
channel potentiation. The outward current elicited by baclofen seen in the absence of mGluR1 activation
represents K+ conductance [5], but the identity of the K+ channel(s) activated in response to GABABR
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agonist in Purkinje neurons remains undefined. Although Purkinje cells express G protein-activated
inwardly rectifying K+ (GIRK) channels, the GABABR agonist-evoked outward current was unlikely
mediated by GIRK, but instead might be attributable to Ca2+-activated K+ channels [5,18]. In such a
case, the potentiated TRPC3 activity could have multiple ways to augment the activity of Ca2+-activated
K+ channels. First, the enhanced Ca2+ influx through TRPC3 could increase the K+ channel activity.
Second, the enhanced Na+ influx could induce stronger membrane depolarization, which could open
more voltage-gated Ca2+ channels for more Ca2+ influx. Third, if the large conductance Ca2+-activated
K+ channel, which is expressed in Purkinje cells, were involved, the membrane depolarization would
also intensify its activity directly because of its voltage dependence. Finally, the rise of cytosolic Ca2+
also inhibits TRPC3 channel activity via a negative feedback mechanism [29,30]. Therefore, multiple
mechanisms may act in concert to terminate the increase in Purkinje cell firing induced by mGluR1
activation in a timely manner.
Purkinje neurons represent the sole output of the cerebellar cortex. Their function is important for
various motor functions, including movement control, learning, and coordination. Both mGluR1 and
TRPC3 have been clearly shown to be critical for motor function. In mice, genetic deletion of mGluR1
leads to severe symptoms of ataxia [31]. The knockout of TRPC3 causes a less severe phenotype than
that of mGluR1 but motor coordination deficit is clearly evident [3]. In humans, motor coordination is
strongly impaired by autoantibodies against mGluR1 [32]. Patients with a point mutation of TRPC3
gene (R762H) show late-onset unidentified ataxia [33,34]. It has also been postulated that TRPC3
signaling is disrupted in spinocerebellar ataxia 1 (SCA1) disease [4]. Interestingly, autoantibodies
against GABABRs have been found in an agrypnia patient showing ataxia [35]. Although no causal
relationship has been established between the GABABR antibodies and motor coordination impairment
of this patient, the current finding that GABABRs play an important role in shaping the response
of Purkinje neuron firing to mGluR1 activation, a process mediated by the TRPC3 channel, brings
an intriguing possibility that disrupting GABABR function may interfere with motor coordination
through deregulation of mGluR1/TRPC3 mediated activities in this cell type. In addition to regulating
Purkinje cell firing frequency, sEPSC is closely associated to cerebellar LTD, a long term synaptic
plasticity change that underlies motor learning [12]. It is therefore speculated that the potentiation of
mGluR1/TRPC3 activity by GABABRs can also impact motor learning. However, the more widespread
expression of GABABRs and TRPC3 in other cell types in the cerebellum rather than just Purkinje
neurons plus the presence of both pre- and postsynaptic effects of the GABABR function make the
investigation of GABABR- and TRPC3-regulated processes in normal conditions and various diseases
very challenging [4,18,19]. Nevertheless, the finding that GABABRs and mGluR1 converge onto the
TRPC3 channel in postsynaptic transmission in Purkinje neurons should open a new avenue to help
improve cerebellar functions, such as motor coordination and learning, and combat cerebellar diseases,
for instance the various types of ataxia.
5. Conclusions
We conclude that TRPC3 is responsible for the potentiation of mGluR1 activation-evoked sEPSC
by GABABRs at the parallel fiber-Purkinje cell synapses in the cerebellum and this regulation helps
put a timed break on the sEPSC-induced increase in Purkinje cell firing.
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Abstract: Transient receptor potential classical or canonical 4 (TRPC4) and TRPC5 channels
are members of the classical or canonical transient receptor potential (TRPC) channel family of
non-selective cation channels. TRPC4 and TRPC5 channels are widely accepted as receptor-operated
cation channels that are activated in a phospholipase C-dependent manner, following the Gq/11
protein-coupled receptor activation. However, their precise activation mechanism has remained
largely elusive for a long time, as the TRPC4 and TRPC5 channels were considered as being insensitive
to the second messenger diacylglycerol (DAG) in contrast to the other TRPC channels. Recent findings
indicate that the C-terminal interactions with the scaffolding proteins Na+/H+ exchanger regulatory
factor 1 and 2 (NHERF1 and NHERF2) dynamically regulate the DAG sensitivity of the TRPC4 and
TRPC5 channels. Interestingly, the C-terminal NHERF binding suppresses, while the dissociation of
NHERF enables, the DAG sensitivity of the TRPC4 and TRPC5 channels. This leads to the assumption
that all of the TRPC channels are DAG sensitive. The identification of the regulatory function of the
NHERF proteins in the TRPC4/5-NHERF protein complex offers a new starting point to get deeper
insights into the molecular basis of TRPC channel activation. Future studies will have to unravel the
physiological and pathophysiological functions of this multi-protein channel complex.
Keywords: TRPC channels; diacylglycerol; TRPC4; TRPC5; NHERF
1. Introduction
Transient receptor potential classical or canonical 4 (TRPC4) and TRPC5 channels belong to the
transient receptor potential classical or canonical (TRPC) cation channel subfamily, which comprises
seven members. TRPC channels are regarded as non-selective, receptor-operated cation channels
that are important for calcium homeostasis. They are activated via the Gq/11-signaling cascade as
a function of phospholipase C (PLC) [1]. Moreover, the TRPC4 and TRPC5 channels can also be
activated following the Gi/o-protein coupled receptor activation [2–4]. However, the mechanism of
the Gi/o-mediated TRPC4/5 channel activation is still not completely understood and might involve
either a direct Gi/o-protein interaction [3], or the activation of the PLC isoform, PLCδ1 [2]. Even
a Gs-protein mediated activation mechanism was proposed for the TRPC5 channels [5]. Therefore,
elevating the intracellular cyclic adenosine monophosphate (cAMP) levels might potentiate the TRPC5
currents by increasing the channel trafficking to the plasma membrane. Additionally, a store-operated
activation mechanism for the TRPC4 [6–9] and TRPC5 channels [10–12] was proposed, and is still
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under discussion [13,14]. This article will only focus on the Gq/11-protein mediated signaling pathway
leading to the TRPC4 and TRPC5 channel activation.
All of the TRPC channels are tetramers formed by four TRPC protein subunits, which was
confirmed recently by structural analysis [15–18]. TRPC proteins can form not only homotetrameric
but also heterotetrameric cation channels [19–22] with distinct channel properties, such as altered
calcium permeability [21,23–25]. Because of their sequence homology, the TRPC channel family
can be divided into the following subgroups: TRPC1, TRPC4/5, and TRPC3/6/7. TRPC2 has a
special role as it represents a pseudogene in humans that is not functionally expressed because of
several stop codons in the open reading frame [26,27]. However, in rodents, the TRPC2 channels are
functionally expressed (e.g., in the olfactory cells of the vomeronasal organ, where they are important
for pheromone sensing [28]).
Although the Gq/11-protein mediated TRPC channel activation is widely accepted, the precise
signaling pathway resulting in the channel opening has remained elusive for quite some time.
The activation of the Gq/11-protein coupled receptors leads to the activation of PLC, which cleaves
phosphatidylinositol-4,5-bisphosphate (PIP2) into the second messengers, inositol-1,4,5-trisphopshate
(IP3) and 1,2-diacyl-sn-glycerol (DAG), and to an oxonium ion [29,30]. There is broad agreement that
the TRPC3/6/7 subfamily is directly activated by DAG, the cleavage product of PIP2 [31]. However,
IP3 might also contribute to the activation of endogenously expressed TRPC7 channels [32]. Notably,
a DAG binding site has not been identified until now, and it is not clear whether DAG directly activates
the channel or whether it first interacts with an additional protein, which in turn causes the channel
activation. Unfortunately, the recent structural analysis of the TRPC3, TRPC4, and TRPC6 channels
only displays a closed channel conformation [15–18]. However, the structural model of TRPC3 reveals
two lipid-binding sites, one being sandwiched between the pre-S1 elbow and the S4–S5 linker, and the
other being close to the pore-forming domain, where the conserved “LWF” motif of the TRPC family
is located [16]. Perhaps these lipid binding sites reflect potential DAG binding sites. Interestingly,
it was recently reported that the exchange of a highly conserved amino acid located close to the
pore-forming domain, affects the DAG recognition of the TRPC3 channels [33]. Thus, the second lipid
binding site might indeed reflect a potential DAG binding site. TRPC2 channels are also regarded
as being DAG sensitive [34,35]. In contrast to the TRPC2, TRPC3, TRPC6, and TRPC7 channels,
the TRPC4 and TRPC5 channels were commonly considered as DAG insensitive [31], as DAG or the
membrane permeable DAG analogue 1-oleoyl-2-acetyl-sn-glycerol (OAG) even inhibited the basal
TRPC5 currents [36]. Interestingly, Venkatachalam and colleagues showed that the DAG-induced
TRPC5 channel inhibition is related to the protein kinase C (PKC) activation [36]. Moreover,
it was demonstrated that the homotetrameric TRPC4 and TRPC5 channels are activated by PIP2
depletion [37,38]. In contrast, the heterotetrameric TRPC1/4 and TRPC1/5 [39] and homotetrameric
TRPC6 and TRPC7 channels [40] are instead inhibited by the PIP2 depletion. These contradictory
findings suggest that the TRPC channel-lipid interaction is rather complex. Another unique structural
feature of the TRPC4 and TRPC5 channels is their capability to interact with the PDZ I domain of the
scaffolding proteins Na+/H+ exchanger regulatory factor 1 and 2 (NHERF1 and NHERF2) [41–43].
The NHERF1 and NHERF2 proteins are structurally related; can form homodimers [44]; and possess
two PDZ binding domains as well as a C-terminal binding domain, which enables crosslinking with
the actin cytoskeleton via ezrin, radixin, and moesin proteins [41,45]. Thus, NHERF1 and NHERF2
proteins are commonly regarded as adapter proteins that crosslink integral membrane proteins with
the cytoskeleton, thereby increasing their membrane localization [46–48].
2. DAG-Mediated Activation Mechanism of TRPC4 and TRPC5 Channels
The first evidence that the TRPC5 channels might be DAG sensitive was presented by Lee and
colleagues, who performed electrophysiological whole-cell measurements on murine gastric smooth
muscle cells endogenously expressing TRPC5 channels, and found that the channels are activated by
OAG [49]. However, the mechanistic insights into the DAG mediated TRPC5 channel activation were
54
Cells 2018, 7, 218
missing. A remarkable structural difference between TRPC4 and TRPC5, and the well characterized
DAG sensitive TRPC3/6/7 channels, is the PDZ binding motif with the amino acid sequence “VTTRL”
at the very end of the C-terminus [41,42,50]. This PDZ binding motif includes a potential PKC
phosphorylation site, which was identified as being important for the TRPC5 current inactivation
following the receptor activation [51]. The amino acid exchange from threonine to alanine at position
972 (T972A) in the murine TRPC5 channels resulted in a loss of current desensitization during the
receptor activation with carbachol [51]. Thus, this was the first evidence that the PKC phosphorylation
might regulate the TRPC5 channel function [36,51].
The C-terminal PDZ binding motif allows for interactions with the adapter proteins NHERF1
and NHERF2. This C-terminal TRPC4/5 interaction was demonstrated several times by performing
co-immunoprecipitations and functional studies using the patch-clamp technique [41–43]. However,
only a slight enhancement of the membrane expression was found to be similar to what was
observed when analyzing the chloride channel cystic fibrosis transmembrane conductance regulator
(CFTR) [52] and other integral membrane proteins. Thus, the functional implications of the
TRPC4/5-NHERF interaction were missing. Interestingly, our recent findings indicate that the TRPC4
and TRPC5 channels are DAG-sensitive similar to other TRPC channels [53]. However, in contrast
to TRPC3/6/7, their DAG-sensitivity is tightly regulated by the C-terminal NHERF1 and NHERF2
interaction. The Gq/11-protein coupled receptor activation causes a cleavage of PIP2, resulting in
a conformational change of the C-terminus, which in turn causes the dissociation of the NHERF
proteins from the C-terminus of the channel. This dynamic dissociation was monitored employing the
method of dynamic intermolecular fluorescence resonance energy transfer (FRET) between fluorescence
tagged TRPC5 and NHERF proteins. The separation of the NHERF proteins from the C-terminus
was a prerequisite for DAG sensitivity. Moreover, the C-terminal NHERF interaction strongly
depended on the PKC phosphorylation status of the C-terminal PDZ binding motif “VTTRL” [53].
The PKC inhibition resulted in the DAG sensitivity, and the PKC phosphorylation mutant T972A
of murine TRPC5 was sensitive to DAG, suggesting that PKC phosphorylation is a prerequisite for
NHERF binding, thereby suppressing the DAG sensitivity. Thus, the NHERF proteins are dynamic
regulators of the TRPC4 and TRPC5 channel activity. This signaling pathway was also observed in the
primary cell lines (e.g., in proximal tubule cells and in hippocampal neurons, which endogenously
express TRPC4 and TRPC5 channels, respectively) [53]. This activation model has the potential to
integrate the contradictory findings of different research groups concerning the TRPC4 and TRPC5
channel activation. Therefore, the pieces of the puzzle like the PLC dependent receptor-mediated
TRPC4/5 channel activation [1], the inhibitory effect of DAG or DAG analogues [31,36] on the native
TRPC4/5-NHERF-channel complex [41–43], the activation by PIP2 depletion [37,38], the inhibitory
effect of PKC phosphorylation on DAG sensitivity [36], and the DAG sensitivity of the endogenous
gastric TRPC5 channels [49] coalesce into a consistent picture. These findings lead to a new
concept, that all of the TRPC channels are DAG-sensitive, and that classifying the TRPC channels as
DAG-sensitive and -insensitive channels should be avoided. Consequently, a common DAG binding
site for TRPC channels can be proposed. Perhaps the highly conserved amino acid near the TRPC pore
domain that affects the DAG activation [33] participates in DAG binding.
Altogether, a new model of Gq/11-protein mediated TRPC4 and TRPC5 channel activation can be
proposed. The agonist-induced Gq/11-protein coupled receptor activation causes the activation of PLC,
which in turn cleaves PIP2 into the two second messengers IP3 and DAG. The PIP2 cleavage causes
a conformational change at the C-terminus of TRPC4 and TRPC5, which results in a dissociation of
the NHERF proteins from the C-terminus, thereby evoking a DAG-sensitive channel conformation.
Then, the PIP2 cleavage product DAG can activate the channel. This model is illustrated in Figure 1.
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Figure 1. Diacylglycerol (DAG)-mediated activation of transient receptor potential classical or
canonical 4/5 (TRPC4/5) channels. Left: Na+/H+ exchanger regulatory factor (NHERF) proteins and
phosphatidylinositol-4,5-bisphosphate (PIP2) interact with the C-termini of TRPC4/5, which depicts
the closed state of the channel. Right: receptor activation (not displayed) leads to the cleavage of
PIP2, resulting in the dissociation of NHERF and in DAG binding, which represents the open state of
the channel. Sodium cations (dark green circles), calcium cations (light green circles), and potassium
cations (yellow circles) are displayed. The potassium efflux is mainly relevant in the excitable cells.
3. Physiological and Pathophysiological Roles of NHERF Proteins
NHERF1 and NHERF2 proteins belong to a family of scaffolding proteins that crosslink the
integral membrane proteins with the cytoskeleton. It is commonly accepted that NHERF proteins
increase the membrane localization of several membrane proteins, like transporters, receptors, and ion
channels [46–48]. However, besides their anchoring function, the NHERF proteins are of the utmost
importance for the maintenance of essential cellular functions (e.g., in the kidney or in the small
intestine, where they interact with transporters, ion channels, signaling proteins, transcription factors,
enzymes, G-protein coupled receptors, and tyrosine kinase receptors) [47,48,54–56]. Thus, NHERF
proteins are involved in numerous physiological processes. For example, in proximal tubule cells,
NHERF proteins regulate phosphate transport [57]. A mutation in the PDZ I domain of human NHERF1
was found in patients with impaired renal phosphate reabsorption due to a reduced expression of the
renal phosphate transporter NPT2a [58]. In astrocytes, NHERF proteins regulate the activity of the
glutamate transporter (GLAST) and of the metabotropic glutamate receptor (mGlu5) [59,60], and in
the small intestine, they control ion transport via interactions with the Na+/H+ exchanger (NHE3) [61].
Moreover, the mice lacking NHERF1 and adult humans harboring NHERF1 mutations suffer from
osteopenia [62,63], which might be due to abnormal osteoblast differentiation [64]. Furthermore,
NHERF proteins influence proliferation [65,66], and they may be involved in carcinogenesis and in
the progression of liver, breast, and colon cancer; small-cell lung carcinoma; and glioblastoma [67–70].
A mutation in the PDZ I domain of NHERF1 was identified in the patients with medullar breast
carcinoma [71]. This mutation resulted in a reduced interaction of NHERF1 with the epidermal
growth factor receptor, thereby promoting the progression of breast cancer. Another mutation in the
PDZ II domain of human NHERF1 resulted in a nuclear translocation of NHERF1, thereby inducing
carcinogenesis [72]. Recently, in the tumors from ovarian cancer patients, a mutation in the PDZ II
domain of NHERF1 was identified, which might contribute to the disease progression [73]. These data
suggest that wild-type NHERF1 may act as a tumor suppressor. The subcellular NHERF expression
also plays a critical role in cancer cells. In breast cancer cells, the subcellular NHERF expression might
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even serve as a prognostic marker, as a high cytoplasmic expression of NHERF was associated with
a high aggressiveness and poor prognosis [74]. Furthermore, aberrant nuclear NHERF1 expression
might be important for the carcinogenesis and progression of colon [74] and breast cancer [72].
The specific role of NHERF proteins for channel function is poorly understood. Beside the
regulatory role of NHERF proteins on TRPC4 and TRPC5 channel function [53], the interaction with
NHERF was identified as playing an important role in the proper function of the CFTR chloride
channel [52]. Mutations in the CFTR channel are known to cause cystic fibrosis [75], which is
characterized by the accumulation of viscous mucus, because of impaired fluid transport. Furthermore,
CFTR mutations can cause congenital absence of the vas deferens and male infertility [76]. Interestingly,
the NHERF2 interaction with the lysophosphatidic acid receptor 2 (LPAR2) promotes the assembly
of CFTR–NHERF2–LPAR2 protein complexes, which results in an impaired CFTR function [77,78].
The disruption of this protein complex might enhance the CFTR function of patients suffering from
cystic fibrosis [52]. Altogether, the NHERF proteins or their protein complexes might be interesting
novel targets for the treatment of diseases
4. Physiological and Pathophysiological Roles of TRPC4 and TRPC5 Channels
TRPC4 and TRPC5 channels are expressed in several cells and tissues (e.g., in the brain [79–83],
kidney [80,84,85], and vascular system [7,8,86]). In particular, the TRPC4 and TRPC5 channel
expression is very high in the central nervous system [7,79,82]. Here, the TRPC4 and TRPC5
channels are involved in the amygdala function and account for fear-related behavior against aversive
stimuli [87,88]. In addition, the TRPC4 and TRPC5 channels are important for peripherally induced
neuropathic pain behavior. Microinjections of the TRPC4 and TRPC5 channel blocker ML-204 into
the amygdala of rats reduced the sensory and the affective pain sensitivity [89]. Thus, in the future,
TRPC4/5 blockers that are able to cross the blood–brain barrier might be used as novel anxiolytics or
even as innovative analgesics against peripheral neuropathies. Furthermore, the TRPC4 and TRPC5
channels are expressed in the dorsal root ganglia, where they contribute to axonal regeneration after
nerve injury [90], to itching [91], and to cold detection [92].
Moreover, in the hippocampal CA1 pyramidal cells from rats, the calcium and sodium influx
through the TRPC5 channels generated a plateau potential [93] that is also observed during epileptic
seizures [94,95]. In accordance with this neurophysiological evidence, the TRPC5 gene-deficient mice
exhibited significantly reduced seizures. Thus, future studies will have to show whether TRPC5
channels represent interesting novel target structures for the treatment of epileptic disorders.
Furthermore, the TRPC5 channels reduce the hippocampal neurite length and growth cone
morphology by reducing the filopodia length growth, which leads to impaired axon guidance [96].
The TRPC5 channels also play a role in podocytes and in fibroblasts. Interestingly, in these
cells, the TRPC5 and TRPC6 channels have opposite effects on the actin cytoskeleton [97]. The
receptor-operated TRPC5 channel activation by angiotensin II decreased the number of parallel stress
fibers via the activation of the small guanosine-5′-triphosphate (GTP)ase protein Rac1, leading to a
motile and non-contractile phenotype in vitro, while the TRPC6 activation by angiotensin II increased
the formation of parallel stress fibers via the activation of the small GTPase protein Rho A, resulting in
a contractile but non-motile phenotype [97]. These differential channel functions might be due to a
specific subcellular localization of TRPC5 and TRPC6 channels in podocytes, or be caused by a distinct
signaling elicited by the podocyte-specific TRPC6 and slit membrane protein channel complex [98,99].
The reorganization of the actin cytoskeleton characterized by a reduction of the parallel stress fibers
results in podocyte injury, leading to the loss of podocyte foot processes, which in the end results
in the disruption of the slit diaphragm and in massive proteinuria [100–102]. Thus, the TRPC5
channel blockers might be useful for the treatment of podocyte diseases by preventing end-stage renal
disease [103,104].
In addition, the TRPC4 and TRPC5 channels might play a pathophysiological role in cancer
cells. The increased TRPC5 channel activity in breast cancer [105] and in colorectal cancer
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cells [106] caused an increased expression of the ABC transporter P-glycoprotein (MDR1). MDR1
is an important molecular correlate for drug-resistance against chemotherapeutic agents. For example,
MDR1 eliminates the well-known and commonly used DNA intercalating drug doxorubicin, the
tubulin-targeting drug paclitaxel, and the antimetabolite 5-fluorouracil. In breast cancer cells, the
transcription factor NFATc3, and in colorectal cancer cells, the structural protein and transcription
factor β-catenin, are thought to enhance the MDR1 expression [105,106]. In contrast, the potent TRPC4
and TRPC5 channel activator (-)-englerin A showed pronounced cytotoxic effects on diverse cancer
cell lines, with an EC50 value of ~ 20 nM [107,108]. (-)-englerin A was even effective on triple-negative
breast cancer cells [109], which do not express the drug targets of estrogen, progesterone, and human
epithelial growth factor (HER2) receptor. Of all breast cancer patients, 15% have triple-negative breast
cancer [110], which is regarded as very aggressive [111]. The main treatment is surgery, but specific
targets for target-orientated chemotherapeutic agents are missing, and patients suffer from frequent
relapses within the first three years [112]. A more targeted medical treatment would be of great
benefit for these patients. Notably, although (-)-englerin A was selectively cytotoxic to cancer cell
lines, adverse reactions were observed in mice and rats after (-)-englerin A injections [108], which were
mediated by the TRPC4/5 channels [113]. Thus, the therapeutic application of (-)-englerin A might
be limited.
There is evidence that the TRPC5 channel activity increases angiogenesis in cases of breast cancer
by the activation of the transcription factor hypoxia-inducible factor 1 (HIF-1), leading to vascular
endothelial growth factor (VEGF) formation [114], thereby promoting cancer growth. In contrast,
it was reported that the TRPC4 channel activation reduces angiogenesis in cases of renal cell carcinoma
cells by the secretion of the inhibitor of angiogenesis thrombospondin-1 [115]. Moreover, the TRPC4
and TRPC5 channel activation in the endothelial cells increases vasculogenesis [116,117], indicative of
a pro-angiogenetic effect of these channels. Furthermore, the increased expression of TRPC1, TRPC3,
TRPC4, and TRPC6 in ovarian cancer cells increased the migration and proliferation, and therefore
had a tumorigenic effect [118]. Thus, other TRPC channels, like TRPC1, TRPC3, and TRPC6, might
also function as targets for chemotherapeutic agents. However, at present, the majority of publications
point to the TRPC4 and TRPC5 channels as potential new drug targets [119].
The novel role of the NHERF adapter proteins as dynamic regulators of the TRPC4 and TRPC5
channel activity [53,120] might also be important for several other physiological or pathophysiological
processes. Interestingly, the NHERF1 protein/channel interaction is of the utmost importance for the
proper function of CFTR channels. The NHERF1 proteins stabilized and enhanced the membrane
expression of the misfolded CFTR mutant channels [121], which partially restored the channel activity
after the NHERF binding.
The TRPC4 and TRPC5 channels, and the NHERF proteins are co-expressed in various excitable
and non-excitable cells and tissues. Hence, it can be speculated that the inhibitory effect of the
NHERF interaction on the TRPC4/5 channel function may contribute to several physiological
or pathophysiological conditions. For example, in tumor cells, the TRPC4/5 channels and the
NHERF proteins and NHERF mutations account for cancer progression. However, the effect of
the TRPC4/5-NHERF protein complex on tumor growth has largely remained elusive until now.
The NHERF interaction also inhibited the DAG mediated TRPC4/5 channel activation in murine
hippocampal neurons and in proximal tubule cells [53], suggesting a regulatory role. Altogether,
further studies will be needed to show whether the TRPC4/5-NHERF protein complexes have the
potential to serve as novel target structures for therapeutics.
5. Conclusions
The new concept that all TRPC channels are DAG sensitive is not only a new starting point
for deeper insights into the activation mechanism of TRPC channels on a molecular level, but it
might also help to unravel the physiological and pathophysiological roles of these channels, which
have not been fully understood until now. On the molecular level, the conformational changes and
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the kinetics of the conformational changes leading to the TRPC4 and TRPC5 channel activation are
largely elusive, as a structure analysis only revealed the inactive channel states. Moreover, the role
of the NHERF proteins as dynamic regulators of the TRPC4 and TRC5 channel activation sheds
new light on the function of ion channels and adapter proteins in multi-protein complexes. In the
TRPC4/5-NHERF protein complexes, the NHERF proteins suppress the DAG sensitivity. Thus, for
screening purposes, wildtype TRPC5 channels as well as DAG sensitive PKC phosphorylation site
mutant T972A, which cannot interact with NHERF, might be used. Without the inhibitory NHERF
binding, it can be speculated that other hits will be identified. As the expression pattern of NHERF
proteins and TRPC4/5 channels is altered in several cancer cell lines and might be linked to cancer
progression, the TRPC4/5–NHERF channel complexes should also be reconsidered as potential
novel targets for cancer therapeutics. Future studies will have to unravel the physiological and
pathophysiological roles of these channel complexes. However, a thorough analysis of the TRPC
channel functions on a molecular level is of the utmost importance to lay the foundation for a better
understanding of the role of TRPC channels in health and disease.
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Abstract: Allergy and autoimmune diseases are characterised by a multifactorial pathogenic
background. Several genes involved in the control of innate and adaptive immunity have been
associated with diseases and variably combine with each other as well as with environmental factors
and epigenetic processes to shape the characteristics of individual manifestations. Systemic or local
perturbations in salt/water balance and in ion exchanges between the intra- and extracellular spaces
or among tissues play a role. In this field, usually referred to as elementary immunology, novel
evidence has been recently acquired on the role of members of the transient potential receptor (TRP)
channel family in several cellular mechanisms of potential significance for the pathophysiology of
the immune response. TRP canonical channel 6 (TRPC6) is emerging as a functional element for the
control of calcium currents in immune-committed cells and target tissues. In fact, TRPC6 influences
leukocytes’ tasks such as transendothelial migration, chemotaxis, phagocytosis and cytokine release.
TRPC6 also modulates the sensitivity of immune cells to apoptosis and influences tissue susceptibility
to ischemia-reperfusion injury and excitotoxicity. Here, we provide a view of the interactions between
ion exchanges and inflammation with a focus on the pathogenesis of immune-mediated diseases and
potential future therapeutic implications.
Keywords: TRPC6; elementary immunology; inflammation; calcium; sodium; neutrophils;
lymphocytes; endothelium; platelets
1. Introduction
Ion exchanges between the intra- and extracellular spaces constitute fundamental mechanisms
for the control of cell metabolism and activation state. Changes in the rate of crucial cell reactions such
as energy accumulation, protein synthesis and cytoskeleton assembly in response to environmental
stimuli are required for the long-term maintenance of homeostasis in complex organisms. Accordingly,
genes encoding proteins expressed on the cell membrane to regulate its permeability to ions are crucial
for the most complex intra- and intercellular tasks. In particular, ion channels (which account for up to
1% of the human genome [1] and allow the communication among different cells in an organism [1].
The nervous system is important to coordinate the ability of multicellular organisms to sense, adapt,
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record and possibly predict external stimuli [2]. The role of ion channels in neuronal activation has
been investigated leading to seminal discoveries on their role in physiology and disease.
The current set of human ion channels genes marks the pillars of adaptive immunity [2],
suggesting a link between ion channel specialisation and novel biological functions committed to
host defence. Consistently, growing evidence is accumulating on the ability of ions, ion channels and
transporters and their pharmacological modulators to influence the behaviour of the immune system
at the cellular and clinical level, a phenomenon also known as elementary immunology [3].
Transient receptor potential (TRP) channels comprise a wide family of membrane proteins
behaving as sodium/calcium permeable molecules. Their role in the deployment of the innate and
adaptive immune response has received growing attention [4]. In this setting, TRP canonical channel 6
(TRPC6) has emerged as a modulator of calcium homeostasis in leukocytes and tissues involved by
the inflammatory response. Here, we will review the potential mechanisms related to TRPC6 function
considering its similarities and interactions with the elements of the cellular machinery committed to
ion balance control.
2. Elementary Immunology: An Expanding Landscape
Ion channels and transporters affect immune responses [5] mainly by trimming endosomal
pH [6–9] and intracellular calcium concentrations [3,10,11] (Table 1, Figure 1). This latter mechanism
involves the intrinsic biophysical properties of a given ion channels or transporter and its ability to
allow or facilitate the passage of calcium through the cell membrane. Changes in permeability
of calcium channels or transporters can be triggered by either engagement of specific ligands
(receptor-operated calcium entry, ROCE), feedforward responses to the release of calcium from
intracellular stores (store-operated calcium entry, SOCE) and/or changes in cell polarisation
(voltage-operated calcium entry, VOCE) and in the strength of the sodium driving force.
In the majority of cells, the most significant contribution to the rise of intracellular calcium
concentrations is due to SOCE events [12–15], which are primed by the release of intracellular
calcium stores downstream cell-specific activation pathways. These latter include the B- and T-cell
receptor (BcR and TcR) or the Fc receptors pathways [15,16]. The main player in this setting is
constituted by a functional triad comprising (a) an inositol-1,4,5-triphosphate (IP3) receptor channel
expressed on the endoplasmic reticulum, which allows calcium to flow into the cytoplasm; (b) a set of
cytoplasmic sensors called stromal interaction molecules (STIM); and (c) a membrane channel, bound
to STIMs and composed of homo- or heteromers of members of the ORAI channel family [17,18].
The combination of ORAI and STIM protein is usually referred to as the calcium release-activated
calcium channel (CRAC). The generation of IP3 is due to the activity of several types of phospholipases
and is paired with the production of diacylglycerol (DAG), which in turn constitutes a ligand for
several receptor/channels [19,20]. Intracellular phospholipases are involved in the signal cascades
downstream BcR or TcR and can be modulated by the activity of ancillary ion-pathways such as those
involving magnesium or zinc interchanges between the intra and extracellular space [21–26]. Auto- or
paracrine adenosine triphosphate (ATP), adenosine diphosphate ribose (ADPR), and multiple other
chemical ligands or physical stimuli modulate ROCE [27–30].
Voltage-gated calcium channels (Cav) are required for leukocyte survival and are thought to be
responsive to variations in cell polarisation [31]. Among the Cav subtypes, those belonging to the
α1 pore-forming subunit family have been identified in lymphocytes [32]. Indirect pharmacological
evidence suggests a role of Cav in myeloid-derived cells [31]. Sodium–calcium exchangers exploit
gradients provided by the sodium-potassium ATPases to extrude calcium from the intracellular space.
However, sodium depletion and prolonged cell depolarisation promote calcium entry through these
transporters and favour cell activation [33,34].
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Figure 1. Ion channels and transporters. Ion channels and transporters may affect the behaviour of
innate and adaptive immune cells at several levels. Under resting conditions, ion gradients between the
intra- and extracellular space are actively generated through the Na/K ATPases. These gradients
are exploited by transporters (1, 2) to trim the concentrations of other ions, including calcium.
Cell activation after engagement of a cell-specific receptor (R), e.g., the BcR or TcR for lymphocytes or
the FcR for myeloid cells, promotes the deployment of downstream signalling cascades that ultimately
affect gene expression, protein synthesis and cause cytoskeletal remodelling, enabling cells to perform
effector tasks such as chemotaxis, phagocytosis and release of antimicrobial moieties or cytokines.
Activation of surface ion channels is integral to these events. A first set of ion channels are activated by
physical or biochemical stimuli such as voltage (3), intracellular osmotic pressure (4) or engagement
of extracellular (5) or intracellular (6) ligands, which in turn may be directly or indirectly induced
by the activation of cell-specific receptors. Conversely, ion currents generated by voltage-operated
or receptor-operated channels can exert feedback or feedforward effects on cell activating receptors.
Specifically, raised calcium concentrations play a prominent role in mediating cell activation. However,
to this regard store-operated calcium entry (SOCE, 7) generally provides a more significant contribution
compared to voltage-operated or receptor-operated calcium entry (VOCE, ROCE). SOCE is propitiated
by the activation of a inositol-1,4,5-triphosphate (IP3) receptor channel on the surface of the endoplasmic
reticulum (ER, 7b). Increased intracellular IP3 concentrations are part of the changes induced by cell
activation downstream cell-specific receptors (R). The release of calcium from ER stores is then sensed
by adaptor proteins such as stromal interaction molecules (STIM; 7a), which in turn activate surface
receptors (7), such as those of the ORAI family. Beside the cell surface, ion channels and transporters
can also be expressed on intracellular compartments such as the phagolysosomes (φ). In this setting,
they trim the endosomal pH, thus favouring the digestion of microbes and/or other dangerous moieties.
Gain of function mutations in the sodium–calcium exchanger 1 (NCX1) gene, highly expressed
at the level of arterial smooth muscle cells, which show a constitutionally slow recovery from
depolarisation, associate with arterial hypertension, especially in the setting of sodium overload [35,36].
Enhanced activation and pro-inflammatory differentiation of macrophages and T-lymphocytes
and enhanced formation of neutrophil extracellular traps occur in sodium-enriched extracellular
environments [37–42]. NCX1 risk alleles for salt-sensitive hypertension influences the course of
nephritis in patients with systemic lupus erythematosus (SLE) [43]. While sodium overload can
prompt NCX1 overactivity and enhanced cell activation, sodium-depleting conditions can also promote
NCX1-mediated calcium responses and induce TNFalpha release from macrophages, mimicking
lipopolysaccharide stimulation [44], and accelerate neutrophil recovery from an activation boost by
68
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increasing the speed of replenishment of intracellular calcium stores [11]. Voltage-gated potassium or
sodium channels such as Kv1.3 and Nav1.5, calcium-activated potassium channels such as KCa3.1 and
chloride channels, all play significant roles in the modulation of membrane polarisation, respectively,
favouring or limiting calcium currents [27,45–49]. Macrophages from patients with cystic fibrosis,
who have dysfunctional chloride currents due to mutations in the Cystic Fibrosis Transmembrane
Conductance Regulator (CFTR) gene, are characterised by persistent pro-inflammatory activation
and defective phagocytosis, facilitating chronic infection [50,51]. Ion channels and transporters
also selectively exert a specifying modulatory role on geographically distinct compartments within
immune-committed cells [52].
Besides the modulation of calcium currents, ion channels and transporters involved in the
modulation of protons, sodium and calcium influence the functionality of immune cells by regulating
the generation of reactive oxygen species (ROS) and interfering with the signalling pathways involved
in the processing of immune stimuli [53,54]. Sodium-based transporters are fundamental for the
modulation of energy uptake, which ultimately affect the cell lifespan [55]. Immune cells alternatively
exploit ion channels and transporters to regulate the unconventional release of cytokines such
IL-1β [29,56,57] or modulate their expression by modifying ion balances within the cell nucleus [58,59].
The variety of biochemical effects of ion channels and transporters on cell homeostasis ultimately
influences the processing of immune stimuli [15]. Persistent alterations in the control of ion exchanges
at the cellular level might ultimately contribute to hypersensitivity and autoimmunity while altered
function of ion channels and transporters might influence the ability of target tissues to cope with
inflammation-induced damage.
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3. Multiple Roles for Members of the TRP Channel Family in Inflammation
TRP channels are widely expressed and contribute to the control of cell homeostasis. Thus,
variations in the functionality of TRP might influence the physiological deployment of the immune
response [4,123,124] (Table 1). Six subgroups within the TRP family have been described in humans
according to structural homology between members: canonical (i.e., more similar to the original set
of channels isolated in Drosophila [125], TRPC), vanilloid (TRPV), analogues of melastatin-1 receptor
(TRPM), mucolipins (TRPML), polycystins (TRPP), endowed with ankyrin repeats (TRPA). The TRPN
subclass owes its name to the NO-mechano-potential C receptor of the worm Caenorhabditis elegans.
No members of this subclass have been identified in humans, with fishes being the only vertebrates in
which this TRP subclass appears to be expressed [123,126].
TRPC channels play a major role in the modulation of calcium currents. In this setting,
the formation of heteromeric complexes between different TRPC monomers might extend the spectrum
of potential effects of this subclass of TRP channels on calcium homeostasis. In particular, TRPC1,
has been proposed as a prototypic biochemical regulator for other membrane receptors thanks to its
supposed ability to form heteromers [127–130]. TRPC1 might thus affect the activity of the ORAI/STIM
complex as well as of other TRPC, such as TRPC6, to regulate SOCE. However, the evidence supporting
this hypothesis is controversial due to the lack of highly specific anti-TRPC1 antibodies and to the
need of tissue-restricted models of ORAI/STIM knockout (complete ORAI/STIM deficit is lethal at
the embryonic stage in mice) [127]. TRPC1 is highly expressed in the endothelium, where it enhances
vascular permeability after TNF/thrombin stimulation [65–67]. The potential ability of TRPC1 to
orchestrate the function of other calcium channels is crucial for the maintenance of an intracellular
calcium gradient for neutrophil chemotaxis in experimental models [52]. Animal models also suggest
that TRPC1 plays a role in the control of IL1β release from macrophages [57]. Similarly, TRPC1 might
affect the late effects of anaphylaxis by controlling TNF release from mast cells [121].
TRP channels play an even more relevant role as receptor-operated channels. TRPM2 and TRPC3
are expressed in a wide range of immune cells, including macrophages and lymphocytes, and play a
role in T-cell activation after TcR engagement [69,70,76]. TRPM2 is responsible for a significant fraction
of calcium currents within endothelial cells and neutrophils [71]. Accordingly, mice lacking TRPM2
show reduced neutrophil infiltrate and less extensive damage following myocardial infarction [72,73].
The main ligand of TRPM2 is ADPR, which lies downstream an intracellular stress-response pathway
to ROS. ADPR-mediated activation of TRPM2, in turn, promotes the final step of a regulatory feedback
loop that leads to the inhibition of NADPH-oxidase. This process is crucial in macrophages to
control the extent of oxidative stress generation during the inflammatory response [54,74]. In this
setting, lysosomal expression of TRPM2 is also required for phagocytosis [71,75]. In contrast to the
anti-inflammatory effects of TRPM2 on macrophage activity, the role of TRPC3 on macrophage-driven
inflammation is less clear. TRPC3 can be activated by DAG and is thought to contribute to vascular
inflammation [77,78]. On the other hand, upregulation of TRPC3 downstream the pathway of
brain-derived neurotrophic factor might have a protective role against neuronal inflammation and
myocardial injury [28,91,92].
TRPV1 contributes to T cell activation by associating to TCR and responding to its engagement
with increased calcium flux towards the intracellular space [95], whereas TRPV2 is upregulated
by FCγR activation in macrophages and is involved in the deployment of phagocytosis and
chemotaxis [96]. A recent study suggests that clustering of TRPV2 in lipid rafts is crucial for bacterial
phagocytosis and is defective in patients with cystic fibrosis [51]. TRPM7 has also a crucial role in
macrophage activation and is required for the physiological development of functional B- and T cells.
Similar to the role of MagT1 receptor in T cells, TRPM7 responds to variation in Mg2+ concentrations
(itself being more permeable to Mg2+ than to Ca2+) and enhances phospholipase activity downstream
the BCR/TCR [98,99]. In addition, TRPM7 is crucial for mast cell survival and activation [100,101] as
well as for macrophage survival and alternative activation [102]. TRPM7 might work by sensitising
leukocytes to relatively low Mg2+ levels, rather than responding to acute variations in the concentration
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of the cation [103]. This is consistent with the evidence of lon8g-term, rather than sudden effects of
TRPM7 deletion on leukocytes, with the partial compensatory role of exogenous Mg2+ [24] and with
the clinical efficacy of MgSO4 in acute allergic reactions.
TRPC5, TRPV5 and TRPV6 have also been proposed to mediate calcium-dependent activation of
leukocytes, although their precise pathways of activation have been less clearly defined [93,94,97,131–133].
TRPM4 exerts an inhibitory effect on calcium currents by promoting membrane depolarisation
through calcium-induced sodium entry in macrophages and mast cells [105,106]. In addition,
thanks to differential expression levels, TRPM4 exhibits distinct regulatory effects in Th1 and Th2
lymphocytes [107].
4. TRPC6 and Immune Responses
TRPC6 is a member of a TRP subgroup with a probable dual role in SOCE and ROCE (Table 1) [20].
The fraction of calcium currents sustained by TRPC6 varies according to the inciting stimulus and
to the cell type [134]. Evidence from neoplastic cell lines suggests that TRPC6-related calcium
currents are crucial for the survival and activation of a multitude of histotypes [135–140]. The main
physiological agonist of the receptor in the setting of ROCE is DAG. Conversely, endocytosis is the
main mechanism for regulating TRPC6 function [141]. TRPC6 is expressed in a wide range of cell
types, including neutrophils, lymphocytes, platelets and the endothelium (Table 1, Figure 2) [5].
During the acute phase response, TRPC6 plays a crucial role in neutrophil mobilisation as it
enhances macrophage inflammatory protein 2 (MIP-2)- and CXCR2-related chemotactic responses by
increasing Ca2+ concentration within the intracellular space and promoting actin-based cytoskeleton
remodelling [79,80].
During trans-endothelial leukocyte migration TRPC6 acts on the endothelial side by mediating
the downstream effects of platelet/endothelial cell adhesion molecule (PECAM/CD31) engagement,
thus modulating endothelial permissibility [81]. TRPC6 contributes to loosen the endothelial junctions
during acute inflammation, enhancing the effects of cellular and humoral immune mediators on
target tissues [82,83]. Histamine-induced vascular leakage, which constitutes the core pathogenic
mechanism in an acute hypersensitivity response, is also dependent on TRPC6, at least in animal
models [142]. Finally, TRPC6 cooperates in lipopolysaccharide-induced endothelial activation after
being itself activated by increasing intracellular concentrations of DAG, downstream the activation of
Toll-like receptor 4 [143]. TRPC6 expressed on macrophage phagolysosomes is thought to promote
their acidification and ultimately favour anti-microbial responses [8]. Chronically stimulated lung
macrophages from patients with chronic obstructive pulmonary disease (COPD) express TRPC6 at
high levels [144].
Calcium currents within T-lymphocytes are influenced by TRPC6 [145,146]. TRPC6 knockout
dampens Th2-driven hypersensitivity responses in sensitised mice after airway allergen
re-challenge [147] while sustained inward calcium currents due to TRPC6 may be indispensable
for antimicrobial T cell responses during sepsis [148]. Notably, inhibitors of TRPC6 also have protective
effects on the development of lymphocyte apoptosis [84]. This finding is in line with observations from
others and us on the potential modulatory role of TRPC6 on cell death. TRPC6 influences endothelial
apoptosis in an experimental model of atherosclerosis [148] and we observed that polymorphic gene
variants of TRPC6 associate with susceptibility to apoptosis of peripheral blood mononuclear cells and
diverging responses to the pharmacological inhibition of the channel in patients with SLE [84].
Enhanced apoptosis and unbalanced cell debris production to clearance ratios are fundamental,
often calcium-dependent, events in autoimmunity, especially in the setting of SLE [149–152], a systemic
autoimmune disease characterised by the production of autoantibodies against cell nuclear components
and inflammatory manifestations involving multiple tissues and organs, such as skin and mucosal
surfaces, joints, kidneys, serosae, central and peripheral nerves as well as circulating blood cells.
TRPC6 gene variants might influence the secretory profile of SLE lymphocytes [84]. Retrospective
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clinical data from a well-characterised cohort of patients with SLE suggests the association between
TRPC6 genetic polymorphisms and the risk of developing neuropsychiatric manifestations [85].
Figure 2. Effects of TRPC6 on immune cells. Activation of TRPC6 plays a critical role in the control
of key cellular functions in several immune-committed cells, such as neutrophils (panel (A–D)),
lymphocytes (panel (E–G)), macrophages (panel (H)), platelets (panel (I–L)) and the endothelium (panel
(A–D,L)). TRPC6 contributes to neutrophil activation, adhesion to the vascular walls and extravasation
by enhancing the stimulatory effects on chemo-attractants such as MIP-2 and CXCR2 (A); by promoting
the downstream effects of endothelial cell adhesion molecules such as platelet/endothelial cell adhesion
molecule (PECAM; (B)) or surface sensors of pro-inflammatory stimuli such as TLR-4 (D); by favouring
the signal cascades that lead to looser transcellular junction between endothelial cells (C). Enhanced
TRPC6 activation in lymphocytes might accelerate apoptosis, which could constitute a further trigger
for inflammation in autoimmune disorders such as SLE (E). The expression of TRPC6 in T cells promotes
cytokine release (F) and cell activation (G), which eventually translate in more aggressive inflammatory
or allergic responses. In macrophages, TRPC6 is required for the acidification of endophagolysosomes
(H). Platelets express high amounts of TRPC6 and might exploit its activation within ROCE (I,J) or SOCE
(K) to undergo activation. Receptor-operated stimulation of TRPC6 downstream the thromboxane A2
(TXA2) pathway might be responsible for surface expression of crucial adhesion molecules such as
GPIIb-IIIa or P-selectin (J) and for the release of platelet dense granules (J). This latter event might
also occur as the result of TRPC6 activation after mobilisation of calcium from intracellular stores
(K). Whether these events might impact on the interaction between platelets, leukocytes and the
endothelium is still unknown (L).
Megakaryocytes and platelets abundantly express TRPC6 on the plasma membrane [153]. TRPC6
promotes calcium entry after being activated by intracellular ligands such as DAG. TRPC6-mediated
ROCE in human platelets is restricted to the thromboxane pathway and might induce the expression of
surface molecules such as glycoproteins IIb-IIIa or P-selectin and the release of platelet-dense granules.
TRPC6 might also be involved in dense granules secretion downstream the thrombin receptors pathway
through SOCE [68]. These events play a role in haemostasis and accordingly, prolonged bleeding
time and delayed formation of clots have been observed after TRPC6 inhibition or genetic deletion in
mice [154,155]. However, evidence from murine models is controversial, as other authors reported
normal platelet function and haemostasis in TRPC6 knockout mice [153]. Platelets are part of an
interactive network that involves the endothelium and circulating leukocytes and sustains acute and
long-term inflammatory responses [156,157]. While evidence has been provided to support a potential
77
Cells 2018, 7, 70
place for TRPC6 as a target for anticoagulation [154], little is known about the impact of TRPC6
inhibition in modulating platelet–leukocyte interactions and related clinical phenotypes [158–161].
5. Effects of TRPC6 Activation and Function on Inflamed Tissues
TRPC6 is a modulator of tissue susceptibility to inflammatory injuries. The channel is expressed
in the lungs and is involved in the pathogenesis of ischaemia-reperfusion lung injury [162], septic
acute lung injury [143] and idiopathic pulmonary arterial hypertension [163,164]. These events reflect
the prominent expression and homeostatic action of TRPC6 on the lung vasculature, in particular
at the level of the endothelium and of pulmonary artery smooth muscle cells [163,165]. TRPC6
might also play a role in the biology of other lung-residing cells [136]. Hypoxia-induced elevation of
DAG vascular smooth muscle cells promotes ROCE through TRPC6 and subsequent vasoconstriction,
which eventually exacerbates ischaemia [166]. Similar vasomotor effects have been demonstrated
in aortic smooth muscle cells [167,168] and in the medial layer of coronary arteries in porcine
models [169]. In addition, TRPC6-dependent surges in intracellular calcium concentrations contribute
to the susceptibility of cardiomyocytes to ischaemia-reperfusion injury [170,171] and to long-term
maladaptive responses leading to cardiac remodelling [172,173].
Animal models in which TRPC6 expression had been silenced revealed that TRPC6-mediated
cellular responses prevented necroptosis of renal tubular epithelial cells [174], suggesting that TRPC6
contributes to protect the kidney from ischemia-reperfusion injury. Downregulation of TRPC6
influences the ability of mesangial cells to contract following angiotensin II stimulation [175,176]
while overactive TRPC6 in podocytes promotes cytoskeletal remodelling due to sustained increased
intracellular calcium concentrations with podosome disassembly and eventual proteinuria. Gain of
function mutations of TRPC6 have been associated with familial forms of focal segmental glomerular
sclerosis [177,178]. TRPC6 inhibition improves protein retention in rat models of nephrosis, suggesting
that aberrant TRPC6 function might also exacerbate the clinical picture of patients with acquired forms
of glomerular injury [179,180]. Accordingly, higher levels of TRPC6 RNA were found in urines of
patients with more aggressive forms of lupus nephritis in a pilot study [181]. More recently, TRPC6
has also been implicated in the pathogenesis of tubular interstitial fibrosis [182].
These latter observations are consistent with the wider role of TRPC6 in sustaining wound
healing and tissue remodelling responses after injury. In particular, in line with its role as a promoter of
vascular smooth muscle cell contraction, TRPC6 is required for myofibroblast trans-differentiation from
resting fibroblasts [183]. Recent evidence suggests the implication of this phenomenon in pulmonary
fibrosis [184] and in intestinal strictures in patients with Crohn’s disease [185].
TRPC6 is expressed in neuronal tissues. TRPC6 activity in the nervous system seems to contrast the
sequelae of brain ischaemia and reperfusion. Neurons are protected from post-ischaemic excitotoxicity
by an indirect effect of TRPC6 on NMDA receptors [186,187] while under ischaemic conditions,
TRPC6 degradation is enhanced in murine neurons by an IL17-dependent pathway. Inhibition of
IL17 or of the downstream proteolytic enzyme calpain restores TRPC6 functions and reduces the
area of post-ischemic necrosis [188]. A role for TRPC6 in modulating synaptic plasticity [189,190] and
enhancing microglial activation [62] has been proposed.
6. Conclusions
The modulation of salt–water balance and electrolyte exchanges between the intra- and
extra-cellular space has effects on the deployment of the immune response. Among the ion channels
and transporters concurring to define the shape of the landscape of elementary immunology, TRPC6
seems to play a role in the regulation of several inflammatory events. More robust evidence from
controlled human studies is required to pave the way to possible applications of TRPC6 as a target for
diagnostic assessment or therapeutic intervention.
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Abstract: The chemosensory transient receptor potential ankyrin 1 (TRPA1) ion channel perceives
different sensory stimuli. It also interacts with reactive exogenous compounds including the chemical
warfare agent sulfur mustard (SM). Activation of TRPA1 by SM results in elevation of intracellular
calcium levels but the cellular consequences are not understood so far. In the present study we
analyzed SM-induced and TRPA1-mediated effects in human TRPA1-overexpressing HEK cells
(HEKA1) and human lung epithelial cells (A549) that endogenously exhibit TRPA1. The specific
TRPA1 inhibitor AP18 was used to distinguish between SM-induced and TRPA1-mediated or
TRPA1-independent effects. Cells were exposed to 600 μM SM and proteome changes were
investigated 24 h afterwards by 2D gel electrophoresis. Protein spots with differential staining
levels were analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
and nano liquid chromatography electrospray ionization tandem mass spectrometry. Results were
verified by RT-qPCR experiments in both HEKA1 or A549 cells. Heat shock 70 kDa protein 6 (HSPA6)
was identified as an SM-induced and TRPA1-mediated protein. AP18 pre-treatment diminished the
up-regulation. RT-qPCR measurements verified these results and further revealed a time-dependent
regulation. Our results demonstrate that SM-mediated activation of TRPA1 influences the protein
expression and confirm the important role of TRPA1 ion channels in the molecular toxicology of SM.
Keywords: 2D gel electrophoresis; AP18; HEK293; HSP70; MALDI-TOF MS(/MS); nanoHPLC-ESI
MS/MS; proteomics; sulfur mustard; TRPA1
1. Introduction
The chemical warfare agent sulfur mustard (SM) causes severe damage to the skin, eyes, and the
respiratory system [1,2]. Although SM and the associated injuries have been intensively investigated
over decades, the molecular toxicology is still not understood in detail. In aqueous environments,
SM forms a highly reactive sulfonium and subsequent carbenium ion [3]. A plethora of nucleophiles
including the N7 atom of guanine bases in the DNA helix are targeted by SM. Monofunctional DNA
alkylation and in particular DNA crosslinks were regarded as the exclusive mechanism of toxicity.
However, Stenger et al. demonstrated that the alkylating substances CEES (2-chloroethyl-ethyl sulfide,
a mono-functional SM analogue) and SM activate transient receptor potential ankyrin 1 cation channels
(TRPA1) in vitro, thereby affecting cell viability [4].
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TRPA1 channels belong to the TRP channel superfamily and are located in the plasma membrane
of different human cell types, predominantly of neuronal cells [5].
They usually form homotetramers, but heterotetramers with TRPV1 have also been described [6,7].
TRP channels share the overall architecture of voltage-gated ion channels with six transmembrane
domains (TMs). TM5 and TM6 form the pore region that is permeable for monovalent K+, Na+ and
bivalent Ca2+ or Mg2+ cations [8]. The intracellular N-terminus of TRPA1 possesses multiple
characteristic ankyrin repeat domains that contain free cysteine residues that are important for channel
activity [9]. The physiological function of TRPA1 is the perception of sensory stimuli like pain and
cold but also of certain reactive chemicals such as acrolein, a highly reactive substance present in tear
gas or vehicle exhausts [10–12]. The activation of TRPA1 by reactive compounds is assumed to rely on
covalent modification of cysteine residues in the ankyrin repeat sequence [9,10,12]. Reactive oxygen
species (ROS), hypochlorite and protons were also identified as TRPA1 activators [13–18]. The latter
seem to interact with an extracellular interaction site of TRPA1 and not via modification of intracellular
cysteines [13].
The highly reactive SM and CEES were also identified as distinct TRPA1 activators with a not yet
identified binding site [4,19]. Both chemicals provoked a TRPA1-dependent increase of intracellular
calcium levels ([Ca2+]i) that could be efficiently prevented by pre-incubation with the TRPA1-specific
blocker AP18 [4,19]. There is some evidence that TRPA1 activation is involved in the molecular
toxicity of alkylating compounds [4,20,21]. However, the cellular consequences of an SM-induced
and TRPA1-mediated elevation of [Ca2+]i have not been investigated in detail so far. In the present
study we analyzed TRPA1-dependent effects after SM exposure in human TRPA1-overexpressing HEK
cells (HEKA1). Proteome changes were analyzed by 2D gel electrophoresis (2D-GE) with subsequent
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS(/MS))
and nano high performance liquid chromatography electrospray ionization tandem mass spectrometry
(nanoHPLC-ESI MS/MS). AP18 was used to distinguish between TRPA1-dependent and -independent
effects on protein expression. Results were validated by RT-qPCR in HEKA1 cells and as well as in
human A549 lung epithelial cells endogenously expressing TRPA1 channels [22–24].
2. Materials & Methods
2.1. Chemicals
SM was made available by the German Ministry of Defense and integrity as well as purity
was proved by NMR in house. Allylisothiocyanat (AITC), iodoacetamid (IAA), ethanol (EtOH),
glycerol, glycine, trifluoroacetic acid (TFA), acetonitrile (ACN), penicillin/streptomycin (P/S) and
Trypsin Profile IGD Kit for proteolysis of protein spots were obtained from Sigma-Aldrich (Steinheim,
Germany). 2D-Clean-UP Kit, Silver Staining Kit (protein), 2D-Quant-Kit and Coomassie Brilliant
Blue Solution were obtained from GE Healthcare (Freiburg, Germany). Bromophenol blue and
sodium dodecyl sulfate (SDS) were purchased from Bio-Rad (Munich, Germany). RT2 First
Strand Kit, RT2 SYBR Green/ROX qPCR Mastermix, RNeasy Protect Mini Kit and RT2 Custom
Profiler PCR 96-well plates with specific customized primers were purchased from QIAGEN
Sciences (Venlo, The Netherlands). Dulbecco’s minimal Eagle medium (DMEM), fetal bovine
serum (FBS), trypsin–EDTA (ethylenediaminetetraacetic acid) and phosphate-buffered saline (PBS)
were obtained from Life Technologies (Gibco, Karlsruhe, Germany). AP18 was delivered by
Bio-Techne (Wiesbaden-Nordenstadt, Germany). α-cyano-4-hydroxycinnamic acid (CHC) as matrix
for MALDI-TOF measurements was obtained from Bruker Daltonics (Bremen, Germany).
2.2. Cell Culture
HEK293 wild-type cells (introduced as HEKwt) and HEK293-A1-E cells (introduced as
HEKA1) with a stable expression of human TRPA1 (hTRPA1) were kindly donated by the
Walther-Straub-Institute of Pharmacology and Toxicology (Ludwig-Maximilians-Universität, Munich).
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Cells were grown in DMEM containing 4.5 g/L glucose, Earl’s salts and L-glutamine. This medium was
supplemented with 10% FBS (v/v) and 1% P/S (v/v). Cells were cultured in a humidified atmosphere
at 5% (v/v) CO2 and 37 ◦C (standard conditions). HEKwt cells were split every 2–3 days while HEKA1
cells were subcultivated every 3–4 days. Cells were detached using trypsin-EDTA for 3 min and
resuspended in the respective medium. A549 cells were grown in DMEM (Biochrom, Berlin, Germany)
supplemented with FBS (Biochrom, Berlin, Germany) and gentamycin (5 μg/mL). Cells were split
every 2–3 days detached by trypsin-EDTA for 5 min.
2.3. Sample Preparation
HEKwt, HEKA1 or A549 cells were exposed to 600 μM SM according to Stenger et al. [4,19].
A concentration of 25 μM AITC was used to stimulate HEKwt and HEKA1 cells. Cell lysates
of SM-exposed or AITC-treated cells were generated at 24 h for 2D-GE. Pre-incubation with the
TRPA1-specific inhibitor AP18 (2 μM, application 5 min prior to SM or AITC exposure) was also
performed according to Stenger et al. for all groups [4]. Controls were incubated without AITC or
SM but with medium and, if applicable, with AP18. After the respective incubation time, cells were
washed with PBS first and then harvested with trypsin-EDTA for 3 min and resuspended in 10 mL
DMEM. Cell number was determined using a Neubauer counting chamber (NanoEnTek, Seoul, Korea).
Cells were lysed in lysis buffer (7 M urea, 2 M thiourea, 4% w/v CHAPS, 2% v/v IPG buffer, 40 mM
DTT) for 2D-GE. Samples were sonicated (4 cycles with 10 s) on ice. Supernatants were collected after
centrifugation (30 min, 4 ◦C and 21,130 RCF) and subsequently cleaned up using the 2D Clean-Up Kit
according to the manual of the provider. Protein concentration was determined using the 2D-Quant
Kit. Samples were aliquoted and frozen at −80 ◦C.
For RT-qPCR, HEKA1 cells were investigated 1, 3, 5, or 24 h after exposure while HEKwt and A549
cells were analyzed after 24 h only. Approx. 10 × 106 cells were collected in 1 mL of RNA protection
reagent from QIAGEN (Hilden, Germany) at the respective time points. RNA was extracted using
the RNeasy Mini Protect Kit (QIAGEN, Hilden, Germany) according to the instructions given by the
manufacturer. In brief, cell pellets were lysed in 600 μL RLT lysis buffer and homogenized using a QIA
shredder (QIAGEN). RNA was precipitated in 600 μL 70% (v/v) EtOH and purified by washing several
times in different buffers according to the manufacturer’s protocol. The concentration of RNA was
measured using the NanoDrop 8000 Spectrophotometer from Thermo Scientific (Schwerte, Germany).
2.4. 2D Gel Electrophoresis and Image Analysis
IPG strips (Immobiline Drystrips 7 cm, pH 4–7 or pH 6–11, linear, or pH 3-11 non-linear,
GE ealthcare, Chicago, IL, USA) were rehydrated with 8 M urea, 2% (w/v) CHAPS, 0.5% (w/v)
DTT, 0.5% (v/v) IPG buffer together with 60 μg for pH 4–7 strips, 150 μg for pH 6–11 strips or 6 μg for
pH 3–11 strips of the protein lysates. Following rehydration loading for approx. 17 h in an Immobiline
DryStrip IPGbox (GE Healthcare), first dimension isoelectric focusing (IEF) was performed using an
Ettan IPGphor II (GE Healthcare) for 8 kVh at a maximum voltage of 5000 V and a limiting current of
50 μA/strip. Afterwards, gel strips were equilibrated in 10 mg/mL DTT equilibration buffer (6 M urea,
75 mM Tris-HCl pH 8.8, 29.3% v/v glycerol, 2% w/v SDS) for 15 min and afterwards in 25 mg/mL
IAA equilibration buffer for further 15 min. Strips were transferred on 10% Bis-Tris gels (Thermofisher
Scientific, Waltham, MA, USA), sealed with agarose sealing solution (25 mM Tris base, 192 mM
glycine, 0.1% w/v SDS, 0.5% w/v agarose, 0.002% w/v bromophenol blue) and separated in a second
dimension according to electrophoretic mobility with constant voltage of 180 V for 1 h (SDS-PAGE).
Proteins separated by pH 4–7 strips or pH 6–11 strips were then stained with colloidal Coomassie
Brilliant Blue (CBB, GE Healthcare) for 35 min and scanned on a Microtek Bio-5000 scanner (Serva,
Heidelberg, Germany). Proteins separated on pH 3–11 strips were stained using the Silver Staining
Kit (GE Healthcare). In short, gels were soaked in fixing solution (30% v/v EtOH, 10% v/v glacial
acetic acid) for 60 min and then sensitized in sensitizing solution (30% v/v EtOH, 5% w/v sodium
thiosulphate, 6.8% w/v sodium acetate) for a further 60 min. After washing with distilled water for
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four times, silver solution (2.5% w/v silver nitrate solution) was added for 60 min. A developing
solution (2.5% w/v sodium carbonate, 37% w/v formaldehyde) was added until spots reached desired
intensity. Then, gels were transferred to a stopping solution (1.5% w/v EDTA-Na2) before a preserving
solution (30% EtOH, 87% w/w glycerol) was added. Gels were scanned on a Microtek Bio-5000 scanner
(Serva, Heidelberg, Germany).
Protein spots with significant different staining levels were identified using Progenesis SameSpots
software v5.0.0.7 (Nonlinear Dynamics, Newcastle, UK). Threshold levels were defined with a fold
change > 2.0 and an ANOVA p value < 0.05. Spots were filtered to identify only those which applied to
both criteria. At least 3 biological replicates were investigated for each group. EtOH solvent control
gels were chosen as reference.
2.5. MALDI-TOF MS(/MS) or NanoHPLC-ESI MS/MS Analysis
Relevant protein spots were excised and proteolyzed in-gel using the trypsin profile IGD kit
(Sigma-Aldrich). In brief, the gel piece was covered with 200 μL destaining solution and incubated
at 37 ◦C for 30 min. The gel piece was dried before 20 μL (0.4 μg of trypsin) of the prepared trypsin
solution and 50 μL of the trypsin reaction buffer were added. It was incubated overnight at 37 ◦C.
Following tryptic cleavage, peptides were desalted and concentrated using ZipTip-C18 pipette tips
(Merck Millipore, Darmstadt, Germany). First, ZipTip was equilibrated using 10 μL methanol and
10 μL 0.1% (v/v) TFA. Afterwards, sample was loaded by pipetting the digested protein up and down
for 10 times. ZipTip was washed with 10 μL 0.1% (v/v) TFA before sample was eluted with 10 μL of
acetonitrile/0.1% (v/v) TFA (80/20 v/v). Using the dried-droplet technique, samples were spotted
onto a polished steel target by mixing 1 μL each of sample and CHC (5 mg/mL in a 1:2 mixture of
ACN and 0.1% v/v TFA).
MALDI-TOF MS(/MS) measurements were performed in the positive reflector ion mode using an
Autoflex III smartbeam mass spectrometer (Bruker, Billerica, MA, USA) equipped with a modified
pulsed all-solid-state laser 355 nm (Bruker Daltonics). A peptide mass fingerprint (PMF) was recorded
in a mass range from m/z 900–3400 with the following settings: Ion source I, 19 kV; ion source II,
16.5 kV; lens, 8.3 kV; reflector I, 21 kV; reflector II, 9.75 kV. MS/MS experiments were executed in the
LIFT mode with the following parameters: Ion source I, 6 kV; ion source II, 5.3 kV; lens, 3.0 kV; reflector
I, 27 kV; reflector II, 11.6 kV; LIFT I, 19 kV; LIFT II, 4.2 kV.
The mass spectrometer was calibrated using the peptide standard mixture of bradykinin (1–7),
angiotensin II, angiotensin I, substance P, bombesin, renin substrate, ACTH clip (1–17), ACTH clip
(18–39) and somatostatin (peptide calibration standard II, Bruker Daltonics).
Mass spectra were recorded using the flex control software v.3.0 (Bruker, Billerica, MA, USA) and
further processed by flex analysis v.3.0 and BioTools v.3.1.2.22 (both Bruker). Identification of proteins
was achieved via the SwissProt protein database using MS ion search of the Mascot search engine
(Matrix Science, London, England) with following search criteria: Taxonomy Homo sapiens (human),
enzyme trypsin, fragment mass tolerance 0.1%, significance threshold p < 0.05, maximum number of
hits 20.
Protein spots that could not be identified by MALDI-TOF MS(/MS) were analyzed by more
sensitive nanoHPLC-ESI MS/MS (proteome factory AG, Berlin, Germany). The LC MS/MS system
consisted of an Agilent 1100 nanoHPLC system (Agilent, Waldbronn, Germany), PicoTip electrospray
emitter (New Objective, Woburn, MA, USA) and an Orbitrap XL mass spectrometer (ThermoFisher
Scientific, Bremen, Germany). Peptides were first trapped and desalted on the enrichment column
(Zorbax 300SB-C18, 0.3 × 0.5 mm, Agilent, Santa Clara, CA, USA) for five minutes (solvent: 2.5%
ACN/0.5% formic acid). Then, they were separated on a Zorbax 300SB-C18, 75 μm × 150 mm column
(Agilent) using a linear gradient from 15% to 40% B (solvent A: 0.1% formic acid in water, solvent
B: 0.1% formic acid in ACN). Ions of interest were data-dependently subjected to MS/MS according
to the expected charge state distribution of peptide ions. MS/MS data were matched against the
SwissProt protein database using MS/MS ion search of the Mascot search engine (Matrix Science,
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London, UK) with following parameters: Enzyme trypsin, fixed modifications carbamidomethyl (C),
variable modifications deamidated (NQ) and oxidation (M), mass values monoisotopic, peptide mass
tolerance 3 ppm, fragment mass tolerance 0.6 Da, significance threshold p < 0.05, taxonomy Homo
sapiens (human).
2.6. Real-Time qPCR
Extracted RNA (500 ng) was transcribed into complementary DNA (cDNA) using the RT2 First
Strand Kit. Transcription was performed according to the manufacturer’s protocol. In brief, 10 μL
of a reverse transcriptase mixture was added to the RNA samples. The mixture was incubated for
15 min at 42 ◦C and then for another 5 min at 95 ◦C. From each resulting cDNA sample, 675 μL were
mixed with 675 μL of RT2 SYBR Green/ROX qPCR Mastermix. A volume of 25 μL from each sample
was transferred into a specially designed RT2 Custom Profiler PCR 96-well plate using a TECAN
freedom evo (TECAN, Crailsheim, Germany). 96-well plates were pre-spotted with specific primers
according to the results of 2D-GE. Plates were sealed with cap s–trips and placed into the Mastercycler
2S (Eppendorf, Hamburg, Germany). The qPCR was carried out with the following PCR program:
10 min at 95 ◦C followed by 40 cycles of 15 s at 95 ◦C, and 1 min at 60 ◦C. At the end of the PCR
program, a melting profile of the DNA amplifications was measured with the following settings: 95 ◦C
for 15 s, 60 ◦C for 15 s and a final temperature gradient from 60 ◦C to 95 ◦C over 20 min. PCR data were
analyzed with the realplex software from Eppendorf and with an online software from QIAGEN [25].
3. Results
3.1. 2D Gel Electrophoresis and Mass Spectrometry
Analysis of HEKA1 cells exposed to SM and investigated after 24 h revealed differential detection
of 22 protein spots compared to the control group (Figure 1A) in CBB-stained 2D gels. Three of these
spots were identified with a threshold level of a fold change > 2.0 together with a p value < 0.05 and to be
dependent on TRPA1 (Figure 1B–D). Dependency on TRPA1 was proven as pre-incubation with AP18
prevented SM-induced effects. Up-regulation of one (Figure 1B) and down-regulation of two protein
spots (Figure 1C,D) were observed. The up-regulated protein was identified by MALDI-TOF MS
peptide mass fingerprint (Figure 2A) and subsequent MS/MS analysis of characteristic protein-derived
peptides as heat shock 70 kDa protein 6 (HSPA6, UniProtKB-P17066). Fragmenting of the ion at m/z
1487.5 is exemplarily shown in Figure 2B and documents the internal peptide (39–51). The overall
sequence coverage was 35.5% (Figure 2C). The Mascot probability score was calculated to be 86.6.
Identification of the two down-regulated protein spots was not successful by the MALDI-TOF
technique. Therefore, spots were analyzed by the more sensitive nanoHPLC-ESI MS/MS which
identified 4 proteins for each spot all with a high probability score. Table 1 gives an overview on the
detected proteins. Values for the respective molecular weight were taken from UniProt database.
Silver-stained 2D gels identified 28 additional protein spots (12 up- and 16 down-regulated) that
were affected after SM exposure (Figure S1). AP18 pre-incubation did not influence the SM-induced
changes, thereby excluding the involvement of TRPA1 (data not shown).
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Figure 1. Representative 2D CBB-stained gel electrophoresis of HEKA1 cells. The proteome of HEKA1
control, 600 μM SM-exposed or 2 μM AP18-pre-incubated and SM-exposed cells was investigated.
Isoelectric focusing of cell lysates was performed by 7 cm strips (pH 4–7 and pH 6–11, linear). Proteins
were separated by 10% Bis-Tris gels. (A) Overview gel displaying 22 differential protein spots after
SM exposure compared to controls (white open circles). White frames indicate three SM-induced and
TRPA1-regulated proteins. (B) Zoom of the HSPA6 spot and (C,D) zoom of the two protein spots which
proteins are listed in Table 1. Experiments were carried out with n = 3 per group. Molecular weight is
indicated on the left and the pI value on top of the gels.
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Figure 2. MALDI-TOF MS(/MS) measurements of a protein spot after tryptic cleavage identified
HSP6A. (A) Peptide mass fingerprint of HSPA6 identified by MASCOT database matching resulted in
a score of 86.6. (B) MS/MS spectrum of the ion at m/z 1487.5 resulted in a sequence tag of 13 amino
acids. The complete series of y-ions could be found. (C) A sequence coverage of 35.5% was found for
HSPA6 (UniProtKB-P17066). Assigned peptides are indicated with a yellow background. The sequence
of the peptide subjected to MS/MS fragmentation depicted in (B) (amino acids 39–51) is highlighted
with a red background.
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Table 1. Protein assignment of differentially down-regulated protein spots. SM-induced and
TRPA1-dependent down-regulated spots were analyzed by nanoHPLC-ESI MS/MS. Peptides were
identified by NCBInr protein database search. Molecular weights (MW) were taken from UniProt
database and theoretical pI values were calculated using isoelectric point calculators [26,27]. MS/MS
















CAPRIN1 Caprin-1 Q14444 78.5 5.0 17 864
STRN4 Striatin 4 Q9NRL3 81.3 5.1 13 787
NCL Nucleolin P19338 76.6 4.5 10 443
GPHN Gephyrin Q9NQX3 80.4 5.1 7 372
Figure 1D
SFXN1 Sideroflexin 1 Q9H9B4 35.9 9.4 10 689
FHL1 Four and a half LIMdomain protein 1 Q13642 38.0 9.2 9 592
NOSIP Nitric oxide synthaseinteracting protein Q9Y314 33.7 9.1 11 554
ELAVL1 ELAV like protein 1 Q15717 36.2 9.6 8 445
3.2. RT-qPCR
The results of 2D-GE analysis were confirmed by independent RT-qPCR experiments (Figure 3).
Accordingly, genes for HSPA6, CAPRIN1, ELAVL1, FHL1, GPHN, NOSIP, NCL, SFXN1 and STRN4
were chosen as targets. Effects on transcription of these genes were assessed 24 h after SM
exposure. In HEKA1 cells, SM significantly increased HSPA6 mRNA (16.0 × [14.4 − 17.6, 95% CI])
compared to controls (normalized to 1.0) (Figure 3A). AP18 attenuated this up-regulation significantly
(9.78 × [8.9 − 10.66, 95% CI]) (Figure 3A). As these results confirmed findings from the 2D-GE,
additional time points (1, 3, 5 h and 24 h) were investigated. A minor increase of HSPA6 mRNA levels
was detectable already 1 h after SM exposure (1.99 × [1.75 − 2.23, 95% CI]) (Figure 3A). After 3 h,
a more pronounced increase (9.5 × [8.2 − 10.8, 95% CI]) was observed, which further increased after
5 h (11.7 × [10.6 − 12.8, 95% CI]) (Figure 3A). AP18 pre-incubation significantly decreased HSPA6
mRNA levels after 3 h and beyond (1 h: 1.6 × [1.5 − 1.9]; 3 h: 6.7 × [6.1 − 7.4]; 5 h: 8.7 × [7.0 − 10.4])
(Figure 3A).
AITC treatment, also with AP18 pre-incubation, of HEKA1 was conducted to elucidate the role of
TRPA1 activation in more detail (Figure S2). As expected, AITC resulted in a pronounced increase of
HSPA6 mRNA levels 24 h after treatment that was minimized to less than 50% by AP18. AP18 alone
without AITC did not affect HSPA6 mRNA. Also, no changes of HSPA6 mRNA levels were observed
in HEKwt cells after AP18 or SM exposure (Figure S2).
Human A549 cells, endogenously expressing TPRA1, responded with a distinct increase of HSPA6
mRNA levels after SM exposure measured 24 h after exposure (6.8 × [6.5 − 7.2]) that was significantly
diminished by AP18 (5.0 × [4.7 − 5.3]) (Figure 3B).
Levels of FHL1, NOSIP or STRN4 mRNA showed some slight SM-induced changes, but levels
were not in the range of ±1.5-fold compared to controls. CAPRIN1, ELAVL1, GPHN, NCL and SFXN1
mRNA levels were down-regulated 24 h after SM exposure. However, AP18 was unable to increase
these mRNA levels. A summary of the fold change values is given in Table S1.
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Figure 3. RT-qPCR measurements for potentially SM-affected and TRPA1-regulated genes. mRNA
levels of (A) HSPA6 in HEKA1 cells, (B) HSPA6 in A549 cells and (C) CAPRIN1, ELAVL1, FHL1, GPHN,
NOSIP, NCL, SFXN1 and STRN4 in HEKA1 cells were analyzed 24 h after 600 μM SM exposure by
RT-qPCR. White bars indicate the fold change values after SM exposure while grey bars illustrate the
effect of 2 μM AP18 pre-incubation on mRNA levels. The dashed lines represent normalized levels of
the control samples and dotted lines indicate ±1.5-fold change ranges. Significant differences (p < 0.05)
are displayed by asterisks (*). Error bars represent the 95% confidence intervals. Data are derived
from independent biological experiments (n = 3). Gene names correspond to the following proteins:
Caprin-1 (CAPRIN1), ELAV like protein 1 (ELAVL1), Four and a half LIM domain protein 1 (FHL1),
Gephyrin (GPHN), Nitric oxide synthase interacting protein (NOSIP), Nucleolin (NCL), Sideroflexin 1
(SFXN1) and Striatin 4 (STRN4).
4. Discussion
Cell damage caused by alkylating compounds is assumed to rely on DNA mono-adducts and
particularly on DNA crosslinks or the biological consequences thereof [28–30]. However, cytotoxic
effects of alkylating agents are strongly attenuated by cellular DNA repair processes [29,31–33].
Therefore, additional complex mechanisms have been proposed including PARP signaling, nitric
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oxide and oxidative stress and activation of multiple cellular pathways that contribute to
cytotoxicity [28,34–39]. In this context, chemosensing TRPA1 channels were described as targets
of SM and related alkylating compounds [4,19]. A distinct increase of [Ca2+]i occurred after the
activation of TRPA1 by SM. Some biological effects thereof, e.g., influence on cell viability, have already
been described [4]. Additional SM-induced and TRPA1-mediated effects have not been studied so far
and were investigated in this study.
HEKA1 cells, overexpressing human TRPA1 channels, as well as human A549 lung epithelial
cells, endogenously expressing TRPA1, were chosen as the in vitro model. Both cell types were used
in several studies before and were found very well suited for the investigation of TRPA1-related
effects [23,40,41]. Several genes and proteins have been reported to be specifically up-regulated in
mouse skin and in human keratinocytes after exposure to SM [42,43]. Thus, we focused on proteome
changes after SM exposure with special focus on the involvement of TRPA1.
2D-GE with subsequent protein identification by MS were used to detect changes of protein
levels in HEKA1 cells. Cell lysates from controls, which were only treated with the solvent EtOH,
were selected as control group. SM-treated or cells pre-incubated with the specific TRPA1 inhibitor
AP18 [44], were examined to unambiguously identify SM-induced and TRPA1-regulated proteins.
Our results indicated 22 differentially expressed protein spots after SM exposure in HEKA1
cells compared to un-exposed controls (Figure 1A). It should be noted that we have chosen 7 cm
first dimension gel strips covering pH-ranges between 4–7 or 6–11 and proteins were visualized
after SDS-PAGE separation by CBB staining. CBB staining detects high-abundant proteins with
a very good chance of success for the identification by MALDI-TOF MS(/MS) while changes in
low-abundant proteins may be undiscovered. Additional silver staining experiments were conducted
and identified 28 further protein spots. However, AP18 pre-incubation had no effect on these spots,
thereby excluding a role of TRPA1. Nevertheless, we successfully identified three SM-induced and
TRPA1-regulated protein spots 24 h after exposure with one up-regulated and two down-regulated
proteins (Figure 1B–D). The up-regulated protein was unequivocally identified as heat shock 70 kDa
protein 6 (HSPA6) by MALDI-TOF MS peptide mass fingerprint and further MS/MS fragmentation
of prominent peptide ions (Figure 2A,B). Identification of the down-regulated protein spots by
MALDI-TOF MS was not successful, most probably due to insufficient protein amounts. Therefore,
nanoHPLC-ESI MS/MS was chosen as an alternative method. Using this highly sensitive MS/MS
method, multiple proteins with high probability scores were unambiguously verified (Table 1).
All proteins that were assigned to the respective spot revealed a similar MW and a pI, in line with the
2D-GE results. It is not uncommon in 2D-GE that protein spots, especially of high-abundant proteins,
do not represent a single protein. Instead proteins with similar MW and pI can overlap which is
also the case in our experiments. The identity of proteins was confirmed by RT-qPCR. SM exposure
resulted in down-regulation of all investigated mRNA except STRN4 (Figure 3C). Some effects were
weak and failed to meet the criteria of a ±1.5-fold change (STRN4, FHL1, NOSIP) while CAPRIN1,
GPHN, NCL and ELAVL1 mRNA were down-regulated to some extend (Figure 3C). However, AP18 did
not significantly influence mRNA levels in any case. Our results indicate that TRPA1 has no major
effect on mRNA transcription of these genes. Effects on translation, post-translational modification or
degradation of target proteins that could explain the obtained results in 2D-GE may be present but
have not been elucidated so far.
SM-affected proteins identified in our study are involved in several steps of gene transcription
or mRNA translation. Caprin-1 is discussed to mediate the transport and translation of mRNAs
of proteins involved in cell proliferation and migration in multiple cell types [45]. Striatin-4 binds
calmodulin in a calcium-dependent manner and may function as scaffolding or signaling protein [46].
Nucleolin is a nucleolar phosphoprotein involved in fundamental aspects of transcription regulation,
cell proliferation and growth [47]. It is thought to play a role in pre-rRNA transcription and ribosome
assembly and in the process of transcriptional elongation [48]. GPHN and FHL1 are proteins involved
in organization of the cytoskeleton and protein-cytoskeleton interactions [49,50]. In addition, FHL1 is
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involved in nuclear gene regulation processes [50]. ELAVL1 is an RNA-binding protein that binds
to the 3’-UTR region of mRNAs and increases their stability [51,52]. Only for SFXN1, a protein that
might be involved in the transport of a component required for iron utilization into or out of the
mitochondria [53,54], and NOSIP, a ubiquitin-protein ligase that negatively regulates nitric oxide
production by inducing NOS1 and NOS3 translocation to actin cytoskeleton and inhibiting their
enzymatic activity [55], a direct function in protein biosynthesis has not been described yet. Whether
the identified proteins are indeed involved in the molecular toxicology of SM or related compounds
has to be proven but is not part of this study.
Exposure of human keratinocytes with CEES (a monofunctional analog of SM) increased HSPA6
levels [56]. In addition, CEES was identified as an activator of TRPA1 [4]. Results obtained in our
study suggest a link between the expression of HSPA6 and TRPA1 activation by alkylating compounds:
SM increased HSPA6 mRNA levels beginning 3 h after exposure, which was significantly prevented by
AP18 pre-treatment (Figure 3A) and induced HSPA6 protein formation after 24 h (Figure 1B). HEKwt
cells did not respond to SM while human A549 lung epithelial cells, endogenously expressing TRPA1,
revealed similar results with regard to HSPA6 mRNA levels compared to HEKA1 cells (Figure 3B).
HSPs are molecular chaperones that regulate the folding, degradation and assembly of
proteins [57]. After cellular stress such as intense heat, heavy metal exposure, UVB light, oxidative
stress or inflammation, HSPs are up-regulated to protect cell proteins against aggregation [58,59].
HSPA6 is especially responsible for the correct folding and activation of many proteins [60].
It is well known that SM exposure results in the formation of reactive oxygen species (ROS) or
reactive nitrogen species in vitro [34,35]. ROS can induce protein damage, instability, aggregation
and can even provoke cell death but have also been shown to induce HSPs [61]. Therefore, it is
reasonable to assume that HSP induction may also be the consequence of SM-induced oxidative stress
in our experiments.
It was previously postulated that elevation of [Ca2+]i through TRP channel activation (in particular
TRPA1 and TRPV1) activates the mitochondrial tricarboxylic acid cycle, which generates ATP as well
as ROS [62,63]. In a study by Gould et al., CEES was proven to affect mitochondrial function in lung
cells resulting in ROS formation [64]. Ray et al. demonstrated that SM induced an increase of [Ca2+]i
localized to mitochondria [65]. However, TRP channels were not considered as potential mediators of
the observed phenomena.
Our work suggests a distinct role of TRPA1 beyond an immediate effect of SM on mitochondria.
Inhibition of TRPA1 by AP18 is suggested to attenuate the SM-induced increase of [Ca2+]i and thus,
the generation of ROS and HSPA6 subsequently. However, AP18 was insufficient to completely prevent
HSPA6 induction in our experiments indicating that TRPA1 is not exclusively responsible for HSPA6
up-regulation. In addition to TRPA1-mediated ROS formation, SM-induced depletion of antioxidants,
lipid oxidation or direct effects on mitochondria can cause severe oxidative stress which is independent
of TRPA1 and may also trigger HSPA6 expression [66–68].
Other biological effects of SM-induced increase of [Ca2+]i such as phospholipase A activation
and subsequent arachidonate release, terminal differentiation of human keratinocytes, induction
of cell death through caspases, in addition to the above discussed Ca2+/ROS/HSPA6 cascade,
were described [4,65,69–71]. A synopsis depicting the interaction of cellular events after SM-exposure
with focus on TRPA1 and HSPA6 is given in Figure 4.
100
Cells 2018, 7, 126
Figure 4. Schematic overview suggesting TRPA1-mediated induction of HSPA6 after SM exposure.
SM activates TRPA1 channels with a still unknown extra- or intracellular binding site (bold dotted
lines). SM as well as AITC treatment increase intracellular Ca2+ ([Ca2+]i) levels. AP18 prevents both
SM- and AITC-induced TRPA1 activation. [Ca2+]i affects mitochondrial function thereby producing
ROS which triggers HSPA6 induction. SM may also cause ROS formation through disturbance of
mitochondrial function or other yet not well-defined mechanisms thereby potentially contributing to
HSPA6 induction (dashed line) without involvement of TRPA1. Elevation of [Ca2+]i also results in
additional biological effects (open triangles). Text boxes list references describing the illustrated effects.
Activation, increase or induction is marked with “+” while impairment of mitochondria is indicated
with “−”.
Our results suggest that SM causes an increase of [Ca2+]i and subsequent induction of HSPA6,
which is in part mediated by TRPA1 channels. Increase of ROS, presumably originating from
mitochondrial stress, is a feasible cause for the observed HSPA6 induction. An inhibition of TRPA1
in HEKA1 and A549 cells attenuated the SM-induced expression of HSPA6 and thereby pointing to a
distinct role of TRPA1 ion channels. Whether induction of HSPA6 after SM exposure is a protective
cellular defense mechanism as it may protect against stress-induced apoptosis [72] cannot be answered
at this point and should be addressed in future research. Nevertheless, TRPA1 channels were proven
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to be part of the very complex molecular toxicology of SM and a step closer into the spotlight of
SM research.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/7/9/126/s1,
Figure S1. Representative 2D silver-stained gel electrophoresis of 600 μM SM-exposed HEKA1 cells. Figure S2.
RT-qPCR measurements of relative HSPA6 mRNA levels in HEKA1 and HEKwt cells. Table S1. Fold change
values of RT-qPCR.
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Abstract: Salivary glands secrete saliva, a mixture of proteins and fluids, which plays an extremely
important role in the maintenance of oral health. Loss of salivary secretion causes a dry mouth
condition, xerostomia, which has numerous deleterious consequences including opportunistic
infections within the oral cavity, difficulties in eating and swallowing food, and problems with
speech. Secretion of fluid by salivary glands is stimulated by activation of specific receptors
on acinar cell plasma membrane and is mediated by an increase in cytosolic [Ca2+] ([Ca2+]i).
The increase in [Ca2+]i regulates a number of ion channels and transporters that are required for
establishing an osmotic gradient that drives water flow via aquaporin water channels in the apical
membrane. The Store-Operated Ca2+ Entry (SOCE) mechanism, which is regulated in response to
depletion of ER-Ca2+, determines the sustained [Ca2+]i increase required for prolonged fluid secretion.
Core components of SOCE in salivary gland acinar cells are Orai1 and STIM1. In addition, TRPC1 is a
major and non-redundant contributor to SOCE and fluid secretion in salivary gland acinar and ductal
cells. Other TRP channels that contribute to salivary flow are TRPC3 and TRPV4, while presence of
others, including TRPM8, TRPA1, TRPV1, and TRPV3, have been identified in the gland. Loss of
salivary gland function leads to dry mouth conditions, or xerostomia, which is clinically seen in
patients who have undergone radiation treatment for head-and-neck cancers, and those with the
autoimmune exocrinopathy, Sjögren’s syndrome (pSS). TRPM2 is a unique TRP channel that acts as a
sensor for intracellular ROS. We will discuss recent studies reported by us that demonstrate a key
role for TRPM2 in radiation-induced salivary gland dysfunction. Further, there is increasing evidence
that TRPM2 might be involved in inflammatory processes. These interesting findings point to the
possible involvement of TRPM2 in Sjögren’s Syndrome, although further studies will be required to
identify the exact role of TRPM2 in this disease.
Keywords: TRP channels; calcium signaling; salivary glands; xerostomia; radiation; inflammation
1. Introduction
Salivary glands secrete fluid composed of water and electrolytes in response to neurotransmitter
stimulation of plasma membrane receptors that cause an elevation of cytosolic [Ca2+] ([Ca2+]i) in acinar
cells, which are the primary site of fluid secretion [1–3] (Figure 1). The [Ca2+]i increase is initiated
by stimulation of the major receptors regulating fluid secretion, such as muscarinic cholinergic and
α1-adrenergic receptors, which triggers activation of phospholipase C (PLC), phosphatidylinositol
4,5-bisphosphate (PIP2) hydrolysis, generation of inositol 1,4,5, trisphosphate (IP3), and release of Ca2+
from the endoplasmic reticulum (ER) Ca2+ stores, mediated via the IP3 receptors (IP3R). In the absence
of extracellular Ca2+, release from the ER causes a transient increase in [Ca2+]i that is not sufficient to
maintain prolonged fluid secretion. The latter requires sustained increases in [Ca2+]i that is supported
by Ca2+ influx into the cells. The primary function of the [Ca2+]i increase is to regulate the function of
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ion transporters and channels such as Na+/K+/2Cl− cotransporter 1 (NKCC1), Anoctamin 1 (ANO1),
and Ca2+-dependent K+ (KCa), which cause vectorial transport of Cl− from the basolateral to the
luminal side of the cell, and the generation of an osmotic gradient across the luminal membrane of
the cell. The latter provides the driving force for water secretion through the apical membrane via the
water channel, Aquaporin 5 (AQP5).
Figure 1. Ca2+ signaling and ion channel regulation underlying salivary gland fluid secretion. Salivary
gland acinar cell (depicted in the figure) secretes fluid composed of water and electrolytes in response
to neurotransmitter stimulation of plasma membrane receptors and consequent elevation of cytosolic
[Ca2+] ([Ca2+]i) (see description in the text).
In salivary gland acinar cells, IP3-mediated Ca2+ release occurs primarily via IP3R2 and -3 [4,5].
Importantly, the resulting decrease in ER-[Ca2+] triggers the activation of Ca2+ influx. This type of
Ca2+ entry, termed store-operated Ca2+ entry (SOCE), provides critical Ca2+ signals for regulation of
salivary fluid secretion [6–8]. SOCE has two types of components; (i) plasma membrane Ca2+ channels
and (ii) regulatory proteins that sense the change in ER-[Ca2+] and gate the channels. The main Ca2+
channels involved in SOCE in salivary gland cells are Orai1 and TRPC1. STIM1, an ER-Ca2+ binding
protein, functions as the ER-[Ca2+] sensor and the gating component of both these channels [9–15].
In addition, STIM2 also contributes to SOCE by enhancing the sensitivity of SOCE activation under
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conditions when ER-Ca2+ stores are not substantially depleted [16]. Several different studies have
demonstrated that TRPC1 is an essential channel for salivary gland function, where loss of the channel
causes significant loss of fluid secretion and SOCE [17–19]. While Orai1 has been extensively studied,
its exact role in salivary gland function has not yet been established. One possible function of Orai1
in the gland could be to regulate TRPC1 function, since studies with salivary gland cell lines have
demonstrated that TRPC1 function is completely dependent on Orai1 [20–23].
While [Ca2+]i increases are essential for the regulation of salivary gland function, disruption
of Ca2+ homeostasis, either in resting or stimulated cells, results in salivary gland dysfunction.
Two major conditions result in loss of salivary gland function and tissue damage: primary Sjögren’s
syndrome (pSS), a chronic autoimmune disease involving lymphocytic infiltration and loss of secretory
function in salivary and lacrimal glands [24,25], and radiation-induced salivary gland dysfunction.
Radiation-induced xerostomia, or dry mouth condition, occurs in patients who undergo radiation
therapy for head-and-neck cancers, that results in irreversible damage of salivary glands. Loss of
salivary fluid secretion leads to complications such as difficulty swallowing, rampant dental caries,
oral mucosal lesions, and fungal infections that together severely affect the quality of life for
patients [26,27]. This condition has been reproduced in several animal models, such as mouse, rats,
mini-pigs, and non-human primates. Interestingly, irradiation (IR) induces considerable loss of saliva
flow in the absence of extensive tissue damage or loss of acinar cells. While fibrosis and loss of tissue
can occur, the onset and severity of this phase of cellular damage differs among the various species.
Thus, the mechanism underlying IR-induced loss of salivary gland function is a subject of great interest
in the field, with clinical studies being directed towards assessing therapies targeted to recovery of
cell function, prevention of functional loss, or regrowth of salivary glands. In this review we will
summarize the current knowledge regarding the role of TRP channels in salivary gland function and
radiation-induced secretory dysfunction.
2. Historical Overview of Transient Receptor Potential (TRP) Channels
An extensive search for the molecular components of SOCE led to the identification of the transient
receptor potential (TRP) superfamily of cation channels. These channels are expressed in a variety of
organisms, including worms, flies, zebrafish, mice, and humans, and are broadly divided into two
groups based on sequence and topological similarities. Group 1 TRPs consist of five subfamilies that
bear strong homology to the founding member, Drosophila TRP [28]. Of these, the TRPC subfamily is
most related to Drosophila TRP. Other subfamilies in the group include TRPV, TRPM, TRPA, and TRPN.
The TRPN proteins are not found in mammals, although they are expressed in some vertebrates,
such as zebrafish. The group 1 TRPs have six transmembrane segments, including a pore loop situated
between the fifth and sixth transmembrane segments. TRPC, TRPM, and TRPN channels also contain
a TRP domain, which follows the sixth transmembrane segment and is quite conserved between the
channels. Apart from the TRPM channels, the other group 1 TRPs have multiple ankyrin repeats
in the N-terminus. Three TRPM channel members, TRPM2, TRPM6, and TRPM7, are unique in
that they have a pore as well as a catalytic functional domain and thus, are often referred to as
chanzymes [29,30]. Group 2 TRPs consist of TRPP and TRPML channels, which share substantial
sequence homology over the transmembrane segments and contain a large loop separating the first
two transmembrane domains. The first TRPP and TRPML members were discovered as gene products
mutated in autosomal dominant polycystic kidney disease (ADPKD) and mucolipidosis type IV
(MLIV) respectively [31–34]. It should be noted that other TRP channels have also been associated
with conditions of inflammation, cell damage, and disease. For example, TRPC5 and TRPC6 have been
linked to the most common gastrointestinal obstruction disease in infants. TRPM2 have been suggested
to underlie neurodegenerative disorders that cause movement disorders, whereas a mutation in TRPA1
was implicated in debilitating body pain. TRPV4 has been implicated to multiple channelopathies
involving the musculo-skeletal system As such, it is not surprising that many members of the TRP
superfamily are considered to be promising targets for the development of novel therapeutics [35–40].
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TRPs are non-selective cation-channels which display variable calcium permeability. They,
however, contribute to calcium signaling mechanisms and regulation of many physiological processes
in a plethora of cell types. Almost all TRP channels, except TRPC subfamily members, have been
reported to have sensory function. There is substantial evidence to show that regulation of TRP
channels is polymodal and that they can mediate transduction of a wide variety of environmental
stimuli including mechanical, thermal, or chemical stimuli [41]. A large group of TRP channels
respond to thermal stimuli. While TRPV1 was the first heat-activated channel to be identified,
to date, 10 thermoTRP channels with distinct range of thermoensitivity have been identified in
mammals: TRPV (TRPV1, TRPV2, TRPV3, and TRPV4), TRPM (TRPM2, TRPM3, TRPM4, TRPM5,
and TRPM8), and TRPA (TRPA1). In rodents, TRPV1, TRPV2, and TRPM3 are activated by noxious heat,
while TRPV3, TRPV4, TRPM2, TRPM4, and TRPM5 are activated by warmth [42–44]. Channels such
as TRPM8 [45–49] and TRPA1 [50] have been reported to be activated by cold stimuli. However,
the thermal sensitivity of TRPA1 from both humans and rodents remains a subject of debate [51,52] due
to contradictory observations. TRPA1 from mice was first reported to be activated by cold stimulation
when heterologously expressed in cultured cells [50]. However, a later study contended that TRPA1
was not a temperature-sensitive channel [53]. Note that TRPA1 channel activity can be modulated by
Ca2+, receptor stimulation, pH, and osmotic pressure, which may explain the apparent contradictory
observations by different studies [51,54–60]. A peculiar feature of thermoTRP channels is that they
can also be activated by non-thermal stimulation. For example, TRPV4 is activated by hypotonic
and mechanical stimulation [61,62], while TRPV1 is activated by capsaicin, contained in chili pepper,
and also by extracellular acidic stimulation [46,63]. TRPA1 is activated by various irritating chemical
compounds contained in plants, as well as environmental irritants such as acrolein contained in exhaust
gas and cigarette smoke [64]. It is interesting that the sensitivity for thermal activation of TRP channels
can be modified by other factors such as reduction of cellular PIP2 levels [65–68]. The physiologic
roles and activation mechanisms regulating thermoTRP channels have been summarized in several
comprehensive reviews [69–71].
3. TRPC Channel Regulation and Function
The TRPC subfamily consists of seven members (TRPCs 1–7) that are divided into four subsets
based on their amino acid homology: TRPC1, TRPC2, TRPC3/TRPC6/TRPC7, and TRPC4/TRPC5.
All TRPC channels display channel activation in response to receptor-stimulated PIP2 hydrolysis
and have six transmembrane domains with a pore-forming domain located between the fifth and
sixth domains. These channels contain N-terminal ankyrin repeats, and in the C-terminus, a highly
conserved TRP domain, several calmodulin (CaM)-binding domains, and a putative IP3R binding
site [72–74]. TRPC channels show diverse tissue expression, physiological functions, and channel
properties. Recent reviews have presented a general overview of the molecular components
and mechanisms regulating SOCE [22,75], as well as overviews of the individual TRPC channels:
TRPC1 [76], TRPC2 [77], TRPC3 [78], TRPC4 [79], TRPC5 [80], TRPC6 [81], and TRPC7 [82]. TRPC2 is
a pseudogene in humans [83,84]. To date, almost all TRPC channels have been proposed as possible
molecular components of channels mediating SOCE. However, data for some TRPCs are not very
consistent. So far, the strongest evidence for the contribution of TRPC channels to SOCE has
been provided for TRPC1 and TRPC4, whereas the contribution of TRPC3 to SOCE appears to be
dependent on cell type and level of expression. TRPCs 5, 6, and 7 have been generally described
to be store-independent, with a few exceptions.TRPC1 was the first mammalian TRPC channel to
be cloned [83,84], and early studies established that it is activated by conditions resulting in store
depletion and associated with the generation of a relatively Ca2+-selective cation current that was
termed ISOC (store-operated Ca2+ current; [85]) to differentiate it from ICRAC, the current generated by
functional Orai1 [86]. TRPC1 has been reported to contribute to SOCE in a variety of cell types [87,88],
although heterologous expression of the channel does not always result in enhancement of SOCE.
Note that unlike with Orai1 or STIM1, TRPC channel contribution to SOCE is not seen in all cell
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types. Importantly, while TRPC1 clusters with and is activated by STIM1 following store-depletion,
its function is also dependent on Orai1 channel activity [21]. It was shown that Orai1-mediated Ca2+
entry triggers recruitment of TRPC1 to the plasma membrane. Thus, TRPC1 and Orai1 form separate
channels that are activated by STIM1 following neurotransmitter simulation of salivary gland cells
and contribute to the [Ca2+]i increase seen in stimulated cells. Orai1 is the first channel to be activated
while recruitment and activation of TRPC1 leads to amplification and modulation of [Ca2+]i increase
that is induced by Orai1. However, since TRPC1 is activated by STIM1 following clustering of the two
proteins within ER-PM-junctions, TRPC1 function is dependent on ER-Ca2+ depletion as well as Orai1
channel activity [21].
4. TRPC Channel Function in Exocrine Glands
As noted above, early studies established that Ca2+ influx is the primary determinant of sustained
fluid secretion from salivary acinar cells [6]. It is now widely accepted that the primary mode
of Ca2+ entry in acinar cells that is required for fluid secretion is mediated by SOCE. The main
molecular components involved in SOCE in salivary gland acinar cells have now been identified as
members of the transient receptor potential canonical (TRPC) family, TRPC1 and TRPC3. Both channels
contribute to SOCE in dispersed acinar cell preparations, as well as cultured salivary gland cell
lines [6,17,89]. Knockdown of endogenous TRPC1 significantly decreased SOCE in the human salivary
gland (HSG) cell line, as well as primary cultures of mouse pancreatic and submandibular gland
cells [17]. Further conclusive evidence was provided by studies with mice lacking TRPC1 (TRPC1−/−),
which showed reduced SOCE in salivary gland and pancreatic acinar cells as well as attenuation
of Ca2+-dependent physiological functions [17,18], despite having normal viability, development,
and behavior [81]. SOCE is fundamentally important for fluid secretion in salivary glands and for
protein secretion in the exocrine pancreas. TRPC1−/− mice displayed reduction in salivary gland
fluid secretion that was associated with a decrease in SOCE and KCa activity in acinar cells from
the mice [18,89]. Similarly defects in Ca2+-activated Cl− channel activity and protein secretion, as a
consequence of reduced SOCE, were reported in pancreatic acinar cells [17]. Notably, while there is
no change in Orai1 in salivary gland and pancreatic acinar cells from TRPC1−/− mice, the channel
does not appear to compensate for the lack of TRPC1 or support cell function on its own. Hence,
decreased secretory function in these exocrine glands is primarily due to the loss of TRPC1-mediated
SOCE. The caveolae-residing protein, caveolin-1 (Cav-1), is an important modulator of TRPC1 activity
and functions as a plasma membrane scaffold for the channel. In the absence of Cav-1, TRPC1 is
mislocalized and unable to interact with STIM1 [90]. Consistent with this, localization of TRPC1,
its interaction with STIM1, as well as SOCE were disrupted in salivary gland acinar cells from
Cav-1−/− mice [91]. These cellular defects were associated with reduced fluid secretion in the mice.
Together, these findings establish a vital role for TRPC1 in salivary gland fluid secretion.
TRPC3 is reported to contribute to both the store-operated and receptor-activated calcium entry
pathways, and has been associated with the generation of a non-selective, Ca2+-permeable channel
in response to receptor-stimulated PIP2 hydrolysis. While the channel can be directly activated by
application of diacylglycerol to cells, it also contributes to SOCE under some conditions. Mice lacking
TRPC3 show reduced SOCE and fluid secretion [92]. Interestingly, the contribution of TRPC3 to
SOCE is dependent on the presence of TRPC1, as TRPC1−/− mice do not display TRPC3-dependent
SOCE [93]. Thus, it has been proposed that either the channels are assembled as a store-operated
heteromeric channel, or that TRPC1 is required for store-dependent regulation of TRPC3. Indeed,
TRPC3–TRPC1 interaction is necessary for STIM1 regulation of the channels in salivary gland ductal
cells. The two TRPC channels coimmunoprecipitate following cell stimulation together with STIM1.
Loss of TRPC1 eliminates the association of STIM1 with TRPC3 [93,94]. TRPC3-mediated Ca2+ entry
can also contribute to exocrine gland pathology and tissue damage. Pancreatic acini from TRPC3−/−
mice showed significant protection from acute pancreatitis induced by hyper-activation of SOCE.
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Similar effects were seen by blocking channel function in TRPC3+/+ mice by treatment with pyrazole
3, a TRPC3 channel inhibitor [92,95].
Orai1 is a critical and essential component of SOCE [10,12]. Although the role of Orai1 in salivary
gland function is yet to be determined, it has been examined in two other exocrine glands, lacrimal and
pancreatic. Orai1−/− mice display loss of lacrimal gland function and reduced SOCE in lacrimal gland
acinar cells [96]. Further, knockdown of Orai1 in isolated pancreatic ductal cells also resulted in loss of
SOCE and Ca2+-activated ion channel activity that was similar to that seen in TRPC1−/− cells [17].
Targeted knockout of Orai1 in pancreatic acinar cells of adult mice led to loss of SOCE and severely
compromised pancreatic secretion. Antimicrobials secreted by pancreatic acini play an important role
in shaping the gut microbiome, as well as maintaining the innate immunity and barrier function in
the intestines [97]. Mice lacking acinar Orai1 exhibited intestinal bacterial outgrowth and dysbiosis,
ultimately causing systemic translocation, inflammation, and death.
5. TRPV4 and Other TRP Channel Function in Salivary Glands
Regulation of cell volume in response to changes in osmolarity is critical in salivary gland
fluid secretion. In response to carbachol (CCh) stimulation, cells undergo a decrease in cell volume,
which then recovers via a regulatory volume increase (RVI). Conversely, hypotonic conditions lead
to cell swelling and volume recovery via regulatory volume decrease (RVD). Both these processes
depend on the water permeability of the cells, which in salivary gland cells is determined by the level
of AQP5 in the membrane. A role for TRPV4 in RVD was previously reported by an earlier study
reported by us [98]. TRPV4 was activated by cell swelling under hypoosmotic conditions and that
Ca2+ entry via TRPV4 was important for regulating the ion fluxes involved in driving RVD. This study
demonstrated a novel association between osmosensing TRPV4 and AQP5. Acinar cells from mice
lacking either TRPV4 or AQP5 displayed greatly reduced Ca2+ entry and loss of RVD in response to
hypotonicity, although the extent of cell swelling was similar. Recent studies have shown a more direct
role for TRPV4 in fluid secretion. TRPV4 is activated by endogenous arachidonic acid metabolites,
4α-phorbol-12,13 didecanoate, GSK1016790A, moderate heat, and mechanical stress. Pharmacological
TRPV4 activation using the selective agonist GSK1016790A caused Ca2+ influx in isolated acinar cells
in a basal-to-apical wave. Consistent with these observations, GSK1016790A elicited salivation in
the perfused submandibular gland that was dependent on extracellular Ca2+ [99]. Another study
reported a functional interaction between TRPV4 and the Ca2+-activated chloride channel, ANO1,
in acinar cells isolated from mouse salivary and lacrimal glands [100]. Activation of TRPV4 induced an
increase in fluid secretion, ANO1 activation and a volume decrease in acinar cells by increasing [Ca2+]i.
Muscarinic stimulation of saliva and tear secretion was downregulated in both TRPV4-deficient mice
and in acinar cells treated with a TRPV4-specific antagonist (HC-067047). Furthermore, the temperature
dependence of muscarinic salivation was shown to depend mainly on TRPV4. This study also showed
a novel association between TRPV4, IP3Rs, and ANO1 that collectively contributes to the regulation of
salivation and lacrimation.
Additional TRP channels have also been identified in salivary glands. Immunohistochemistry
has revealed the presence of TRPM8, TRPA1, TRPV1, TRPV3, and TRPV4 in myoepithelial, acinar,
and ductal cells of the sublingual, submandibular, and parotid glands. Interestingly, perfusion of
the entire submandibular gland with the TRPV1 agonist capsaicin (1 μM) via the submandibular
artery significantly increased CCh-induced salivation, whereas perfusion with TRPM8 and TRPA1
agonists (0.5 μM WS12 and 100 μM allyl isothiocyanate) decreased it. Application of agonists for each
of the thermosensitive TRP channels increased [Ca2+]i in a cultured submandibular epithelial cell
line. These results indicate that temperature-sensitive TRP channels are localized and distributed in
acinar, ductal and myoepithelial cells of salivary glands, and that they might have a functional role
in regulating and/or modulating saliva secretion. Further studies will be needed to characterize the
exact role of temperature-dependent regulation of salivary gland function and the involvement of TRP
channels in this mechanism.
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6. Role of TRPM2 in Salivary Gland Dysfunction
6.1. Regulation and Activation of TRPM2
TRPM2 is the second member of the TRPM subfamily, which includes eight functionally diverse
members, namely TRPM 1–8. TRPM2 (previously known as LTRPC2 or TRPC7) is a Ca2+ permeable,
non-selective cation channel. It is predominantly expressed in the brain and has also been detected
in bone marrow, spleen, heart, liver, lung and immunocytes, salivary gland [101–103]. TRPM2 is
unique in that its structure contains a Ca2+-permeable non-selective cationic pore fused to an enzyme
of the Nudix family of pyrophosphatases. Adenosine diphosphate ribose (ADPR) is considered
the primary gating molecule of TRPM2 [104]. The channel displays a linear current-voltage (I–V)
relationship, and substantial permeation to cations such as Na+, K+, Ca2+, Mg2+, and Zn2+, with relative
permeabilities of PK/PNa ∼ 1.1, PCa/PNa ∼ 0.9, and PMg/PNa ∼ 0.5. Most importantly, TRPM2 serves
as a sensor for reactive oxygen species (ROS) in cells, since increase in cellular ROS or nitrogen species,
cause formation ADPR. Intracellular Ca2+ also facilitates TRPM2 activation by enhancing the channel
sensitivity to ADPR [101].
Under oxidative stress, ADPR formation is mediated through activation of the PARP/PARG
(Poly(ADP-ribose) polymerase/glycohydrolase) pathway in the nucleus. ADPR is also synthesized
in the mitochondria, which contain the largest pool of intracellular nicotinamine adenosine
diphosphate (NAD+), and is released into the cytosol [105,106]. Convincing evidence has been
presented to show that ROS-induced TRPM2 activation is also triggered via the production of
ADPR from mitochondria [107,108]. It is now clearly established that TRPM2 channel serves
as an important pathway for oxidative stress-induced increases in [Ca2+]i, which regulate Ca2+
signaling mechanisms that include regulation of ion channel activities, gene expression, secretion,
apoptosis, and inflammasome assembly. TRPM2 also responds to warm temperatures that act
synergistically with ADPR, NAD+, and cADPR at concentrations that otherwise cannot activate
the channel [101,102,105,106,109]. In normal physiological states, a major function of TRPM2 is to
modulate the immune system by controlling cytokine release in human monocytes, including tumor
necrosis factor-alpha (TNFα), interleukin 6 (IL-6), IL-8, and IL-10, and the maturation and chemotaxis
of dendritic cells. Non-physiological stimulation of TRPM2 is suggested to lead to pathology
and dysfunction.
6.2. TRPM2 and Radiation-Induced Loss of Salivary Flow
A debilitating side effect of radiation treatment in patients with head and neck cancers is
xerostomia, or dry mouth, as a result of severe decrease in saliva secretion. While acute effects
of IR could be induced by membrane/protein damage, the more delayed and long-term effects have
been proposed to be caused by damage of progenitor cells within the adult salivary gland [110–112].
However, the decrease in saliva secretion cannot be strictly correlated with a decrease in acinar cells
or damage of the gland. In fact, in mouse models of radiation, glandular loss, and fibrosis are not
seen for about four-to six months after radiation while loss of function is almost immediate and
persists even after the radiation-induced ROS in the tissue has been cleared [113,114]. Our recent
studies demonstrate a critical role for TRPM2 in radiation-induced persistent loss of salivary gland
fluid secretion (Figure 2). TRPM2 is present in salivary gland acinar cells and is activated under
conditions which increase ROS, such as by treatment with H2O2 or following radiation treatment of
the salivary glands in mice [103]. Importantly, while TRPM2+/+ mice display persistent loss of salivary
gland fluid secretion that is detected within 10 days after radiation, mice lacking TRPM2 (TRPM2−/−)
demonstrate transient loss of function with >80% recovery of function by 30 days after IR. Activation of
TRPM2 by radiation has been supported by data showing that Ca2+ influx is constitutively activated in
acinar cells isolated from TRPM2+/+ mice 24 h after radiation. This increase in plasma membrane Ca2+
permeability is not seen in acini from irradiated TRPM2−/− mice. Treatment of mice with the PARP1
inhibitor, 3-AB, prior to radiation suppresses TRPM2 activation and exerts protection of salivary gland
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function. Further, TEMPOL, a redox-cycling nitroxide and ROS scavenger that has been reported
to protect several organs, including the heart and brain, from ischemia/reperfusion damage [115],
also protects salivary gland function in irradiated mice [103,114]. Thus, the presence of TRPM2 in
acinar cells converts an inherently reversible loss of salivary gland function, following radiation
treatment to an irreversible one.
Figure 2. Role of TRPM2 in radiation -induced salivary gland dysfunction. See text for description.
In searching for the mechanism(s) linking early activation of TRPM2 by radiation to the persistent
loss of salivary fluid secretion, we have now demonstrated that persistent reduction in STIM1 protein,
and SOCE, underlies radiation-induced loss of salivary gland function. Furthermore, the decrease
in STIM1 protein levels is linked to activation of TRPM2 [113]. A major finding of this study was
that TRPM2-mediated increase in [Ca2+]i in response to radiation causes an increase in mitochondrial
[Ca2+] and ROSmt but a decrease in mitochondrial membrane potential. This is accompanied by
a relatively slower appearance of activated caspase-3 which persists for about a month after the
treatment. In irradiated TRPM2−/− mice, the increases in [Ca2+]mt, ROSmt and activated caspase-3
are substantially attenuated. Importantly, TRPM2-dependent activation of caspase-3 is correlated
with loss of STIM1. These interesting findings reveal that radiation-induced loss of salivary gland
fluid secretion is mediated via a TRPM2-dependent pathway that impacts mitochondrial function and
leads to irreversible loss of SOCE. Notably, cleavage of STIM1 by calpain and γ-secretase has been
associated with stress and Alzheimer’s disease, respectively [116,117]. Further, proteasome inhibition
reduces SOCE by promoting autophagy-mediated degradation of STIM1/2 [118]. Future studies will
need to clarify exactly how the long-term suppression of STIM1 expression is controlled. Most likely,
remodeling of gene expression or other epigenetic changes occurring in irradiated salivary glands
might be involved. Ca2+ entry mediated by SOCE, via Orai1 channels, is critical for the regulation
and activation of transcription factors such as NFAT and cFos, as well as other channels that regulate
NFκB (e.g., TRPC1). Attenuation of these signaling mechanisms due to loss of channel activation
could impact the expression of STIM1 or other cellular proteins, further depressing the occurrence
of downstream events that are triggered by these signaling events. It is also important to consider
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that loss of STIM1 and SOCE can potentially affect other cellular processes, including regeneration of
salivary gland cells [119]. In a salivary gland cell line, silencing the mitochondrial Ca2+ uniporter or
caspase-3, or treatment with inhibitors of TRPM2 or caspase-3 prevented irradiation-induced loss of
STIM1 and SOCE. Importantly, expression of exogenous STIM1 in the salivary glands of irradiated
mice increases SOCE and fluid secretion. Thus, targeting the mechanisms underlying the loss of
STIM1 would be a potentially useful approach for preserving salivary gland function after radiation
therapy [113].
6.3. TRPM2 in Inflammatory Disorders
Oxidative stress plays a critical role in various pathophysiological processes, including cancer,
acute and chronic neurodegenerative disorders (Alzheimer’s and Parkinson’s diseases);
diabetes mellitus, atherosclerosis, ischemia/reperfusion injury, and autoimmune disease; and in
normal cellular functions [120]. Main pro-inflammatory molecules present in chronic inflammatory
responses are ROS, reactive nitrogen species (RNS), IL-2, IL-4, IL-5, IL-7, IL-13, IL-9, IL-10, IL-12,
IL-17, IL-21, interferon (IFN)-γ, transforming growth factor (TGF)-β, and tumor necrosis factor
(TNF)-α. Salivary gland epithelial cells themselves synthesize and secrete cytokines to maintain
barrier protection and regulate anti-inflammatory processes. Furthermore, immune cells produce
ADPR via CD38 and CD157 signaling or by activating the PARP pathway, both of which can facilitate
activation of TRPM2. Although there are no data available presently that demonstrate a role for TRPM2
in inflammatory disorders of the salivary gland, the available information suggests that the channel
could be activated in response to inflammatory conditions and contribute to the pathogenesis.
There is increasing evidence for the involvement of TRPM2 in innate immunity, inflammation,
regulation of cytokine production, cellular migration and ROS production [105]. NADPH oxidase-
dependent ROS production in phagocytic cells is triggered in response to infection and plays a key role
in inflammation. Activation, migration as well as regulation of the effector mechanisms of immune
cells critically depend on Ca2+-entry into the cell. While Orai1 channels also mediate this type of
calcium influx to regulate the function of T cells and B cells, TRPM2 can also contribute to the elevation
of [Ca2+]i as it is expressed in the plasma membrane of neutrophils, T and B lymphocytes, and dendritic
cells. In T cells, cross-linking of cell surface receptors induces a rise of ADPR endogenously generated
from NAD+ which can activate TRPM2 [121]. Importantly, inhibition of NAADP signaling in T
cells [122] reduces antigen-induced proliferation and cytokine production and ameliorates clinical
symptoms of experimental autoimmune encephalomyelitis (EAE, [122]). The role for TRPM2 in
lymphocyte function is now been widely accepted. It has been shown that TRPM2-mediated Ca2+
influx regulates T cell proliferation and proinflammatory cytokine secretion following polyclonal T
cell receptor stimulation. TRPM2-deficiency or treatment with TRPM2 channel blockers significantly
modulate effector T cell function [123,124]. Moreover, TRPM2 channels impact the maturation and
chemokine-activated directional migration of dendritic cells, which function as antigen-presenting
cells [125]. TRPM2 can also be activated by triggering of toll-like receptors by LPS and cytokine
receptors (TNFα) as well as by intracellular ADPR. It is suggested that inhibition of TRPM2 channels
in autoimmune inflammatory disorders will likely dampen the adaptive T cell-mediated immune
response without favoring prolonged T cell survival and inflammatory tissue damage.
On the other hand, it has been reported that TRPM2-mediated Ca2+ influx controls
the ROS-induced signaling cascade responsible for chemokine production, which aggravates
inflammation [126]. TRPM2 expressed in macrophages and microglia aggravates peripheral and spinal
pro-nociceptive inflammatory responses, and contributes to the pathogenesis of inflammatory and
neuropathic pain [127]. TRPM2 critically influences T cell proliferation and proinflammatory cytokine
secretion following polyclonal T cell receptor stimulation. Consistently, TRPM2-deficient mice exhibit
an attenuated clinical phenotype of EAE with reduced inflammatory and demyelinating spinal cord
lesions [128]. In addition, TRPM2 regulates macrophage polarization and gastric inflammation during
Helicobacter pylori infection [129]. TRPM2 channels mediate bleomycin-induced lung inflammation
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in alveolar epithelial cells [130], and contributes to antigen-stimulated Ca2+ influx in mucosal mast
cells [131].
Numerous proinflammatory cytokines are produced during the innate immune response
to infection and inflammation, several of which have been linked with activation of TRPM2.
Knockdown of TRPM2 attenuates LPS-induced production of IL-6, IL-8, IL-10, and TNF-α in THP1
monocytic cells. The corresponding decrease in LPS-induced Ca2+ influx under these conditions
supports the suggestion that TRPM2-mediated Ca2+ influx has a significant role in generating these
cytokines. Zymosan-induced production of granulocyte colony-stimulating factor (G-CSF) and IL-1α
was also strongly attenuated in macrophages from the TRPM2−/− mice. Sulfur mustard (SM),
an alkylating agent used in chemical warfare, causes tissue damage and induces inflammatory
responses. SM-induced production of IL-6, IL-8, and TNF-α by human neutrophils requires
TRPM2-mediated Ca2+ influx to activate the p38 mitogen-activated protein kinase (p38 MAPK)
signaling pathway [132]. The production of IL-6 and TNF-α was however enhanced in LPS-treated
macrophages from the TRPM2−/− mice and in response to LPS-induced infection in these mice [133].
Evidently, further studies are required to clarify the noticeable discrepancies from these studies that
used different infection stimuli and cell preparations. The production of IL-12 and IFN-γ after dextran
sulfate sodium-induced colon inflammation is significantly decreased in the TRPM2−/− mice [126].
Further analysis suggests that the TRPM2 channel function is required for the production of IL-12,
the early inflammatory cytokine produced by dendritic cells and possibly other immune cells as
well, which elicits IFN-γ-mediated innate immune responses. The deficient production of IL-12 and
IFN-γ in the TRPM2−/− mice led to a significantly lower survival rate after Listeria monocytogenes
infection, supporting a vital role for the TRPM2 channel in the innate immune response to this
infection [134]. A recent study shows that LPS/IFN-γ-induced increase in the [Ca2+]i and subsequent
release of nitric oxide in microglia also depends on the TRPM2 channel function [135]. Immune cells
such as macrophages and microglia also produce IL-1β, a key proinflammatory cytokine in innate
immunity [136]. The priming signal stimulates a Toll-like receptor (TLR) such as TLR4 by LPS or
other receptors to initiate signaling pathways leading to synthesis of pro-IL-1β. TRPM2 channels
mediate Ca2+ influx as the major ROS-induced Ca2+ signaling mechanism in macrophages [137],
which regulates NLRP3 inflammasome activation in macrophages by particulates such as charged
lipids, silica, and alum. This process is impaired in macrophages from the TRPM2−/− mice [138]. Thus,
TRPM2-mediated Ca2+ influx is a critical step in coupling ROS generation to NLRP3 inflammasome
activation and IL-1β maturation.
Notably, Sjøgren’s Syndrome (SS) has been associated with overexpression of proinflammatory
cytokines, including TNF-α, IL-7, IL-1β, IL-6, IL-10, IL-17, IL-18 and gamma-interferon
(γ-IFN) [139–141]. Moreover, one of these cytokines, IL-6, was correlated with poor quality of life in SS
patients [140]. Based on a body of evidence related to different pathological conditions, TNF-α and its
interactors are recognized to be involved in a pro-inflammatory/pro-oxidant condition, implicating
the relevance of redox imbalances in SS pathogenesis [142,143]. Related to excess expression of
proinflammatory cytokines, a pro-oxidant state could be postulated in SS based on the established
evidence for a mechanistic association of a pro-inflammatory condition and oxidative stress in a
number of disorders including, e.g., cancer, cardiovascular, neurological and pulmonary diseases,
and diabetes [143–146]. Furthermore, it should be noted that ROS is also produced by activated
granulocytes during inflammation both in SS pathogenesis and in other systemic disorders with
autoimmune features (e.g., systemic sclerosis). Cejková et al. has reported that Trpm2 knockout mice
showed attenuation of inflammatory indicators such as production of CXCL2, neutrophil infiltration
and ulceration [147]. Thus, ROS-evoked Ca2+ influx via TRPM2 could represent a key inflammatory
mediator in monocytes and in the epithelium of both salivary and lacrimal glands of SS patients.
It will be very important to investigate the role for this channel in SS-induced salivary gland pathology.
Establishing this will provide new strategies for treatment of the disease.
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7. Conclusions
Studies done over the past 30 years have provided a tremendous amount of information about
the key molecular components that regulate salivary gland fluid secretion, including those involved in
Ca2+ signaling, ion transport, and water transport. Future studies should be focused on establishing
the mechanisms underlying salivary gland dysfunction. Such studies should provide novel targets
and strategies for treatment. On such target in salivary glands is TRPM2, which appears to be
critically involved in radiation-induced irreversible loss of salivary gland fluid secretion. Based on
data reported by us and others, potential therapeutic strategies could include manipulating channel
activity, developing specific inhibitors of the channel or TRPM2-dependent signal transduction cascade.
In the case of radiation-induced salivary gland dysfunction, we propose that inhibitors of TRPM2 or
caspase-3, scavengers of ROS in the cytosol or mitochondria, as well as inhibitors of PARP1 could be
used to protect against loss of function. Additionally, its ability to respond to ROS has made TRPM2
a potential therapeutic target for chronic inflammation and neurodegenerative diseases. TRPM2 ion
channel and its gating molecule ADPR are previously unsuspected players necessary for robust
cytokine production and innate cell activation during intracellular bacterial infection. These findings
highlight the potential of the metabolic manipulation of ADPR levels or modulating TRPM2 activation
modalities to exert immunomodulation. However, currently, direct evidence for TRPM2 involvement
in Sjøgren’s Syndrome (SS) is lacking. Based on currently available data highlighting the role of
TRPM2 in inflammatory process, it will be very important to assess whether TRPM2 contributes to
Sjøgren’s Syndrome (SS). Identification of the role of other, including sensory, TRP channels in salivary
gland function will also provide additional targets for modulating water secretion from the gland.
Future studies should focus on these potentially novel and important roles of these TRP channels.
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Abstract: The transient receptor potential cation channel subfamily M member 4 (TRPM4) channel
influences calcium homeostasis during many physiological activities such as insulin secretion,
immune response, respiratory reaction, and cerebral vasoconstriction. This calcium-activated,
monovalent, selective cation channel also plays a key role in cardiovascular pathophysiology;
for example, a mutation in the TRPM4 channel leads to cardiac conduction disease. Recently,
it has been suggested that the TRPM4 channel is also involved in the development of cardiac
ischemia-reperfusion injury, which causes myocardial infarction. In the present review, we discuss the
physiological function of the TRPM4 channel, and assess its role in cardiovascular pathophysiology.
Keywords: TRPM4 channel; cardiovascular system; physiology; pathophysiology
1. Introduction
The transient receptor potential (TRP) melastatin-like subfamily member 4 (TRPM4) is
a 1214-amino-acid-long transmembrane protein encoded by TRPM4, which is located on human
chromosome 19 [1,2]. As a member of the TRP family, it participates in mediating the flux of Na+
and K+ across the plasma membrane into the cytoplasm [3]. In contrast to most of the functionally
characterized TRP channels, which are nonselective Ca2+-permeable cation channels, TRPM4 and
TRPM5 are permeable only to monovalent cations, and not to Ca2+ or Mg2+. The Ca2+ impermeability
of the TRPM4 channel plays a role in the accumulation of intracellular Ca2+, which leads to the
depolarization of the plasma membrane [2–5]. Although it is impermeable to Ca2+, TRPM4 is
a Ca2+- and voltage-activated channel, and its activation is regulated via a variety of methods.
Phosphatidylinositol 4,5-bisphosphate (PIP2) is an effective modulator of TRPM4 as the channel
can be rapidly desensitized to intracellular Ca2+ [6,7]. In addition, adenosine triphosphate (ATP),
protein kinase C (PKC)-dependent phosphorylation, and calmodulin (CaM) also play a role in TRPM4
activation [8–11], which will be discussed later on in the review.
Like other TRP channels, TRPM4 also comprises six transmembrane domains. The NH2
and COOH terminal regions of TRPM4 contain binding sites that are related to the channel’s
activation [1,10]. TRPM4 is highly expressed in a number of tissues and organs and involved
in complicated physiological and pathological mechanisms, especially in calcium-dependent
mechanisms, such as insulin secretion, immune response, respiratory reaction, tumor development,
and cardiovascular diseases [12–15]. Cardiovascular risks have a detrimental impact on human health,
and some research has implicated TRPM4 in cardiac hypertrophy, myocardial ischemia-reperfusion
injury (IRI), and hereditary arrhythmia [16–24]. In the present review, we focus on the physiological
role of TRPM4, and discuss its involvement in cardiovascular pathophysiology.
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2. Physiological Characteristics of TRPM4
2.1. TRP Overview
TRP cation channels were first reported in Drosophila spp. In 1975, and over 50 family members
have been characterized to date [1,25]. In general, they can be divided into seven subfamilies in
accordance with the amino acid sequence homology: TRPC, TRPV, TRPM, TRPP, TRPML, TRPA,
and TRPN. At present, 28 genes of the TRP family have been found to be expressed in mammalians
in succession, but only 27 different members are in humans [1,3,26]. The biophysical properties of
TRP family members have been described previously according to the reviews of Clapham et al.,
Watanabe et al., and Zheng et al. [11,15,26,27]. As mentioned earlier, all the TRPs contain six
transmembrane domains and are tetramerized to form functional channels. Therefore, the classical
structure of multiple cation channels is mimicked, such as voltage-dependent ion channels. It is
well known that Ca2+ is involved in many important cellular response mechanisms as a major
intracellular messenger [27–29]. The changes in intracellular Ca2+ concentration are closely related to
the physiological and pathological mechanisms in important tissue systems; for example, alteration in
calcium concentration in culture medium affects epidermal cell proliferation and differentiation [30].
It is widely acknowledged that the dynamic stability of extracellular and intracellular Ca2+
is beneficial to bone health and in maintaining the endocrine balance [31–33]. In recent years,
intracellular Ca2+ overload has been regarded as key in a series of cardiovascular risks such as coronary
artery diseases, arrhythmia, and cardiac failure; and clinically, calcium antagonists have been used
effectively in treating angina, hypertension, and supraventricular tachyarrhythmias, which illustrates
that maintenance of Ca2+ homeostasis confers cardioprotective benefits [34–40]. a majority of TRP
channels are permeable to Ca2+ and play a unique role as cell sensors [41]. They are involved in
various cellular functions mediated by Ca2+, such as contraction, proliferation, and apoptosis [42–44].
In other words, TRP channels act as gatekeepers in homeostasis [14,45–48]; for example, it has been
reported that the TRP channels maintain the dynamic equilibrium between Mg2+ and Ca2+ in epithelial
tissues [49].
The multiple functions played by the TRP channels and their activated multimodality
characteristics imply that correct channel gating or infiltration may facilitate the study of complex
pathophysiological mechanisms [1,14,16,50]. In the last ten years, several studies from Nilius et al.,
Watanabe et al., and Kaneko et al. have successively shown that TRP channels are highly expressed in
the gastrointestinal tract, genitourinary system, immune system, endocrine system, respiratory system,
nervous system, and cardiovascular system, which are involved in complicated physiological and
pathological processes [12–14].
In contrast to other TRP family members, TRPM4 can be activated by an intracellular accumulation
of Ca2+ [8,51]. In addition, TRPM4 is permeable to the monovalent cations with the following
ionic selectivity: Na+ > K+ > Cs+ > Li+ [52]. However, TRPM4 shows no Ca2+ permeability,
which induces intracellular Ca2+ accumulation and overload to cause depolarization of the cell
membrane, which further leads to cell damage or death [2,15]. Therefore, we will systematically
analyze the physiological and pathological role of TRPM4 in the cardiovascular system as far as the
specificity of TRPM4 for the non-permeability of Ca2+ is concerned.
2.2. Comparison between TRPM4 and TRPM5
Additionally, TRPM is a multifunctional group of TRP channels. As well as other TRPs,
the majority of TRPM members are cation channels with Ca2+-permeability, except for TRPM4 and
TRPM5. It has been described that there is 50% amino acid sequence homology between the two
channels [1,4]. The activity of TRPM5 is also initiated by a rise in the intracellular Ca2+, which is
quite similar to TRPM4, also being involved in numerous physiological and pathological mechanisms
by modulating Ca2+ homeostasis. For example, according to Banik et al., TRPM4 and TRPM5 are
both essential in transduction of taste stimuli [53]. Additionally, TRPM4 and TRPM5 are regulated by
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voltage and PIP2. TRPM5 has been regarded as a heat-activated channel, which shows temperature
sensitivity in the range of 15–35 ◦C. As a close homolog of TRPM5, the temperature sensitivity of
TRPM4 may be similar to that of TRPM5; studies have shown that its voltage-dependent activation
curve may turn toward a more negative potential with an increasing temperature [9,54–56].
In contrast to the similarities described above, there are several differences between TRPM4 and
TRPM5. For example, the tissue distributions of TRPM4 and TRPM5 are widely divergent. In research
by Fonfria and colleagues, compared to TRPM4 expression, TRPM5 expression was observed only
in a limited number of tissues including the intestine, pancreas, prostate, kidney, and pituitary.
On the other hand, TRPM4 is highly expressed in the heart, lung, brain, bone, and stomach [57].
TRPM4 is involved in action potential generation in mouse atrial cardiomyocytes [58]. In 2014,
Demir et al. found that the TRPM4 gene expression was increased slightly after exposure to myocardial
ischemia-reperfusion. In contrast, TRPM5 was not detected in the heart [59].
2.3. TRPM4 Structure
As a member of the TRP channel family, TRPM4 contains various transmembrane and cytosolic
domains that form a three-decker structure [60,61]. There is a wide selectivity filter of TRPM4 that is
permeable to the monovalent cations owing to the pore-forming area between the transmembrane
domains S5 and S6 [4,52,62]. As reported previously, the N-terminal nucleotide-binding domain and
the C-terminal coiled coil in the NH2 and COOH terminal regions influence the tetrameric composition
of TRPM4, and two ATP-binding cassette transporter-like motifs at the N-terminal nucleotide-binding
domain are involved in the inhibition of TRPM4 activity [60].
Moreover, there are several PKC phosphorylation sites, five CaM-binding sites, four Walker B
motifs (which are putative ATP-binding sites), a putative PIP2-binding site, and a coiled-coil domain,
all of which participate in the modulation of TRPM4 function [1,10,60].
2.4. Activation of TRPM4
As a Ca2+- and voltage-activated channel, there are diverse ways in which TRPM4 is activated,
and we will discuss the mechanisms underlying TRPM4 activation in terms of the following
modulators: PIP2, ATP, PKC-dependent phosphorylation, and CaM.
2.4.1. PIP2
PIP2 is a minor phospholipid component of the cell membrane, where it is a substrate for
a number of important signaling proteins [63,64]. As a substrate of phospholipase C (PLC), PIP2
regulates all types of ion channels and transporters, including the voltage-gated K+ and Ca2+
channels [65,66]. In 2005–2006, the studies of Zhang et al. and Nilius et al. showed that PIP2 is
a powerful enhancer of TRPM4, which may lead to a desensitization effect on TRPM4 activity through
PLC-mediated PIP2 decomposition [6,7]. With the hydrolysis of PIP2 in the plasma membrane due
to Ca2+-mediated PLC activation, TRPM4 gradually becomes insensitive to Ca2+, which leads to
a move toward the state of negative potential [6,9]. Under a Ca2+-desensitized condition, TRPM4
shows voltage-dependent gating with increased open-state probability at a depolarizing membrane
potential [51,60]. It has been demonstrated that poly-L-lysine, which is a type of PIP2 scavenger, can
trigger a sharp desensitization [7].
Previous studies have additionally shown that loss of PIP2 results in a rapid attenuation of the
TRPM4 current, in accordance with Nilius et al., which has been detected by adding PIP2 or inhibiting
PIP2 extracellularly of HEK293 cells, both of which can reverse the depletion of the TRPM4 current [6].
Furthermore, depression of PLC activity with U73122, an inhibitor of PLC [67], is also able to preserve
the level of PIP2 [6,9,68].
In summary, PIP2 is a critical auxiliary factor in the activation of TRPM4. PIP2 cannot activate
TRPM4 on its own, but can rectify desensitization, increase the sensitivity of TRPM4 to Ca2+, and restrict
the voltage dependence of TRPM4 [6,7,10,69,70]. To date, two PIP2-binding sites have been discovered
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at the C-terminal of TRPM4, which implies that the alteration of these binding sites may affect the
sensitivity of TRPM4 to PIP2 and Ca2+ [6,71].
2.4.2. ATP
Owing to the structure of TRPM4, Ca2+ sensitivity of TRPM4 can be modulated by ATP, PKC
phosphorylation, and binding of CaM to the C-terminus [8–11]. ATP can restore the Ca2+ sensitivity
of TRPM4 after desensitization has been clarified previously [8]. In the absence of Ca2+, TRPM4 can
revert from desensitization when the cytoplasmic side of the membrane is exposed to Mg2+-chelated
ATP [8,9]. However, TRPM4 currents would attenuate in the case of ATP deficiency after recovery.
Therefore, addition or depletion of ATP has become vital in regulating the activation of TRPM4. As
mentioned earlier, the ATP-binding sites, which include two Walker B motifs in the N-terminus and
ABC transporter signature motifs, can be predicted from the amino acid sequence of TRPM4 [8,72,73].
It was also reported that TRPM4 currents are eliminated sharply when all the sites predicted to
affect the ATP-binding of the channel carry mutations, which suggests that ATP is involved in the
preservation of TRPM4’s Ca2+ sensitivity [8].
2.4.3. PKC Phosphorylation
PKC-mediated TRPM4 phosphorylation can increase the Ca2+ sensitivity of TRPM4. A PKC
activator, phorbol 12-myristate 13-acetate (PMA), can reduce the Half maximal effective concentration
(EC50) level of Ca2+ in TRPM4 from 15 to 4 μM [8,74], which suggests that the increased activity of
PKC helps improve the Ca2+ sensitivity of TRPM4 and resist its desensitization. This effect of PMA
disappears when both the readily-phosphorylated amino acid residues, S1145A and S1152A, at the
C-terminus of TRPM4 carry mutations [8].
2.4.4. CaM
A previous study by Nilius et al. found that dominant-negative mutants of CaM reduce the
activation of TRPM4. CaM partially counters the reduction of Ca2+ sensitivity of endogenous TRPM4.
Mutations in the C-terminal binding site of CaM can significantly reduce TRPM4 current amplitude
and promote faster current decay. This suggests that the C-terminal binding site of CaM is vital for the
Ca2+ sensitivity of TRPM4 [8,75].
The following sections discuss why it is important to understand TRPM4’s role in diseases by
exploring the activated mechanism of the channel.
2.5. Inhibitors of TRPM4
Flufenamic acid is one of the inhibitors of TRPM4 and widely used in research [1]. Originally,
according to Winder et al., flufenamic acid was identified in the 1960s as a member of the anthranilic
acid-derivative class of nonsteroidal anti-inflammatory drugs (NSAID) due to its anti-inflammatory
property, which is able to inhibit the production of prostaglandins. Subsequently, it has been found
that flufenamic acid could act as an ion channel regulator that mainly impacts the nonselective cation
channels. The TRPM4 channel can be significantly inhibited by flufenamic acid in the range of 4–12 μM.
However, it affects sodium, potassium, calcium, and chloride channels as well [76].
Glibenclamide is another TRPM4 inhibitor, which can block TRPM4-like currents in sinoatrial
node cells completely at a concentration of 100 μM [77]. The inhibiting effect of glibenclamide on
TRPM4 channel is weaker than that on ATP-dependent K+ channels, which are vital therapeutic targets
of type II diabetes [78]. Compared to the chemicals above, 9-phenanthrol, which is a tricyclic aromatic
compound, inhibits TRPM4 activity specifically [79,80].
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3. TRPM4 and Cardiovascular Disease
3.1. TRPM4 and Arrhythmia
Arrhythmia is a group of conditions with abnormal frequency of cardiac pulsation and/or
rhythm, caused in the origin of heart activity and/or conduction disturbances, such as atrial sinus
node dysregulation, excitement outside the sinoatrial node, agitation, slow conduction, and blocked or
abnormal channel conduction [81–84]. Arrhythmia is an important class of diseases with respect to
cardiovascular risk. The reverse transport of the sodium–calcium exchanger (NCX) on cardiomyocytes
is one of the major pathways that leads to intracellular Ca2+ overload [85–89]. The research of Voigt et al.
In 2011 demonstrated that increased NCX expression and activity can delay afterdepolarization,
which triggers and promotes chronic atrial fibrillation [86,90–92]. Interestingly, the coupling of TRP
channels with NCX proteins (TRP–NCX-mediated Ca2+ signaling) is able to disrupt intracellular Na+
and Ca2+ concentration, which produces a sudden accumulation of intracellular Ca2+, especially in the
case of TRPC3 [93–95].
It is clear that TRPM4 is highly expressed in atrial cardiomyocytes [1,77]. Being a member of
the TRP channel family, it is worth considering whether a coupling between TRPM4 and reverse
mode-NCX may induce atrial arrhythmias [12]. In 2009, a TRPM4 mutation was detected in a patient
with hereditary heart disease: the glutamate at position 7 was replaced with lysine, which induced
progressive cardiac bundle-branch block [96]. This is the first case to closely link TRPM4 mutation
to the pathophysiology of human cardiovascular disease [1,96]. The researchers subsequently
demonstrated that although these mutations did not change the physiological characteristics of
TRPM4, the SUMOylation—a post-translational modification to regulate the protein function by
combining a member of the small ubiquitin-like modifier (SUMO) family and the target protein—of the
mutant protein caused the alternation of TRPM4 protein expression and its current level at the plasma
membrane [16–18,97].
However, the link between the function of TRPM4 and cardiac conduction block remains unclear.
Perhaps the dysfunction of the voltage-dependent Na+ channel takes place, considering that TRPM4
switches on the depolarization of the cell membrane potential, which subsequently injures the cardiac
conduction system [52,98,99]. Recently, other studies have also illustrated that TRPM4 mutations
are associated with isolated cardiac conduction disease, right bundle-branch block, tachycardia,
and Brugada syndrome [17–21].
In summary, the fluctuation of Na+ and Ca2+ is involved in the regulation of the cardiac conduction
system and is closely linked to the development of arrhythmia. As a result, TRPM4, which is
an important Ca2+ regulator, may also be involved in cardiac conduction system diseases.
3.2. TRPM4 and Cardiac Hypertrophy
Cardiac hypertrophy is one of powerful adaptive mechanisms of the cardiovascular system,
which is mainly manifested by an increase in cell volume and weight [100–102]. Adaptive alteration,
which is so-called physiological hypertrophy, occurs to meet the increased demand of blood circulation.
Under the physiological condition, the cardiac function can be performed in an orderly manner [93].
However, if it exceeds the range of compensation owing to cardiac pressure or volume overload, such as
high levels of angiotensin II (AII), chronic hypertension, valvular dysfunction, myocardial infarction,
and even excessive training, the hypertrophy shifts to an irreversible pathology, which induces severe
arrhythmia or cardiac failure [22,103–106].
Calcium is indispensable in the excitation–contraction coupling and heart contractility under
normal physiological conditions [87,88]. In the opinion of Lopea et al. In 1997, intracellular Ca2+ levels
in the cardiomyocytes of humans with myocardial hypertrophy were sustained at high levels [107],
which might be due to the following two methods: First, the activation of the phosphoinositide-specific
PLC pathway leads to the generation of inositol 1,4,5-trisphosphate and diacylglycerol (DAG) via the
hydrolysis of PIP2, both of which function as secondary messengers mediating the release of Ca2+
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from the smooth endoplasmic reticulum and sarcoplasmic reticulum [22,108–110]. Second, the nuclear
factor of activated T cells (NFAT), one of the transcription factors regulated by calcium signaling, also
takes part in the regulation of decompensated cardiac hypertrophy. CaM activates serine/threonine
phosphatase calcineurin (CN), and activated CN rapidly dephosphorylates the serine-rich region
and serine-proline (SP)-repeats in the amino termini of NFAT, resulting in its translocation from the
cytoplasm to the nucleus and producing pathological cardiac hypertrophy [111–114]. There is no doubt
that Ca2+ plays a significant role in inducing cardiac hypertrophy. Therefore, if the mechanisms that
maintain intracellular Ca2+ homeostasis are perturbed, the evolution of the hypertrophic alteration at
the stage of compensation and decompensation in the myocardium is affected. Thus, calcium-regulated
ion channels act as typical mediators.
TRP channels are important targets in myocardial remodeling because they are capable of
transmitting long-term calcium signals [115–117]. Studies have shown that TRPM4 seems to be
involved in the occurrence and development of cardiac hypertrophy, in accordance with Demion et al.,
Kecskés et al., and Guefer et al. [104,118,119]. Indeed, TRPM4 has been shown to play a role in cardiac
hypertrophy by the construction of a typical model that mimics the ventricular hypertrophic alteration
in spontaneously hypertensive rats (SHRs) [120]. Changes in TRPM4 current and mRNA levels are
detectable in SHRs. Compared with WKY rats (control group), the expression levels of TRPM4 mRNA
in SHRs were almost 50-fold.
Although a significant level of TRPM4 current exists in SHRs, it is quite challenging to find it
in WKY rats even by facilitating the TRPM4 current with application of PKC. TRPM4 properties can
be monitored by the Patch-Clamp measurement to illustrate the existence of a nonselective cation
channel in ventricular cardiomyocytes isolated from SHRs. Thus, TRPM4 is crucial during the process
of ventricular remodeling [22,120].
TRPM4 is a negative regulator of cardiac hypertrophy induced by angiotensin II (AII)
stimulation [104]. In this previous study, the researchers selectively removed the exons 15 and
16 from TRPM4 for establishing a cardiac-specific TRPM4-knockout mouse line (TRPM4cKO). They
intended to compare cardiac hypertrophic changes between TRPM4cKO mice and wild-type mice
(littermate controls; TRPM4+/+) under AII stimulation. Their results showed significantly higher
cardiac hypertrophy at the morphological level in TRPM4cKO mice compared with the wild-type mice,
including increased heart size and weight. In addition, high levels of hypertrophy-related genes such
as atrial natriuretic peptide (ANP), α-actin, and Rcan1 were detected in the TRPM4cKO mice.
TRPM4 deficiency increases the hypertrophic response to chronic AII in cultured neonatal
myocytes. Increased intracellular Ca2+ concentration in isolated ventricular cardiomyocytes of
TRPM4cKO mice after AII stimulation reconfirmed that TRPM4 is a key regulator of intracellular Ca2+.
There was also a significant rise in CN phosphatase activity in the hearts of TRPM4cKO mice following
AII treatment. In these mice, Rcan1 mRNA, which is a reporter of the calcineurin–NFAT activation
typical in cardiac hypertrophy, is overexpressed. Additionally, store-operated calcium entry (SOCE),
which is helpful in promoting intracellular Ca2+ collection from the extracellular environment, has
been regarded as having an important role in mediating cardiac hypertrophy [104,117,121]. The study
of Kecskés et al. showed that AngII-mediated SOCE was increased in Trpm4−/− myocytes [104].
It means that TRPM4 is related to modulation of the Ca2+ influx through SOCE to induce pathological
hypertrophy [104,117,121]
TRPM4 is important for the beneficial cardiac remodeling induced by endurance training, and the
role of TRPM4 in physiological and pathological cardiac hypertrophy has also been studied [118].
In TRPM4+/+ mice, enhanced cardiac function in response to endurance training was observed.
In contrast, a high number of apoptotic DNA fragments are detectable in TRPM4−/− mice after
endurance training. This illustrates that TRPM4 can obstruct the progress from adaptive hypertrophy
to irreversible cardiac remodeling. In the pathological cardiac hypertrophy, Ca2+ entry via SOCs causes
activation of the calcineurin–NFAT pathway. The TRPM4 channel inhibits the SOCs and thus prevents
pathological remodeling [118].
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The link between TRPM4 and arrhythmia, wherein 9-phenanthrol can inhibit TRPM4 and can
shorten the duration of action potentials (APs), has been confirmed previously, which implies that
TRPM4 can delay AP repolarization [119]. It has been hypothesized that TRPM4 is implicated in the
prolongation of AP duration, which may be present in the hypertrophied heart, but has not been
verified to date [122–124].
Thus, TRPM4 is an essential regulator of the hypertrophic alteration and is likely to supply a novel
direction for the treatment of cardiovascular diseases caused by cardiac hypertrophy [22,122].
3.3. TRPM4 and Myocardial IRI
Ischemic heart diseases (IHDs) have become the most frequently reported threat to human
health [125,126]. Myocardial ischemia originates owing to a reduction in coronary blood flow,
which may result in an imbalance between myocardial supply and demand of oxygen. Typical
symptoms include chest pain, chest discomfort, weakness or dyspnea after exercise, and mental
stimulation or overeating, which are detrimental to the quality of life. Restoring the blood flow
is an effective therapeutic strategy to treat ischemia, as achieved through thrombolysis, coronary
artery bypass graft, and percutaneous coronary intervention. However, secondary injuries after
recanalization are risk factors to IHD patients, such as contractile dysfunction, arrhythmia, and sudden
death, which are also known as myocardial IRI [127–129].
The mechanism underlying myocardial ischemia-reperfusion injury (IRI) is complex [130–132].
At the onset of ischemia, ATP decreases progressively, which subsequently causes a dysfunction of
ion pumps, leading to the accumulation of intracellular Ca2+, especially in the mitochondria. This
promotes the depletion of ATP with increased Ca2+, leading to cell death. With the return of blood
flow, even if it is conducive to the recovery of ATP, a large burst of Ca2+ and reactive oxygen species
in the mitochondria occurs at the onset of reperfusion, which opens the mitochondrial permeability
transition pore and causes further myocardial damage. Thus, reduced ATP and disrupted calcium
metabolism eventually lead to myocardial IRI. It has also been identified that Ca2+ increase and ATP
depletion are involved in the activation of TRPM4, and a link between TRPM4 and myocardial IRI has
been reported [36,130–134].
Inhibition of TRPM4 with 9-phenanthrol (9-Phe) has been shown to confer cardioprotective
effects against IRI in the rat heart [24]. In the Langendorff-perfused rat heart, the TRPM4 inhibitor
9-Phe produced a dramatic recovery of the damaged left ventricular contractile function caused by
experimental IRI. Furthermore, 9-Phe treatment could effectively resist the ventricular fibrillation
induced by IRI. This showed that damaged cardiac contractile function caused by IRI could be
rescued through the inhibition of TRPM4, which may confer cardioprotection mainly via an anti-
arrhythmic effect. After IRI, the infarcted area of myocardium was smaller in the rats treated with
9-Phe, which further elaborated that regulation of TRPM4 is important in reversing the myocardial
damage induced by IRI [24].
The relationship between TRPM4 and myocardial IRI has been explored more deeply in vitro
as well [23]. In rat ventricular cardiomyocytes H9c2, 9-Phe treatment prevented cellular damage
caused by two types of IRI models: one being reactive oxygen species stimulation (ROS) by hydrogen
peroxide (H2O2) exposure, and the other being hypoxia/reoxygenation (H/R) induction. Moreover,
the viability of cardiomyocytes with the TRPM4 knocked down through small interfering RNA (siRNA)
transfection was significantly higher than that of the nontransfection group following ROS damage and
H/R induction. It can also be suggested that inhibition of TRPM4 protects cardiomyocytes against IRI
both in vivo and in vitro, and 9-Phe treatment confers remarkable cardioprotection against oxidative
stress injury. Therefore, inhibiting TRPM4 might be promising in treating myocardial IRI for IHD
patients [23].
TRPM4 is closely related to intracellular Ca2+ dynamic equilibrium, and the mechanism of
intracellular Ca2+ overload-induced IRI has already been elucidated [8,116,122,135]. Therefore, the role
131
Cells 2018, 7, 62
of inhibiting TRPM4 in ameliorating an abrupt increase in intracellular Ca2+ during myocardial IRI is
being explored.
3.4. TRPM4 and Endothelial Cell Injury and Apoptosis
Endothelial injury is the risk factor and may cause a series of cardiovascular system
disorders [136,137]. Due to the research conducted by Gerzanich et al., Becerra et al., and Ding et al.,
the expression of TRPM4 could be upregulated when the vascular endothelium is damaged under
a variety of pathological conditions. For example, TRPM4 expression levels increase by more than
33% in endothelial cells damaged owing to a high-salt diet [138–141]. Moreover, the expression
of TRPM4 in both protein and mRNA forms increases in human umbilical vein endothelial cells
under hypoxic and ischemic conditions [10,142]. It has also been shown that TRPM4 is involved
in lipopolysaccharide-induced vascular endothelial injury [139]. Thus, inhibiting the expression or
activity of TRPM4 via 9-Phe and glibenclamide can effectively protect vascular endothelial cells against
lipopolysaccharide-induced damage.
In a lipopolysaccharide-treated group, more than 40% of the endothelial cells were apoptotic,
whereas the apoptosis in the TRPM4-inhihition group reduced significantly [139]. Lipopolysaccharide
induces endothelial cell death because it promotes a rise in intracellular ROS [143]. Furthermore,
the expression of TRPM4 is significantly upregulated upon treatment with exogenous ROS (H2O2),
which results in endothelial cell apoptosis. However, this could be reversed through the inhibition of
TRPM4 activity with 9-Phe [138]. Thus, it is implied that the involvement of TRPM4 in endothelial
injury is also mediated by ROS [131,133,134,144].
It is clear that under the influence of various vascular injury factors, the upregulation of TRPM4
in vascular endothelial cells produces complete or maximal depolarization, resulting in the continuous
influx of sodium ions [137–139]. Soon afterwards, the rise of intracellular Na+ and Cl− is able to
cause enlargement of osmotic pressure, which drives the influx of H2O, inducing cell swelling or
rupture [140].
4. Conclusions
Overall, TRPM4 is an important nonselective cation channel involved in cellular calcium
regulation. a majority of cardiovascular diseases are closely related to calcium homeostasis. As the
research on TRPM4 progresses, more functions will be recognized and intrinsic links between TRPM4
and the development of cardiovascular diseases may be discovered.
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Abstract: The enzyme-coupled transient receptor potential channel subfamily M member 7, TRPM7,
has been associated with immunity and immune cell signalling. Here, we review the role of this
remarkable signalling protein in lymphocyte proliferation, differentiation, activation and survival.
We also discuss its role in mast cell, neutrophil and macrophage function and highlight the potential of
TRPM7 to regulate immune system homeostasis. Further, we shed light on how the cellular signalling
cascades involving TRPM7 channel and/or kinase activity culminate in pathologies as diverse as
allergic hypersensitivity, arterial thrombosis and graft versus host disease (GVHD), stressing the need
for TRPM7 specific pharmacological modulators.
Keywords: TRPM7; kinase; inflammation; lymphocytes; calcium signalling; SMAD; TH17;
hypersensitivity; regulatory T cells; thrombosis; graft versus host disease
1. Introduction
The melastatin-like TRPM7 channel conducts divalent cations, specifically calcium (Ca2+),
magnesium (Mg2+) and zinc (Zn2+) [1–3]. It has been implicated in cellular and systemic Mg2+
homeostasis [4–6], Zn2+-mediated toxicity [7,8] and intracellular Ca2+ signalling [9–12]. The TRPM7
channel is considered to be constitutively active and its activity to be negatively regulated by
intracellular cations (Mg2+, Ba2+, Sr2+, Zn2+, Mn2+), Mg-ATP, polyamines, chloride (Cl−) and
bromide (Br−) concentrations, low intracellular pH and hydrolysis of the acidic phospholipid
phosphatidylinositol 4,5-bisphosphate (PIP2) [13–16]. Resting free cytosolic Mg2+ (0.5–1 mM [Mg2+]c)
and Mg-ATP (3–9 mM) concentrations [17] seem to be sufficient to block native TRPM7 channel
activity [4,18–20]. TRPM7’s unique enzyme encodes a serine-threonine kinase closely related to
eukaryotic elongation factor-2 kinase [21], phosphorylating mainly within α-helical loops [22]. A few
in vitro TRPM7 kinase substrates have been identified early on, including annexin A1 [23,24], myosin
II heavy chain [25] and PLCγ2 [26]. Only recently, with the development of novel mouse models,
the first native kinase substrate, SMAD2, was discovered, paving the way for more to follow [11,20,27].
Genetic disruption of TRPM7 in mice (Trpm7−/−) is embryonic lethal [4,28]. Deletion of
the exons encoding the TRPM7 kinase domain only (Trpm7Δk/Δk) also leads to early embryonic
lethality [4]. However, the latter phenotype could be attributed to a reduction in channel activity
in this mutant, particularly, as mice bearing a single point mutation at the active site of the
kinase (K1646R, Trpm7R/R), thus inactivating its catalytic activity, are viable and display no obvious
phenotype [29,30]. Heterozygous Trpm7+/Δk mice are also viable but develop hypomagnesaemia
upon Mg2+ restriction [4]. Deletion of the TRPM7 kinase domain at amino acid (aa) 1538 yields in
reduced current amplitudes, while caspase-induced deletion at aa 1510 results in enhanced TRPM7
currents [4,31]. Inactivation of kinase activity via the K1646R mutation (Trpm7R/R), though, does not
affect current development [29,30,32] (Figure 1). However, it was reported to show increased
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basal current activity right after break-in in macrophages [29]. Recently, it was shown that the
Mg2+-sensitivity of the TRPM7 channel is reduced almost two-fold in kinase-deficient Trpm7R/R mouse
mast cells. The tested Mg2+ concentrations, however, suggest that this effect will not influence TRPM7
currents in intact cells with [Mg2+]c close to 1 mM [20]. Accordingly, how TRPM7 channel and kinase
activities affect each other is still incompletely understood. It is thought that they are interdependent in
that Mg2+ enters through the channel pore and the kinase domain requires Mg2+ ions to function [3,22],
while the kinase domain rather than the catalytic activity are crucial for channel function [4,29–31].
 
Figure 1. TRPM7 topology. Each TRPM7 protein consists of six transmembrane segments (1 to 6) with the
channel pore located between segment 5 and 6. Within the N-terminus are melastatin homology domains
(MHD), characteristic for TRPM family members. The cytoplasmic C-terminus contains a transient receptor
potential domain (TRP), a coiled-coil domain (CC) and a kinase substrate domain (SD) upstream the
atypical α-type serine/threonine protein kinase domain (KD). Mutation at the catalytic side of the kinase
(K1646R) abolishes kinase activity without affecting current activity. Deletion of the KD at different amino
acids (aa) results in either enhanced or reduced current activity. The black star indicates the location
of the point mutation, crosses mark the kinase deletion. TRPM7 is negatively regulated by depletion
of phosphatidylinositol 4,5-bisphosphate (PIP2), physiologic free cytosolic magnesium concentrations
[Mg2+]c, Mg-ATP, polyamines, low pH and chloride (Cl−) and bromide (Br−) concentrations.
TRPM7 kinase requires Mn2+ or Mg2+ for its activity and uses mainly Mg-ATP for phosphorylation [22].
Massive auto-phosphorylation of TRPM7 increases kinase activity and substrate recognition [33–36].
Considering the ubiquitous expression of TRPM7, it is not surprising that the protein has a fundamental
and non-redundant role in cellular physiology [1,37]. It is involved in processes as diverse as
proliferation, growth, migration, apoptosis, differentiation and exocytosis [38]. Tissue-specific deletion
of TRPM7 in thymocytes or macrophages, as well as inactivation of the kinase activity (Trpm7R/R) in
mice, highlight the importance of this unique signalling protein for an operating immune system that
is still kept in check [20,28,39].
2. The Channel-Kinase TRPM7 in Immune Cell Signalling
2.1. TRPM7 Kinase Regulates Mast Cell Reactivity
Mast cells are associated with the progression of different pathologies such as immediate and
delayed hypersensitivity reactions, arthritis, atherosclerosis, heart failure, as well as neuroinflammatory
diseases [40–42]. Upon stimulation, mast cells release granules, filled with inflammatory mediators
such as histamine, proteases, cytokines and growth factors [43,44]. Mast cells are present in all
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organs in close proximity to blood vessels, neurons and lymphatic vessels, thus disseminating local
inflammatory signals [40]. While classically, mast cells are activated via crosslinking of the IgE
receptor (FcεRI) upon antigen binding [45], their activation can be triggered by many other stimuli
including toll-like receptor (TLR) ligands, complement and neuropeptides. Receptor stimulation in
mast cells leads to a network of stimulatory and inhibitory signals [44] encoded via intricate Ca2+
signalling events [46,47]. Store operated Ca2+ entry is essential for mast cell activation in vitro and
in vivo [48,49]. Recently, TRPM7 has been implicated in receptor-induced Ca2+ release as well as
store-operated Ca2+ entry [9,12]. In primary human lung mast cells (HLMCs) and in the human
mast cell lines, LAD2 and HMC-1, TRPM7 expression and function was shown to be essential
for cell survival. Using adenoviral-mediated knock-down of TRPM7 in HLMC or HMC-1 authors
observed enhanced cell death, which was not rescued by extracellular Mg2+ supplementation [50].
First indications that TRPM7 is involved in degranulation processes and release of cytokines in rat
bone marrow-derived mast cells (BMMCs) were gained in 2014. TRPM7 mRNA expression levels
were significantly higher in asthmatic rat BMMCs than in controls. Genetic or pharmacological
inhibition of TRPM7 significantly decreased β-hexosaminidase activity and secretion of histamine as
well as the release of the pro-inflammatory cytokines IL-6, IL-13 and TNF-α in the asthmatic group
compared to the control group. Authors concluded that inhibition of TRPM7 currents reduces mast
cell degranulation and cytokine release [51]. However, functional TRPM7 channel or kinase activities
were not shown. The pharmacological antagonist used to inhibit TRPM7, 2-Aminoethoxydiphenyl
Borate (2-APB), supposedly only blocks channel and not kinase activity but has various off-target
effects. Importantly, at the applied concentrations (100–200 μM) 2-APB blocks store operated Ca2+
entry (SOCE) via inhibition of Ca2+ release activated calcium (CRAC) channels [52]. Thus, it is possible
that observed 2-APB effects were in fact not mediated by TRPM7 but SOCE. Authors, however,
confirm the reduction in β-hexaminidase activity as well as in histamine and cytokine release, using a
lentiviral siRNA-mediated knock-down of TRPM7 in primary BMMCs [51]. Nonetheless, the question
remained, whether kinase and/or channel activity were responsible for the observed phenotype.
As kinase-deficient Trpm7R/R mutant mouse mast cells showed normal current amplitudes but no
kinase activity, this model allowed the independent study of TRPM7 channel versus kinase moieties in
mast cells [32]. Utilizing the two TRPM7 kinase mutant mouse models (Trpm7+/Δk, Trpm7R/R), it was
shown that the kinase regulated G protein-coupled receptor-activated histamine release, independently
of channel activity. TRPM7 kinase activity, moreover, regulated Ca2+-sensitivity of G protein-triggered
mast cell degranulation. TRPM7 kinase-deficiency resulted in suppressed IgE-dependent exocytosis
and slower cellular degranulation rates. Besides, extracellular Mg2+ was necessary to guarantee
regulated IgE-induced exocytosis. Authors concluded that the TRPM7 kinase activity controls murine
mast cell degranulation and histamine release independently of TRPM7 channel function [32]. Thus,
TRPM7 might inflict its immune-modulatory role on mast cells via its kinase domain.
2.2. TRPM7 in Neutrophil Migration
Neutrophils, the most abundant leukocytes in the blood, are one of the key players of the innate
immune system, contributing to the clearance of acute inflammation and bacterial infection [53].
During acute inflammation neutrophils are one of the first responding cells. The signalling cascades
triggered after neutrophil activation start with migration of neutrophils towards the inflammatory
site. The cascade ends with elimination of pathogens via secretion of chemokines, which attract
other leukocytes, phagocytosis to maintain tissue homeostasis and degranulation and release of
neutrophil extracellular traps (NETs) to prevent the spread of the infection. It is well established
that Ca2+ signalling is pivotal for the recruitment cascade and activation of neutrophils, highlighting
the importance of ion channels for neutrophil function [54,55]. TRPM7 channel activity has been
implicated as a regulator of cell migration by facilitating Ca2+ oscillations [56–58]. Using a human
neutrophil cell line, it was shown that TRPM7 is recruited into lipid rafts in a CD147-dependent manner.
Knock-down of CD147, a glycoprotein required for neutrophil recruitment and chemotaxis, caused
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significant decrease in lipid raft localization of TRPM7. Thus, TRPM7 was suggested to be involved in
the CD147-triggered Ca2+-induced chemotaxis, adhesion and invasiveness of human neutrophils [59].
However, Wang and colleagues did not show functional TRPM7 ion channel activity and one needs to
keep in mind that neutrophil-like cell lines are controversially discussed regarding their comparability
to primary neutrophils [53]. During acute lung injury (ALI), the permeability of the alveolar-capillary
membrane is increased, which in turn can lead to migration of neutrophils [60]. A septic rat model
treated with salvianolic B showed that sepsis-induced ALI was reduced due to decreased levels of
TRMP6 and TRPM7 mRNA in lung tissue, potentially linking TRPM7 to neutrophil migration and
infiltration [61]. As patients with inherited neutrophil deficiencies suffer from severe infections that
are often fatal, underscoring the importance of this cell type in immune defence, it is critical to gain
a better understanding of the role of TRPM7 channel and kinase activities in the signalling cascades
triggering neutrophil migration [53].
2.3. TRPM7 Guides Macrophage Activation and Polarization
Blood monocytes and tissue macrophages are major components of innate immunity, strategically
positioned throughout the body tissues to orchestrate inflammatory processes. Similar to neutrophils,
they maintain tissue homeostasis via phagocytosis of dead cells, debris or potentially harmful
pathogens. As antigen presenting cells they are able to activate and coordinate the adaptive immune
system [62,63]. Various TRP proteins have been associated with macrophage-mediated inflammatory
responses [64]. TRPM7 has also been linked to the activation and proliferation of monocytes and
macrophages [29,65–68]. However, controversies on the role of TRPM7 for macrophage activation
in response to LPS remain [39,68]. On the one hand, TRPM7 channel activity was suggested to
be essential for macrophage proliferation and polarization into the alternate or anti-inflammatory
M2-subtype [68]. LPS and co-stimulatory cytokines IFN-γ (pro-inflammatory M1-type) or IL-4 and
IL-13 (anti-inflammatory M2-type) trigger the polarization of macrophages [69,70]. Interestingly,
the activity of TRPM7 increased significantly in response to stimulation with IL-4. The TRPM7 inhibitor
NS8593 [71] blocked IL-4 and M-CSF induced proliferation and reduced the inhibitory effect of IL-4 or
M-CSF on the LPS-induced expression of the pro-inflammatory cytokine TNF-α, thus, counteracting
the differentiation into the M2 subtype [68]. On the other hand, more recently, TRPM7 channel activity
has been implicated in macrophage activation in response to LPS and LPS-induced peritonitis [39].
In TRPM7-deficient macrophages (Trpm7fl/fl(LysM Cre)) IL-1β secretion was significantly reduced and
also the gene expression upon LPS stimulation was altered, indicating a key function of TRPM7 in the
activation process of macrophages. In addition, it was found that TRPM7 is pivotal for the endocytosis
of LPS-TLR4-CD14 signalling complexes with TRPM7-deficient macrophages showing significantly
reduced internalization of TLR4 and CD14. Schappe et al. demonstrated that these defects upon
LPS stimulation were due to diminished TRPM7-mediated Ca2+ influx. They speculate that TRPM7
not only controls TLR4 internalization but also regulates downstream IRF3 and NFκB signalling by
mediating cytosolic Ca2+ elevations. Moreover, in a LPS-dependent model of peritonitis, Trpm7fl/fl
(LysM Cre) mice had decreased serum cytokine levels after LPS treatment, preventing pathological
inflammation. Specifically, the expression levels of Tnfa and Il1b were significantly reduced, resulting
in a diminished recruitment of immune cells into the peritoneum. Thus, Trpm7fl/fl (LysM Cre) mice
were protected from the development of LPS-induced peritonitis. Consequently, it was suggested that
TRPM7 channel blockade could be beneficial for the treatment of chronic infections or septic shock [39].
The difference in the macrophage response to LPS might depend on different protocols used. However,
to date there is no consensus, whether LPS induces Ca2+ elevations resulting in macrophage activation.
Several studies have found no changes in cytosolic Ca2+ concentrations in response to LPS treatment
in macrophages [72,73].
The role of TRPM7 kinase activity in macrophage or dendritic cell function is far less understood.
TRPM7 kinase-deficient mice (Trpm7R/R) show no defects in percentages of macrophages [29]. Also,
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Trpm7R/R CD11c+ dendritic cells develop normally and display regular major histocompatibility
complex II (MHCII) and integrin expression [20].
2.4. TRPM7 Affects Lymphocyte Functions
Lymphocytes forming the adaptive or acquired immune response are activated and regulated
by cells of the innate immune system, that is, macrophages and provide immunologic memory [74].
Antigen specific lymphocytes respond to pathogens with activation induced proliferation and clonal
expansion. This temporal proliferative burst is terminated with a return to cell quiescence and eventual
cell death. The autonomous timing of proliferation ensures an appropriate response magnitude whilst
preventing uncontrolled expansion. Thus, a detailed understanding of the regulatory principles
governing lymphocyte activation, proliferation, differentiation and survival is essential to a cohesive
picture of the immune system homeostasis [75].
2.4.1. TRPM7 Kinase Regulates Intracellular Calcium Signals and Proliferation in Lymphocytes
Upon T cell receptor (TCR) or B cell receptor (BCR) stimulation, phospholipase C (PLC) is
activated, catalysing the hydrolysis of PIP2 into diacylglycerol (DAG) and inositol (1,4,5) triphosphate
(IP3). Subsequently, IP3 triggers Ca2+-release from the endoplasmatic reticulum (ER) Ca2+-store via
the IP3-receptor (IP3R). Upon depletion of Ca2+ from the ER lumen, the stromal interaction molecule
(STIM) translocates to the plasma membrane and triggers SOCE via CRAC channels. This prolonged
increase in intracellular Ca2+ concentrations is essential for the nuclear factor of activated T cells
(NFAT) to translocate into the nucleus and induce transcription of genes essential for cell proliferation
and clonal expansion (Figure 2) [38].
Recently, Romagnani et al. revealed that TRPM7 kinase-dead (Trpm7R/R) CD4+ T cells show
slightly but significantly decreased Ca2+ signals upon stimulation with plate-bound anti-CD3/CD28
antibodies, whereas basal cytosolic Ca2+ concentrations ([Ca2+]c) were unaltered [20]. These experiments
were performed using extracellular 2 mM Ca2+ concentrations. Similarly, Beesetty et al. showed that
receptor-mediated Ca2+ signalling was significantly diminished in Trpm7R/R T cells using anti-CD3
crosslinking in 0.4 mM extracellular Ca2+ levels, and differences in 2 mM Ca2+ concentrations were
even more pronounced. Nevertheless, basal [Ca2+]c was also unchanged. In addition, SOCE was
decreased in Trpm7R/R splenocytes upon pre-treatment with phorbol 12-myristate 13-acetate (PMA)
and ionomycin, while there was no difference in ER-store Ca2+ content. Basal [Ca2+]c, however,
were lower in PMA and ionomycin pre-activated Trpm7R/R T cells compared to wild-type (WT) [10].
These results are in line with recent studies, suggesting that TRPM7 regulates store-operated Ca2+ entry.
Faouzi et al. linked TRPM7 channel and kinase moieties to direct involvement in SOCE. Trpm7-deficient
chicken B lymphocytes exhibited down-regulation of SOCE, which was mainly attributed to missing
kinase activity [12]. Moreover, it was shown that TRPM7 channels seem to be essential to sustain the
Ca2+ content of intracellular stores in resting cells. Authors speculate that TRPM7 kinase may directly
phosphorylate STIM2, thereby influencing Ca2+ entry via SOCE, yet found no effect on phosphorylation
of STIM1 or STIM2 [12].The first indication that TRPM7 activity is involved in SOCE was found in 2005.
Matsushita and colleagues reported that SOCE, in response to thapsigargin-induced store depletion,
was increased in HEK293 cells transfected with WT TRPM7 but did not change in cells transfected
with a kinase domain-deleted TRPM7ΔKD (aa 1-1599) mutant construct, compared to mock transfected
controls. However, the described TRPM7ΔKD mutant displayed almost no current activity, leaving
the question of the role of TRPM7 channel versus kinase moieties unanswered [76]. Also, the impact
of TRPM7 kinase activity on T cell proliferation efficiency, following Ca2+ signalling events, remains
controversial. While Romagnani et al. discovered that Trpm7R/R T cells proliferate independently of
their kinase activity in response to TCR stimulation (plate-bound anti-CD3/CD28) [20], Beesetty et al.
showed a reduced T cell proliferation, in response to PMA and ionomycin treatment during the
first 24 hours, which was compensated for after 48 and 72 hours [10]. As the reported reduction in
Ca2+ signalling was very small, using plate-bound anti-CD3/CD28 antibodies, it is not surprising
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that Trpm7R/R T cell proliferation was not altered [20]. The decrease in SOCE upon pre-treatment
with PMA ionomycin in Trpm7R/R splenocytes however, was much more pronounced, resulting in
reduced proliferation [10]. The combination of PMA—directly activating protein kinase C—with the
calcium ionophore ionomycin, which increases [Ca2+]c, is a fast and powerful stimulus, circumventing
classical receptor activation. Thus the observed alterations in proliferation depend on the experimental
conditions used, suggesting that TRPM7 kinase might influence proliferation depending on the stimuli
and that receptor-operated mechanisms might be compensating [10,20]. Summarizing, these studies
highlight a potential role of TRPM7 kinase activity in regulating Ca2+ signalling and subsequent
activation processes in T cells and suggest TRPM as key regulator of the temporal proliferative burst.
However, how exactly TRPM7 channel and kinase activities interplay to regulate Ca2+ signalling and
subsequent proliferation in T lymphocytes still needs further investigation.
 
Figure 2. Role of TRPM7 kinase in calcium signalling and proliferation of T cells. Upon T cell
receptor (TCR) binding, phospholipase C (PLC) is activated and hydrolyses phosphatidylinositol
4,5-biphosphate (PIP2) to inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). DAG in
conjunction with Ca2+ activates protein kinase C (PKC), thus inducing cell proliferation. IP3 induces
Ca2+ release from the endoplasmic reticulum (ER) via IP3 receptor (IP3R), followed by the translocation
of the stromal interaction molecule (STIM) to the plasma membrane. STIM triggers Ca2+ influx from
the extracellular space via ORAI/CRACM channels. Ca2+ is rapidly removed from the cytosol by the
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), refilling the ER Ca2+ stores. The prolonged
increase in cytosolic Ca2+ concentrations leads to the activation of calcineurin, resulting in the
dephosphorylation and nuclear translocation of nuclear factor of activated T cells (NFAT) and
subsequent cytokine expression, e.g., interleukin 2 (IL-2), triggering clonal expansion of T cells.
2.4.2. TRPM7 in Cell Growth, Activation and Development of B Cells
A Trpm7-deficient B-lymphocyte cell line (chicken DT40 cells) exhibits a selective defect to
proliferate in regular media but can do so in media supplemented with 10 mM Mg2+. After 24 h
in regular media, TRPM7-deficient B cells accumulated in the G0/G1 phase of the cell cycle and were
reduced in average cell size. Authors conclude that TRPM7-deficient cells display a defect in growth,
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failing to increase in size and mass. This defect was attributed to the lack of signalling downstream of
phosphoinositide 3-kinase (PI3-K) with impaired mammalian target of rapamycin complex 1 (mTORC1)
signalling, ribosomal S6 kinase (S6K) and Akt activation, whereas ERK phosphorylation was unaltered.
Interestingly, overexpression of constitutively active AKT was not sufficient to overcome this growth
defect. However, provision of a heterologous sustained PI3K signal, utilizing a constitutively active
form of the catalytic subunit of PI3K, p110α, counteracted the failure of TRPM7-deficient cells to
grow and proliferate in regular media. Thus TRPM7 was positioned alongside PI3K signalling as
a central regulator of lymphocyte growth [77]. Moreover, TRPM7 was shown to be essential for
cell-cycle progression, as Trpm7-deficient DT40 B cells showed an up-regulation of p27kip, a key cell
cycle regulator which blocks the transition from G0 to S phase. The quiescence was reversible and
rescued by Mg2+ supplementation or TRPM7 overexpression [78]. Utilizing the same Trpm7-deficient
DT40 B cell line and a DT40 cell line expressing the kinase-dead mutant (K1648R), it was recently
shown that TRPM7 is essential for early events of B cell activation through both kinase and channel
activities. TRPM7 channel activity controlled antigen uptake and presentation to T cells [27]. Previously,
TRPM7 kinase has been suggested to regulate non-muscle myosin IIA filament stability as well as
actomyosin contractility by phosphorylating myosin IIA heavy chain [25], while the Mg2+ influx through
the channel was also correlated with maintenance of myosin II-dependent cytoskeletal organization [79].
TIRF microscopy revealed that expression of TRPM7 in B cells controlled actin dynamics and slowed
antigen internalization, resulting in prolonged B cell signalling. Authors conclude that TRPM7 signalling
is essential for B cell affinity maturation and antibody production [27]. Moreover, recent findings
indicate that TRPM7 expression is required for murine B cell development. Mice with tissue specific
deletion of TRPM7 in B cells failed to generate peripheral B cells due to a developmental defect
at the pro-B cell stage and increased apoptosis of B cell precursors in the bone marrow. In vitro
the development of Trpm7-deficient B cells could be rescued via Mg2+-supplementation. Whereas,
TRPM7 kinase-deficiency did not affect the development of B cells in the bone marrow or the percentage
of peripheral B cells. Interestingly, the deletion of the entire TRPM7 protein in B cells lead to increased
percentages of neutrophils, eosinophils and monocytes in the spleen of mutant mice, compared to WT
which could be attributed to the primary lack of B cells [80]. Thus, TRPM7 channel and kinase activities
seem unique and non-redundant for proper B cell function.
2.4.3. TRPM7 in Murine T Cell Development, Differentiation and Transcriptional Regulation
In murine T lymphocytes TRPM7 is required for thymic development and thymopoiesis.
Conditional knock-out of Trpm7 in the T cell lineage was shown to disrupt thymopoiesis,
with thymocytes remaining in the double negative (CD4−CD8−) state and resulted in altered
chemokine and cytokine expression profiles [28], indicating that TRPM7 channel and/or kinase
are important for T cell function. Using the homozygous kinase-dead Trpm7R/R mouse model,
recently it was shown that TRPM7 kinase activity is not essential for thymopoiesis [10,20]. However,
the enzymatic activity of TRPM7 is required for intra-epithelial T cell homeostasis. Trpm7R/R mice
almost completely lack gut intraepithelial T lymphocytes (IELs) [20]. Intestinal IELs represent a first
line of defence within the largest immune organ of our body [81]. Numerous effector T lymphocytes
differentiate in the intestine, from where they migrate into the periphery [82,83]. Thus, understanding
the gut immune system, harbouring ∼70% of the total lymphocytes in the human body, is of utmost
importance [81,84] for regulating of immune homeostasis. Analysis of the percentage of remaining
TRPM7R/R IELs revealed a significant reduction in pro-inflammatory TH17 cell subsets, while the
percentage of anti-inflammatory Treg cells was unaffected compared to WT. Consistently, the in vitro
differentiation of naïve Trpm7R/R T cells into TH17 cells was also compromised, while the Treg cell
differentiation proceeded unperturbed. These findings were coherent with the robust reduction of
IL-17 concentration in serum from Trpm7R/R mice [20]. As TGF-β/SMAD pathways are crucial for the
polarization of CD4+ T cells into TH17 cells [85], it is likely that the TGF-β/SMAD signalling pathway
is affected by TRPM7 kinase activity (Figure 3). Notably, Western Blot analysis of Trpm7R/R naïve CD4+
146
Cells 2018, 7, 109
T cells treated with TGF-β1 revealed a significant reduction in SMAD2 phosphorylation, while SMAD3
phosphorylation was unaltered. Analysis of the TGF-β1-induced SMAD2 translocation was also
significantly reduced in Trpm7R/R naïve CD4+ T cells. Thus, authors conclude that the TRPM7 kinase
regulates TH17 cell differentiation via TGF-β/SMAD2 dependent pathways. An in vitro kinase assay
using highly purified recombinant TRPM7 kinase, SMAD2, as well as C-terminally truncated SMAD2
revealed that TRPM7 phosphorylates SMAD2 in a dose dependent manner but fails to phosphorylate
the truncated SMAD2. Thus, the C-terminal Ser465/467-motif of SMAD2 was identified as a novel
substrate for the TRPM7 kinase [20]. The upregulation of the integrin αE, also known as CD103,
enables T cells to migrate into the gut epithelium [86,87] and is dependent on SMAD2 TGF-β/SMAD2
signalling cascades [88], which was significantly impaired in TGF-β-treated Trpm7R/R T cells. Using a
chromatin immunoprecipitation (ChIP) assay, the authors demonstrated a defective binding of SMAD2
to the Itgae (CD103) promoter in Trpm7R/R T cells in response to TGF-β. Consequently, the expression
of the gene encoding for CD103, Itgae, was also significantly reduced in primary Trpm7R/R IELs as
well as in response to TGF-β and T cell receptor co-stimulation in naïve Trpm7R/R T cells. Consistently,
the expression of the signature transcription factor for TH17 cells, Rorc, as well as the cytokine IL-17,
which both depend on SMAD2 phosphorylation and translocation into the nucleus, were also impaired
in Trpm7R/R T cells (Figure 3). Interestingly, the CD103 expression in Trpm7R/R CD11c+ dendritic cells
was normal, compared to WT [20]. If or how TRPM7 kinase is triggered via TGF-β stimulation in T cells
is still under investigation. One emerging concept, however, could involve a constitutively active
TRPM7 kinase that phosphorylates SMAD2 once it is anchored to the plasma membrane following
TGF-β receptor activation (Figure 3). Importantly, this selective defect of SMAD2 signalling in T cells
culminating in reduced pro-inflammatory TH17 cell differentiation, while leaving anti-inflammatory
Treg cell differentiation unaffected (Figure 4A,B), highlights the essential function of TRPM7 kinase in
immune homeostasis [20]. These results suggest that TRPM7 kinase might serve as molecular switch
from pro-inflammatory to anti-inflammatory milieu and highlights the potential of TRPM7 kinase
inhibition for the treatment of pro-inflammatory diseases.
 
Figure 3. TRPM7 kinase in T cell signalling and transcriptional regulation. Upon binding of tumour
growth factor β1 (TGF-β1), the TGF-β receptor complex (TGFβRI/II) initiates the phosphorylation
of the c-terminal SXS-motif of SMAD2. Results gained from TRPM7 kinase deficient murine T cells
suggest an additional mechanism by which the TRPM7 kinase phosphorylates SMAD2 directly, once it
is anchored to the plasma membrane. Phosphorylated SMAD2 interacts with SMAD4 and promotes
the transcription of Itgae, Il-17 and Rorc genes. The interleukin 6 (IL-6) dependent STAT3 as well as
Erk1/2 phosphorylation pathway is unaltered in TRPM7 kinase deficient murine T cells.
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To date, very little is known regarding the role of TRPM7 in human lymphocytes. Pharmacological
inhibition of TRPM7 in a human T cell line results in growth arrest and reduced proliferation [89].
TRPM7 was suggested to be involved in the migration of activated human T cells, where it is located
in the uropod, in conjunction with the calcium-activated potassium channel, KCa3.1, facilitating T cell
migration. Knock-down via siRNA resulted in a significant reduction in number and velocity of
migrating cells [90]. Moreover, TRPM7 was associated with TNF-α-induced necroptosis in T cells.
Knock-down of TRPM7 in a T cell line protected it from necroptosis [91]. Nonetheless, it will be
necessary to determine if the observed crucial functions of TRPM7 kinase and channel moieties in
murine lymphocytes also applies to human counterparts.
Figure 4. TRPM7 kinase is essential for T cell differentiation into the pro-inflammatory TH17
cell type and the development of graft versus host disease. (A) Naïve CD4+ T cells differentiate
into pro-inflammatory TH17 cells in the presence of TGF-β and IL-6. For the differentiation into
anti-inflammatory regulatory T cells (Tregs), the cytokines TGF-β and IL-2 are required. (B) Genetic
inactivation of TRPM7 kinase activity (Trpm7R/R) results in reduced TH17 cell differentiation, indicated
via diminished Rorc and Il-17 mRNA expression as well as IL-17 serum levels, while Treg cell
differentiation, evident via FoxP3 expression and IL-10 serum levels, is unaltered. In addition,
integrin αE (CD103) expression is reduced in TRPM7 kinase deficient T cells. (C) Transplantation
of bone marrow cells (BMC, C57BL/6) in conjunction with splenocytes (SPL, C57BL/6) triggers the
development of graft versus host disease (GVHD) in lethally irradiated mice with different genetic
background (BALB/c), manifesting in massive tissue destruction of the intestine but also lung and skin
tissues. TRPM7 kinase deficient BMC and SPL transplantation does not induce inflammation in the
intestine and ameliorates or even prevents disease progression, suggesting TRPM7 kinase inhibition as
valid tool for the treatment of GVHD. n.a. (not altered).
3. TRPM7-Mediated Hematologic and Inflammatory Diseases
3.1. Hypomagnesaemia and TRPM7 Kinase in Delayed-Type Hypersensitivity Reactions
Mg2+ is a vital mineral macronutrient. Considering that low serum Mg2+ levels have also been
linked to memory decline, neurodegenerative diseases, decrease in muscle performance, heart failure,
certain cancers, autoimmune diseases and allergic reactions, it is of critical importance to further
identify the mechanisms regulating the availability of this macronutrient [92,93]. Recently, it was
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shown that TRPM7, in conjunction with its sister channel TRPM6, regulates systemic Mg2+ homeostasis
via absorption of Mg2+ in the intestine [94]. The interconnection between nutrient metabolism and the
immune system occurs at many levels, ranging from endocrine signalling to direct sensing of nutrients
by immune cells [95]. Interestingly, adult Trpm6-deficient mice suffered from hypomagnesaemia and
displayed a degeneration of many lymphoid organs. The thymus of mutant mice was only rudimentary
present with an essentially undistinguishable cortex region. Also, the red pulp of the spleens
of Trpm6-deficient mice was substantially reduced. Dietary Mg2+ supplementation rescued these
phenotypes, indicating that indeed hypomagnesaemia was responsible for the observed deficits [94].
While homozygous genetic deletion of the ubiquitously expressed TRPM7 kinase domain in
mice leads to early embryonic lethality, heterozygous Trpm7+/Δk mice are viable and develop a severe
hypomagnesaemia upon Mg2+ restriction, leading to increased mortality, susceptibility to seizures as
well as prevalence for allergic hypersensitivity [4]. It is known that low, systemic Mg2+ levels correlate
with cell-extrinsic enhancement of systemic inflammatory and allergic responses [96]. To evaluate the
level of delayed-type hypersensitivity responses in Trpm7+/Δk mice, oxazolone sensitization experiments
were performed. Trpm7+/Δk mice displayed an elevated oxazolone-induced contact hypersensitivity,
compared to WT [4]. Interestingly, homozygous mice with genetic inactivation of TRPM7 kinase
activity, via a point mutation within the active site of the kinase, Trpm7R/R, were viable and did
not develop hypomagnesaemia or hypersensitivity responses. In fact, they even displayed reduced
oxazolone-induced delayed type hypersensitivity responses [30]. Their systemic Mg2+ and Ca2+
levels were similar to WT, as the channel function was not affected by the point mutation [29,30,32].
Since allergic reactions are triggered by mast cell-mediated histamine release, the role of TRPM7 in mast
cell degranulation and histamine release was studied using Trpm7+/+, Trpm7+/Δk and Trpm7R/R mice.
As reported, degranulation and histamine release proceeded independently of TRPM7 channel function.
However, as extracellular Mg2+ was essential to control unperturbed IgE-DNP-dependent exocytosis
and removal of Mg2+ exaggerated histamine release, the observed differences in hypersensitivity
responses could be attributed to the different systemic Mg2+ levels in Trpm7+/Δk versus Trpm7R/R
mice. G-protein-coupled receptor stimulation revealed strong suppression of histamine release in
both kinase-deficient mast cells (Trpm7+/Δk and Trpm7R/R), whereas removal of extracellular Mg2+
caused the phenotype to revert, suggesting that the TRPM7 kinase activity regulates murine mast cell
degranulation by changing its sensitivity to intracellular Ca2+ and extracellular Mg2+ concentrations [32].
Thus, TRPM7 might inflict its immune-modulatory role by sensing cations via its kinase domain. To date,
little is known about activation mechanisms or physiologic substrates of TRPM7 kinase.
3.2. The TRPM7 Channel-Kinase in Arterial Thrombosis and Stroke
TRPM7 kinase has been suggested to regulate myosin IIB filament stability as well as actomyosin
contractility by phosphorylating myosin IIA [25]. Recently, it was shown that TRPM7 channel activity
also affects myosin IIA activity independently of kinase function. In conditional Trpm7-deficient
mice (Trpm7fl/fl-Pf4Cre), TRPM7 modulates platelet function via regulation of cellular Mg2+ homeostasis
and cytoskeletal myosin IIA activity. Members of a human pedigree with mutations in TRPM7
(p.C721G), causing disrupted channel activity, suffer from macrothrombocytopenia and arterial
fibrosis. The defect in platelet biogenesis is mainly caused by cytoskeletal alterations resulting in
impaired pro-platelet formation by TRPM7-deficient megakaryocytes, which is rescued by Mg2+
supplementation [79]. In contrast, homozygous kinase-dead TRPM7R/R mice show normal platelet
counts, size and morphology, thus suggesting that the lack of TRPM7 channel rather than its kinase
activity accounts for the macrothrombocytopenia in Trpm7fl/fl-Pf4Cre mice [79]. However, the kinase
controls platelet function in arterial thrombosis via regulation of Ca2+ responses, Syk and PLCγ2
activity. Bone marrow (BM) chimeras revealed that the kinase is not only relevant for platelet function,
as both, recipients of WT BM as well as WT recipient of Trpm7R/R BM, developed reduction in infarct
size and improvement of neurological and motoric functions in an in vivo transient middle cerebral
artery occlusion (tMCAO) model. Thus, TRPM7 kinase activity in neurons and glial cells may also be
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critical for the progression of ischemic brain infarction [11]. These findings highlight TRPM7 kinase as
a potential target for the treatment of thrombosis thus protecting from stroke or myocardial infarction.
3.3. TRPM7 Kinase Signalling Supports Graft versus Host Reactions
Graft versus host disease (GVHD) is the most common side effect of an allogeneic hematopoietic
stem cell transplantation (HCST). In this immune reaction the donor T cells recognize the patients
human leukocyte antigen (HLA) as foreign, causing an inflammatory cascade [97]. GVHD can
be divided into acute and chronic, depending on the time of diagnosis [98]. In acute GVHD the
pre-transplant radiation may cause tissue damage in the host, leading to the activation of antigen
presenting cells followed by activation of the donor T cells. This can lead to severe damage of liver,
skin, mucosa and the gastrointestinal tract [99]. All in all, GVHD causes 15–30% of death after HCST,
highlighting the importance of enhancing the understanding of this disease and finding improved
treatments. Recently, it was shown that TRPM7 kinase activity promotes gut colonization by T cells
in acute GVHD. During this process, naïve donor CD4+ T cells recognize alloantigens on antigen
presenting cells in target organs, including the intestine (Figure 4C).
The role of different TH subsets and signalling pathways in the pathogenesis of GVHD is
incompletely understood. To address whether defective intestinal colonization by CD4+ T cells
lacking TRPM7 kinase activity could affect acute GVHD, the bone marrow (BM) of BALB/c WT mice
was lethally irradiated and replaced by bone marrow (BM) cells from WT C57BL/6 mice together with
WT or TRPM7R/R splenocytes. As expected, injection of WT splenocytes resulted in massive intestinal
damage and most mice died within 35 days after transplantation. In contrast, injection of TRPM7R/R
splenocytes did not cause intestinal damage and resulted in a dramatically increased survival of these
mice within the first 60 days after transplantation [20]. These results unravel a fundamental role of
TRPM7 kinase in T cell function and suggest a therapeutic potential of kinase inhibitors in averting
acute GVHD.
4. Conclusions
The involvement of TRPM7 in the pathogenesis of deregulated immune responses highlights
the necessity for novel pharmacological tools. TRPM7 represents a new promising drug target for
the treatment of pro-inflammatory diseases and hypersensitivity. It is tempting to speculate that
pharmacological modulation of TRPM7 may reinstate immune system homeostasis. Particularly
appealing is the fact that TRPM7 kinase-deficiency in mice does not result in an obvious phenotype
and only moderately affects haemostasis. Thus, TRPM7 kinase inhibition should not cause major side
effects. Therefore, new TRPM7 kinase inhibitors and novel kinase substrates have to be identified.
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Abstract: Recent evidence supports the role of menthol, a TRPM8 agonist, in enhanced energy
expenditure, thermogenesis and BAT-like activity in classical WAT depots in a TRPM8 dependent
and independent manner. The present study was designed to analyse whether oral and topical
administration of menthol is bioavailable at subcutaneous adipose tissue and is sufficient to
directlyinduce desired energy expenditure effects. GC-FID was performed to study menthol
bioavailability in serum and subcutaneous white adipose tissue following oral and topical
administration. Further, 3T3L1 adipocytes were treated with bioavailable menthol doses and
different parameters (lipid accumulation, “browning/brite” and energy expenditure gene expression,
metal analysis, mitochondrial complex’s gene expression) were studied. No difference was observed
in serum levels but significant difference was seen in the menthol concentration on subcutaneous
adipose tissues after oral and topical application. Menthol administration at bioavailable doses
significantly increased “browning/brite” and energy expenditure phenotype, enhanced mitochondrial
activity related gene expression, increased metal concentration during adipogenesis but did not alter
the lipid accumulation as well as acute experiments were performed with lower dose of menthol
on mature adipocytes In conclusion, the present study provides evidence that bioavailable menthol
after single oral and topical administration is sufficient to induce “brite” phenotype in subcutaneous
adipose tissue However, critical dose characterization for its clinical utility is required.
Keywords: adipose tissue; bioavailable; menthol; topical; TRPM8
1. Introduction
The imbalance between energy intake and energy expenditure is a well-known aspect of the
escalating prevalence of obesity throughout the world as a major nutritional challenge [1,2]. Multiple
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factors like physical activity, dietary energy intake, basal metabolic rate, variation in environmental
and body temperature are reported to influence energy expenditure [3,4]. Enhancement of energy
expenditure is one of the cardinal approach toward prevention of body weight gain and obesity [5].
Numerous studies have reported the direct relation of cold exposure with non-shivering thermogenesis,
followed by reduction in body fat [6–8]. Interestingly, clinical studies have also reported a vital link
between cold-exposure and elevated energy expenditure through adaptive thermogenesis [9]. Studies
on adipocytes have also reported a relationship between cold receptor, TRPM8 and energy expenditure
showing upregulated expression of UCP-1 and PGC-1α owing to TRPM8 activation [10].
Complex physiology of the body makes it difficult to understand the exact mechanisms involved
in energy expenditure. Transient receptor potential cation channel subfamily Melastatin member 8
(TRPM8) is a thermoreceptor present on the sensory nerve endings innervating the gut and skin [11–13]
that senses non-noxious cold stimuli ranging from 18–25 ◦C, hence making it attractive target for cold
mimicking. Involvement of TRPM8 dependent and independent pathways in mediating cold-induced
energy expenditure is well reported. Recently we have published that anti-obesity effect of menthol,
a TRPM8 agonist is mediated through glucagon dependent mechanisms particularly in adipose
tissues [14]. Activation of TRPM8 receptors in the gut and skin by oral and topical administration
of menthol leads to increase in serum glucagon levels, thus activating several downstream catabolic
processes like glycogenolysis, gluconeogenesis, browning of white adipose tissue (WAT) and activation
of energy expenditure markers in WAT and brown adipose tissue (BAT) [14]. This is supposedly an
indirect action of menthol on adipose tissue wherein presence of TRPM8 is not essential. On the other
hand, studies from our laboratory provide a strong evidence of significant expression of TRPM8 in
undifferentiated (pre-adipocytes) and differentiated (adipocytes) 3T3-L1 cells suggesting its significance
in adipogenesis [15]. Also, TRPM8 is functionally expressed in rodent WAT [16] and BAT [17] as well as
human WAT [18]. Alternatively, Ma et al. showed that the mouse BAT expresses TRPM8 receptor which
upon activation by menthol, significantly increased the levels of p-PKA that further phosphorylates
the transcription factor cyclic AMP-responsive element-binding protein (CREB), ultimately leading to
enhanced UCP1 expression [17,19]. Thus, chronic dietary menthol increased thermogenesis, core body
temperature, prevented diet-induced obesity and the abnormal glucose homeostasis in wild-type mice
but not in UCP1(−/−) and TRPM8(−/−) mice [17], suggesting TRPM8 receptor presence on adipose tissue
is essential. Other studies also demonstrated the induction of white-to-brown-like phenotype through
TRPM8 activation on human WAT [18,20], summarizing the importance of the presence of TRPM8 on
adipose tissue.
We hypothesize that different TRPM8 dependent and independent actions are contributing to the
anti-obesity effect of menthol. The present study is an attempt to reveal whether topical (10% w/v) or
oral (200 mg/kg, p.o.) administration of menthol used during acute studies in our previous work is
bioavailable at subcutaneous adipose tissue (direct or through serum). Further, using in-vitro 3T3L1
cell line model, we attempted to study that whether bioavailable menthol at subcutaneous adipose
tissue is sufficient to induce direct effect on “browning” and mitochondrial energy metabolism followed
by enhanced energy expenditure effects. Furthermore, this manuscript endeavours to elucidate the
presence of metal ions and their role in mitochondrial electron transport chain for significant elevation
in energy expenditure owing to the menthol treatment.
2. Materials and Methods
2.1. Chemicals
Mouse 3T3-L1 preadipocytes were obtained from National Centre for Cell Science (NCCS, Pune,
India). Dulbecco’s Modified Eagle Medium (DMEM), Foetal Bovine Serum (FBS), Penicillin-Streptomycin
and Phosphate-Buffered Saline (PBS) was procured from Lonza Inc. (Walkersville, MD, USA). Menthol,
AMTB hydrate, Isopropyl alcohol (IPA), 3-isobutyl-1-methylxanthine (IBMX), Dexamethasone (DMS),
Insulin, Oil-Red-O (ORO) powder, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide
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(MTT)and Dimethyl Sulfoxide (DMSO) were obtained from Sigma Aldrich Co. (St. Louis, MO, USA).
GeneZol RNA Extraction Reagent was obtained from Genetix Biotech Asia Pvt. Ltd. (New Delhi, India).
Absolute Ethanol (Biotechnology grade) was procured from Amresco Inc. (Cochran Road, Solon, OH,
USA). Nitric acid (Trace Metal Grade) was obtained from Fisher Scientific UK Limited (Bishop Meadow
Road, Loughborough, Leicestershire, UK) and Dichloromethane (DCM) was procured from Central Drug
House (New Delhi, India). All other reagents used were of analytical grade and were procured from
local supplier.
2.2. Animal Treatment
21 Swiss Male Albino mice (25–30 g) bred in Central Animal Facility of National Institute of
Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India were used for the experiment.
3 mice per cage were housed on a 12 h light/dark cycle with ad libitum food and water supply.
The experiment was approved by the Institutional Animal Ethical Committee, NIPER, Mohali, Punjab,
India. All the experiments were conducted in accordance with the Committee for the Purpose of
Control and Supervision in Experiments on Animals (CPCSEA) guidelines on the use and care of
experimental animals. Mice were randomly divided into 3 different groups consisting 3 animals for
control group, 9 animals for oral administration of menthol and 9 animals for topical administration
of menthol. Oral administration of menthol was given at the dose of 200 mg/Kg in 0.1% tween-80,
while topical administration of menthol was given on abdominal area by 1 mL topical application
of 10% menthol in 0.1% tween 80. Animals were euthanized after 30, 60 and 120 min of menthol
administration by cervical dislocation, blood was collected by cardiac puncture for serum isolation
and subcutaneous white adipose tissues were collected for pharmacokinetic profiling of menthol [14].
2.3. Gas Chromatography-Flame Ionization Detector (GC-FID) for Menthol Bioavailability in Serum and
Subcutaneous WAT
2.3.1. Extraction Procedure
Both serum and adipose tissue samples were extracted fromDCM containing 200 ng/mL of thymol
as internal standard. The samples were continuously vortexed for 3 min and centrifuged at 6000 rpm
for next 3 min. After centrifugation, the supernatant was isolated and again extracted in DCM as
discussed above. The supernatant finally obtained was used for the pharmacokinetic evaluation of
menthol both in serum and adipose tissue.
2.3.2. GC-FID Protocol
Separation and detection was done by injecting 1 μL of target analyte in gas chromatograph
(Agilent 7890B) equipped with split less injector system and flame ionization detector. Ultra-pure
nitrogen gas was passed through a molecular sieve and oxygen trap and was used as carrier gas with
flow rate of 1 mL/min. The injection port was held at 240 ◦C operated at split less mode. Separation
was done using DB5 capillary column (Agilent Technologies) with dimension 30 m × 320 μm × 1 μm
with oven temperature kept at 40 ◦C and then increased to 250 ◦C at the rate of 10 ◦C/min, hold time for
2 min. and sample run time for 23 min. the FID temperature was maintained at 280 ◦C for detection.
Flow of hydrogen gas used for FID was at the rate of 30 mL/min. The flow of air for FID was 300 mL/min
along with makeup flow at the rate of 25 mL/min. Calculations were done using EZ Chrome Software
(Menlo Park, CA, USA).
2.4. 3T3-L1 Cell Culture
Mouse 3T3-L1 pre-adipocytes were allowed to culture in basal medium comprising DMEM
supplemented with 10% v/v FBS and 1% penicillin-streptomycin. Whole cell culture was maintained
at 37 ◦C in a humidified incubator along with continuous supply of 95% O2 and 5% CO2. At 60%
confluency, cellular differentiation from 3T3-L1 pre-adipocytes to adipocytes was induced using
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differentiation medium containing basal medium supplemented with 0.1 mM IBMX, 0.1 μM DMS
and 1 μg/mL insulin for 48 h. Stock solutions of 0.1 μM DMS and 0.1 mM IBMX were prepared in
absolute ethanol and DMSO respectively and were directly supplemented to DMEM culture medium.
Further, the cells were shifted to maintenance medium (basal medium with 1 μg/mL insulin) for 10 days
with medium replacement on every alternate day. Working solutions of 1, 50, 100, 200 and 300 μM
menthol for the treatment were also prepared in absolute ethanol and directly supplemented to culture
(differentiation/maintenance) medium during adipogenesis. Dose selection of menthol for in-vitro
study was done on the basis of in-vivo pharmacokinetic profile of menthol in serum and adipose
tissues. Two different sets of experiments were performed, (A) Effect of menthol administration at
different doses (1, 10, 30 and 50 μM during adipogenesis. (B) Effect of menthol administration (1 μM)
on matured adipocytes after 1 h of treatment. The entire cell culturing experiments were carried out as
per American Type Culture Collection (ATCC) guidelines.
2.5. Cell Viability Assay
Cell cytotoxicity was assessed using MTT assay. Undifferentiated 3T3-L1 preadipocyte cells were
seeded in a 96 well plate at density of 1 × 104 cells/well and incubated with varying concentrations
(50, 100 and 300 μM) of menthol dissolved in <0.001% ethanol at 37 ◦C for 24 h. For control,
undifferentiated pre-adipocytes treated with ethanol (<0.001%) were taken. After 24 h, media was
replaced with MTT as per the instructions by manufacturer (Sigma Aldrich Co., St. Louis, MO, USA).
Formazan crystals formed by live cells are solubilized in isopropanol and absorbance was measured at
570 nm using microplate reader (Spectra max M5e, Molecular Devices LLC, San Jose, CA, USA) [21].
2.6. Oil-Red-O Staining
A stock solution of 0.5% w/v of ORO was prepared IPA and was stored at room temperature.
A working solution of ORO stain was prepared by diluting the stock solution with distilled water in the
ratio 3:2. For staining, the supernatant in the culture plates after treatment with varying concentrations
of menthol (1, 50 and 200 μM) was removed and cells were washed using PBS. After washing, mature
adipocytes were fixed with 10% v/v formaldehyde in PBS and kept for 30 min at room temperature
followed by three subsequent washing with PBS. Then, the PBS was aspirated and 60% of IPA was
added followed by incubation for 5 min. Further, the cells were stained in ORO working solution filled
in culture plates to completely cover the plate bottom (1.25 mL per well for 6-well culture plate) and
kept for incubation for 10 min. The cells were then washed with 60% IPA to rinse away excess ORO
dye followed by final elution of dye in 100% IPA (2.5 mL per well for 6-well culture plate). The plates
were again kept for incubation at room temperature for 10 min. Now, 200 μL of each eluate was added
to a 96 well microtiter plate. Also, 200 μL of 100 % IPA was filled on the same microtiter plate as blank.
Finally, intracellular lipid content was quantified after extracting ORO bound cells with 100% IPA and
absorbance was taken at 570nm using Nano Quant–Infinite M200 Pro (Tecan, Switzerland) [22,23].
2.7. ICP-MS for Metal Analysis
Cells from control and test samples (1, 50 and 200 μM administration of menthol during
differentiation) were pellet down and digested with nitric acid using Microwave Reaction System (Mars
6, CEM Corporation, Matthews, NC, USA). The concentration of different elements was estimated
in the digested samples using standard protocol for inductively coupled plasma mass spectrometry
(ICP-MS:77006, Agilent Technologies, Santa Clara, CA, USA) [14].
2.8. qRT-PCR for Browning/Energy Expenditure Genes
Total RNA from both control and treated adipocytes was extracted after 10 days of treatment using
Acid guanidinium thiocyanate-phenol-chloroform extraction method with GeneZol RNA Extraction
Reagent, IPA, Chloroform and was reversely transcribed to cDNA from 1 μg of RNA using iScript
cDNA Synthesis Kit (Bio-Rad Laboratories Inc., Hercules, CA, USA). Quantitative real time-polymerase
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chain reaction (qRT-PCR) was performed with the cDNA as templates in 40 cycles using Custom
RT2 PCR Array Kit (CLAM 30615C, Qiagen Lifesciences, Waltham, MA, USA) and RT2 SYBR Green
ROX qPCR Mastermix (Qiagen Lifesciences) keeping GAPDH as internal control and 7 gene specific
primers for adipogenesis including TNFRSF9, PPARGC1A, PRDM16, CIDEA, TLE3, HOXC10 and
NRIP1. The qRT-PCR process was performed by programming thermocycler (CFX96 Touch Real-Time
PCR Detection System (Bio-Rad Laboratories Inc., Hercules, CA, USA)) to apply initial cycle for
denaturation at 95 ◦C for 2 min, followed by 40 cycles of annealing and elongation at 60 ◦C for 30 s
and denaturation at 95 ◦C for 5 s. The complete experiment was performed using three biological
replicates [14]. Analysis of relative gene expression was done using 2−ΔΔct method [24] and values
were expressed in the terms of fold change with reference to control [14].
2.9. Gene Expression Analysis of Mitochondrial Energy Metabolism
Total RNA from both control and treated adipocytes was extracted after 10 days of treatment using
Acid guanidinium thiocyanate-phenol-chloroform extraction method with GeneZol RNA Extraction
Reagent, IPA, Chloroform and was reversely transcribed to cDNA from 5 μg of RNA using RT2 first
strand kit (Qiagen Lifesciences). qRT-PCR was performed using RT2 Profiler PCR Array Kit for Mouse
Mitochondrial Energy Metabolism (PAMM 008ZC-12, Qiagen Lifesciences, Waltham, MA, USA) and
RT2 SYBR Green ROX qPCR Mastermix (Qiagen Lifesciences). The thermocycler (Applied Biosystem
7500F Real Time PCR System (Applied Biosystems, Fosters City, CA, USA)) was programmed to apply
initial cycle for denaturation at 95 ◦C for 10 min, followed by 40 cycles of annealing and elongation
at 60 ◦C for 1 min and denaturation at 95 ◦C for 15 s. Three biological replicates were used for this
experiment [14]. Analysis of relative gene expression was done using 2−ΔΔct method [24] and values
were expressed in the terms of fold change with reference to control [14].
2.10. Statistical Analysis
All the values are expressed as mean ± SEM. A group comparison in in-vivo study was
carried outusing unpaired student t-test and two-way ANOVA followed by Tukey’s post-hoc test.
Group comparison in-vitro study was done using unpaired student t-test and one-way ANOVA
followed by Tukey’s post-hoc test. Pearson correlation was performed and representative matrix was
made using Gitools 2.3.1. (San Fernando Rd, Burbank, CA, USA). p ≤ 0.05 was considered statistically
significant. Correlation matrix and clustering was done by k-means ++Manhattan distance clusters 6.
3. Results
3.1. Pharmacokinetic Profile of Acute Oral Administration and Topical Application of TRPM8 Agonist
(Menthol) in Mice
Serum menthol concentration after oral (200 mg/kg) and topical administration (10% w/v) was
determined at different time intervals of 0, 30, 60 and 120 min. The peak plasma concentration after
oral and topical administration was attained at 30 and 60 min respectively. Bioavailable concentration
of menthol in serum after oral administration at 30, 60 and 120 min was found to be 3.28 μg/mL
(20.4 μM), 1.51 μg/mL (9.66 μM) and 0.76 μg/mL (4.86 μM) respectively. Serum concentration after
topical administration at 30, 60 and 120 min was found to be 1.60 μg/mL (10.23 μM), 2.71 μg/mL
(17.28 μM) and 0.82 μg/mL (5.2 μM) respectively (Figure 1A). Area under the curve of concentration
and time graph was also determined and no significant difference was observed in serum metal
concentration between oral and topical administration (Figure 1B).
Similarly, menthol concentration in the adipose tissue was also determined at the same time
intervals. The peak concentration after oral and topical administration was attained at 30 min.
Concentration of menthol after oral administration at 30, 60 and 120 min was found to be 28.33 μg/mL
(181.09 μM), 17.38 μg/mL (111.2 μM) and 12.51 μg/mL (79.98 μM) respectively. Menthol concentration
in the adipose tissue after topical administration at 30, 60 and 120 min was found to be 53.09 μg/mL
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(339.74 μM), 28.94 μg/mL (185.19 μM) and 20.11 μg/mL (128.69 μM) respectively (Figure 1C). Area under
the curve of concentration and time graph for topical administration was significantly higher than the
oral administration which signifies that higher amount of menthol was available in the adipose tissue
after topical administration (Figure 1D).
Figure 1. Pharmacokinetic of menthol administration upon oral and topical administration(A) Time
dependent changes in serum concentration of menthol; (B) Area under the time-concentration curve
in serum of menthol treated mouse; (C) Time dependent changes in concentration of menthol in
subcutaneous adipose tissue; (D) Area under the time-concentration curve in subcutaneous adipose
tissue of menthol treated mice. Oral- Single dose of oral menthol administration at 200 mg/kg.
Topical-Single dose of topical menthol application at 10% concentration (300 μL/animal). n = 3. All the
values are expressed as mean ± S.E.M; * p < 0.05.
3.2. Menthol Treatment Did Not Affect Cellular Differentiation, Lipid Accumulation and Cell Viability in
3T3-L1 Cells In-Vitro
No change in cell viability was observed with menthol treatment in comparison to the vehicle
treated group up to 300 μM dose (Figure 2A). Oil red O staining is used as a quantitative method
to analyse the difference in the degree of differentiation and lipid accumulation in adipocytes in cell
culture. The effect of varying concentrations of menthol (1 μM, 50 μM, 100 μM and 200 μM) was
evaluated during adipogenesis. Slight decrease in lipid accumulation was observed with menthol
1 μM dose as compared to vehicle treated group and no change was observed with 50 and 200 μM
doses (Figure 2B). No significant difference in cellular differentiation of 3T3-L1 cells was observed
between the vehicle and menthol treated cells (Figure 2C).
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Figure 2. Effect of menthol on adipogenesis in 3T3-L1 cells. (A) Cell viability in pre-adipocytes treated
with menthol for 24 h. (B) Effect of menthol on lipid accumulation in 3T3-L1 cells. (C) Effect of various
concentration of menthol on differentiation of 3T3-L1 cells. Red spots in images represents area stained
by Oil Red O dye. All values are expressed as mean ± S.E.M. (n = 3). One-way ANOVA followed by
Tukey’s multiple comparison post hoc test was applied. * each vs. vehicle.
3.3. Menthol Treatment Altered Metal Concentration and Browning Gene Markers in 3T3-L1
Pre-Adipocytes In-Vitro
The effect of 1, 50 and 200 (data not shown) μM concentrations of menthol treatment during the
adipogenesis process on different concentrations of metals in matured adipocytes was evaluated by
ICP-MS. Significant increase in the concentrations of iron and copper was observed after 1 μM menthol
treatment as compared to their respective controls. Similar pattern was also observed with 50 μM
menthol treatment, showing marked elevation in levels of iron, copper and zinc as compared to their
corresponding controls. However, significant reduction in cobalt metal levels was observed with both
doses of menthol (1 and 50 μM) as compared to vehicle treated group. No significant change in the
level of metals like calcium and magnesium was observed with both doses of menthol (Figure 3A,B).
There was no significant difference in metal concentrations at 50 μM and 200 μM doses of menthol,
hence we used 1 and 50 μM for further studies.
Treatment with 1, 10, 30 and 50 μM concentrations of menthol was given during the process
of adipogenesis to check the mRNA expression of browning markers. At 1 μM menthol increase
in the mRNA expression of browning markers that is, Peroxisome proliferator-activated receptor
gamma (PPARCG1A), Homeobox C10 (HOXC10), Tumour necrosis factor receptor superfamily member
9 (TNFRSF9) and Uncoupling protein (UCP1) was observedas compared to vehicle treated group.
A marked reduction in the mRNA expression of Transducin like enhancer of split 3 (TLE3) and
no change was observed in PR domain containing16 (PRDM16), Cell Death inducing DFFA like
effector A (CIDEA) and Nuclear receptor-interacting protein 1 (NRIP1) at 1 μM menthol treatment.
At 10 μM, there was a significant reduction in gene expression of CIDEA, NRIP1, TLE3 and TNFRSF9.
No significant change in levels of PRDM16, HOXC10, UCP1 and PPARGC1A, similar pattern of change
in levels of gene expression was observed at 30 μM. Although at 50 μM menthol treatment significantly
reduced the mRNA expression of CIDEA only. There was no significant difference observed in
expression of HOXC10, PRDM16, UCP1, NRIP1 and PPARGC1A as compared to control (Figure 4A).
Acute experiment was performed at 1 μM concentration of menthol for 1 h on mature adipocytes.
Significant increase in the gene expression of browning markers that is, PRDM16, PPARGC1A, TNFRSF9,
TMEM26 and UCP1 was observed (Figure 4B).
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Figure 3. Effect of menthol treatment on. (A) Metal concentration (Ca, Co, Fe, Mg, Zn, Cu) in 3T3-L1
cells at 1 μM dose; (B) Metal concentration (Ca, Co, Fe, Mg, Zn, Cu) in 3T3-L1 cells at 50 μM dose;
n = 3–5; All the values are expressed as mean ± S.E.M; Analysis was carried out by student unpaired
t-test; * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 4. Effect of menthol treatment on: (A) Relative expression of energy expenditure genes in
3T3-L1 cells at 1 μM, 10 μM, 30 μM and 50 μM menthol treatment; (B)Relative expression of energy
expenditure genes in 3T3-L1 cells at 1 μM menthol treatment for 1 h. n = 3–5; All the values are
expressed as mean ± S.E.M; Analysis was carried out by student paired t-test and one-way ANOVA
followed by Tukey’s multiple comparison; * p < 0.05, ** p < 0.01, *** p < 0.001.
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3.4. Menthol Treatment Modulated Mitochondrial Activity Gene Markers for Energy Metabolism in 3T3-L1
Pre-Adipocytes In-Vitro
The effect of 1 μM and 50 μM of menthol treatment on different mitochondrial genes was studied.
In the NADH dehydrogenase (Complex I), significant increase in the gene expression of Ndufa1, Ndufb2,
Ndufc1, Ndufc2, Ndufa6, Ndufb3, Ndufb5, Ndufs6 was observed as compared to vehicle treated group.
Significant increase in expression of Uqcrq gene in cytochrome c reductase (complex III) was observed
as compared to vehicle treated group. In the cytochrome c oxidase (complex IV) significant increase
in expression of Cox6a1, Cox6c genes were also observed. In the F-Type ATP synthase (complex V)
significant elevation in the Atp5j gene expression was also observed as compared to vehicle treated
group (Figure 5A,B). Although, 50 μM menthol supplementation also displayed a modulatory effect
over gene expressions for mitochondrial energy metabolism, however, the change observed was
insignificant in comparison to vehicle treated group (Figure 5A).
Figure 5. Heat map analysis of gene expression; and genes with statistically significant differential
expression in 1 μM menthol treated group. (A) Heat map shows gene expression in vehicle, 1 μM
and 50 μM menthol treated 3T3-L1 cells (n = 3 each). Colour from red to green indicates high to low
expression. (B) Comparative analysis of selected genes in 1 μM menthol treated group. Normalization
was done with reference gene B2M (β-2-microglobulin). The relative fold change in gene expression
for mitochondrial biogenesis genes was compared in the three groups. Statistical analysis was done
for genes i-vi using two-way ANOVA and for genes vii-xii using two-tailed unpaired t-test. * p <0.05,
** p <0.01, *** p <0.001, each vs vehicle treated group.
4. Discussion
In our recently published manuscript, we have shown that the oral and topical administration of
menthol, a TRPM8 agonist, has anti-obesity potential through a TRPM8 mediated glucagon dependent
mechanism [14]. We provided evidence that TRPM8 mediated increase in serum glucagon and resultant
increase in “glucagon machinery” in liver and adipose tissue is the signature of global shift from
“fat storing state” to “fat burning state” in response to menthol administration [14]. During this work,
we could suggest that the presence of TRPM8 receptor on adipose tissue is not required and the effect
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is selective to the glucagon receptor present on adipose tissue, hence we may say that it is an indirect
action of menthol on adipose tissue. Also, recent paper by Clemmemsen and colleagues suggested
that icilin, a TRPM8 agonist, effect on BAT energy expenditure cannot be explained by direct effects of
icilin on adipocytes suggesting indirect actions to increase thermogenesis, likely through induction of
sympathetic tone [25]. However, the literature provide evidence for the presence of functional TRPM8
receptors on mouse and human adipose tissue, both white and brown [16–18,26] and adipocyte cell
lines [15]. These studies have mentioned that menthol induced increase in calcium influx in adipose
tissue, mitochondrial activation and enhanced gene expression is mediated by TRPM8 receptors
present on adipose tissue. The doses used in these studies are not based on the bioavailability profile of
menthol, hence to establish a link between bioavailable doses of menthol and its functional effects on
adipocytes is warranted. In this work, we tend to answer the question that at the acute doses showing
anti-obesity effect [14], how much of menthol was bioavailable in serum and subcutaneous WAT. Also,
whether this bioavailable menthol has any direct action on adipose tissue mediated through TRPM8 or
others to induce energy expenditure.
Menthol was bioavailable to adipose tissues via both routes, oral and topical, through serum and
direct absorption, respectively. Serum concentration of menthol reached a maximum at 30 min and
60 min respectively in the case of oral and topical administration; however, the total area reached
under the curve/peak concentration was similar over a period of 2 h. The concentration of menthol in
subcutaneous WAT reached a maximum at 30 min in the case of both oral and topical administration,
with a maximum peak concentration significantly higher in the case of topical administration. We can
easily argue that due to proximity of subcutaneous WAT to the site of application (topical), we see
a significantly higher concentration. Menthol is lipophilic in nature and its partitioning in adipose tissue
through topical application is significantly higher as compared to oral administration. We understand
that partitioning in rodent adipose tissue is positively predictive of partitioning in human adipose
tissue [27], hence we suggest that this data has clinical utility through the direct effect of menthol on
adipose tissue [14]. Previous literature also supports that L-menthol administration increases metabolic
rate and thermogenesis in humans [27]. In the same study, authors have concluded that these effects are
minor in oral administration as compared to topical administration due to faster metabolism of menthol
(glucoronidation) and higher values of menthol glucuronides levels in blood [27]. Summarizing,
route of administration is important for the action of menthol on subcutaneous adipose tissue whereas
in serum both oral and topical are similarly bioavailable.
Now, the question is whether bioavailable menthol after topical administration is enough to show
the desired effects in adipose tissue, may be directly. We used pharmacokinetic based mathematical
calculations to convert the bioavailable concentration of menthol in μM concentrations. We calculated
that there is a range of concentration that is, 1μM to 200μM which will sufficiently cover the bioavailable
amount of menthol on adipose tissues after topical administration. At these concentrations of menthol,
3T3L1 cells were viable as assessed by MTT assay. Also, at these doses there was no significant change
in the accumulation of fat in differentiating adipose cells as shown by ORO staining. There was minor
observation that some of cells were of smaller sizes.
There is lot of recent literature linking adipose tissue metal concentration with adipose tissue
health, differentiation and “browning” of white adipose tissue. Specifically, in this regard, iron and
copper has major significance [28,29]. Iron and copper are essential components of the mitochondrial
inner membrane complexes constituting the electron transport chain, therefore, the involvement of
copper and iron in energy metabolism via their involvement in mitochondrial function (brown adipose
tissue activation) is not surprising [29].We performed metal analysis in differentiated adipocytes after
treating cells with 1, 50 and 200 μM of menthol during differentiation. We selected few important one
based on their importance to adipose tissue health (calcium and cobalt), adipose tissue inflammation
(zinc, calcium and iron), mitochondrial activation (iron and copper), cell toxicity (cobalt), glucose
utilization and transport (zinc and magnesium), initiation of “brite” phenotype in white adipose tissue
(iron and copper) for analysis [28,30–35]. Menthol administration during differentiation significantly
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increased the levels of iron and copper at 1 μM whereas there was no significant change in the levels of
magnesium, calcium and zinc. Cobalt concentration was significantly decreased in menthol treated
differentiated adipocytes. However, at higher doses, 50 and 200 μM (data not shown) there was
significant increase in the levels of iron, copper, zinc and magnesium whereas significant decrease in
cobalt concentration with no change in calcium concentration. Looking into the metal concentration
profile after menthol administration during differentiation of pre-adipocyte to adipocytes, we could
suggest that menthol caused mitochondrial activation and increase in “brite” phenotype. This data
further supports our previous finding where we linked HFD, metal concentration in adipose tissue
and menthol administration in an in-vivo model of obesity [14].
Based on metal concentration changes, we selected 1 and 50 μM (both 50 and 200 μM had similar
metal concentration profile) for further gene expression studies. We studied the change in expression
of energy expenditure and “browning” related genes in differentiating adipose tissue. By critically
looking into the gene expression data we could understand that (a) at 1 μM, menthol administration
significantly modulated these genes which is very well corroborated with the existing literature [16],
(b) these changes are not dose dependent, as at higher doses 10, 30 and 50 μM of the effect was
reversed, although not dose dependently in some of the genes. Although we have not done these
experiments but we may speculate that it may be due to desensitization of TRPM8 at this dose due to
chronic presence of menthol during the process of adipogenesis. Further, we suggest that menthol at
higher concentration might be acting through either TRPM8 dependent or independent mechanisms.
There are numerous other actions of menthol which has link with energy expenditure phenomenon
like its action of other excitatory or inhibitory channels, its role in TRPM8 independent increase in
intracellular calcium, its role in oxidative effects [36]. Importantly at higher doses menthol acts on
TRPV3 [37] and TRPA1 channels [38] which are closely related to adipogenesis, glucose utilization,
hormone release and “browning.” This should be further explored to understand numerous actions
of menthol. Based on these effects, we studied the effect of menthol on the mitochondrial activity
complexes genes using PCR arrays (84 gene array). The effect on mitochondrial activation genes
(approx. 40/84 genes) was positively correlated with energy expenditure genes, significantly higher at 1
μM and at 50 μM, it was decreased, which can be attributed to possible desensitization. In our previous
study with TRPV1 agonist, capsaicin, we did see the same phenomenon increase in “browning” at 1 μM
and decrease at 50 μM, which was correlated to the combination of desensitization and increase in
the levels of PPAR-γ at higher doses [23]. We cannot rule out this kind of mechanism with menthol
given that both these channels are calcium permeable and in homogenous matrix their agonists can
show similar effects. At 1 μM, the changes in metal concentration, especially iron and copper, energy
expenditure genes and mitochondrial complex genes are positively correlated (Figure 6). We may
say that at 1 μM menthol induces energy expenditure and mitochondrial activation, hence “brite”
phenotype in differentiating adipocytes. Linking our bioavailable menthol with “brite” phenotype
induction in differentiating adipocytes, we can suggest that even the topical dose less than 10%, may
be 2% or 5% will be sufficient to induce this effect.
There are some limitations of this study. We could have included further experiments to have
a clear picture of desensitization or any other mechanisms responsible for the decrease in effect at
50 μM. We are planning extensive studies along these lines to establish the role of TRPM8 (using
pharmacological antagonism), other TRP channels (TRPV3 or TRPA1) or non-TRP channels (calcium
channels, GABA/glycine receptors) in menthol’s action. Further about the toxicity of menthol, there are
number of human studies both as oral administration as well as topical application (patch) [39–41].
Orally LD50 of menthol for rodents was observed approx. 3000 mg/kg of body weight and in canine it
is approx. 1 g/kg in cats. The dose which we have used is quite less as compared to these [42]. However,
further characterization will enable us to finalize the dose both topically and orally. Also, topical
administration at multiple doses should be done to clearly establish cause and effect relationship.
These studies will help us to develop topical menthol application as a therapeutic/preventive strategy
against obesity and related co-morbidities.
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Figure 6. Correlation matrix and clustering of all the data generated through the experiments. The
correlation matrix using K-means and Manhattan distance algorithms was drawn, which showed the
clustered genes/parameters with respect to each other. Intensity of colours green and red indicate
the negative or positive correlation respectively. Genes/parameters along X-axis are clustered using
Manhattan distance plot, colour bars showing nearest related groups of genes/parameters.
5. Conclusions
Over all, summarizing this study, we have provided evidence that a single dose of menthol is
sufficiently bioavailable to induce energy expanding “brite” phenotype in differentiating adipocytes
which is dependent on TRPM8 at a lower concentration (Figure 7). These findings can be further
exploited to devise dietary (mint based nutraceuticals) or non-dietary (cold mimicking) approaches to
combat obesity and type-2 diabetes.
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Figure 7. Summary of effect of bioavailable menthol on adipose tissue using in-vitro model. Using the
bioavailable concentrations of menthol in adipose tissue and serum upon oral/topical administration,
the dosage were decided for in-vitro menthol treatment and effect was checked on expression of genes
involved in adipogenesis, browning, mitochondrial biogenesis and energy expenditure. The results
showed enhanced energy expenditure markers, which indicates improved negative energy balance
leading to reduction in obese phenotype.
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Abstract: The presence of transient receptor potential vanilloid type-1 receptor (TRPV1)-like
immunoreactivity (LI), in the form of nerve fibres and terminals, is shown in a set of discrete gray
matter subregions placed in the territory of the human cuneate nucleus. We showed previously that
those subregions share neurochemical and structural features with the protopathic nuclei and, after
the ancient name of our town, collectively call them Locus Karalis, and briefly Locus K. TRPV1-LI
in the Locus K is codistributed, though not perfectly overlapped, with that of the neuropeptides
calcitonin gene-related peptide and substance P, the topography of the elements immunoreactive to
the three markers, in relation to each other, reflecting that previously described in the caudal spinal
trigeminal nucleus. Myelin stainings show that myelinated fibres, abundant in the cuneate, gracile and
trigeminal magnocellular nuclei, are scarce in the Locus K as in the trigeminal substantia gelatinosa.
Morphometric analysis shows that cell size and density of Locus K neurons are consistent with those
of the trigeminal substantia gelatinosa and significantly different from those of the magnocellular
trigeminal, solitary and dorsal column nuclei. We propose that Locus K is a special component of the
human dorsal column nuclei. Its functional role remains to be determined, but TRPV1 appears to
play a part in it.
Keywords: human medulla oblongata; cuneate nucleus; dorsal column nuclei; TRPV1; calcitonin
gene-related peptide; substance P
1. Introduction
The transient receptor potential vanilloid type-1 receptor (TRPV1) is a polymodal ion channel
expressed in primary sensory neurons, critically involved in the perception of mechanical and thermal
stimuli as well as in pain modulation, and in allodynia and hyperalgesia in neuropathic pain [1–7].
Temperature (over 42 ◦C), low extracellular pH and capsaicin represent TRPV1 activators often used
in experimental studies. To date, TRPV1 is viewed as a molecular integrator of different stimuli
in the peripheral polymodal nociceptors; thus, it is activated by noxious heat, acidic and basic pH,
voltage, endogenous lipid-derived compounds, and a variety of substances, among which the agonist
resiniferatoxin is the best known [1,2,4,8–11]. In rodents, TRPV1 is expressed by a subset of peripheral
sensory neurons involved in pain sensation [12–22]. Available studies on human tissue show the
occurrence of TRPV1 in neurons of dorsal root ganglia (DRG) [15,23–28] and trigeminal ganglion
(TG) [29,30], and their central and peripheral endings [25,31–33]. TRPV1, in addition to Calcitonin
Gene-Related Peptide (CGRP) and Substance P (SP), is localized in primary sensory neurons and,
in particular, in those of small and medium size, with poorly myelinated or unmyelinated small
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calibre fibres, responsible for the reception of nociceptive protopathic stimuli. It has been shown
that, in primary sensory neurons, TRPV1 activation triggers the release of CGRP and SP [11,33–37],
typical markers of the capsaicin-sensitive sensory neurons [8]. The neuropeptides in turn activate their
effector cell receptors, leading to neurogenic inflammation and sensitization of nociceptors [8,11]. The
aberrant activation of TRPV1 has been implicated in different neuropathological conditions including
inflammation [38–43], neuropathic pain [26,27,31,43], visceral pain [40,41,43–45], nerve injury [43,46,47]
and migraine [33]. In humans, the local injection of capsaicin has been shown to cause sensitization of
the cutaneous afferents [48–50], release of CGRP from peripheral nerve endings [11,51,52] and pain in
the deep somatic tissues [53–56].
Classically, the dorsal column nuclear complex consists of the larger cuneate, gracile and
external cuneate nuclei, and of the smaller medial and lateral pericuneate nuclei, nucleus Z and
nucleus X of Pompeiano and Brodal [57]. For the most part, they receive large myelinated primary
afferent fibres conveying somatic epicritic, kinesthetic and proprioceptive sensation from the trunk
and limbs, and relay to the thalamus and cerebellum. Several substances have been identified
as synaptic neurotransmitters in the dorsal column nuclei. Thus, glutamate and glycine and
gamma-aminobutyric acid act as excitatory and inhibitory neurotransmitters [58–66], and other
molecules, such as adenosine triphosphate, acetylcholine, and monoamines, may also function as
transmitters and/or modulators [58,67–69]. As a general rule, neuropeptide immunoreactive elements
are less abundant in dorsal column nuclei than in regions that relay protopathic and nociceptive stimuli,
namely the spinal dorsal horn and the spinal trigeminal and solitary nuclei, both in humans [70–75] and
in laboratory animals [76–91]. Recently, we have formally defined additional distinctive subdivisions
of the human dorsal column nuclei, evident from prenatal to old life [92]. Extending early observations
on the presence of gray matter areas that are strongly immunoreactive to SP in the territory of the
human cuneate nucleus and adjacent fascicle [70,71], we have shown that the cuneate nucleus fields
rich in SP also host neural structures immunoreactive to the neuropeptides CGRP, methionine- and
leucine-enkephalin, peptide histidine-isoleucine, somatostatin and galanin, the trophin glial cell
line-derived neurotrophic factor, and the neuroplasticity proteins polysialylated neural cell adhesion
molecule and growth-associated protein-43 [92] and references therein. Moreover, the topographical
distribution of the structures immunoreactive to all those markers in relation to each other clearly
showed that the neurochemistry of those cuneate nucleus gray matter fields, at variance with the
remaining nuclear territory, was strikingly similar to that of the spinal cord dorsal horn and the spinal
nucleus of the trigeminal nerve [70,71,92–97]. As a tribute to the place where M.D.F. first observed
and described those discrete cuneate nucleus subregions, after the ancient name of our town, Cagliari,
we collectively call them Locus Karalis and briefly Locus K [98,99].
With the aim of further describing the capsaicin-sensitive component of the human nervous
system, here we show that the Locus K, identified by its immunoreactivity to SP and CGRP, also
contains TRPV1-like immunoreactivity (LI) in specimens from prenatal and neonatal life to adult age.
Furthermore, we show that the cyto- and myeloarchitecture of the Locus K also harmonize with those
of the protopathic and nociceptive sensory nuclei.
2. Materials and Methods
2.1. Tissue Sampling
Specimens of medulla oblongata were obtained at autopsy from subjects with no signs of
neuropathology, at age ranging 21 gestation weeks to 88 years (Table 1). The sampling and handling of
human specimens conformed to the guidelines of the local Ethics Committee of the National Health
System and complied with the principles enunciated in the Declaration of Helsinki. R.D. and A.C.
collected the human tissues and R.D. was the only one to have access to identifying information about
the autopsied subjects. The used specimens had been stored as part of the standardized procedure
for autopsy samples at the section of Forensic Medicine of the Department of Public Health, Clinical
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and Molecular Medicine. The Ethics Committee formally stated that the present study complied with
the ethical principles and does not need approval because all the used specimens were processed
anonymously (Report No. 9, 15/07/2015). Fixation in 4%, freshly prepared phosphate-buffered
formaldehyde, pH 7.3, for 4–6 h at 4 ◦C, was followed by overnight rinsing in 0.1 M phosphate buffer
(PB), pH 7.3, containing 5–20% sucrose.
Table 1. List of specimens.
Case Age Sex Primary Cause of Death
Post-Mortem
Hours
1 Fetus 21 w.g. F Cardiorespiratory failure 29
2 Pre-term newborn 6 d (25 w.g.) F Pneumonitis 25
3 Pre-term newborn 1 d (34 w.g.) M Cardiorespiratory failure 29
4 Pre-term newborn (38 w.g.) M Cardiorespiratory failure 38
5 Full-term newborn (40 w.g.) M Cardiorespiratory failure 28
6 Full-term newborn 1 d M Cardiorespiratory failure 24
7 Full-term newborn 2 d F Persistence of fetal circulation 38
8 Full-term newborn 7 d F Cardiorespiratory failure 27
9 Adult 44 y M Stabbing 40
10 Adult 53 y F Cardiorespiratory failure 31
11 Adult 56 y F Cardiomyopathy 34
12 Adult 71 y M Renal failure 25
F, female; d, days; h, hours; M, male; y, years; w.g., weeks of gestation (calculated from the 1st day of the latest
menstrual cycle).
2.2. Immunohistochemistry and Histology
Adjacent transverse slices of the medulla oblongata were cut with a cryostat at 10–14 or 30 μm and
collected in series on chrome alum-gelatin coated slides. The avidin–biotin-peroxidase complex (ABC)
immunostaining technique was used. Slides were treated with 0.1% phenylhydrazine (Sigma Aldrich,
St Louis, MO, USA) in phosphate buffered saline (PBS) containing 0.2% Triton X-100 (PBS/T) to block
the endogenous peroxidase activity, and successively with 20% of normal goat serum (Vector Labs Inc.,
Burlingame, CA, USA) to minimize non-specific staining. Rabbit polyclonal antibodies against TRPV1
(Thermo Scientific, Waltham, MA, USA), diluted 1:500, and against CGRP (Chemicon, Temecula, CA,
USA), diluted 1:1000, and a guinea-pig polyclonal antibody against SP (AbCam, Cambridge, UK),
diluted 1:1200, were used as primary antibody. Biotin-conjugated goat anti-rabbit and anti-guinea-pig
sera (Vector), both diluted 1:400, were used as secondary antiserum. The immunoreaction was
revealed with 30 min of incubation with the ABC (BioSpa Div. Milan, Italy), diluted 1:250, and
followed by incubation with a solution of 0.1 M phosphate buffer (PB), pH 7.3, containing 0.05% 3,
3’-diaminobenzidine (Sigma Aldrich, St Louis, MO, USA), 0.04% nickel ammonium sulfate and 0.01%
hydrogen peroxide. All antisera and ABC were diluted in PBS/T. The specificity of the TRPV1 antibody
has been validated by Western blot analysis on protein samples of human pre-term and adult TG and
caudal medulla oblongata, and reported in a previous work [30]. Negative control preparations were
obtained either by incubating tissue sections with the diluted primary antibody preabsorbed with
10 mM of the respective peptide for 24 h at 4 ◦C or by omitting the primary antibody. Cresyl violet,
Black-Gold II staining kit (Biosensis, Thebarton, Australia) and/or Klüver–Barrera techniques were
used as Nissl and myelin stainings. Observations and photographs were made with a photomicroscope
Olympus BX61 (Hamburg, Germany), and with a slide scanner Nanozoomer 2.0-RS (Hamamatsu).
2.3. Morphometric Analysis
Morphometric analysis was performed on cuneate nucleus, gracile nucleus, external cuneate
nucleus, Locus K, caudal spinal trigeminal nucleus substantia gelatinosa and magnocellular part,
and solitary nucleus. Cell size analysis was performed on digital images captured with a 20×
objective magnification. Cell mean diameters were automatically measured by Leica Application
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Suite Advanced Fluorescence (LAS AF) Software; statistical parameters (mean, minimum, maximum,
S.D.) and histograms of the cell sizes were obtained by the Statistica 7 software (Version 7.0.61.0;
StatSoft Inc., Palo Alto, CA, USA). Cell density (number of cells/mm2) was measured on digital images
captured with a 10× objective magnification; statistical analysis was performed with One-way analysis
of variance (ANOVA) and the Tukey’s post-hoc test by means of the software GraphPad Prism 6 for
Windows (GraphPad Software, La Jolla, San Diego, CA, USA)
3. Results
In the human caudal medulla oblongata of all examined specimens, from fetal and neonatal age
(Figure 1a,b and Figure 2a) to adult life (Figure 3a,b), at levels between the pyramidal decussation and
the obex, the territory of the cuneate nucleus contains distinct areas of gray matter that include TRPV1
strongly positive networks of varicose filaments and dot-like structures, interpreted as nerve fibres and
terminals. By contrast, the remaining territory of the cuneate nucleus hosts scarce immunoreactivity.
No evidence of immunoreactive cell bodies was found. Compared to the outcome in newborn
tissue, the density of TRPV1-like immunoreactive structures appears reduced in adult specimens. No
gender differences were observed. Immunostaining for CGRP and SP in adjacent sections allows
for ascertaining that the TRPV1-LI is localized to the Locus K (Figures 1a–d and 2a,b). However,
though codistributed, the immunoreactivity for the receptor and the neuropeptides do not strictly
overlap. In fact, though present in the superficial dorsal edge of the gray area, the bulk of TRPV1-LI,
compared with the CGRP- and SP-LI, occupies a deeper zone of the Locus K (Figures 1a–d and 2a,b).
This is congruent with the previously described localization of the three markers in the substantia
gelatinosa of the caudal spinal trigeminal nucleus [27]. As described for the neuropeptides [67,68,89],
TRPV1-like immunoreactive fibres, either isolated or in thin bundles, are detectable within the cuneate
fascicle (Figure 3c). No positive labelling is detectable at levels rostral to the obex. Alternate sections
immunolabelled for TRPV1 and the neuropeptides, and histochemically stained for myelin (Figures 1
and 2) effectively contribute to demonstrate the topographical localization of the TRPV1-LI of the
Locus K and show its myeloarchitectural organization. In particular, analysis of myelin stained
sections shows that the cuneate nucleus subregions with strong immunoreactivity to TRPV1 and
the two neuropeptides contain rare myelinated fibres, whereas numerous stained fibres can be seen
running across the territory of the main cuneate nucleus (Figures 1–3). As previously described for the
other markers, at certain levels, two distinct components of the Locus K, both containing TRPV1-LI,
are detectable in the horizontal plane (Figure 2). The two regions are both located along the dorsal
boundary of the cuneate nucleus, one in a dorsal and/or medial position, and the other one lateral
to the cuneate nucleus and medial to the dorsomedial end of the caudal spinal trigeminal nucleus
substantia gelatinosa (Figure 2). The medially located region may show a triangular, oval or arched
profile, whereas the lateral one is round-shaped and the immunoreactivity is mostly confined to its
crescent-shaped dorsal border (Figure 2). The histochemical stainings show that myelinated fibres,
abundant in the cuneate nucleus, gracile nucleus, and caudal spinal trigeminal nucleus magnocellular
part, conversely are scarce in both the Locus K and caudal spinal trigeminal nucleus substantia
gelatinosa (Figure 1c,d, Figures 2c and 3a,b).
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Figure 1. Full-term newborn, case 6. Left side dorsal quadrant in two consecutive sections of the
caudal medulla oblongata immunostained for TRPV1 (a,b) and for CGRP followed by myelin Black
Gold II counterstaining (c,d). Strongly TRPV1- and CGRP-like immunoreactive areas, along the dorsal
border of the cuneate nucleus (Cu), are located in the Locus K (box in (a,c)) and are shown at higher
magnification in (b,d), respectively. Gr, gracile nucleus. Scale bar: (a) = (c): 250 μm; (b) = (d): 50 μm.
Nissl staining performed on adult tissue sections (Figure 4) indicates that, in the LK, the cells are
smaller and more closely packed (Figure 4g,h and Figure 5) than in the cuneate nucleus (Figure 4e,f
and Figure 5), the histological aspect of the Locus K appearing rather similar to that of the caudal
spinal trigeminal nucleus substantia gelatinosa (Figure 4i,j and Figure 5). The obvious tissue structure
differences are proved by the analysis of cell size (histograms in Figure 4) and density (Figure 5). In the
Locus K, as in the trigeminal substantia gelatinosa, the measured neurons show mean cell diameters
between 5 and 18 μm (mean 8.55 and 8.68 μm, respectively), whereas, in the magnocellular part of
the caudal spinal trigeminal nucleus, the mean diameters range 5 to 35 μm (mean 11.7 μm) and in
the solitary nucleus 5 to 26 μm (mean 11.4 μm). In dorsal column nuclei, namely cuneate, external
cuneate and gracile nuclei, the cell size is definitely larger, the mean cell diameter ranging 5 to 32 μm
(mean 15 μm) in the cuneate and gracile nuclei, and 13 to 38 μm (mean 22 μm) in the external cuneate
nucleus. As for the cell density (Figure 5), the mean value is 872.37/mm2 in Locus K, 579.63/mm2 in
the substantia gelatinosa of caudal spinal trigeminal nucleus, 257.7/mm2 in the magnocellular part of
caudal spinal trigeminal nucleus, 323.09/mm2 in the solitary nucleus, and between 125 and 159/mm2
in the dorsal column nuclei (cuneate, external cuneate and gracile nuclei). One-way ANOVA showed
that scored differences in density are statistically significant (p < 0.0001); single p-values adjusted for
multiple comparisons among the seven examined nuclear regions are reported in Table 2.
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Figure 2. Full-term newborn, case 6. (a–c): right dorsal quadrant of three consecutive sections of the
caudal medulla oblongata immunostained for TRPV1 (a) and SP (b), and stained for myelin with Black
Gold II (c). TRPV1-LI (boxes in (a)) and SP-LI (boxes in (b)) are codistributed in a parallel way in the
Locus K (LK) and in the spinal trigeminal nucleus (Sp5C) substantia gelatinosa. cc, central canal; Cu,
cuneate nucleus; Gr, gracile nucleus. Scale bar: (a,b) = (c) 250 μm.
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Figure 3. Adult, case 9. Right dorsal quadrant of caudal medulla oblongata immunostained for TRPV1
and counterstained with Klüver–Barrera (a). Locus K (LK) containing TRPV1-LI (box in (a)) is shown
in (b) at higher magnification. c: thin fibre bundles in the dorsolateral fasciculus cuneatus (cu). cc,
central canal; Cu, cuneate nucleus; Gr, gracile nucleus; Sp5C, caudal spinal trigeminal nucleus. Scale
bar: (a) 250 μm; (b,c) 20 μm.
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Figure 4. Adult, case 9. Nissl stained gracile nucleus (Gr), cuneate nucleus (Cu), external cuneate
nucleus (ECu), Locus K (LK), caudal spinal trigeminal nucleus substantia gelatinosa (Sp5C2) and
magnocellular region (Sp5C3/4), solitary nucleus (Sol) and relative size frequency histograms. In
histograms, x-axis values represent the mean cell diameters expressed in μm, y-axis values report the
relative percent frequency. Curves superimposed on the histograms represent the theoretical normal
distribution. Scale bar: (a, c, e, g, i, k) = (m) 50 μm.
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Figure 5. Adult, case 9. Histogram of mean cell density in the Locus K (LK) as compared to protopathic
sensory nuclei and dorsal column nuclei of the human medulla oblongata. Differences in density
among the seven regions are statistically significant (see Table 2). Caudal spinal trigeminal nucleus
substantia gelatinosa (Sp5C2) and magnocellular region (Sp5C3/4), solitary nucleus (Sol), cuneate
nucleus (Cu), external cuneate nucleus (ECu) and gracile nucleus (Gr).
Table 2. P-values, calculated by means of one way ANOVA followed by Tukey’s post-hoc test, relevant
to pair-wise contrasts between mean cell densities of Locus K (LK) and those of protopathic sensory
and dorsal column nuclei in the human medulla oblongata (see histogram in Figure 5). Each p-value is
adjusted to account for multiple comparison (significance level: 0.05; confidence level: 95%). Caudal
spinal trigeminal nucleus substantia gelatinosa (Sp5C2) and magnocellular region (Sp5C3/4), solitary
nucleus (Sol), cuneate nucleus (Cu), external cuneate nucleus (ECu) and gracile nucleus (Gr).
Nuclei Summary Adjusted p-Value
Sp5C3/4 vs. Sol * 0.0267
Sp5C3/4 vs. LK ** 0.0033
Sp5C2 vs. LK **** <0.0001
Sp5C2 vs. Cu ns 0.5456
Sp5C2 vs. ECu **** <0.0001
Sp5C2 vs. Gr ns 0.1186
Sp5C3/4 vs. Cu **** <0.0001
Sp5C3/4 vs. ECu **** <0.0001
Sp5C3/4 vs. Gr **** <0.0001
Sol vs. LK **** <0.0001
Sol vs. Cu **** <0.0001
Sol vs. ECu **** <0.0001
Sol vs. Gr **** <0.0001
LK vs. Cu **** <0.0001
LK vs. ECu **** <0.0001
LK vs. Gr **** <0.0001
Cu vs. ECu ns 0.9998
Cu vs. Gr ns 0.9203
ECu vs. Gr ns 0.9771
*, p < 0.05; **, p < 0.005, ****, p < 0.0001; ns, not significant.
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4. Discussion
The results obtained provide evidence for the presence of TRPV1-LI, in the form of a network
of nerve fibres and terminals, within a set of distinct subnuclear areas located in the territory of the
human cuneate nucleus, which we designate as Locus Kalaris or, briefly, Locus K. In a previous study,
we provided a three-dimensional reconstruction of those areas [92], showing that the Locus K spans
longitudinally from the pyramidal decussation to the obex level, first appearing caudally at the level
of the cuneate nucleus caudal pole, and being located along the dorsal border of the cuneate nucleus.
Similarly to several other markers, such as neuropeptides and molecules indicative of trophism and
neuroplasticity [70,71,92–97], TRPV1-LI is detectable in the Locus K throughout life, from fetal to
adult age. The present study also provides the first description of the morphometric features of the
Locus K and a comparative analysis between Locus K and a number of the human medulla oblongata
sensory nuclei. Among them, the mean cell size shows the lowest values in the Locus K and in the
spinal trigeminal nucleus substantia gelatinosa, is somewhat higher in the spinal trigeminal nucleus
magnocellular part and solitary nucleus, and is by far larger in the cuneate, gracile and external cuneate
nuclei. A similar, though reversed, trend among the same nuclei is maintained with regard to the
mean cell density, which shows the highest value in the Locus K followed by the spinal trigeminal
nucleus substantia gelatinosa, whereas it lessens in the spinal trigeminal nucleus magnocellular part
and solitary nucleus, and is greatly reduced in the cuneate, external cuneate and gracile nuclei. Thus,
the concurrent immunohistochemical labelling for TRPV1 and the neuropeptides CGRP and SP (this
study), which in turn are codistributed with several other markers [92], and the outcome of the cyto-
and myeloarchitectural analysis, display the remarkable similarity in the neurochemical and structural
arrangement between the Locus K and the protopathic sensory nuclei of the human medulla oblongata.
Moreover, the pattern of immunolabeling and relative distribution of TRPV1-, CGRP- and SP-LI
uphold the possibility that the Locus K is structurally organized in a laminar pattern, likewise the
spinal trigeminal nucleus substantia gelatinosa. All of these observations induce consideration of a
role in protopathic sensory neurotransmission for the Locus K and a functional involvement of TRPV1
in it, similar to that proposed in the spinal dorsal horn and, more generally, in the protopathic sensory
nuclei. Ample evidence on the neurochemical anatomy of the somatosensory system in different
animal species, including man, shows that immunoreactivity to several neuropeptides is concentrated
in the superficial laminae of the spinal dorsal horn, in the caudal spinal trigeminal nucleus substantia
gelatinosa, and in the solitary nucleus, being generally scarce to absent in the dorsal column nuclei [92]
(and references therein), [100,101]. In a similar way, at a central level, the majority of TRPV1-containing
structures occur in the superficial laminae of the rat spinal cord dorsal horn [22,102–105], in the rat [106]
and human trigeminal substantia gelatinosa [27], and have a recognized role in transduction and
transmission of noxious stimuli. In these territories, TRPV1 has been localized to unmyelinated (C) or
thinly myelinated (Adelta) primary sensory afferents [1,11,14,102,106] that terminate mostly in lamina
I and the inner part of lamina II of the rat spinal cord dorsal horn [102,103]. We showed a similar
distribution in the human spinal trigeminal nucleus substantia gelatinosa [30]. However, postsynaptic
TRPV1 has also been reported in the rodent superficial dorsal horn [103,107–109]. Moreover, together
with that in somatic pain perception, TRPV1 appears to play an important role in visceral pain. In fact,
at L4-S1 levels of the spinal cord dorsal horn [104,110] and sacral dorsal commissural nucleus [111],
TRPV1 expression has been associated with visceral afferents innervating the urinary bladder and
other pelvic organs, and TRPV1-bearing terminals have been shown in the solitary nucleus [112,113].
The existence of a region with the neurochemical and structural characteristics as the Locus K in
the territory of the dorsal column nuclei, as well as the occurrence of TRPV1-LI in it, may sound in
marked contrast with the classical functional role of those nuclei, which is epicritic sensibility. However,
in keeping with a role in pain and protopathic perception, the dorsal columns, largely composed of
thick myelinated fibres involved in the transmission of fine touch, vibratory sense and proprioception,
also include a large proportion of thin and unmyelinated fibres [114–116], which may reach up to 25%
in the human sacral spinal cord [117]. In the rat, these fibres have been identified as primary afferents
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and many of them are immunoreactive to CGRP and SP [117–121]. Additionally, nociceptive second
order sensory fibres run in the dorsal column, composing the post-synaptic dorsal column (PSDC)
pathway. The latter originates from neurons located in the central area of the spinal cord [122–124] and
includes neuropeptidergic fibres [125]. The PSDC pathway carries visceral nociceptive information and
clinical reports show that its surgical interruption effectively relieves intractable visceral pain in cancer
patients [124,126,127]. Thus, on the one hand, the main involvement in sensory neurotransmission
for TRPV1 and several neuropeptides, namely CGRP and SP, remains related to the protopathic
sensory perception. On the other hand, the possibility that these molecules play a role in the epicritic
sensibility classically attributed to the dorsal column nuclei may also be taken into account. In fact,
at both peripheral and central level, TRPV1 may also contribute to mechanotransmission, especially
after injury [108,128–131], and TRPV1-immunostaining has been detected in laminae III-V of the
spinal cord dorsal horn, receiving, among others, primary afferents involved in proprioception [104].
Moreover, TRPV1- [132] and CGRP-positive fibres [128] have been shown to innervate light touch
mechanoreceptor Meissner’s corpuscles in monkey and rat, respectively, and SP-positive fibres also
occur in human and rat Meissner’s corpuscles and other mechanoreceptors [133–135]. We did not
detect TRPV1-positive cell bodies in the LK. However, besides the likely prospect that the TRPV1-like
immunoreactive fibres of the LK belong to neurons composing a sensory pathway, the possibility that,
at least in part, they represent processes of local neurons or glial cells can not be ruled out, as shown
in the rat spinal cord, with a role for the receptor in the control of pain transmission and onset of
neuropathic pain disfunctions, such as hyperalgesia and allodynia [22,107,109]. Finally, the possibility
should also be considered that the TRPV1-like immunoreactive fibres in the LK belong, at least in part,
to descending projections. In fact, experimental evidence underlines the role of supraspinal TRPV1
in pain modulation, the rostral-ventrolateral medulla (RVM), periaqueductal grey (PAG), amygdala,
solitary tract nucleus, locus coeruleus, somatosensory and anterior cingulated cortex, and insula being
the territories most involved in this functional meaning [15,136–142]. Although the knowledge of
the TRPV1 role in most of these systems is still incomplete, the TRPV1-mediated activation of the
PAG-RVM antinociceptive pain pathway has drawn attention as a possible pharmacological target for
some types of intractable pain [142].
At the present time, the possible functional involvement of the Locus K remains a matter of
speculation. The localization pattern of TRPV1-, CGRP- and SP-LI in it shows that the elements containing
the three markers do not overlap perfectly. This agrees with our findings on the substantia gelatinosa
of the spinal trigeminal nucleus [30] and suggests that, especially in the deep part of the Locus K, the
TRPV1-LI may reside in non peptidergic [13,14] and perhaps in non presynaptic [102,143] elements.
In conclusion, the Locus K is still a “Nucleus in Search of a Function”. However, on a positive
note, TRPV1 must be considered one of the Characters playing in it.
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Abstract: The Transient Receptor Potential (TRP) family of selective and non-selective ion channels is
well represented throughout the mammalian gastrointestinal track. Several members of the Transient
Receptor Potential Vanilloid (TRPV) subfamily have been identified in contributing to modulation
of mobility, secretion and sensitivity of the human intestine. Previous studies have focused on
the detection of TRPV mRNA levels in colon tissue of patients with inflammatory bowel disease
(IBD) whereas little information exists regarding TRPV channel expression in the colonic epithelium.
The aim of this study was to evaluate the expression levels of TRPV1, TRPV2, TRPV3 and TRPV4 in
mucosa epithelial cells of colonic biopsies from patients with ulcerative colitis (UC) in comparison
to colonic resections from non-IBD patients (control group). Immunohistochemistry, using specific
antibodies and quantitative analyses of TRPV-immunostained epithelial cells, was performed in
semi-serial sections of the samples. TRPV1 expression was significantly decreased whereas TRPV4
expression was significantly increased in the colonic epithelium of UC patients compared to patients
in the control group (p < 0.05). No significant difference for TRPV2 and TRPV3 expression levels
between UC and control specimens was detected (p > 0.05). There was no correlation between TRPV
channel expression and the clinical features of the disease (p > 0.05). Further investigation is needed
to clarify the role of TRPV channels in human bowel inflammatory response.
Keywords: TRPV1; TRPV2; TRPV3; TRPV4; mucosal epithelium; ulcerative colitis; inflammatory
bowel disease
1. Introduction
The importance of the Transient Receptor Potential family (TRP) of selective and non-selective
cation channels in cellular homeostasis via regulation of calcium and magnesium ions levels has
been well documented [1]. TRPC (Canonical), TRPV (Vanilloid), TRPM (Melastatin), TRPA (Ankyrin),
TRPN (no mechanoreceptor potential C-NOMPC), TRPP (Polycystin) and TRPML (Mucolipin) are
TRP subfamilies [2]. Certain TRP channels serve as “cellular sensors” for a wide range of extracellular
stimuli such as changes in temperature, osmotic pressure and pH [3]. Additionally, members of the
TRP family appear to be important for the temperature-dependent formation of normal epithelial tight
junctions and thus, in the control of cell proliferation and growth. Besides their well-documented
role in the cell surface, TRP channels are reported to be present in intracellular membranes and are
implicated in the trafficking of interactive proteins [3]. TRP activation in nerve cells enhances cell
excitability leading to increased release of neurotransmitters whereas in peripheral cells (e.g., epithelial
cells, immune cells), it results in increased expression of inflammatory mediators [1–3].
TRPV1, TRPV2, TRPV3, and TRPV4 along with TRPM8 and TRPA1 constitute the thermo-TRPion
channels [4]. In particular, the highest levels of ion permeability of TRPV1 channels are achieved when
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they are exposed to temperatures higher than 42 ◦C. TRPV1 can also be activated by physical stimuli
including acidic pH, mechanic distention and high membrane electric potential. Exogenous substances
(e.g., capsaicin) as well as endogenous derivates like endocannabinoids (e.g., anandamide) and
palmitoylethanolamide augment TRPV1 channel activity. TRPV1 expression has been found in many
parts of the nervous system where it plays a crucial role in clinical conditions such as migraines,
schizophrenia, myasthenia gravis, Alzheimer disease and depression [1–6]. Furthermore, TRPV1
is implicated in neurogenic inflammation, a process which involves perception of pain and both
vasodilation and plasma extravasation aroused from the release of two vasoactive neuropeptides,
calcitonin gene-related polypeptide (CGRP) and substance P (SP), from a subpopulation of peptidergic
neurons which highly express TRPV1 [5]. TRPV2 channels share 50% domain similarity to TRPV1.
They respond to noxious heat with an activation threshold of >52 ◦C, to changes in osmolarity and to
membrane stretch. Accumulating data provide evidence that TRPV2 might participate in neurogenic
inflammation [7]. TRPV3 protein produced by the translation of the same with TRPV1 gene, reaches
the highest levels of its permeability when exposed to temperatures of 33–39 ◦C and chemical stimuli
like menthol, carvacol, camphor, and eugenol. Activation of TRPV3 has been associated with cellular
release of IL-1, a pro-inflammatory cytokine [8]. Temperatures of 27–34 ◦C, low osmolarity, acidic pH,
and mechanical stress are some of the physical stimuli that increase the TRPV4 channel permeability.
Certain epoxyeichosatetraenoic acid derivatives are endogenous TRPV4 agonists and phytochemical
bisandrographolide A, the phorbol ester 4α-phorbol 12,13-didecanoate (4α-PDD), cannabidivarin and
tetrahydrocannabivarin are exogenous TRPV4 agonists [9]. Inflammatory mediators are known to
augment TRPV1 and TRPV4 activity by sensitization. Experimental data implicate TRPV1 and TRPV4
channel contribution in allodynia, thermal hyperalgesia and visceral hypersensitivity [10–13].
Ulcerative colitis (UC), Crohn’s disease (CD) and indeterminate colitis are the constituents of
the inflammatory bowel disease (IBD). UC mainly affects the mucosa of the colon and rectum and
is characterized by usually long-term remissions between flares and mild to severe exacerbations
of abdominal pain and bloody diarrhea to weight loss, fever and anemia. During a colonoscopy,
small ulcers on the colon’s lining and pseudopolyps may be revealed but the microscopic evaluation
of tissue biopsies is crucial for a definite diagnosis. Increased inflammatory cells in the lamina
propria, alteration of crypt architecture or even crypt abscesses and ulcers are some of the typical
histopathological features of UC tissue specimens [14,15]. Despite the slightly elevated risk of colorectal
cancer and the life-threatening complications of severe exacerbations, no difference in mortality rates
between patients with UC and the background population has been revealed [16,17].
The impact on the quality of patients’ life with IBD on the health care system and society is of great
importance and this partly explains the growing interest in involving new molecules for the treatment
of the disease [18]. To that point is the investigation of TRPV1–4 channel expression in IBD patients.
Previous studies have detected increased TRPV1 [19–27] and TRPV4 [28–31] expression in sensory
fibers which was correlated with visceral hypersensitivity and hyperalgesia in inflamed human and
mouse bowel. Quantitation of mRNA levels for TRPV1 [24,26,27] and TRPV4 channels [29,30] has been
also assessed in colon biopsies from IBD patients and healthy controls. Recent data in experimental
animals implicate TRPV2 in the development of colitis [32] whereas contribution of TRPV4 to intestinal
inflammation via chemokine release has been reported [29]. The expression of TRPV1 and TRPV4
in epithelial cells of the human colon [26,29], and TRPV3 presence in distal mouse colon epithelium
has been documented [33]. These findings contribute to current knowledge of nociceptive signals
generated in the intestine by exciting sensitized nociceptors as a result of mechanical stimulation or
distension implying that targeting TRPV channels could be a new therapeutic opportunity for treating
patients with IBD [34–37].
Given the histological changes in the mucosa of patients with IBD and the involvement of TRPV
channels in intestinal inflammation, we aimed to assess the immunohistochemical quantification of
TRPV1, TRPV2, TRPV3, and TRPV4 channel expression in the mucosal epithelium of colonic biopsies
from patients with UC compared with colonic resections from non-IBD patients (control group).
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The relationship between channel expression and patients’ clinical manifestations of the disease was
also investigated.
2. Materials and Methods
2.1. Patients
A total of 52 Greek patients of mean age about 49.17 (±17.96) years old either treated for an
exacerbation of UC or proto-diagnosed with this type of IBD (26 active, 24 quiescent and 2 with
dysplasia) in the Department of Internal Medicine of “Agios Andreas” Hospital, Patras, Greece,
from 1996 to 2014, were included in this study. The corresponding tissue blocks were retrieved
from archival files of the Department of Pathology of “Agios Andreas” Hospital, Patras. The control
group comprised of gut tissue samples from non-IBD patients (n = 12; mean age, 75.25 years, range,
68–83 years) excluded due to colon cancer (retrieved up to 5 cm away from the tumor’s edge),
postoperative ileus, and lipomatosis of the ileocecal valve. The control tissue samples were collected
from the same department, during the same period. The use of the human specimens was in accordance
with the University of Patras Ethics Commission. All research protocols were conducted, and patients
were treated in accordance with the tenets of the Declaration of Helsinki.
2.2. Immunohistochemistry
All tissues were prepared in formalin and embedded in liquid paraffin. Semi-serial sections
of 4 μm collected on poly-L-lysine slides, deparaffinized in xylene and dehydrated using graded
alcohol diluents up to water were used for antigen retrieval which was performed by microwaving
the slides in 0.01 M citrate buffer (pH 6). Endogenous peroxidase activity was quenched by treatment
with 1% hydrogen peroxide solution for 20 min. Incubation at room temperature with 1% bovine
serum albumin (SERVA, Heidelberg, Germany) in Tris-HCL-buffered saline was performed for
10 min. Tissue sections were subsequently incubated with primary antibodies overnight at 4 ◦C
for TRPV1, TRPV2, TRPV3 and 2 h RT for TRPV4. Detection of the TRPV1, TRPV2, TRPV3 and TRPV4
channels was performed using the polyclonal rabbit anti-TRPV1 antibody (cat. no. NBP1-71774;
dilution 1:200; Novus Biologicals, Ltd., Cambridge, UK), polyclonal rabbit anti-TRPV2 (cat. no.
TA317464; dilution 1:200, Acris Antibodies GmbH, Herford, Germany), monoclonal mouse anti-TRPV3
antibody (cat. no. AM20072PU-N; dilution 1:300, Acris Antibodies GmbH, Herford, Germany),
and the rabbit polyclonal to TRPV4 (cat. no. ab39260; dilution 1:200) (Abcam, Cambridge, UK).
These antibodies have been used to detect human TRPV channels in previous studies [38–41].
After three rinses in buffer, the slides were incubated with the un-avidin-biotin complex technique
named Envision (Dako Cytomation; Agilent Technologies, Inc., Santa Clara, CA, USA). Tissue staining
was visualized with 3,3′-diaminobenzidine (DAB) as a chromogen (which yielded brown reaction
products). Slides were counterstained with Mayer’s hematoxylin solution, dehydrated and mounted.
To ensure antibody specificity, negative controls included the omission of primary antibody and
substitution with non-immune serum. Control slides were invariably negative for immunostaining.
Renal tissue was used as positive control for TRPV1, TRPV3, and TRPV4 antibodies and ophthalmic
pterygium for TRPV2 antibody [42,43].
2.3. Scoring
All immunohistochemical sections were assessed blindly and independently by two observers
(TR and MA), followed by a joint review for resolution of any differences. The expression of proteins
was determined as the mean percentage of positive mucosa epithelial cells, manually counted, with the
aid of an ocular grid, in ten non-overlapping, random fields (total magnification, ×400) for each case
(labeling index, LI; % labeled cells). Immunopositively stained endothelial and lamina propria cells
were excluded from the cell counts. Expression of proteins included in this study was examined in
adjacent (semi-serial) sections of each sample. Microphotographs were obtained using a Nikon
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DXM 1200C digital camera mounted on a Nikon Eclipse 80i microscope and ACT-1C software
(Nikon Instruments Inc., Melville, NY, USA).
2.4. Statistical Analysis
Non-parametric methods were used for the statistical analysis of the results. Median comparisons
were performed with Wilcoxon’s Rank-Sum test (equivalent to the Mann–Whitney U test) and the
Kruskal–Wallis test. Correlation analysis was performed by utilizing Kendall’s τ (or Spearman’s ρ) rank
correlation to assess the significance of associations between LIs. p values of <0.05 were considered
to indicate a statistically significant difference. Statistical analyses were carried out using the SPSS
package (version 23.0; SPSS, Inc., Chicago, IL, USA).
3. Results
3.1. Immunolocalization of Transient Receptor Potential Vanilloid Channels in Ulcerative Colitis and Control
Non-IBD Samples
Cytoplasmic TRPV1 immunostaining was detected predominantly in the upper layer of the
epithelium in 98% of UC specimens. All epithelial layers in UC cases demonstrated TRPV2, TRPV3,
and TRPV4 cytoplasmic immunoreactivity, 71%, 89%, and 94% respectively. Strong cytoplasmic
immunoreactivities for TRPV1, weak for TRPV2, moderate for TRPV3, and weak to moderate
for TRPV4 channels were observed in epithelium of all (100%) control tissues. TRPV4 nuclear
immunostaining was also noticed in certain epithelial cells. Scattered cells in the lamina propria,
vascular endothelium, muscularis mucosa, and enteric nervous system displayed immunopositivity
for all TRPV channels (Figures 1–3).
 
Figure 1. TRPV1 immunolocalization in UC and control non-IBD samples (A–E) and TRPV3
nerve fiber immunolabeling in UC (F). (A) Renal tissue sections were used as positive control for
TRPV1-immunostaining; (B) Strong cytoplasmic TRPV1 immunoreactivity in mucosal epithelium of control
group. Note TRPV1-immunostained cells in lamina propria; (C) Cells in enteric nervous system display
strong TRPV1 immunopositivity. Furthermore, endothelial cells are TRPV1-immunoreactive (arrows);
(D) Strong cytoplasmic TRPV1 immunostaining in a few superficial mucosa cells of this UC specimen;
(E) Heterogeneity in TRPV1 in epithelium of UC sample. Note TRPV1-immunonegative mucosa cells nearby
to TRPV1-immunopositive mucosa cells (LI = 50). (F) TRPV3 immunoreactivity in nerve fibers in UC.
Counterstain, hematoxylin; original magnification, ×400 (A–D,F), ×200 (E); scale bar, 50 μm.
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Figure 2. Panel presenting expression patterns of TRPV2 (B,C) and TRPV3 (D,F) in UC and control
samples; (A) Ophthalmic pterygium tissue samples were used as positive controls for TRPV2
immunoreactivity; (B) TRPV2-immunostaining in intestinal epithelial cells of control colon. ((B), insert)
Cells in enteric nervous system display strong TRPV2-immunopositivity; (C) Moderate cytoplasmic
TRPV2 staining in numerous mucosa cells in UC specimen. Several TRPV2-immunopositive cells
are observed in lamina propria cells; (D) Renal tissue sections were used as positive control for
TRPV3-immunostaining; (E) Aberrant cytoplasmic TRPV3-immunostaining in epithelial cells of control
sample. Note the strong-immunostained smooth muscle cells in muscularis mucosa; (F) Cytoplasmic
expression of TRPV3 in epithelium and muscularis mucosa of UC sample. Counterstain, hematoxylin;
original magnification, ×400; scale bar, 50 μm.
 
Figure 3. Panel depicting the cellular distribution of TRPV4 in UC and control intestine specimens.
(A) Renal tissue sections were used as positive control for TRPV4-immunostaining. (B) Weak
TRPV4-immunostaining in intestinal epithelial cells of control colon. (C) Granular cytoplasmic
TRPV4-immunoexpression is identified in the cytoplasm of numerous mucosa cells in UC. (D) Nuclei
of mucosa cells display TRPV4 immunostaining in this UC sample. (E,F) Strong granular cytoplasmic
TRPV4 immunolocalization in superficial mucosa cells and goblet cells whereas there are mucosa cells
with weak immunostaining of UC samples. ((E), insert) Immunostaining is absent in negative control
sections. Counterstain, hematoxylin; original magnification, ×400; scale bar, 50 μm.
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3.2. Quantitative Analyses of the Immunohistochemical Findings
Immunohistochemical findings are illustrated in Table 1. TRPV1 expression levels were
significantly decreased whereas TRPV4 expression levels were significantly increased in UC specimens
compared with control non-IBD samples. In contrast, no significant difference was identified for TRPV2
and TRPV3 LIs between UC and control group (Figure 4). A significant correlation was found between
TRPV1 and TRPV3 expression levels (Spearman’s rho = 0.462; p = 0.002) and between TRPV3 and
TRPV4 expression levels (Spearman’s rho = 0.357; p = 0.01) in UC. Finally, TRPV1–4 channel expression
was independent of the extent of colon inflammation, the clinical features and the symptoms of the
disease as well as patients’ age and gender (p ≥ 0.05.)
Table 1. Immunohistochemical expression of TRPV1, TRPV2, TRPV3, and TRPV4 channels in colonic
epithelium of human UC and non-IBD control samples. The (non-parametric) Wilcoxon’s Rank-Sum
test was performed and the level of significant was defined as p < 0.05.
TRPV LIs Ulcerative Colitis (n = 52) Control Group (n = 12)
TRPV1 LIs Mean ± SD, % (range) 68.333 ± 28.28
a,b,c
(0–100)
88.33 ± 16.07 f,g,h
(70–100)
TRPV2 LIs Mean ± SD, % (range) 18.52 ± 23.77
d,e
(0–80)
15.00 ± 13.22 i
(0–25)
TRPV3 LIs Mean ± SD, % (range) 51.00 ± 36.19(0–100)
60.66 ± 51.78 k
(2–100)
TRPV4 LIs Mean ± SD, % (range) 47.80 ± 33.09(0–100)
22.50 ± 15.00
(10–40)
LI, the percentage of positive-labeled cells from the total number of epithelial cells counted; Mean, mean labeling
index; SD, standard deviation; a p < 0.001 vs. TRPV2 expression in UC; b p = 0.01 vs. TRPV3 expression in UC;
c p = 0.002 vs. TRPV4 expression in UC; d p < 0.001 vs. TRPV3 expression in UC; e p < 0.001 vs. TRPV4 expression
in UC; f p < 0.001 vs. TRPV2 expression in control group; g p < 0.02 vs. TRPV3 expression in control group;
h p < 0.001 vs. TRPV4 expression in control group; i p < 0.001 vs. TRPV3 expression in control group; k p = 0.01 vs.
TRPV4 expression in control group.
Figure 4. Comparison of TRPV channel expression in mucosa epithelial cells of UC and non-IBD control
samples. Significant differences between UC and non-IBD group for TRPV1 and TRPV4 expression was
detected (p < 0.05). No significant difference was observed regarding TRPV2 and TRPV3 expression (p > 0.05).
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4. Discussion
Previous studies have focused on quantitation of mRNA levels for TRPV channels in IBD. Thus,
Kun et al. [26] demonstrated a decreased TRPV1 gene expression in UC patients and downregulation
of TRPV1 transcripts in Trpa1 KO animals parallel to the enhanced inflammation upon DSS treatment.
In contrast, Keszthelyi et al. [24] found no changes in mRNA levels of TRPV1 in UC patients in
remission. Additionally, Fichna et al. [30] showed that TRPV4 mRNA expression was significantly
elevated in patients with UC compared with healthy subjects whereas D’Aldebert et al. [29] reported
no significant difference for TRPV4 mRNA quantitative expression in UC. Considering that colonic
nerve fibers in IBD patients highly express TRPV1 and TRPV4 channels [19,22,28], it is obvious that
these neurons largely contribute to the TRPV mRNA levels detected in colonic samples.
In the present study, TRPV channel immune-expression was quantitated in mucosal epithelium
of UC and non-inflamed intestine samples (control group). The percentage of positively (labeled)
cells out of the total number of epithelial cells was counted and the data was statistically analyzed.
UC patients showed statistically decreased TRPV1 expression and statistically increased TRPV4
expression compared with the control group. Vinuesa et al. [44] have shown increased carcinogenesis
in mice genetically deficient in TRPV1 which was strongly related to inflammation. Therefore, TRPV1
decreased expression in epithelium of UC samples may be associated with the exacerbated colon
inflammation and consequently with the loss of the protective role of TRPV1 against colon cancer.
However, in a similar study of Luo et al. [45] a significant upregulation of TRPV1 in colonic epithelium
was observed in active IBD patients. Future investigations would clarify the involvement of epithelial
TRPV1 channels in pathogenesis of IBD.
Activation of TRPV4 channels in mouse intestinal epithelial cells has been implicated in
paracellular epithelial cell permeability, increased intracellular calcium concentrations and maintenance
of chronic inflammation via chemokine release and recruitment of monocytes, macrophages,
neutrophils and Th1 cells [29]. The increased TRPV4 expression in human mucosa epithelial cells of
patients with UC may indicate a possible role of this channel in the inflammation process and provides
TRPV4 as an attractive therapeutic target for human IBD. It is worthy to note that TRPV4 staining
was mainly localized in the cytoplasm but there were cases in which TRPV4 immunostaining was
present in the nucleus of epithelial cells. The feature of TRPV4 localization only in the nucleus has been
also shown in myocardium of neonatal mice [46]. Although TRPV1 and TRPV4 were differentially
expressed in inflamed bowel tissues, there was no significant correlation with clinical features of the
patients and disease severity. Furthermore, the apparent difference in mean age between control and
diseased groups did not influenced the data.
Low expression levels of TRPV2 were identified in both UC and normal intestine tissue and
there are no published data referring to the contribution of TRPV2 in human ulcerative colitis.
However, previous knowledge indicates the possible involvement of TRPV2 in experimental colitis [32].
Additionally, the role of TRPV3 in the human alimentary canal has not been well investigated. TRPV3
levels were slightly decreased in patients with ulcerative colitis in this study. It has been reported that,
TRPV3 channels are important for the integrity of the epidermal barrier [8]. It would be interesting
to define the contribution of TRPV3 channels in gastrointestinal inflammation and maintenance of
the mucus integrity. Statistical analyses revealed the existence of positive correlation between TRPV1
and TRPV3 expression levels and between TRPV3 and TRPV4 expression levels in UC samples. Since,
the heterotetramerization of TRPV1 and TRPV3 has already been documented [5], the effects of
co-expression of TRPV3 and TRPV4 should be studied.
It is important to note that a variety of cells in the lamina propria exhibited TRPV
immunoreactivity. Accumulating data show the presence of TRPV1 and TRPV4 in inflammatory
cells including macrophages, leukocytes [26,30]. Furthermore, blood vessels demonstrated strong
immunopositivity for all TRP channels. It is known that in endothelial cells, TRPV1 is activated
by endocannabinoids, TRPV3 by dietary agonists, and TRPV4 by shear stress, epoxyeicosatrienoic
acids and downstream of Gq-coupled receptor activation. Ca2+ entry through endothelial TRPV
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channels triggers NO− and EDHF-dependent vasodilation [47,48]. Specifically, TRPV4 activation
and Ca2+ entry may occur by mechanical stimulation of the endothelium by increased fluid viscosity
and thus shear stress [49]. It would be interesting to define the role of endothelial TRPV channels in
angiogenesis and carcinogenesis as recent published data implies that TRPV3, TRPV4, TRPV5, TRPM4
and TRPC6 may be thought of as potential genes contributing to colorectal cancer tumorigenesis [50].
Further investigation is needed for the TRPV channels’ involvement in IBD and any possible correlation
between the expression levels of these channels and the presence of dysplasia as well as the patients’
complications and treatment, in large-scale studies.
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41. Sterle, I.; Zupančič, D.; Romih, R. Correlation between urothelial differentiation and sensory proteins P2X3,
P2X5, TRPV1, and TRPV4 in normal urothelium and papillary carcinoma of human bladder. Biomed. Res. Int.
2014, 2014, 1–9. [CrossRef] [PubMed]
42. Kassmann, M.; Harteneck, C.; Zhu, Z.; Nürnberg, B.; Tepel, M.; Gollasch, M. Transient receptor potential
vanilloid 1 (TRPV1), TRPV4, and the kidney. Acta Physiol. 2013, 207, 546–564. [CrossRef] [PubMed]
43. Assimakopoulou, M.; Pagoulatos, D.; Nterma, P.; Pharmakakis, N. Immunolocalization of cannabinoid
receptor type 1 and CB2 cannabinoid receptors, and transient receptor potential vanilloid channels in
pterygium. Mol. Med. Rep. 2017, 16, 5285–5293. [CrossRef] [PubMed]
44. Vinuesa, A.G.; Sancho, R.; García-Limones, C.; Behrens, A.; Ten Dijke, P.; Calzado, M.A.; Muñoz, E. Vanilloid
receptor-1 regulates neurogenic inflammation in colon and protects mice from colon cancer. Cancer Res. 2012,
72, 1705–1716. [CrossRef] [PubMed]
45. Luo, C.; Wang, Z.; Mu, J.; Zhu, M.; Zhen, Y.; Zhang, H. Upregulation of the transient receptor potential
vanilloid 1 in colonic epithelium of patients with active inflammatory bowel disease. Int. J. Clin. Exp. Pathol.
2017, 10, 11335–11344.
46. Zhao, Y.; Huang, H.; Jiang, Y.; Wei, H.; Liu, P.; Wang, W.; Niu, W. Unusual localization and translocation
of TRPV4 protein in cultured ventricular myocytes of the neonatal rat. Eur. J. Histochem. 2012, 56, e32.
[CrossRef] [PubMed]
47. Baylie, R.L.; Brayden, J.E. TRPV channels and vascular function. Acta Physiol. 2011, 203, 99–116. [CrossRef]
[PubMed]
48. Köhler, R.; Heyken, W.T.; Heinau, P.; Schubert, R.; Si, H.; Kacik, M.; Busch, C.; Grgic, I.; Maier, T.;
Hoyer, J. Evidence for a functional role of endothelial transient receptor potential V4 in shear stress-induced
vasodilatation. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 1495–1502. [CrossRef] [PubMed]
49. Hoyer, J.; Köhler, R.; Distler, A. Mechanosensitive Ca2+ oscillations and STOC activation in endothelial cells.
FASEB J. 1998, 12, 359–366. [CrossRef] [PubMed]
50. Sozucan, Y.; Kalender, M.E.; Sari, I.; Suner, A.; Oztuzcu, S.; Arman, K.; Yumrutas, O.; Bozgeyik, I.; Cengiz, B.;
Igci, Y.Z.; et al. TRP genes family expression in colorectal cancer. Exp. Oncol. 2015, 37, 208–212. [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Purification of Functional Human TRP Channels
Recombinantly Produced in Yeast
Liying Zhang 1, Kaituo Wang 1, Dan Arne Klaerke 2, Kirstine Calloe 2, Lillian Lowrey 2,
Per Amstrup Pedersen 3, Pontus Gourdon 1,* and Kamil Gotfryd 1,*
1 Department of Biomedical Sciences, University of Copenhagen, Nørre Allé 14,
DK-2200 Copenhagen N, Denmark; liying.zhang@sund.ku.dk (L.Z.); kaituo@sund.ku.dk (K.W.)
2 Department of Veterinary and Animal Sciences, University of Copenhagen, Dyrlægevej 100,
DK-1870 Frederiksberg C, Denmark; dk@sund.ku.dk (D.A.K.); kirstinec@sund.ku.dk (K.C.);
lillianclowrey@gmail.com (L.L.)
3 Department of Biology, University of Copenhagen, Universitetsparken 13,
DK-2100 Copenhagen OE, Denmark; papedersen@bio.ku.dk
* Correspondence: pontus@sund.ku.dk (P.G.); kamil@sund.ku.dk (K.G.);
Tel.: +45-50-33-99-90 (P.G.); +45-41-40-28-69 (K.G.)
Received: 3 January 2019; Accepted: 3 February 2019; Published: 11 February 2019
Abstract: (1) Background: Human transient receptor potential (TRP) channels constitute a large
family of ion-conducting membrane proteins that allow the sensation of environmental cues. As the
dysfunction of TRP channels contributes to the pathogenesis of many widespread diseases, including
cardiac disorders, these proteins also represent important pharmacological targets. TRP channels
are typically produced using expensive and laborious mammalian or insect cell-based systems.
(2) Methods: We demonstrate an alternative platform exploiting the yeast Saccharomyces cerevisiae
capable of delivering high yields of functional human TRP channels. We produce 11 full-length
human TRP members originating from four different subfamilies, purify a selected subset of these to
a high homogeneity and confirm retained functionality using TRPM8 as a model target. (3) Results:
Our findings demonstrate the potential of the described production system for future functional,
structural and pharmacological studies of human TRP channels.
Keywords: ion channels; overproduction; production platform; protein purification; Saccharomyces
cerevisiae; sensors; transient receptor potential (TRP) channels; yeast
1. Introduction
Transient receptor potential (TRP) channels constitute one of the largest families of ion channels
and serve as cellular sensors that permeate cations, such as calcium, magnesium and sodium,
in response to physical or chemical stimuli. Human TRP channels are widely expressed throughout
the body, including brain, heart, liver, lung, small and large intestine, skeletal muscle, skin, pancreas,
as well as in inflammatory and immune cells [1,2]. Changes of temperature, pH, the concentration
of chemicals or membrane potential modulate TRP channel activity, highlighting their essential
physiological roles in the sensation of thermal shifts [3], pain [4], taste [5] and pressure [6]. Malfunction
of TRP channels significantly contributes to the development of many pathological conditions,
including bipolar disorder, diabetes mellitus, various types of cancer, coronary heart disease and
muscular dystrophia [7]. Consequently, TRP channels represent attractive pharmacological targets and
indeed several TRP-modulating compounds currently undergoing clinical trials [8].
Based on sequence homology, topology and function, human TRP channels are divided into six
subfamilies (Figure 1A): TRPC (canonical), TRPV (vanilloid), TRPM (melastatin), TRPA (ankyrin),
TRPP (polycystin) and TRPML (mucolipin). Moreover, two additional subfamilies, i.e., TRPN and
Cells 2019, 8, 148; doi:10.3390/cells8020148 www.mdpi.com/journal/cells201
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TRPY have been identified in Drosophila melanogaster and yeast, respectively. Structurally, TRP channels
assemble as homo- or hetero-tetramers with a single pore formed in the center. Each subunit consists
of intracellular N- and C-termini, six transmembrane helices (TM1-TM6) interconnected by relatively
short loops, with a pore forming loop (P) inserted between the TM5 and TM6 (Figure 1B,C) [9,10].
Currently, several structures are available for the TRP family (Table 1), including TRPA [11],
TRPPP2-3 [12,13], TRPV1-6 [14–19], TRPC3-6 [20–24], TRPML1 and 3 [25,26], as well as TRPM2,
4 [27,28] and 7-8 [29,30] from different species. In addition to revealing the overall architectures,
the gathered structural information provided mechanistic insights explaining fundamental regulatory
and functional mechanisms [9,31], as well as facilitated drug development, with, e.g., TRPV1 being a
highly medically relevant target [32].
Figure 1. Human transient receptor potential (TRP) channels. (A) Phylogenetic distribution of the
human TRP channel family including six subfamilies comprising proteins with distinct channel
properties. Protein sequences were aligned using MEGA7 (https://www.megasoftware.net/).
Structurally determined channels are highlighted with stars (not all structures were of protein with
human origin, see also Table 1). (B) Topology of TRP channels showing in detail distinct architecture
of the intracellular N- and C-termini across TRP channel subfamilies. (C) Overall structure of TRP
channels with three out of the four monomers shown in pale colors (the structure of TRPV1, PDB-ID:
3J5P [14], was used as a model). TRP channel monomers consist of six transmembrane helices (TM1 to
TM6) that assemble as tetramers with a single ion conducting central pore in the center formed by TM5,
TM6 and the interconnecting pore-loop (P).
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Being membrane proteins, many types of studies of TRP channels are nevertheless hindered
by the difficulty of producing protein samples of sufficient quantity and quality in an economically
sustainable manner. Systematic analysis of heterologous expression systems utilized for production
of TRP channels for structural studies reveals that mammalian and insect cell-based platforms are
the most commonly used (Table 1). TRPV1 [14], TRPM2 [27] and TRPV3 [16] channels were isolated
from modified human HEK cells, whereas TRPML3 was overproduced using an insect (Sf9) cell-based
platform [26]. To our knowledge, yeast, i.e., Saccharomyces cerevisiae, has been exploited to deliver
the structures of two TRP channels only, namely TRPV2 from Rattus norvegicus [15] and TRPV5
from Oryctolagus cuniculus [18], whereas no structure is available originating from a bacterial host,
despite attempts [33].
For many researchers, the primary expression system, also for the production of integral
membrane proteins, has traditionally been Escherichia coli, due to the ease of genetic manipulation,
availability of optimized expression plasmids, high-speed of growth and low cost [34,35]. However,
generation of many proteins from higher sources frequently requires a eukaryotic expression system,
such as insect, mammalian or yeast as hosts [36]. Compared to E. coli, the establishment of insect
or mammalian cell-derived expression is nevertheless cost- and time-consuming. In this context,
S. cerevisiae has advantages as it offers a cheap and robust large-scale production of properly-folded
proteins with post-translational modifications combined with user-friendly genetic manipulations
and simple culture conditions [36–38]. Hence, yeast represents an attractive complement for
synthesis of high-quality protein, which has potential to permit in-depth biophysical and biochemical
characterization, as well as drug discovery of many important targets, including TRP channels, for basic
and applied sciences.
Here, we describe the development of an economic and effective method to isolate purified,
functional human TRP channels applying a previously described robust S. cerevisiae membrane protein
production platform [34,36,37]. Briefly, we approached 11 selected human TRP members belonging
to 4 different subfamilies and produced these as full-length channels C-terminally fused to green
fluorescent protein (GFP). We proceeded further with one member from each subfamily, i.e., TRPC4,
TRPV3, TRPML2 and TRPM8, screened for suitable detergents for membrane extraction and assessed
the quality of the solubilized samples by florescence-detection size-exclusion chromatography (F-SEC).
Subsequently, we performed large-scale purification using affinity chromatography and investigated
homogeneity of the samples employing SEC. Finally, for TRPM8, a medically significant target for
the development of drugs to treat cold-associated respiratory disorders [39] and prostate cancer,
respectively [40], we confirmed retained channel function following reconstitution into artificial lipid
bilayers. Overall, our results suggest that S. cerevisiae is suitable for obtaining large-scales of active
human TRP channels for numerous down-stream applications.
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2. Materials and Methods
2.1. Cloning and Construction of Plasmids
All cDNAs encoding full-length human TRP channels were codon-optimized for S. cerevisiae and
purchased from GenScript (New Jersey, NJ, USA). Codon-optimization algorithm involves adjustment
of a variety of parameters, including codon adaptability, mRNA structure, and various cis-elements
critical in transcription and translation. TRP channel cDNAs and GFP were PCR amplified with
AccuPol DNA polymerase (Amplicon, Odense, Denmark) and the primers listed in Supplementary
Table S1. Each TRP channel-GFP-His8 fusion was generated by homologous recombination by
co-transforming the S. cerevisiae PAP1500 strain [41] with a TRP PCR fragment, a GFP PCR fragment,
as well as BamHI, HindIII and SalI digested pEMBLyex4 vector [42]. The PCR primers were designed
to encode a Tobacco Etch Virus (TEV) protease cleavage site (GENLYFQ↓SQF) between the TRP channel
and the GFP-octa-histidine (His8)-tag. Transformants were selected on agar plates containing synthetic
defined (SD) medium with leucine (60 mg L−1) and lysine (30 mg L−1). The accuracy of all constructs
was confirmed by DNA sequencing.
2.2. Small-Scale Expression of TRP Channels and Live Cell Bioimaging
All TEV-GFP-His8-fusions were expressed in the S. cerevisiae strain PAP1500 essentially as
previously described [43]. Briefly, transformants were inoculated in 5 mL of SD media [44] containing
glucose (20 g L−1), leucine (60 mg L−1) and lysine (30 mg L−1), and grown overnight at 30 ◦C.
The following day, 200 μL of the culture was transferred to 5 mL of the same media lacking leucine
and grown for 24 h at 30 ◦C to increase plasmid copy number upon leucine deprivation. Subsequently,
5 mL of the culture was scaled up to 50 mL in the same medium for another 24 h and used to
inoculate 2 L of media supplemented with amino acid (alanine (20 mg L−1), arginine (20 mg L−1),
aspartic acid (100 mg L−1), cysteine (20 mg L−1), glutamic acid (100 mg L−1), histidine (20 mg L−1),
lysine (30 mg L−1), methionine (20 mg L−1), phenylalanine 50 mg L−1), proline (20 mg L−1), serine
(375 mg L−1), threonine (200 mg L−1), tryptophan (20 mg L−1), tyrosine (30 mg L−1) and valine
(150 mg L−1)), glucose (10 g L−1) and glycerol (3% v/v). Following glucose consumption, protein
expression was induced by adding galactose to a final concentration of 2% and allowed for 48 h at
15 ◦C until the cells were harvested. Obtained material typically yielded in ~10 g of wet cell pellet.
Localization of expressed TEV-GFP-His8-fused TRP channels was performed by bioimaging of
GFP fluorescence in vivo using the Nikon Eclipse E600 microscope (Nikon, Japan) equipped with a
Optronics MagnaFire camera (Optronics, Muskogee, OK, USA).
2.3. Membrane Preparation, Detergent Screens and F-SEC
S. cerevisiae cells were homogenized mechanically (BioSpec, Bartlesville, OK, USA) using
glass beads and crude membranes were prepared as previously described [45]. Briefly, following
ultracentrifugation (205,000× g, 3 h, 4 ◦C), membranes were resuspended in ice-cold solubilization
buffer (SB; 20 mM Tris-NaOH pH 7.5, 500 M NaCl, 10% glycerol, 1 mM EDTA, 1 mM EGTA)
supplemented with SIGMAFAST protease inhibitor cocktail (Sigma, St. Louis Missouri, MO, USA),
1 mM PMSF (Sigma) and 2 mM 2-mercaptoethanol (Sigma), and stored at −80 ◦C until further
use. Isolated membranes from yeast overexpressing the respective TRP channel were subjected to
detergent screening to test solubilization efficacy. Briefly, solubilization was performed at vigorous
rotation (2 h, 4 ◦C) in SB in the presence of n-dodecyl-D-maltoside (DDM; Anatrace, Maumee,
OH, USA), n-decyl-D-maltoside (DM; Anatrace) or 2,2-didecylpropane-1,3-bis-β-D-maltopyranoside
(LMNG; Anatrace) in a final concentration of 2% (1:1 detergent-to-membrane mass ratio) or
n-dodecylphosphocholine (FC-12; Anatrace) or n-heksadecylphosphocholine (FC-16; Anatrace) in a
final concentration of 1% (1:2 detergent-to-membrane mass ratio). Insoluble material was removed
by ultracentrifugation (50,000× g, 20 min, 4 ◦C) and 20 μL of the supernatant was used to measure
GFP fluorescence (excitation 485 nm, emission 520 nm) to estimate detergent extraction efficacy.
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The remaining material was loaded on Superose 6 HR 10/30 column (GE Healthcare, Copenhagen,
Denmark) equilibrated with buffer composed of 20 mM Tris-NaOH pH 7.5, 150 mM NaCl and 0.03%
DDM, and subjected to F-SEC performed on ÄKTA Pure system (GE Healthcare) equipped with a
Prominence RF-20A fluorescence detector (Shimadzu, Kyoto, Japan).
2.4. Large-Scale Protein Production, TEV Protease Cleavage and SEC
Large-scale expression of selected TRP channels was performed in 15-L bioreactors essentially as
previously reported [42]. Briefly, 50 mL of the yeast culture described above was scaled up to 1 L in
the same medium and grown overnight at 30 ◦C. The following day, the culture was used to inoculate
10 L of identical medium supplemented with 3% glucose, 3% glycerol, amino acids (excluding leucine),
inorganic salts and vitamins, and the growth was performed in Applikon fermenters connected to an
ADI 1030 Bio Controller (Applikon Biotechnology, Delft, Netherlands) with the automated maintenance
of culture pH at 6.0. Approximately 18 h after inoculation, 1 L of 20% glucose was added to further
increase the growth of cells. Following glucose consumption, protein expression was induced by
adding galactose to a final concentration of 2% and allowed for 96 h at 15 ◦C until the cells were
harvested. Obtained material typically yielded in ~150–200 g of wet cell pellet.
Large-scale protein purification was performed using immobilized metal ion affinity
chromatography (IMAC) with crude membranes isolated from 40 g of fermenter-grown yeast cells
(obtained from ~3 L of cell culture). Membranes were solubilized by vigorous rotation (3 h, 4 ◦C) in
SB containing the detergent of interest in a final concentration of 2% (DDM or DM) or 1% (FC-16).
Insoluble material was removed by centrifugation (35,000× g, 1 h, 4 ◦C) and the supernatant was loaded
onto a HisTrap HP column (GE Healthcare), washed with 50 mL of IMAC buffer (20 mM Tris-NaOH
pH 7.5, 500 mM NaCl, 10% glycerol and 3 × CMC of the respective detergent). Subsequently, bound
protein was eluted in IMAC buffer supplemented with step-wise (60, 250 and 500 mM) imidazole
gradient. Top IMAC fractions were pooled, concentrated on Vivaspin concentrators (MWCO 100 kDa;
Sartorius, Göttingen, Germany) and the GFP-His8-tag was cleaved with TEV-His10-tagged protease
(home source; 16 h, 4 ◦C) mixed with the protein sample in a ratio of 1:10 (w/w). Treatment with
TEV protease was performed with concomitant dialysis against IMAC buffer supplemented with
20 mM imidazole performed in MWCO 10 kDa dialysis bags (ThermoScientific, Waltham, MA,
USA). Following cleavage with TEV protease, reverse IMAC (RIMAC) was performed to rebind
un-cleaved TEV-GFP-His8-fusions, free GFP-His8-tag and TEV-His10-tagged protease. Briefly, samples
were loaded onto a HisTrap HP column (GE Healthcare) equilibrated with 15 mL of IMAC buffer
containing 20 mM imidazole, and the flow through was collected and concentrated to ~5 mg mL−1 as
already described. Subsequently, RIMAC- or IMAC-pure samples were loaded onto a Superose
6 HR 10/30 column (GE Healthcare) equilibrated with SEC buffer (20 mM Tris-NaOH pH 7.5,
150 mM NaCl, 10% glycerol and 3 × CMC of the respective detergent). Following each SEC run,
fractions corresponding to the main elution peak were pooled and concentrated to ~1 mg mL−1 as
already described.
2.5. Measurements of Single Channel Ion Conductance
Single channel ion conductance was measured in lipid bilayers using an Orbit Mini workstation
(Nanion Technologies, München, Germany) with 50 μm MECA4 recording chips with 4 microelectrode
cavities (Ionera Technologies, Freiburg, Germany) as previously described [46]. Voltage was controlled
by the EDR 3 software (Elements, Cesena, Italy). 150 μL of the recording solution (10 mM HEPES
pH 7.2, 200 mM KCl, 100 mM NaCl and 0.2 mM CaCl2) was added to the cavity of the chip and
electrical contact was established between the electrodes. Lipid planar membranes were formed over
the electrode using 10 mM of 1,2-diphytanoyl-sn-glycero-3-phosphocholine (DPhPc; Avanti Polar
Lipids, Alabaster, AL, USA) and 1 mM cholesterol in n-nonane (Avanti Polar Lipids). DDM-solubilized
SEC-purified TRPM8 sample (0.2 μL of 6.34 μg μL−1) was added to recording solution close to the
bilayers on the cis-side of the chip. Voltage was switched between positive and negative values,
206
Cells 2019, 8, 148
increasing by 20-mV intervals to stimulate protein insertion into the membrane. To activate TRPM8,
1.0 μL of icilin (Sigma) was added to a final concentration of 0.2 μM. Once channel activity was detected,
voltage steps to −20, −40, −80, −100, 20, 40, 60, 80 and 100 mV were applied. If no activity was
observed after more than 2.5 min, the solution was gently mixed, and if still no activity, an additional
0.2 μL of protein sample was added. All recordings were obtained at room temperature (20–22 ◦C).
Recordings were low-pass filtered at 0.5 kHz and analyzed using Clampfit 10.7 software
(Molecular Devices, San Jose, CA, USA). For single channel events current amplitude was determined.
Single channel current was plotted as a function of voltage (I/V curve) using Prism 7 software
(GraphPad, San Diego, CA, USA) and slope conductance was determined by linear regression.
3. Results
3.1. Selected TRP-Channel Targets and The Expression System
To investigate the capacity of S. cerevisiae to serve as a host for production of human TRP channels,
we selected 11 human members belonging to 4 of the main subfamilies, hence, representing targets
with a variety of distinct structural (e.g., N- and C-termini) and functional features. Specifically,
the portfolio included the following members: TRPC3, TRPC4, TRPC5, TRPV1, TRPV3, TRPV4,
TRPML1, TRPML2, TRPML3, TRPM1 and TRPM8. Each expression plasmid encompassed full-length
sequences codon-optimized for S. cerevisiae with C-terminal TEV-GFP-His8-tag fusions (Figure 2A)
to enable visualization, affinity purification and quality control of generated targets. Constructs
were designed to employ the hybrid promoter (CG-P) of the pEMBLyex4 vector, enhanced by the
PAP1500 yeast production strain overexpressing the GAL4p transcriptional activator (Figure 2B) [42].
The potency of the system is further increased through selection for leucine autotrophy that significantly
increases the plasmid copy number prior to induction of the protein of interest [47].
Figure 2. Schematic overview of the yeast production system. (A) Map of the employed plasmid
encoding the respective TRP channels fused C-terminally with a Tobacco Etch Virus, TEV, protease
cleavage site followed by green fluorescent protein sequence, GFP, attached to an octa-histidine stretch,
His8-tag (TEV-GFP-His8-tag). Other critical elements of the plasmid include 2μ (yeast 2 micron
origin of replication), leu2-d (poorly expressed allele of the β-iso-propyl-malate dehydrogenase
gene), bla (β-lactamase gene), pMB1 (pMB1origin of replication), URA3 (yeast orotidine-5’-phosphate
decarboxylase gene) and CG-P (hybrid promoter of GAL10 upstream activating sequence and 5’
non-translated leader of cytochrome-1 gene). (B) The Saccharomyces cerevisiae protein production strain
PAP1500 overexpresses the Gal4 transcriptional activator in the presence of galactose. Gal4 is the
limiting factor for expression from galactose regulated promoter. GAL10 p, UASgal, a specific DNA
binding site for GAL4 activator.
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3.2. Small-Scale Production and Localization in S. cerevisiae
As low protein yields obstruct most types of downstream studies, the obtained quantity of the
targets is critical to evaluate. Taking advantage of GFP detection of target accumulation permitted
by the fusion tag, we determined the produced levels of the 11 human TRP channels following 2-day
induction in 2-L cultures. By measuring whole-cell GFP fluorescence [48] and a GFP standard [49],
we estimated the target levels to range from 2.4 to 5.2 mg of protein per liter cell culture (Figure 3A),
representing rather promising yields for further optimization to produce samples for biophysical,
structural and drug discovery efforts. The highest protein levels were achieved for TRPC4, whereas
TRPML1 expressed the lowest, but still with encouraging yields.
Figure 3. Expression and localization of human TRP channels. Data are shown for S. cerevisiae
cell cultures grown in 2-L scale for 48 h at 15 ◦C. (A) Estimates of protein production levels of
11 human TRP-channels. Measured whole-cell GFP fluorescence was converted to the protein amount
and the predicted yield is shown as mg per liter cell of culture. (B) In-gel GFP fluorescence of
SDS-PAGE-separated crude membranes containing the different TRP channel targets. The image
includes all samples separated on the same gel. (C) Live cell bioimaging of yeast cells expressing
selected TRP channels. For each target GFP fluorescence and differential interference contrast
micrographs are shown. Magnification: 1000×.
Subsequently, we took advantage of yet another useful feature of correctly-folded GFP, i.e.,
its SDS-resistance, and employed in-gel GFP fluorescence (visible following SDS-PAGE), to visualize
the targets in crude membrane preparations (Figure 3B). Encouragingly, all the assessed 11 human TRP
channels accumulated in the membranes in the full-length form. The electrophoretic mobility correlated
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well with the predicted molecular weight, with TRPM1 representing the heaviest target (wild-type MW
of 198.7 kDa) and TRPML3 the lightest (wild-type MW of 57.7 kDa), respectively. For TRPC4 and TRPM1,
an additional weak fluorescent band of lower molecular mass was observed, indicating marginal protein
degradation. TRPM8 migrated as two fluorescent bands, reflecting monomeric and higher oligomeric
(here dimeric) forms. In addition, the appearance of an additional blurred and smeary band for TRPM8
may indicate posttranslational glycosylation as previously reported for this protein [50]. However, as
we achieved acceptable expression levels for this target, we did not attempt further optimization by
removing glycosylation sites that were previously reported to enhance protein secretion [51].
Based on these highly promising production levels and indicative sample quality, as well as
the fact that S. cerevisiae-based heterologous expression of well-behaving TRPV1 channel has been
reported [52], we decided to narrow our target portfolio to characterize further one selected member
from each subfamily, i.e., TRPC4, TRPV3, TRPML2 and TRPM8.
We then evaluated the localization of the produced human TRP channels in S. cerevisiae (Figure 3C).
As seen from live cell bioimaging fluorescent micrographs, TRPC4 and TRPML2 accumulate mainly
in the plasma membrane, whereas TRPV3 and TRPM8 reside in intra-cellular compartments.
Such target-specific compartmental differences in the protein accumulation are frequently observed
and do not affect the final quality of the produced samples [53].
3.3. Solubilization Screen and F-SEC
Successful chromatography purification of membrane proteins necessitates detergent(s) to enable
membrane extraction and stabilization in solution [54]. To identify the most suitable detergents for
solubilization of TRPC4, TRPV3, TRPML2 and TRPM8, we assessed several non-ionic (typically milder)
and zwitterionic (harsher) surfactants, but the majority displayed only partial extraction of the targets
(Supplementary Table S2). Overall, non-ionic DDM and DM (tested at a concentration of 2% w/w),
and zwitterionic FC-12 and FC-16 (1%) were the most efficient (Figure 4A), with the latter being able
to extract 4 TRP targets with at least 44% efficacy as observed for TRPML2. Interestingly, although
used at higher concentration, milder non-ionic DDM and DM were less effective, but still provided fair
solubilization, with only TRPM8 channel being extracted at lower, i.e., 20% efficacy, whereas the yield
for both TRPC4 and TRPV3 exceeded 40%. However, TRPML2 resisted solubilization with non-ionic
detergents and was only extracted with FC-12 and FC-16.
As already mentioned, an ideal extraction detergent should also maintain protein stability,
an essential factor for obtaining high-quality samples for most biochemical, biophysical and biomedical
applications. To evaluate protein behavior following exposure to detergent, we again took advantage
of the TEV-GFP-His8-tag and conducted F-SEC (Figure 4B–E) in presence of 0.03% DDM to minimize
aggregation of tested samples, where the SEC profile of the resulting solubilized fusion protein was
monitored by the fluorescence spectroscopy [55]. For each target two F-SEC runs were performed
to compare the profiles after solubilization with different detergents. In case of FC-16 all obtained
F-SEC profiles were sharp and symmetrical, suggesting that the TRP channels were monodispersed
in this detergent. Only for TRPC4 (Figure 4B) a small fraction of the protein eluted in the void
volume of the column, indicating partial aggregation. TRPC4 exhibited almost identical behavior in
DDM (Figure 4B), whereas the F-SEC profile for DDM-solubilized TRPM8 was broader, but devoid of
aggregation (Figure 4E). DM solubilization of TRPV3 revealed marginal aggregation and a main peak
elution across a relatively large volume span, suggesting partial disruption of the tetramer (Figure 4C).
The F-SEC profile of FC-12-solubilized TRPML2 demonstrated two major fluorescence peaks, indicating
dissociation of the oligomeric state towards a lower oligomeric (or monomeric) state (Figure 4D).
Considering the findings from the solubilization screen and F-SEC analysis, as well as previous
reports demonstrating that fos-cholines can be detrimental to membrane proteins [55,56], and the
fact that both DDM and DM are popular detergents for structural and functional studies (also
of TRP channels) [9,57], we decided to use primarily these milder surfactants for the subsequent
large-scale purifications.
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Figure 4. Solubilization and fluorescence-detection size-exclusion chromatography (F-SEC) of selected
human TRP channels. (A) Solubilization efficacy in FC-12 (at a concentration of 1%), FC-16 (1%),
DDM (2%) and DM (2%) of crude S. cerevisiae membranes for selected TRP channels. Solubilization
was performed for 2 h at 4 ◦C and GFP fluorescence of the solubilized material (supernatant following
ultracentrifugation) was used to calculate the percentage of extraction. (B–E) F-SEC analysis of
the detergent-solubilized samples. Concentrations of the corresponding detergents used during
solubilization are indicated. Normalized F-SEC profiles were obtained for solubilized material separated
on Superose 6 HR 10/30 column where GFP fluorescence was monitored. The void volume of the
column (Superose 6 HR 10/30) is ~8 mL.
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3.4. Purification
Affinity purification of the selected 4 targets was performed based on crude membranes isolated
from 40 g fermenter-grown S. cerevisiae cells (obtained from ~3 L of cell culture) induced for 96 h at
15 ◦C (Figure 5A–D). Membranes were solubilized for 3 h at 4 ◦C with the detergents indicated in
the respective panels of Figure 4, based on the prior F-SEC analysis. As observed from the respective
chromatograms, all TRP channels eluted at imidazole concentrations of ~250 mM. The total yield
of the purified protein ranged from 0.5 to 1.5 mg per liter cell culture (for TRPM8 and TRPV3,
respectively) and the overall purity already following the initial purification step was fair (see
insets with Coomassie-stained SDS-PAGE gels). We subsequently concentrated the top fractions
and attempted TEV protease facilitated removal of the GFP-His8-tag. However, only the TRPC4- and
TRPV3-fusions were successfully cleaved, whereas TRPML2 and TRPM8 remained refractory to the
TEV treatment (data not shown). This likely reflects poor accessibility of the C-termini in the two
latter constructs, preventing proteolytic activity. For TRPC4 and TRPV3, we performed reverse affinity
purification (R-IMAC), and obtained samples of higher purity as contaminants rebound to the resin
(data not shown).
Figure 5. Purification of selected human TRP channels. (A–D) Selected targets were purified from
crude S. cerevisiae membranes isolated from 40 g of fermenter-grown cells (obtained from ~3 L of cell
culture) induced for 96 h at 15 ◦C. Membranes were solubilized with the indicated detergents for 3 h at
4 ◦C. Affinity protein purification was performed using immobilized metal ion affinity chromatography
(IMAC). Concentrations of the corresponding detergents used for protein elution are indicated. IMAC
profiles display UV280 signal for eluted protein (blue) and the corresponding imidazole gradients
used for elution (green). Insets: Coomassie-stained SDS-PAGE gels with concentrated affinity-purified
samples. Black arrows indicate the MW for the corresponding fusion protein.
The (reverse) affinity-purified TRP channels were subjected to SEC run with 3 × CMC of the
corresponding detergents used for solubilization, to further verify the sample quality (Figure 6A–D).
Tag-free TRPC4 eluted as a symmetric peak, indicating a high degree of homogeneity (Figure 6A).
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Similarly, although the SEC analysis of TRPV3 displayed some signs of aggregation, the overall shape
and proportion suggested mono-dispersity of the sample (Figure 6B). We also obtained an acceptable
SEC profile for TRPML2, however, the main peak was preceded by a significant shoulder, indicating
the presence of higher oligomers (or even aggregation) in the sample (Figure 6C). The generated
SEC profile for TRPM8 was symmetric overall, hinting again at a high homogeneity of the purified
protein (Figure 6D).
 
Figure 6. Size-exclusion chromatography (SEC) of selected human TRP channels. (A–D) Normalized
SEC profiles for protein samples previously purified using reverse (TRPC4, A and TRPV3, B) or direct
(TRPML2, C and TRPM8, D) affinity chromatography (immobilized metal ion affinity chromatography,
IMAC). Concentrations of the corresponding detergents used during SEC are indicated. The void
volume of the column (Superose 6 HR 10/30) is ~8 mL.
3.5. Single Channel Current Recordings of DDM-Solubilized TRPM8
Considering the relatively high predicted molecular weight, possible glycosylation, the lowest
extraction efficacy in milder detergents, hence the obtained protein yield, as well as its high medical
relevance, we nominated TRPM8 channel for functional characterization efforts. Current amplitude
was determined (Figure 7A,B) and plotted as a function of voltage (Vm) and a linear regression was
made to determine slope conductance, as shown in Figure 7C. The single channel conductance of
purified TRPM8 channels was determined to 56.9 ± 3.2 pS.
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Figure 7. Single channel activity of affinity and size-exclusion chromatography purified TRPM8.
(A–B) Representative single channel currents of TRPM8 reconstituted in the planar lipid bilayer
membranes. Currents were elicited by positive (A) and negative (B) voltage steps. Channel activity
is observed at all applied voltages. Zero current is indicated by the blue lines. (C) Current (I) was
plotted as a function of voltage (V) and a linear regression was fitted to the data to determine the slope
conductance (56.9 ± 3.2 pS). Results are shown as mean ± SEM, each data point was based on 2–52
single channel events.
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4. Discussion
Membrane proteins, especially those of human origin, remain poorly understood relative to their
soluble counterparts and are underrepresented in protein structure databases, largely due to difficulties
in generation of prime-quality samples required for downstream efforts [58]. Furthermore, membrane
proteins represent very attractive drug targets, and thus, cheap, high-efficiency, easy-to-handle and
reproducible heterologous expression platforms capable of delivering large yields of recombinant
human membrane proteins are still highly demanded.
The most widely exploited system for production of TRP channels from higher organisms
is undoubtedly mammalian cell-based platforms that have provided several targets, including
TRPV1 [14], TRPV6 [19], TRPC3 [20], TRPC4 [22], TRPM2 [27], TRPM4 [28], TRPM8 [30], TRPML1 [25],
TRPA [11] and TRPPP2 [12]. However, complex growth requirements, high costs and modest yields
leave room for alternative approaches [35]. Nevertheless, hitherto only two of the available structures
of mammalian TRP channels, but none of human origin, originate from the protein produced in
S. cerevisiae [15,18]. Compared to the mammalian expression systems, S. cerevisiae offers higher
proteins yields, simpler culture conditions and significantly lower costs [59]. Importantly, as yeast
can commonly contaminate mammalian cell cultures, implementation of careful aseptic routines is,
however, necessary in laboratories culturing concomitantly these two types of cells [60].
In this study, we present a novel approach towards overproduction of human TRP channels
employing an S. cerevisiae-based heterologous expression system. This platform was already
successfully used for generation of several classes of membrane proteins, including the human
ether-à-go-go-related (ERG) channel [49] and aquaporins [61], and even sample that yielded the
first crystal structure of a human aquaglyceroporin [62]. Here, we approached the production of the
challenging human TRP channels in a systematic way, starting from design of suitable plasmids, yield
assessments, localization tests and solubilization screens, to affinity-based purification, SEC-based
analysis and functional characterization of one selected target.
The first critical step in the optimization of recombinant protein overproduction is to assemble
suitable expression plasmids [63]. Here, our strategy was based on the employment of full-length
human TRP channel sequences that were codon-optimized for S. cerevisiae, a common practice used to
improve production levels [64]. Moreover, all constructs possessed C-terminal TEV protease-detachable
GFP-His8-tags, enabling detection and affinity purification of the generated targets to facilitate
downstream characterization [48,65]. Furthermore, the expression vector used here encompassed
several important features, including the possibility to increase the plasmid copy number and an
inducible promoter [42]. Importantly, our strategy involved also the employment of a modified
S. cerevisiae strain that overexpresses the Gal4 transcriptional activator required for galactose induced
transcription [66]. Finally, we took advantage of the ability of S. cerevisiae to perform homologous
recombination to assemble the final constructs [67], a significant economical aspect of utilizing yeast.
The initial expression tests (Figure 3A,B) already indicated the power of our production strategy,
as we were able to recover all 11 human TRP channels selected for this study, all with promising
production yields reaching maximum 5.2 mg of accumulated protein per liter cell culture (Figure 3A).
Moreover, as evident from the in-gel GFP fluorescence signal, all targets were synthesized as
membrane-embedded full-length channels with only marginal signs of protein degradation (Figure 3B),
yet another important advantage of the utilized yeast platform. Moreover, for one target, namely
TRPM8, we observed indications of protein glycosylation (Figure 3B). It has been previously reported
that N-glycosylation is important for the function and regulation of TRP channels, including
TRPA [68], TRPC [69] and TRPM [70,71] subfamilies, respectively. S. cerevisiae PAP1500 strain utilized
here is capable of glycosylating the heterologously expressed human membrane proteins [49,61].
Of importance, S. cerevisiae has been shown to hyper-glycosylate proteins [36] with a detrimental impact
on expression levels [37,51]. Thus, additional optimization of employed constructs by engineering
glycosylation site(s) could be beneficial to further enhance the TRP channel production yields and
activity, however, it was not attempted here.
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The initial expression tests (Figure 3A,B) already indicated the power of our production strategy,
as we were able to recover all 11 human TRP channels selected for this study, all with promising
production yields reaching maximum 5.2 mg of accumulated protein per liter cell culture (Figure 3A).
Moreover, as evident from the in-gel GFP fluorescence signal, all targets were synthesized as
membrane-embedded full-length channels with only marginal signs of protein degradation (Figure 3B),
yet another important advantage of the utilized yeast platform. Moreover, for one target, namely
TRPM8, we observed indications of protein glycosylation (Figure 3B). It has been previously reported
that N-glycosylation is important for the function and regulation of TRP channels, including
TRPA [68], TRPC [69] and TRPM [70,71] subfamilies, respectively. S. cerevisiae PAP1500 strain utilized
here is capable of glycosylating the heterologously expressed human membrane proteins [49,61].
Of importance, S. cerevisiae has been shown to hyper-glycosylate proteins [36] with a detrimental impact
on expression levels [37,51]. Thus, additional optimization of employed constructs by engineering
glycosylation site(s) could be beneficial to further enhance the TRP channel production yields and
activity, however, it was not attempted here.
Mammalian TRP channels are known to differ in subcellular localization and, in addition to
the plasma membrane, can localize to intracellular membranes [72]. For four selected TRP channels,
we also observed differences in localization in the S. cerevisiae cells (Figure 3C), with TRPV3 and
TRPM8 accumulating mainly intracellularly. In accordance, intracellular membrane localization has
previously been observed for these two targets also in human cells [72,73].
To enable successful TRP channel production, suitable detergents for membrane extraction and
maintaining protein stability were identified. The initial choice of detergents for solubilization was
based on our previous large-scale analysis, which compared the efficacy of different compounds
for extracting overproduced human aquaporins using the same expression platform [61]. In the
solubilization screen presented here, we discovered that harsher zwitterionic detergents of the
fos-choline family displayed stronger extraction properties of human TRP channels from the S. cerevisiae
membranes as compared to milder non-ionic maltosides (Figure 4A, Supplementary Table S2). Indeed,
similar observations have also been reported for other membrane protein classes overexpressed in the
same host [74]. In general, all 4 targets tested here were rather resistant to solubilization, with only
TRPM8 channel demonstrating extraction efficacy in FC-16 exceeding 80%. Moreover, when using
FC-16, we observed slightly higher solubilization efficacy of the two targets accumulating in the
intracellular membranes (i.e., TRPV3 and TRPM8) as compared to TRPC3 and TRPML2 that localized
to the plasma membrane. A similar trend was previously reported for the human aquaporin family
produced using the same platform [61]. Fos-choline-solubilized material exhibited moderately more
symmetric F-SEC profiles, however, the mono-dispersity of the maltoside-extracted material was
also relatively high (Figure 4B–E), indicating that milder detergents are promising for isolation of
human TRP channels from crude S. cerevisiae membranes. This is also in agreement with the two
above-mentioned structural reports of human TRPV channels that were overproduced in S. cerevisiae
cells and solubilized in maltosides [15,18].
Affinity-based protein purification yielded milligram amounts of relatively pure samples already
following a single chromatography round (Figure 5A–D). Removal of GFP-His8-tag by TEV protease
cleavage followed by reverse affinity purification was successful for two out of four targets. However,
optimization of neither sequences of employed constructs nor cleavage conditions were attempted
here. The quality of (reverse) affinity-purified samples was evaluated by SEC performed with the
primary detergent, i.e., the respective detergent used for solubilization and affinity purification for
each target, respectively. Strikingly, all tested protein samples, including human TRPML2 isolated
using harsh FC-16, exhibited encouraging SEC profiles (Figure 6A–D).
In our final quality control test, we assessed whether human TRP channels produced using
the described overproduction approach preserved functionality, an important checkpoint for any
heterologous expression platform. DDM-solubilized human TRPM8 was selected as a representative
medically relevant target, with the aim to compare its conductance with permeation properties of
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TRPM8 isolated from other hosts. The slope conductance of TRPM8 reconstituted in lipid bilayers was
56.9 ± 3.2 pS (Figure 7C). Similar conductance (55 ± 3.9 pS) was found for TRPM8 from R. norvegicus
expressed in Xenopus laevis oocytes [75]. Moreover, a study employing human kidney cells reported
mean TRPM8 conductance of 72 ± 12 pS for outward currents, 42 ± 6 pS for inward currents,
respectively, and sub-conductance burst openings at 30 ± 3 pS, suggesting that the channel has
a strong outward rectification [76]. Thus, our functional data obtained for human TRPM8 isolated
from S. cerevisiae are in accordance with the conductance of both rat and human channels expressed in
higher eukaryotic heterologous systems, with subtle quantitative differences that likely are attributed
to variations of the experimental conditions.
All-in-all, obtained results establish our S. cerevisiae-based platform as a cost-effective and
high-throughput approach to produce milligram quantities of stable and functional human TRP
channels. Thus, the approach can be applied in functional, pharmacological and structural studies of
this important family of ion-conducting proteins.
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Abstract: Transient potential receptor (TRP) channels are conserved cation channels found
in most eukaryotes, known to sense a variety of chemical, thermal or mechanical stimuli.
The Saccharomyces cerevisiae TRPY1 is a TRP channel with vacuolar localization involved in the
cellular response to hyperosmotic shock and oxidative stress. In this study, we found that S. cerevisiae
diploid cells with heterozygous deletion in TRPY1 gene are haploinsufficient when grown in synthetic
media deficient in essential metal ions and that this growth defect is alleviated by non-toxic Mn2+
surplus. Using cells expressing the Ca2+-sensitive photoprotein aequorin we found that Mn2+
augmented the Ca2+ flux into the cytosol under oxidative stress, but not under hyperosmotic shock,
a trait that was absent in the diploid cells with homozygous deletion of TRPY1 gene. TRPY1
activation under oxidative stress was diminished in cells devoid of Smf1 (the Mn2+-high-affinity
plasma membrane transporter) but it was clearly augmented in cells lacking Pmr1 (the endoplasmic
reticulum (ER)/Golgi located ATPase responsible for Mn2+ detoxification via excretory pathway).
Taken together, these observations lead to the conclusion that increased levels of intracytosolic Mn2+
activate TRPY1 in the response to oxidative stress.
Keywords: TRP channel; TRPY1; Saccharomyces cerevisiae; calcium; manganese; oxidative stress
1. Introduction
Living cells are continuously exposed to various changes that threaten the dynamic equilibrium
associated with the steady state of homeostatic balance. Such changes—often induced by
stress agents—need to be sensed and signaled by cell components which belong to intricate
networks responsible for homeostatic regulation. Calcium is a secondary messenger used by
all eukaryotes—animal, plants, microorganisms—to connect various stimuli or stresses to their
corresponding cellular responders. The budding yeast Saccharomyces cerevisiae has been constantly
used as a model eukaryote to study the calcium-dependent response to various types of external
stresses, which include salt [1], hypotonic [2,3], hypertonic [1,4,5], salicylate [6], alkaline [7], cold [8],
ethanol [9,10], drugs [11] antifungals [12–16], electric [17] oxidative [18–20] or heavy metal [8,20–22]
insults. The S. cerevisiae cells respond to such stresses by a sudden increase in cytosolic Ca2+—denoted
henceforth [Ca2+]cyt—following the stimulus-dependent opening of Ca2+ channels situated in the
plasma membrane and/or in internal compartments. Abrupt increase in [Ca2+]cyt represents a versatile
and universally used mechanism which triggers either cell survival/adaptation or cell death [23].
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In S. cerevisiae the stress-dependent rise in [Ca2+]cyt can be a consequence of Ca2+ influx via the
Cch1/Mid1 channel on the plasma membrane [1,2] release of vacuolar Ca2+ into the cytosol through the
vacuole-located Ca2+ channel TRPY1 [4,24], or both [19,20]. After delivering the message, the normal
very low level of [Ca2+]cyt is restored through the action of Ca2+ pumps and exchangers [25]. Thus,
the Ca2+-ATPase Pmc1 [26] and a vacuolar Ca2+/H+ exchanger Vcx1 [27,28] independently transport
[Ca2+]cyt into the vacuole, while Pmr1, the secretory Ca2+-ATPase, pumps [Ca2+]cyt into endoplasmic
reticulum (ER) and Golgi along with Ca2+ extrusion from the cell [29,30].
In S. cerevisiae, TRPY1 is almost exclusively localized at the vacuolar membrane [4], playing
an important role in adaptation to environmental stresses [4,19–21]. Initially named Yvc1, TRPY1
is encoded by TRPY1 gene (systematic gene name, YOR087W) and it is the only member of the
TRP (Transient Receptor Potential) superfamily of cationic channels expressed in S. cerevisiae [31].
TRP channels are conserved cation channels found in most eukaryotes, known to sense chemical,
thermal, or mechanical stimuli in animals [32]. In yeast, TRPY1 is the main channel responsible for
of [Ca2+]cyt elevation under hyperosmotic shock [4,31], when calcium accrues predominantly from
vacuolar stores [4]. This behavior can be explained by the mechano-sensitive traits of TRPY1: under
hypertonic conditions water evacuates passively from the cytoplasm and then from the vacuole causing
deformation of the vacuolar membrane and consequently the opening of the TRPY1 channel, with the
release of vacuolar Ca2+ [5,33]. In contrast, under alkaline stress, the elevated [Ca2+]cyt has its origin
exclusively from the cell’s exterior, with the Cch1/Mid1 channel solely responsible for the majority of
Ca2+ entry, and with no contribution of vacuolar Ca2+ [7]. In between these two situations, oxidative
stress triggers [Ca2+]cyt waves which pool both external and vacuolar Ca2+ [19]. TRPY1 is necessary
for attaining a maximum level of [Ca2+]cyt under oxidative stress and TRPY1 depends on [Ca2+]cyt
elevation for maximal gating, in a process known as Ca2+-induced Ca2+ release [34].
TRPY1 gene is not essential for survival and the knockout mutant cells trpy1Δ have no clear
growth defects under various stresses. Rather, it was shown that trpy1Δ cells are slightly more resistant
to the oxidative stress imposed by exogenous hydrogen peroxide or tert-butylhydroperoxide [19] and
Cu2+ [20] but also less fit under high Cd2+ [21] or tunicamycin-induced ER-stress in Ca2+-depleted
medium [31]. In contrast, cells overexpressing the TRPY1 gene are hypersensitive to surplus Ca2+ [4] or
oxidative stress [19]. Also, it was revealed in a wide-scale survey that heterozygous trpy1Δ/TRPY1
diploid cells are less fit under nutrient limiting conditions than the wild-type TRPY1/TRPY1 ([35],
Supplementary material). Haploinsufficiency occurs when the heterozygous mutation of a gene in a
diploid organism results in a reduction of the corresponding gene product which can be correlated with
negative alterations of the wild-type phenotype. In this study, we performed a chemical screen and
found that non-toxic concentrations of Mn2+ alleviated the trpy1Δ/TRPY1 haploinsufficiency observed
by us in minimal growth medium containing half of the recommended amount of essential metal ions,
probably by stimulating the TRPY1-mediated Ca2+ release into the cytosol.
2. Materials and Methods
2.1. Yeast Strains and Growth Media
The S. cerevisiae diploid strains used in this study were isogenic with the “wild-type” (WT)
parental strain BY4743 (MATa/α; his3Δ1/his3Δ1; leu2Δ0/leu2Δ0; met15Δ0/MET15; LYS2/lys2Δ0;
ura3Δ0/ura3Δ0), a S288C-based yeast strain [36]. The strains harbored either heterozygous
(BY4732, orf::kanMX4/ORF) or homozygous (BY4732, orf::kanMX4/orf::kanMX4) knockout mutations of
individual gene open reading frames (ORF). The heterozygous knockout mutants are referred to in the
text as orfΔ/ORF and were cch1Δ/CCH1, mid1Δ/MID1, pmc1Δ/PMC1, pmr1Δ/PMR1, vcx1Δ/VCX1,
trpy1Δ/TRPY1. The homozygous knockout mutants are referred to in the text as orfΔ/orfΔ and were
trpy1Δ/trpy1Δ, smf1Δ/smf1Δ, and pmr1Δ/pmr1Δ. The strains were obtained from EUROSCARF
(European S. cerevisiae Archive for Functional Analysis, www.euroscarf.de) and were propagated,
grown, and maintained in YPD medium (1% yeast extract, 2% polypeptone, 2% glucose) or SD
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(0.17% yeast nitrogen base without amino acids, 0.5% (NH4)2SO4, 2% glucose, supplemented with
the necessary amino acids) [37]. The strains transformed with the plasmids harboring apo-aequorin
cDNA [38] were selected and maintained on SD lacking uracil (SD-Ura). Minimal defined media
(MM) were prepared adding individual components as described [37] using ultrapure reagents (Merck,
Darmstadt, Germany) and contained 1 mM Ca2+, 0.25 μM Cu2+, 2 μM Mn2+, 2 μM Fe3+ and 2 μM Zn2+.
Low-metal minimal defined medium (LMeMM) had 0.5 mM Ca2+, 0.1 μM Cu2+, 1 μM Mn2+, 1 μM Fe3+
and 1 μM Zn2+, corresponding roughly to half of the amount of essential metals recommended [37].
The concentrations of metals in MM and LMeMM were confirmed by inductively coupled plasma with
mass spectrometry (ICP-MS, Perkin-Elmer ELAN DRC-e, Concord, ON, Canada) against Multielement
ICP Calibration Standard 3, matrix 5% HNO3 (Perkin-Elmer Pure Plus, Shelton, CT, USA). All synthetic
media had their pH adjusted to 6.5. For solid media, 2% agar was used. For growth improvement,
all the synthetic media were supplemented with an extra 20 mg/L leucine [39]. All chemicals, including
media reagents were from Merck (Darmstadt, Germany),
2.2. Plasmid and Yeast Transformation
For heterologous expression of aequorin, yeast cells were transformed with the multicopy
URA3-based plasmid pYX212-cytAEQ harboring the apo-aequorin cDNA under the control of the
strong TPI (triosephosphate isomerase) yeast promoter [40]. Plasmid pYX212-cytAEQ was a generous
gift from Martegani and Tisi (University of Milano-Bicocca, Milan, Italy). Yeast transformation [41] was
performed using S.c. EasyComp™ Transformation Kit (Invitrogen, Carlsbad, CA, USA) following
manufacturer’s indications.
2.3. Yeast Cell Growth Assay
2.3.1. Growth in Liquid Media
Unless otherwise specified, cells were incubated at 30 ◦C under agitation (200 rpm). Yeast strains
were pre-grown overnight in MM then diluted (1/20) in fresh MM and grown for 2 h. Cells were
harvested by centrifugation, washed with ice-cold water, and resuspended in liquid LMeMM at
density which corresponded to optical density measured at 600 nm (OD600) = 0.05. Strain growth in
liquid LMeMM was monitored in time by measuring OD600 recorded in a plate reader equipped with
thermostat and shaker (Varioskan, Thermo Fisher Scientific, Vantaa, Finland). Relative growth was
expressed as the ratio between OD600 recorded at time t and OD600 recorded at time 0. For screening
of chemicals against trpy1Δ/TRPY1 haploinsufficiency (HIP), cells shifted to LMeMM (OD600 = 0.05)
were incubated for 2 h before chemicals were added from concentrated sterile stocks. Cell growth
(%) was determined 24 h from chemical addition and calculated relatively to growth (OD600) of WT
strain, no added chemicals. Chemicals used were CuCl2, FeCl2, MnCl2, ZnCl2, ascorbate, ethylene
glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), GdCl3, glutathione (GSH), indole
and were all of high-grade purity.
2.3.2. Growth on Solid Media
For dilution plate assay, exponentially growing cells were 10-fold serially diluted in a 48-well
microtiter plate and stamped on agar plates using a pin replicator (approximately 4 μL/spot). Plates
were photographed after incubation at 30 ◦C for 3 days.
2.4. TRPY1 Gene Expression by Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR)
Wild-type cells BY4743 (TRPY1/TRPY1), heterozygous (trpy1Δ/TRPY1), and homozygous
(trpy1Δ/trpy1Δ) diploid cells from overnight pre-cultures were inoculated at OD600 = 0.1 in MM
or LMeMM and grown to OD600 = 0.5 before Mn2+ was added to final concentration 10 μM, then
incubated for 2 additional hours before being harvested for total ribonucleic acid (RNA) isolation. Total
RNA was isolated using the RiboPure™ RNA Purification Kit for yeast (Ambion™, Thermo Fischer
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Scientific, Vilnius, Lithuania) following the manufacturer’s instructions. Approximately 500 ng of total
RNA was transcribed into cDNA using GoScript™ Reverse Transcription System (Promega, Madison,
WI, USA). Finally, a total of 10 ng cDNA was used for each qRT-PCR done with the GoTaq® qPCR
Master Mix (Promega). Each reaction was performed in triplicate using MyiQ Single-Color Real-Time
PCR Detection System (BioRad, Hercules, CA, USA). Expression of TRPY1 mRNA was normalized to
the relative expression of ACT1 in each sample. The qRT-PCR cycling conditions were 95 ◦C for 1 min,
and 40 cycles of 95 ◦C for 10 s, 59 ◦C for 10 s, 72 ◦C for 12 s. The primers used for amplification of cDNA
were: TRPY1-F: 5′-AGATTCTCAG GGTTACGTTA, TRPY1-R: 5′-CAATATGGAATACCACTCAC;
ACT1-F: 5′-GGTTGCTGCTTTGGTTATTG, ACT1-R: 5′-CAATTGGGTAACGTAAAGTC.
2.5. Assay of Cell Mn2+
Measurements of cell total manganese content were done on cells grown in LMeMM medium
to an OD600 of 1.0. Cells were harvested in triplicate samples, washed two times in ice-cold 10 mM
2-(N-morpholino) ethanesulfonic acid (MES)-Tris buffer (pH 6.0). Cells were finally suspended in
deionized water (OD600 = 10) and used for manganese and cell protein assay. Manganese analysis
was done by ICP-MS after digestion of cells with 65% ultrapure HNO3 (Merck, Darmstadt, Germany).
The metal cellular content was normalized to total cellular proteins, as described [42]. Total cellular
manganese was expressed as nanomoles of metal per mg cell protein.
2.6. Detection of [Ca2+]cyt by Aequorin Bioluminescence Assay
Cells transformed with pYX212-cytAEQ were maintained on SD-Ura selective medium and
prepared for Ca2+ dependent luminescence detection as described [43] with slight modifications.
Overnight pre-cultures of cells expressing apo-aequorin were washed and suspended (OD600 = 0.5) in
LMeMM-Ura then incubated to late exponential phase (OD600 = 1, 4–6 h). For pre-incubation with
Mn2+, MnCl2 was added to the desired concentration and cells were grown for an additional 2 h.
Cells were harvested by centrifugation and resuspened (to OD600 = 10) in LMeMM-Ura in which
the corresponding Mn2+ concentration was maintained. To reconstitute functional aequorin, native
coelenterazine was added to the cell suspension (from a methanol stock, 20 μM final concentration)
and the cells were incubated for 2 h at 30 ◦C in the dark. The excess coelenterazine was removed
by centrifugation. The cells (approximately 107 cells/determination) were finally resuspended in
LMeMM-Ura with corresponding Mn2+ concentration and transferred to the luminometer tube.
A cellular luminescence baseline was determined for each strain by approximately one minute of
recordings at 1/s intervals. After ensuring a stable signal, chemicals tested were injected from sterile
stocks to give the final concentrations indicated, and the Ca2+-dependent light emission was monitored
in a single tube luminometer (Turner Biosystems, 20n/20, Sunnyvale, CA, USA). The light emission
was measured at 1 s intervals and expressed as relative luminescence units (RLU). To ensure that the
total reconstituted aequorin was not limiting in our assay, at the end of each experiment aequorin
activity was checked by lysing cells with 1% Triton X-100 with 5 mM CaCl2 and only the cells with
considerable residual luminescence were considered. Relative luminescence emission was normalized
to an aequorin content giving a total light emission of 106 RLUs in 10 min after lysing cells with 1%
Triton X-100. The relative luminescence maximum (RLM) was the average of the RLUs flanking the
maximum value minus the average luminescence baseline recorded before cells were exposed to the
stimulus (10 values on each side), all normalized as described above.
2.7. Statistics
All experiments were repeated, independently, in three biological replicates at least. For each
individual experiment, values were expressed as the mean ± standard error of the mean (SEM).
For aequorin luminescence determinations, traces represent the mean ± SEM from three independent
transformants. The numerical data were examined by Student t test or by analysis of variance
with multiple comparisons (ANOVA) using the statistical software Prism version 6.05 for Windows
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(GraphPad Software, La Jolla, CA, USA). The differences were considered to be significant when
p < 0.05. One sample t test was used for the statistical analysis of each strain/condition compared
with a strain/condition considered as reference. Asterisks indicate the level of significance: * p < 0.05,
** p < 0.01, and *** p < 0.001.
3. Results
3.1. Haploinsufficiency of Yeast Strain Heterozyous for TRPY1 Is Alleviated by Mn2+
To highlight new aspects related to TRPY1 function in yeast cells, the main target of our study
was to identify conditions which interfere with TRPY1 activity. In this direction, haploinsufficiency is a
genetic trait which can be very useful in the attempts to identify small molecules which influence the
behavior of functional proteins [44]. A genome-wide survey had already pinpointed the heterozygous
trpy1Δ/TRPY1 as possibly less fit under nutrient limiting conditions ([35], Supplementary material).
We noticed that the growth of the heterozygous trpy1Δ/TRPY1 diploid mutant was not significantly
different from the growth of the wild-type diploid when the two strains were incubated in YPD,
SD (data not shown) or MM medium (Figure 1a), but trpy1Δ/TRPY1 cells exhibited somehow slower
growth (p < 0.001) in minimal synthetic medium LMeMM which had approximately half of the amount
of essential metals recommended [37] (Figure 1b).
Figure 1. Growth of heterozygous trpy1Δ/TRPY1. Isogenic diploid strains WT (BY4743,
TRPY1/TRPY1), trpy1Δ/TRPY1 and trpy1Δ/trpy1Δ were shifted at time 0 to (a) minimal medium,
MM or (b) minimum medium with low metal content, LMeMM, as described in Materials and Methods
section. Growth was determined spectrophotometrically at 600 nm as the ratio between OD600 at time
t and OD600 at time 0 for each individual strain.
The haploinsufficiency in LMeMM was noted only for TRPY1; no similar phenotype was recorded
for heterozygous strains with mutations in the genes which encode the other transporters known to
participate in regulating [Ca2+]cyt, e.g., CCH1, MID1, PMC1 or VCX1 (Figure 2a, dark blue bars).
To identify compounds which potentially interact with TRPY1 activity we screened for conditions
which may alleviate or augment the haploinsufficient phenotype observed. The tested substances are
presented in Table 1. These substances were added to the LMeMM at the point where the heterozygous
trpy1Δ/TRPY1 diploid cells were in the early log phase of growth (OD600 = 0.1) and the effect on
growth was determined 24 h after chemical addition. We tested the effect of adding physiological
concentrations of the metals initially depleted in LMeMM (i.e., Ca2+, Cu2+, Fe3+, Mn2+, Zn2+) but also
of glutathione and indole, which had been reported to interact with TRPY1 [45,46]. As glutathione is a
universal intracellular antioxidant, we also tested an exogenous antioxidant, i.e., ascorbate. EGTA was
chosen as a chelator of Ca2+ in the growth medium, while Gd3+ was tested as a blocker of the Ca2+
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channels. The results showing the effect of the tested compounds on trpy1Δ/TRPY1 haploinsufficiency
in LMeMM are included in Supplementary Files, Figure S1.
Table 1. Substances screened for the capacity to alleviate trpy1Δ/TRPY1 haploinsufficiency in LMeMM.
Substance Tested 1 Concentration Range
Effect on trpy1Δ/TRPY1
Haploinsufficiency
CaCl2 2–10 mM No
CuCl2 0.5–50 μM No
FeCl3 1–50 μM No
MnCl2 1–50 μM Alleviation
ZnCl2 1–50 μM No
EGTA 0.1–2 mM Augmentation
GdCl3 0.1–1 mM Augmentation
Ascorbate 1–10 mM No
Glutathione 2 1–10 mM No
Indole 3 1–10 mM No
1 The quantitative results are presented in Supplementary Files, Figure S1. 2 Glutathione depletion leads to TRPY1
activation [45]. 3 Indole activates TRPY1 under hyperosmotic stress [46].
Out of the compounds tested, only Mn2+ alleviated the trpy1Δ/TRPY1 haploinsufficiency
observed in LMeMM. In contrast, EGTA and Gd2+ augmented the LMeMM-associated growth defect
(Figure 2a). The level of TRPY1 gene expression was lower in trpy1Δ/TRPY1 compared with wild-type,
but this level was not significantly influenced by surplus Mn2+ (Figure 2b), suggesting that Mn2+
acts—directly or indirectly—by activating the TRPY1 channel. The trpy1Δ/TRPY1 haploinsufficiency
was also noted on solid LMeMM. In contrast, the trpy1Δ/trpy1Δ growth was not affected (Figure 2c).
Figure 2. Haploinsufficiency of heterozygous trpy1Δ/TRPY1. (a) Mn2+ alleviates trpy1Δ/TRPY1
haploinsufficiency in LMeMM. Diploid strains were shifted to LMeMM (final OD600 = 0.05) and grown
for 2 h before MnCl2 (10 μM), EGTA (0.5 mM) or GdCl3 (50 μM) were added from concentrated
stocks. Cell growth was recorded spectrophotometrically 24 h after the addition of the chemicals and
normalized (%) to the growth of WT in the absence of chemicals. One sample t test compared WT in
the absence of chemicals. * p < 0.05; ** p < 0.01. (b) Relative abundance (RA) of TRPY1 mRNA in WT
(TRPY1/TRPY1) and heterozygous trpy1Δ/TRPY1. Analysis of transcript abundance was done by
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qRT-PCR as described in Materials and Methods section. Expression of TRPY1 mRNA was normalized
to the relative expression of ACT1 in each sample. (c) Heterozygous trpy1Δ/TRPY1 exhibits
haploinsufficiency in LMeMM, but not in normal MM. Cells in log phase (OD600 ~ 0.5) were 10-fold
serially diluted (left to right) in a 48-well microtiter plate and stamped on the agar plates using a pin
replicator (approximately 4 μL/spot). Plates were photographed after 3 days’ incubation at 30 ◦C.
3.2. Mn2+ Potentiates the Increase of [Ca2+]cyt under Oxidative Stress in Strain trpy1Δ/TRPY1
The observation that both EGTA (calcium chelator) and Gd3+ (inhibitor of Ca2+ transport across
plasma membrane) augmented the LMeMM-related haploinsufficiency of the trpy1Δ/TRPY1 strain
prompted the idea that preventing Ca2+ entry into the cell is deleterious to trpy1Δ/TRPY1, while the
observed opposite action of Mn2+ may be the result of Mn2+-related activation of the extant TRPY1
that would compensate the heterozygous loss of TRPY1. To check this possibility, we used cells
expressing aequorin, a system suitable for detecting transient modifications in the [Ca2+]cyt [38].
For this purpose, trpy1Δ/TRPY1 cells were transformed with a plasmid harboring the cDNA of the
luminescent Ca2+ reporter apo-aequorin under the control of a constitutive promoter, which afforded
abundant transgenic protein within the cytosol [40]. The cells expressing apo-aequorin were pre-treated
with the cofactor coelenterazine to reconstitute the functional aequorin, and then the cells were
exposed to various stimuli directly in the luminometer tube. It was noted that while Mn2+ alone
failed to induce any increase in the luminescence of the reconstituted aequorin (data not shown),
cell pre-incubation with 10 μM Mn2+ significantly increased the [Ca2+]cyt elevation induced by H2O2
exposure (Figure 3a). Remarkably, pre-incubation with Mn2+ did not augment the cell luminescence
when aequorin-expressing trpy1Δ/TRPY1 cells were exposed to hyperosmotic shock (HOS, Figure 3b,c).
Surplus Mn2+ reached maximum stimulating activity on trpy1Δ/TRPY1 cells exposed to H2O2 at 10 μM
(Figure 3c), a non-toxic concentration to both WT and trpy1 mutants.
Figure 3. Cont.
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Figure 3. In trpy1Δ/TRPY1 cells, Mn2+ pre-incubation stimulates the increase of [Ca2+]cyt under
H2O2 stress but not under hyperosmotic shock. Heterozygous trpy1Δ/TRPY1 cells expressing
reconstituted aequorin were pre-grown in LMeMM-Ura without or with 10 μM surplus Mn2+ before
being exposed to (a) oxidative stress (5 mM H2O2) or (b) hyperosmotic stress (HOS, 0.8 M NaCl).
[Ca2+]cyt-dependent aequorin luminescence was recorded on samples of approximately 107 cells.
The arrow indicates the time when the stressor was added. The luminescence traces represent the
mean ± SEM from 3 independent transformants. RLU, relative luminescence units. (c) Effect of
pre-incubation with various concentrations of Mn2+ on the maximum intensity of the Ca2+-dependent
aequorin luminescence recorded under 5 mM H2O2, or 0.8 M NaCl (HOS). The relative maximum
luminescence (RLM) was calculated as described in Materials and Methods. Bars represent the
mean ± SEM from 3 independent transformants.
3.3. Mn2+ Stimulates TRPY1 to Release Ca2+ into the Cytosol under H2O2 Stress
Furthermore, we wondered whether Mn2+ influence on elevating [Ca2+]cyt under H2O2 was
the result of TRPY1 stimulation by Mn2+. To test this possibility, we determined the effect of Mn2+
on the Ca2+-mediated response to H2O2 of cells completely lacking TRPY1. It was noticed that in
WT cells expressing reconstituted aequorin, the H2O2-induced Ca2+-dependent luminescence was
significantly increased by cell pre-incubation with 10 μM Mn2+, indicating that in the case of WT
cells too, Mn2+ potentiates the Ca2+-dependent response to oxidative stress (Figure 4a). In contrast,
homozygous knockout mutant trpy1Δ/trpy1Δ exhibited much lower H2O2-luminescence (Figure 4b,
left), which was not altered by pre-incubation with 10 μM Mn2+ (Figure 4b, right). This observation
suggested that Mn2+ augments the H2O2-induced [Ca2+]cyt elevation by activating TRPY1, a phenotype
clearly absent in the trpy1Δ/trpy1Δ homozygous knockout mutant (Figure 4b).
If Mn2+ were required for TRPY1 activation under oxidative stress, it would be expected that cells
with low cytosolic Mn2+ would be less responsive in terms of increasing the [Ca2+]cyt under oxidative
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stress. Mn2+ is an essential metal which is carried into the yeast cell by the divalent metal ion transporter
Smf1, known to have high affinity for Mn2+ [47]. It was noted indeed that the homozygous knockout
mutant smf1Δ/smf1Δ expressing reconstituted aequorin exhibited a significantly lower luminescence
trace when exposed to H2O2 than WT (Figure 4c). In this line of evidence, the pmr1Δ/pmr1Δ cells
expressing reconstituted aequorin responded strongly to H2O2 (in media not supplemented with
Mn2+) with a luminescence curve (Figure 4d) which was not significantly different from that obtained
from WT cells preincubated with 10 μM Mn2+ (Figure 4a, right). PMR1 encodes the major Golgi/ER
membrane P-type ATPase ion pump responsible for transporting Ca2+ and Mn2+ into the Golgi
apparatus [48] providing a major route for cellular detoxification of Mn2+ via the secretory pathway
vesicles [49]. It was shown that cells knockout for PMR1 gene have the intracellular Mn2+ levels
considerably higher than the WT cells [50], a fact that may account for the stronger response of
pmr1Δ/pmr1Δ cells (Figure 4d) compared to WT (Figure 4a, left). In this line of evidence, we found that
pmr1Δ/pmr1Δ cells had significantly (p < 0.05) more cellular Mn2+ than the WT, while smf1Δ/smf1Δ
cell had significantly (p < 0.05) less cellular Mn2+ than the WT (Table 2).
Figure 4. Variation of [Ca2+]cyt in response to H2O2 exposure depends on Mn2+ cellular load. Diploid
cells expressing reconstituted aequorin were pre-grown in LMeMM-Ura with or without 10 μM
surplus Mn2+ before being exposed to oxidative stress (5 mM H2O2) as described in Materials and
Methods. [Ca2+]cyt-dependent aequorin luminescence was recorded on samples of approximately
107 cells. The arrow indicates the time when the stressor (H2O2) was added. The luminescence traces
represent the mean ± SEM from 3 independent transformants. (a) WT (BY4743). (b) trpy1Δ/trpy1Δ;
insets: same representation at lower scale. (c) smf1Δ/smf1Δ. (d) pmr1Δ/pmr1Δ. RLU, relative
luminescence units.
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The influence of Mn2+ on the RLM recorded under oxidative stress for various strains which
expressed reconstituted aequorin was also determined (Figure 5), revealing that Mn2+ significantly
increased the RLM of WT cells exposed to H2O2. RLM determined for trpy1Δ/trpy1Δ was significantly
low and was not augmented by Mn2+, indicating the necessity of functional TRPY1 for Mn2+ action.
RLM for smf1Δ/smf1Δ cells expressing reconstituted aequorin was also low under H2O2 exposure,
indicating that the lack of the high-affinity Mn2+ transporter is associated with cytosolic Mn2+
concentration (Table2) which is too low for an efficient activation of TRPY1. In fact, smf1Δ/smf1Δ
attained responses similar to WT only at higher Mn2+ supplementation (Figure 5, grey line), when Mn2+
cell content was high enough (Table 2) for efficient TRPY1 activation. In contrast to smf1Δ/smf1Δ
strain, pmr1Δ/pmr1Δ expressing reconstituted aequorin attained high RLM upon H2O2 exposure
which was not significantly augmented by surplus Mn2+, suggesting that the intrinsic high level of
cytosolic Mn2+ associated with PMR1 knockout [50] is sufficient for attaining efficient activation of
TRPY1 (Table2). Moreover, it was noted that when applying Mn2+ concentrations higher than 20 μM
the maximum response of pmr1Δ/pmr1Δ to H2O2 started to decline (Figure 5, yellow line) probably
due to the hypersensitivity of this strain to Mn2+ [50].
Figure 5. Effect of Mn2+ pre-incubation on the maximum intensity of the Ca2+-dependent aequorin
luminescence recorded for various strains under H2O2 stress. The relative maximum luminescence
(RLM) was calculated as described in Materials and Methods. Diploid cells expressing reconstituted
aequorin were pre-grown in LMeMM-Ura with or without surplus Mn2+ before being exposed
to oxidative stress (5 mM H2O2) directly in the luminometer tube. [Ca2+]cyt-dependent aequorin
luminescence was recorded on samples of approximately 107 cells. Bars represent the mean ± SEM
from 3 independent transformants.
Table 2. Manganese content (pmoles/mg cell protein) of diploid yeast cells grown in LMeMM
supplemented or not with Mn2+.
Strain
Surplus Mn2+
0 10 μM 50 μM
WT 0.12 ± 0.12 0.64 ± 0.2 0.92 ± 0.3
trpy1Δ/TRPY1 0.11 ± 0.14 0.72 ± 0.1 0.98 ± 0.2
trpy1Δ/trpy1Δ 0.12 ± 0.2 0.7 ± 0.2 0.84 ± 0.2
smf1Δ/smf1Δ 0.01 ± 0.014 0.1 ± 0.2 0.72 ± 0.2
pmr1Δ/pmr1Δ 0.7 ± 0.22 0.84 ± 0.2 8.4 ± 1.2
4. Discussion
TRPY1 of S. cerevisiae is a key component in releasing vacuolar Ca2+ into the cytosol for the
Ca2+-dependent activation of mechanisms involved in the cell response to hyperosmotic [4] and
oxidative stress [19]. Starting from the observation that Mn2+ alleviated the haploinsufficiency
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exhibited by the heterozygous trpy1Δ/TRPY1 strain in synthetic media deficient in essential metals
(LMeMM) we found that Mn2+ differentially stimulated TRPY1 to release Ca2+ from the vacuole
under H2O2 exposure, but not under hyperosmotic shock. Mn2+ alone does not induce [Ca2+]cyt
elevation—neither under low (0.05–1 mM) nor under high (2–10 mM, lethal) surplus [21, unpublished
observations]. The Mn2+ concentrations found to augment the H2O2-induced stimulation of TRPY1
were within the physiological limits (10–50 μM) and far below the concentration that would induce a
hyperosmotic shock, explaining why the TRPY1 was not extra stimulated by Mn2+ under hyperosmotic
stress (Figure 3b). It was shown that the release of vacuolar Ca2+ via TRPY1 can be stimulated by
Ca2+ from outside the cell as well as that released from the vacuole by TRPY1 itself in a positive
feedback, a process known as Ca2+-induced Ca2+ release [34,51]. In this regard, Mn2+ surplus could
stimulate TRPY1 similarly to Ca2+. Mn2+ is an essential cation which strongly resembles Ca2+ not only
in ionic radius but also in its affinity to oxygen-containing ligands, a trait which sometimes makes
Mn2+ a good substitute of Ca2+ [52]; this would explain why other essential cations tested (Cu2+,
Fe3+, Zn2+) failed to alleviate the haploinsufficiency showed by trpy1Δ/TRPY1 strain. That TRPY1
haploinsufficiency in LMeMM is rescued by Mn2+ can be explained in three ways: (1) the supplemental
Mn2+ simply counteracts the deficiency of essential metals of the LMeMM, providing the necessary
amount of cations (albeit surrogate in certain cases) that support cell fitness; (2) Mn2+ stimulates
TRPY1 activity by increasing the Ca2+ release to the cytososl, and consequently by stimulating other
components involved in maintaining the cell fitness; (3) Mn2+ generates reactive oxygen species (ROS)
by a Fenton-like reaction augmenting the oxidative stress and indirectly stimulating TRPY1. The fact
that surplus Mn2+ augments the TRPY1-related increase in [Ca2+]cyt under oxidative stress clearly
correlates with the Mn2+ cytosolic level, as the strain lacking the high-affinity plasma membrane
Mn2+ transporter Smf1 exhibited only a modest increase in [Ca2+]cyt under H2O2, when compared
with WT (Figure 4c). In this line of evidence, it was shown that a haploid smf1Δ was sensitive to
H2O2 [20] probably by not attaining the optimum TRPY1 activation for adaptation to oxidative stress.
On the other hand, it had been shown that deletion of PMR1—which leads to increased cytosolic
Mn2+—suppresses the sensitivity of superoxide dismutase (SOD) mutants to superoxide-generating
drugs due to the Mn2+ capacity to scavenge superoxide ions [50]. In the light of our findings, it is
also possible that the high cytosolic Mn2+ in cells devoid of Pmr1 rescue the SOD mutants from ROS
attack not due to the scavenger traits of Mn2+, but through TRPY1 activation. Whether Mn2+ rescues
the haploinsufficient trpy1Δ/TRPY1 by neutralizing ROS or by directly stimulating TRPY1 are issues
to be addressed in the future; nevertheless, the observation that well-known antioxidants such as
ascorbate or glutathione did not rescue the trpy1Δ/TRPY1 haploinsufficiency rather supports the
latter hypothesis. An open question remains: why is the homozygous trpy1Δ/trpy1Δ apparently
more fit than the heterozygous trpy1Δ/TRPY1. The calcium-mediated responses to environmental
insults are diverse: depending on the intensity or duration of the [Ca2+]cyt waves, the cell can be
led towards adaptation, survival (sometimes with growth arrest or slow growth) or death [19–21,23].
The trpy1Δ/trpy1Δ cells are probably more fit because they are never “bothered” by periodic nuisance
caused by Ca2+ release from the vacuole; on the other hand, trpy1Δ/TRPY1 cells need to find the right
balance in Ca2+ gating while depending on only one gene copy, and sometimes extra help—external
Ca2+ carried by Cch1/Mid1, mechanical force [34,51] or even surplus Mn2+—may contribute to find
the most suitable path to be followed.
Supplementary Materials: The following are available online. Figure S1: Effect of various substances on the
haploinsufficiency of the heterozygous trpy1Δ/TRPY1.
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Abstract: Chemicals can exhibit significant toxic properties. While for most compounds, unspecific
cell damaging processes are assumed, a plethora of chemicals exhibit characteristic odors, suggesting
a more specific interaction with the human body. During the last few years, G-protein-coupled
receptors and especially chemosensory ion channels of the transient receptor potential family
(TRP channels) were identified as defined targets for several chemicals. In some cases, TRP channels
were suggested as being causal for toxicity. Therefore, these channels have moved into the spotlight of
toxicological research. In this review, we screened available literature in PubMed that deals with the
role of chemical-sensing TRP channels in specific organ systems. TRPA1, TRPM and TRPV channels
were identified as essential chemosensors in the nervous system, the upper and lower airways, colon,
pancreas, bladder, skin, the cardiovascular system, and the eyes. Regarding TRP channel subtypes,
A1, M8, and V1 were found most frequently associated with toxicity. They are followed by V4,
while other TRP channels (C1, C4, M5) are only less abundantly expressed in this context. Moreover,
TRPA1, M8, V1 are co-expressed in most organs. This review summarizes organ-specific toxicological
roles of TRP channels.
Keywords: toxicology; TRP channels; organ toxicity; chemicals; pollutants; chemosensor
1. Introduction
Most compounds originating from chemical industry, either as main products, intermediates,
or as pollutants, frequently exhibit toxic properties. Exposure can result in severe adverse health
effects or even death. Although health and safety measures are mandatorily introduced, at least in
industrial nations, accidents may occur at any time [1,2]. One example is the Bhopal incident in India
on 3 December 1984, when more than 40 t of methyl isocyanate, a precursor in pesticide production,
was released, killing at least 2500 people [3]. Another is the accidental release of butene from a cut
gas-pipeline which then became inflamed, and resulted in the explosion of an adjacent ethylene pipeline
at BASF Ludwigshafen Germany in October 2017 [1]. Other omnipresent chemicals are phosgene
and chlorine, which are essential for a broad range of chemical products. Approximately 15 million
tons of chlorine are produced annually only in the US [4]. In addition to the unintended release
of such chemicals, a systematic misuse of chemicals in warfare or terror attacks occurred in the
recent past [5]. The most common route of exposure is through inhalation. Ingestion, dermal,
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and ocular absorption represent other possible entry routes, but account only for a smaller proportion.
Chemicals can exhibit characteristic odors like “rotten eggs” in the case of thiol-containing compounds,
but also pleasant smells like the flower-scented Lewisite, a chemical warfare agent from World War I.
Some chemicals are irritants that trigger protective reflexes such as burning sensations, lacrimation,
or cough. These findings clearly indicate that chemicals do interact with the human sensory system.
As defense mechanisms are regarded to be uniform, a close correlation to the chemical structure of
the causing compound was not suggested. Thus, it was also assumed that the molecular processes
regarding chemical sensing were also rather unspecific. However, research in recent years has clearly
demonstrated that distinct G-protein-coupled taste and olfactory receptors as well as chemosensory ion
channels of the transient receptor potential family (TRP channels)—are fundamentally involved in the
molecular (patho)physiology with regard to chemical perception [6–10]. Especially, TRPA1 channels
were found to be activated by various compounds of different origins, and at least for some chemicals,
certain TRP channels were identified as molecular targets that mediate toxicity. Although the precise
molecular mechanism of TRP channel activation has not been unraveled in all cases, these channels
represent promising therapeutic targets to counteract chemical-induced toxicity. Therefore, it is not
surprising that chemosensing TRP channels are regarded as central players, and are in the spotlight of
today’s experimental, but also clinical pharmacological research [7,11].
In this review we provide a synopsis of published literature dealing with the role of TRP channels
in chemical toxicity. A NCBI PubMed search was performed using the search term “(trp channel) AND
(toxic * OR chemical)”, which returned 579 hits. All abstracts were screened in detail by the authors
according to the scheme provided in Figure 1. Finally, 139 publications were considered for this review
and are listed in the reference section.
Figure 1. Search algorithm for the identification of relevant literature. The PubMed database was searched
using “(trp channel) AND (toxic * OR chemical)” as a search term. The resulting 579 hits were screened.
Literature not related to the topic of this review was excluded. If selected literature pointed to other references
that were initially not identified in the PubMed search, these were also screened and included.
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2. TRP Channels: General Structure and Function
TRP channels were first described in 1969 when Cosens and Manning noticed a distinct behavior of
“a mutant strain of Drosophila melanogaster which, though behaving phototactically positive in a T-maze
under low ambient light, is visually impaired and behaves as though blind” [12]. Electroretinograms
identified the ion channel that was named after its electrophysiological function as transient receptor
potential ion channel [13]. Montell and Rubin investigated the underlying biology in more detail
using a Drosophila visual transduction mutant in which Ca2+-dependent adaptation to light was
impaired [14]. The physiological function of the channel was further characterized by Minke in
1992 [15]. These milestones were the beginning of modern TRP channel research in mammals. Today,
28 mammalian TRP proteins are known, belonging to the TRP channel gene superfamily (Figure 2),
and they represent one of the largest superfamilies of ion channels in the human genome [16–20].
The TRP channel family can be phylogenetically subdivided into six subspecies (TRPA1, TRPP, TRPC,
TRPM, TRPML, and TRPV4 (Figure 2) [18,21], and its members are highly conserved between species,
thus allowing a good translation of interspecies experiments in general [22].
Figure 2. Phylogenetic tree of the transient receptor potential (TRP) channel family. In total, 28 human
TRP channels have been identified so far. TRPN1 is expressed in insects and fish, but not in mammals,
and TRPC2 is a pseudogene in humans. TRP channels that have been reported to be involved in
chemosensing or that are affected by toxic chemicals are indicated by different colors ([20] modified).
TRP channels form homo- or heterotetramers of single TRP proteins. Every protein consists
of six helices, the transmembrane domains (TMs), which resemble the biggest part of the channel
(Figure 3) [23]. TM 5 and 6 form the pore region, while the pore itself is semi-selective for the
corresponding ion [23]. The function of helices 1 to 4 is not fully understood but seems to contain
important channel modulatory binding moieties (e.g., the capsaicin-binding site is located in the
TM2 and TM3 region) and is considered as the “sensor” part of the channel [24]. TRP channels are
permeable to monovalent Na+, K+, and bivalent Ca2+ or Mg2+ cations [24]. Most members of the TRPV
family are described as being rather nonselective in this context, with a preference of TRPV5 and
TRPV6 for Ca2+ [25] while TRPM4 and TRPM5 are reported to be impermeable for Ca2+ [26,27]. The C-
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and N-termini are both located in the cytosol, and differ significantly between families, as they contain
divergent binding motifs and reactive amino acids that modulate the channel function (e.g., the TRPA1
ligand allylisothiocyanate (AITC) has been described to activate the channel by binding to cysteine
residues in the cytosolic ankyrin repeat sequence) [28] (Figure 3). However, it is important to note that
also moieties at the C-terminal end and in the transmembrane parts themselves seem to have channel
modulatory functions [29,30].
Figure 3. Schematic overview of TRP channel structure. “S1–S6” indicates the different segments of
the transmembrane domains. “A” represents ankyrin repeats with reactive cysteines (“C”). “CAV1” is
the caveolin interaction region, “MHR” represents the melastatin family channel homology region,
“PDZ” symbolizes anchoring domain functions, “CAM” stands for calmodulin, “TRP box” is the
motif containing the invariant EWKFAR sequence, “Zn2+” indicates a zinc-binding site, and “CIRB”
is the calmodulin/IP3receptor-binding motif. The complete structure of some TRP channels are not
known in detail. Synopsis from the following references: A1 [6,19,23,31,32], C1 [19,23,33], C4 [6,19,23],
M5 [19,23,34], M8 [6,19,23,34,35], V1 [6,19,23,34], V3 [36–39], and V4 [6,19,23,34].
TRPA1 is the only member of the TRPA family, and it possesses multiple characteristic ankyrin
repeat domains in the N-terminus. Other TRP channels, e.g., TRPV or TRPC, do also exhibit ankyrin
repeat domains at their respective N-terminus, but to a lesser number compared to TRPA1. Another major
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difference is the lack of the so-called TRP-box, the sequence of the amino acids EWKFAR, which can be
found in all TRP channels except TRPA1 [40]. TRPA1 is described to act as a chemo- or nociceptor [41].
The channel can be activated by pungent substances and plant ingredients like allicin from garlic, AITC
from mustard oil, cinnamaldehyde from cinnamon oil, or gingerols from ginger [41–43]. Expression of
TRPA1 is often found in neuronal structures, building heterotetramers with TRPV1 [44]. Here, TRPA1 is
responsible for pain sensation, e.g., after consuming spicy mustard. In addition to the chemo-nociceptor
function, TRPA1 was described to be sensitive to cold, which correlates well with the coexpression of
TRPV1, as the latter is activated upon noxious heat [44–46].
The vanilloid TRP channel family (TRPV) consists of six members. TRPV1–4 show a closer
phylogenetic relationship compared to TRPV5 and TRPV6 [20]. All TRPV channels contain ankyrin
repeat domains at their N-terminus, as well as the TRP-box on the C-terminus. In contrast to other
members of the family, TRPV1 carries a calmodulin-binding site at the C-terminus. TRPV channels
can be activated by a plethora of different chemicals. TRPV1 is known to be sensitive to capsaicin
or resiniferatoxin, and for some TRPA1 agonists, but to a lesser extent. Furthermore, the channel
acts as a nociceptor for heat above 43 ◦C, and is involved in inflammatory pathways [47]. TRPV4,
in contrast, is not known to be activated by plant-derived chemicals, although synthetic agonist like
4α-PDD or GSK1016790A were found to open the ion channel [48–50]. Functions of TRPV4 are related
to controlling osmotic, chemical, and mechanical pressures, as well as sensing temperature [51].
Canonical TRP channels (TRPC) have also ankyrin repeat sequences at the N-terminus,
and a TRP-box at the C-terminal site. As in TRPV channels, they contain a calmodulin-binding
site [52]. In case of TRPC4, a PDZ binding site can be found downstream of the calmodulin binding
site, which is lacking in the TRPC1 protein [52]. In general, all TRPC channels, with the exception of
TRPC1, can be activated by phospholipase C stimulation via diacylglycerol [53,54].
Unlike TRPA, TRPV, or TRPC, TRPM channels do not possess ankyrin repeats at the N-terminus,
but contain a distinct TRPM homology region [23]. A coiled-coil domain is located downstream of the
TRP-specific TRP-box at the C-terminal end [55]. This coiled-coil domain is usually found in structural
proteins like laminins, myosins, or fibrins. TRPM7 presents a kinase activity at its C-terminus, which is
unique for that channel [56]. The physiological meaning is still not clearly understood, but is obviously
related to mineral homeostasis [56].
3. Organ-Specific Expression of Chemosensing and Sensory TRP Channels
TRP channels are ubiquitously expressed. While basic pharmacological channel functions are
well-understood, many organ-specific functions are still elusive in mammals. Screening of the current
literature revealed that TRPA1, TRPM, and TRPV seem to be important for chemical sensing or
organ-specific responses to chemical compounds. TRPA1, TRPM8, and TRPV1 are the most frequently
involved TRP channels in the considered organs regardless of the different cell types present in the
respective tissue. They are followed by V4 while other TRP channels (C1, C4, M5, and V3) are of minor
importance with regard to chemical sensing. Moreover, TRPA1, M8, and V1 are co-expressed in most
organs. Figures 4 and 5 summarize results of the screened literature.
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Figure 4. Schematic overview of chemical-sensitive or sensory TRP channel expression in different
mammalian organs. Only TRP channels are illustrated that are discussed to be involved in chemical
toxicity and are mentioned in this review.
Figure 5. Overall numbers and subtypes of TRP channel expression with chemosensory properties.
According to the considered literature in this review, TRPA1, TRPM8, and TRPV1 were identified as
the most abundant channels. Colors represent organ-related expression.
3.1. Neuronal TRP Channels
In principle, the human nervous system can be divided into two parts: (i) the central nervous
system (CNS) consisting of the brain and spinal cord; and (ii) the peripheral nervous system (PNS),
originating from the dorsal root ganglia (DRG) with the peripheral nerve trajectories. TRP channels
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play a major role in both parts. They are involved in sensing stimuli in the PNS, transferring signals
via DRGs to the CNS, and regulating neuronal network function in the brain. In the respective tissues,
TRPs can be activated by endogenous neurotransmitters and signaling molecules, e.g., diacylglycerol
(DAG) or substance P, but also by mechanical stimuli like pressure or temperature, as well as chemicals
from natural or synthetic origin [40,57,58].
3.1.1. TRP Channels in the PNS and DRG
TRP channels were identified as key players in DRG, which link the peripheral nerve endings
with the CNS. In DRG, TRPA1, and TRPV1 channels that are involved in nociception are found to be
highly expressed, while TRPM8 or TRPV4 are expressed to a lesser extent. TRP channels do not serve
exclusively as sensors of noxious stimuli. They are additionally affected by anesthetics, which are
frequently used in clinical settings to minimize CNS function, or when locally applied, to block PNS
signal initiation and transduction. TRP channels are highly expressed in all nervous tissue. Thus, it is
not surprising that interaction of these channels with local anesthetics and central-acting narcotics
influences analgesia and narcosis. A good example is the substantia gelantinosa, which plays a crucial
role in pain reception. Here, neuronal cells respond with spontaneous L-glutamate release, which is
mediated by TRPV1 and TRPA1 channels [59]. Moreover, induction of activating transcription factor 3
(ATF3), a reliable marker of nerve injury, was also found to rely on TRPV1 channels [60]. Wild type mice
injected with capsaicin, mustard oil, formalin, or menthol into the hind-paw revealed increased ATF3
expression in distinct subpopulations of sensory neurons, whereas TRPV1 deficient mice did not [60].
Remarkably, only capsaicin-activated TRPV1 channels were required, while neither TRPA1, activated
by mustard oil or formalin, nor TRPM8, activated by menthol or icilin, were necessary to increase
ATF3 levels [60]. These findings clearly point to an essential role of especially TRPA1 and TRPV
channels in nociception. Thus, it would be feasible to assume that analgesics and anesthetics should
block these channels to prevent pain. However, some studies revealed that some general anesthetics
surprisingly activate TRPA1 or TRPV1 channels. Eilers et al. found that inhalation of anesthetics with
irritant properties indeed activate TRPA1, thereby inducing mechanical hyperalgesia and bronchial
constriction [61]. Non-irritant anesthetics in contrast did not activate TRPA1, and provided no
evidence for induction of hyperalgesia or bronchial constriction [61]. Other volatile anesthetics,
i.e., isoflurane and the now obsolete chloroform, act as agonists of TRPV1 and TRPM8, while TRPA1
channels are inhibited [62]. These results are not completely in line with Eilers et al., who described
increased sensitization of TRPA1 as a reason for hyperalgesia [62]. Lidocaine is another local
anesthetic and anti-arrhythmic drug, which inhibits fast Na+-channels. Leffler et al. further described
the activation of TRPV1, and in parts of TRPA1, by lidocaine [63]. Interestingly, the vanilloid
binding domain is required for an activation by lidocaine, but not for sensitization of the channel as
induced by other agonists [63]. To prove TRPV1 specificity, known antagonists like capsazepine or
N-(4-t-butylphenyl)-4-(3-chloropyridin-2-yl) tetrahydro-pryazine-1(2H)-carboxamide (BCTC) were
successfully applied in patch-clamp experiments using DRG or HEK293 cells [63]. Beside their narcotic
and analgesic effects, anesthetics activate TRPA1, TRPV1 and TRPM8 channels, which are ubiquitous
present in neuronal structures. Since the modulation of TRPV1 for analgesia seems very promising,
investigations of new compounds are ongoing. Marwaha et al. examined niflumic acids as potential
TRPV1 blockers to treat neuropathic pain [64]. For the experiments, they used an animal pain model
in which stavudine induces TRPV1-mediated pain sensations. Here, TRPV1 protein expression in
the CNS increased after stavudine exposure [64]. Remarkably, treatment with niflumic acid not
only reduced pain, which was measured after different time points with different behavioral tests
for mechanical hyperalgesia, tactile allodynia, motor coordination, heat and cold, but also reduced
nitrosative stress [64].
Bang et al. have elucidated the mechanism of the anesthetic butamben, which has been used as
a topical anesthetic since the early 1960s. It was suggested that voltage gated channels are inhibited by
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this compound, and this was confirmed by their study [65]. Additionally, butamben was shown to act
as an inhibitor of TRPA1 as well as TRPV4, but not as an antagonist of TRPV1 [65].
Other naturally derived compounds may work in a similar way. Pellitorine, an extract of
Tradium daniellii, was recently described as a new antagonist of TRPV1 [66]. A study by Olah and
colleagues focused on pellitorine as a new anesthetic and pain killer. Although the chemical structure of
pellitorine exhibited a relationship to capsaicin, a widely known TRPV1 agonist, the isolated pellitorine
inhibited TRPV1 with an IC50 of 0.69 mM in TRPV1-transfected HaCaT cells after stimulation with
2 μM capsaicin [66].
Another substance found in species of Artemisia, Blumea, and Kaempferia is borneol. It was shown
that this naturally derived compound antagonizes TRPA1 in a dose-dependent manner [67]. Borneol is
already used in traditional medicine against bronchitis, rheumatic disease, or cell swelling [67].
Many other compounds, drugs, and chemicals are thought to interact with TRP channels. Based on
TRPA1-induced hyperalgesia, Nozadze et al. investigated nonsteroidal anti-inflammatory drugs with
regard to their potential to counteract TRPA1-induced side-effects [68]. In the in vivo study, diclofenac,
ketorolac, and xefocam have proven to diminish AITC-induced TRPA1 activation, and hyperalgesia
was mitigated [68].
Patients receiving anti-cancer treatment with oxiplatin frequently complain about neuropathy and
hyperalgesia [69]. After treatment with oxaliplatin increased levels of cyclic adenosine monophosphate
(cAMP) can be detected, which are able to sensitize TRPA1 as well as TRPV1 channels [69].
The study of Anand et al. measured increasing calcium responses after oxaliplatin treatment,
which might cause hyperalgesia [69]. It is suggested that antagonist for TRPA1 and TRPV1 might
be able to countermeasure oxaliplatin side effects [69]. A different study was able to confirm
these results, as calcium signaling was altered after prolonged oxaliplatin treatment, and led to
phosphoinositide-induced increases in intracellular calcium levels compared to the control group [70].
Paclitaxel, another chemotherapeutic drug, acts in a comparable manner. During chemotherapy
patients suffer from neuropathic pain. It can be observed that protease-activated receptor 2
(PAR2, involved in inflammatory responses), as well as both kinases PKA and PKC are upregulated [71].
The upregulation of these proteins is described to sensitize TRPV1, TRPV4 as well as TRPA1 [71]. Thus,
it is comprehensible that application of respective antagonists did attenuate observed pain responses
in mice [71].
Pain relieving cannabinoids are currently in the spotlight of research. In case of the synthetic
compounds R-(+)-(2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrol-[1,2,3-de]-1,4-benzoxazin-
6-yl)-(1-naphthalenyl) methanone mesylate and (R,S)-3-(2-iodo-5-nitrobenzoyl)-1-(1-methyl-2-
piperidinylmethyl)-1 hindole, it is reported that these substances activate TRPA1 and TRPV1 channels,
but also desensitize these channels for other agonists like capsaicin or mustard oil [69,72].
Camphor, among other monoterpenes, is another agonist for TRPA1, which is like the
above-mentioned cannabinoids, in that it effectively desensitizes the channel for more harmful
activators [73].
In a comparable manner, it was shown that nitro-oleic acid desensitizes both TRPA1 and
TRPV1. The inhibition was observed in cells expressing TRPA1 homomers, as well as TRPA1-TRPV1
heteromers [64]. Furthermore, pain reactions in test animals were counteracted by the substance
and might be useful in a clinical environment to prevent unwanted TRPA1/TRPV1-induced
hypersensitivities [64].
These studies have proven that TRP channels play a crucial role in the peripheral nervous
system, as many anesthetics interact with TRP channels, whereas other substances, like many natural
derived compounds, have a more beneficial effect on the body after interacting with a TRP channel.
With increasing knowledge about pain signaling pathways, as well as inflammation, these ion channels
can already be considered as promising pharmacological targets, yet many important crosstalks are
still unknown and need further investigation.
242
Cells 2018, 7, 98
3.1.2. TRP Channels in the CNS and Cranial Nerves
Besides TRPA1 and TRPV1, which are known to be involved in pain sensation, TRPC,
TRPV4, and TRPM8 are essential for signal transmission from the PNS or DRG to the CNS.
Regarding physiological functions, TRPV4 channels are described to be involved in cell swelling
and nociception [74]. TRPC1 and TRPC4 are expressed in the corticolimbic regions in the brain,
controlling vasodilation and neurotransmitter release [75]. TRPC channels are also essential in the
endothelial part of the blood-brain-barrier. Balbuena et al. reported upregulation of TRPC1 and TRPC4
after organophosphorus malathion/oxon or lead exposures in rats [76]. One major symptom that can
be observed after malthion/oxon intoxication is the permeabilization of the blood-brain-barrier (BBB).
Balbuena et al. reported increasing levels of TRPC1 and TRPC4 channels after exposure, which might
lead to abnormal depletion of calcium stores. Subsequently, calcium-dependent pathways are likely to
be dysregulated, contributing to the disruption of the BBB [76].
Comparable results were found by Zhang and colleagues, who blocked TRPC1 expression
via RNA interference, and measured a decrease in lead levels (Pb) in the CNS [77]. In addition,
overexpression of TRPC1 results in even higher levels of Pb in the CNS. Interestingly, knockdown of
stromal interaction molecule 1 (STIM1), which is known as an endoplasmic reticulum Ca2+ sensor and
together with Orai1 orchestrates the store-operated calcium entry, attenuated Pb-acetate entry [77].
Even though not directly related to chemical exposures, involvement of TRP channels in the
pathophysiology of headache is discussed. In case of TRPV4, it is suggested that TRPV4 may lead to
cell swelling in the brain, thereby causing headache due to extended pressure [74]. Treatment with
arachidonic acid, among others found in caraway, or different phorbol ester compounds, agonize the
channel, thereby reducing the pain [74]. Other compounds, e.g., umbellulone (UMB, which can be
found in the leaves of the so-called “headache tree”) were also found to activate TRPA1 and TRPM8,
thereby causing severe headaches and cold sensations [78,79]. Remarkably, UMB inhibited TRPA1
when applied in higher concentrations [79].
TRPA1 and TRPV1 are expressed in trigeminal nerves, and they may fulfill the role of sensing
potential toxic substances or transmitting pain [80]. Despite the well-described activation of these
channels by capsaicin, mustard oil, or allicin, a plethora of irritants affect these channels. Irritants like
acetophenone, 2-ethylhexanol, hexyl isocyanate, isophorone, and trimethylcyclohexanol are channel
agonists, and they were shown to decrease respiratory rates in vivo, which might be caused by direct
interaction with TRPs [81,82].
Clotrimazole represents another potent agonist of those two channels in the trigeminal
nerve [81,83]. Patients often complain about a burning sensation and irritated skin after topical
treatment with the drugs. It was shown by Meseguer et al. that the activation of TRPV1 and TRPA1
might be responsible for this observed adverse effect [83].
Two studies of Kunkler et al. described the activation of TRPA1 as a cause for
environmental-irritant-induced headaches [84,85]. Substances like formaldehyde or acrolein
activated the ion channel, thereby releasing calcitonin gene-related peptide (CGRP) and substance
P, which further resulted in neurogenic inflammation [84]. Additionally, it was reported that the
meningeal blood flow increased after TRPA1 activation, which is in correlation to the increase of
substance P, as the process can be inhibited by the application of CGRP [84].
In this context it is important to note that TRPA1 is most commonly co-expressed with TRPV1.
Kunkler et al. further suggested that the therapy with resiniferatoxin might result in a decreased expression
of TRPV1, which then may also attenuate co-expressed TRPA1 ion channels, thereby decreasing the amount
of released CGRP and substance P. As a result, the blood flow should stabilize. Thus, resiniferatoxin might
be a potential countermeasure against environmental irritant-induced headaches [84].
3.2. Upper Respiratory System, Airways and Lungs
Expression of TRPC, TRPM, TRPV, and TRPA1 has been described in the respiratory system.
TRPA1 was found mainly in sensory nerves [10] and to some extent, also in the lung epithelia [86].
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Stimulation of A549 cells, a human lung cancer epithelial cell line endogenously expressing TRPA1,
with the TRPA1-specific agonist AITC, resulted in the increase of intracellular calcium ([Ca2+]i) and
subsequent activation of MAP kinases [86], providing evidence for a functional role of TRPA1 in
non-neuronal lung tissue.
Eilers et al. reported that the pungent general anesthetic isoflurane is able to activate TRPA1
and induce TRPA1-mediated contraction of guinea pig bronchi [61]. In addition, desensitization of
sensory nerves due to high concentration of the TRPV1 agonist capsaicin prevented isoflurane-induced
bronchoconstriction. However, a TRPV1-specific antagonist alone had no effect on isoflurane-induced
narrowing of the airways [61]. The authors proposed a TRPA1-dependent neurogenic mechanism for
isoflurane-induced bronchoconstriction [61]. Animals also suffered from hyperalgesia after intraplantar
injection of isoflurane, underlining the agonistic effect on TRPA1 channels [61]. These results are
in line with the observed co-expression of TRPA1 and TRPV1 in a subset of C-fiber neurons [87].
Response of C-fibers towards chemical irritants was diminished in the nasal mucosa after pretreatment
with capsaicin and/or AITC [88]. These findings point to a close interaction of TRPA1 and TRPV1
channels. In general, activation of neuronal TRPA1 and TRPV1 channels seems to initiate warning
and defense reflexes, thereby attributing “protective” actions to the channel. In vitro experiments
revealed that activation of TRPA1 by highly toxic alkylating compounds has a direct negative impact
on cell viability [89]. This is in line with results published by Achanta et al., who suggested that TRPA1
and neurogenic inflammation contribute to the deleterious effects of alkylating compounds in vivo,
activated either directly by alkylation, or indirectly, by reactive intermediates or pro-inflammatory
mediators [90]. In contrast, zinc, a compound used in smoke screens, also activates TRPA1 [91] and
induces lung cell injury [92], but not directly through TRPA1 [93]. Reactive oxygen species (ROS) as
well as hypochlorite (OCl−), the oxidizing mediator of chlorine, activated Ca2+ influx and membrane
currents in an oxidant-sensitive subpopulation of chemosensory neurons, which were identified
as TRPA1-expressing cells [94]. TRPA1-mediated Ca2+ influx was also activated by chloramine-T,
a widely used chlorine-releasing chemical disinfectant which is a strong respiratory irritant [94].
TRPA1-deficient (TRPA1−/−) mice were protected from OCl−-induced respiratory depression. In this
study, response to other chemical stimuli remained unchanged in TRPA1−/− mice, pointing to a certain
selectivity of TRPA1 channels [94]. Toxic industrial isocyanates and tear gases, both known to cause
severe pulmonary distress, were also found to activate TRPA1 channels [95]. Genetic ablation or
pharmacological inhibition of TRPA1 dramatically reduced isocyanate- and tear gas-induced effects
after both ocular and cutaneous exposures [95]. As demonstrated by Lehmann et al., in vivo sensory
irritation due to 2-ethylhexanol, a potent human irritant, was dependent on both TRPA1 and TRPV1
channels [82]. Acrolein (2-propenal), a highly toxic and reactive compound present in tear gas, vehicle
exhaust, and smoke from burning vegetation, including tobacco products, is also a very potent
TRPA1 activator [96]. Responses were completely absent in cultures from TRPA1-deficient mice,
demonstrating that TRPA1 is, indeed, an essential transducer of acrolein action [96]. Cells expressing
TRPV1, TRPV2, or TRPM8 did not respond to acrolein [96]. Cigarette smoke-evoked cough was
attenuated by a TRPA1-specific antagonist in guinea pigs [97] and unsaturated aldehydes in the
cigarette smoke were identified as the main causative substances for TRPA1 activation [97].
Stimulation of airway epithelial cells with lipopolysaccharides (LPS), which is part of the wall
of gram-negative bacteria and plays a crucial role in the immune response, resulted in an increase of
[Ca2+]i [98], which was found to be mediated by TRPV4 channels [98] that are abundantly expressed
in these cells [99]. Upon LPS challenge, TRPV4-mediated ciliary beat frequently, and production
of bactericidal nitric oxide increased, suggesting a protective role of TRPV4 [98]. In contrast to
these findings, TRPV4 inhibition counteracts toxic lung edema and inflammation in vivo after chlorine
exposures [100]. Here, chemical induced vascular leakage and airway hyperreactivity were suppressed,
while blood oxygenation was significantly improved [100]. In vivo experiments conducted by
Andres et al. point in the same direction: phosgene-induced pulmonary injury and lethality in mice
were partially improved by post-exposure treatment with ruthenium red (RR), an unspecific TRP
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channel blocker [101]. Although the experimental design did not allow the identification of the distinct
TRP channel, the authors speculate that TRPV4 may be one of the possible candidates.
Unspecific inhibition of TRP channels by intraperitoneal injection of RR attenuated adverse effects
on cardiovascular function in vivo after pulmonary ultrafine nanoparticles exposures. Although the
route of administration as well as the use of the broad and unspecific TRP channel inhibitor RR
does not allow a precise correlation to a distinct TRP channel, the authors suggest a lung-nodose
ganglia-regulated pathway via the activation of pulmonary TRP channels [102].
An involvement of TRPV1 channels in the pathophysiology of asthma triggered by inhalation
of allergens and chemicals, was investigated by McGarvey et al. using pulmonary human tissue and
cells derived thereof [103]. Remarkably, patients that did not respond to standard asthma therapy
(i.e., corticosteroids) revealed a significant increase of bronchial TRPV1 expression compared to
controls [103]. The authors suggest a role of TRPV1 channels especially in patients with severe,
uncontrolled asthma. Both, TRPA1 and TRPV1, together with mast cells were found to play a major
role in chemical-induced immune-mediated asthma after application of toluene-2,4-diisocyanate (TDI),
a chemical with a large number of industrial applications [104]. Remarkably, TDI was unable to
activate TRPV1 in that study, pointing again to a close cross-talk between TRPA1 and TRPV1.
3.3. Colon
Acute enteritis is a common and serious disease after food poisoning in human patients
and animals. The immunological and microbiological aspects of the pathology of gastroenteric
diseases including inflammatory bowel disease (IBD) are studied extensively [105,106]. However,
the neural network is also known for its impact on observed hyperesthesia to various chemical stimuli.
For instance, acetic acid and capsaicin were shown to provoke pelvic nerve activity in a rat model
of inflammatory bowel disease induced by dextran sulfate sodium (DSS) [107]. The induced neural
signaling by capsaicin was enhanced in rats with early stages of colitis, compared to healthy rats.
The frequency of discharge was blocked by RR, an unspecific TRP channel inhibitor. It is assumed
that the augmented nociception to TRPV1 agonists in the colitis model is associated with changes of
inflammatory mediators that regulate the activity of nociceptors. One of these mediators is CGRP,
a neuroinflammatory peptide which is expressed TRPV1-dependent in the colon. The expression
of some, pro-inflammatory cytokines and chemokines like TNFα, IL-1, IL-6, CXCL10, MIP1 can
be attenuated by treatment with icilin, a commonly used TRPM8 agonist [108]. TRPM8 is very
prominent in human and mouse colon tissue. The expression of this TRP channel is upregulated
in inflamed colon tissue from IBD patients, as well as in chemically induced colitis by DSS and
2,4,6-trinitrobenzenesulfonic acid (TNBS) in mice [108]. Administration of TRPM8 agonists in the
colitis models inhibited TRPV1-dependent CGRP expression, reduced pro-inflammatory cytokines,
and attenuated the common hallmarks of colitis such as bowel thickness and infiltration of granulocytes.
These attenuating effects of icilin were not observed in TRPM8-deficient mice, which emphasizes the
potency of TRPM8 as an anti-inflammatory therapeutic target.
The frequent contamination of wheat with the fungi Fusarium leads to food contamination
by trichothecene mycotoxin deoxynivalenol (DON, vomitoxin) [109]. DON suppresses food
intake and thereby affects energy balance, which is a major concern in human and animal
health. The exocytosis of satiety hormones like cholecystokinin and peptide YY3–36 is induced by
DON-activated calcium-sensing receptor (CaSR) and TRPA1-mediated Ca2+ entry into enteroendocrine
cells [110]. Further analysis of the role of CaSR and TRPA1 in the observed anorexia and emesis will
shed light on the underlying mechanisms, and can therefore serve as a model to understand comparable
symptoms induced by other foodborne toxins, environmental toxicants and chemotherapeutic
drugs [109].
245
Cells 2018, 7, 98
3.4. Pancreas
Diabetes mellitus is one of the most common metabolic disorders in the industrialized western
world. Both types of diabetes are diseases in which high blood sugar levels persist over a long
time. Type II diabetes is characterized by the combination of insulin unresponsiveness in the
target tissue and the failure of pancreatic beta cells to secrete sufficient insulin. Treatment options
include glibenclamide, which blocks ATPase-sensitive K+ channels forcing beta cells to secrete more
insulin. In addition, the TRPA1 channel was identified in pancreatic beta cells to transduce cationic
non-selective currents. New studies revealed that the glibenclamide-induced intracellular currents
are TRPA1-dependent [111]. However, the contribution of TRPA1 to diabetes treatment and the
glibenclamide-related side effects like hyperactive bladder or abdominal pain is highly discussed [112].
TRPA1 seems to be a secretagogue which may still induce insulin secretion when cells do not effectively
respond to glibenclamide after long-term treatment [111]. However, TRPA1 also disrupts beta cell
physiology since long-term stimulation with TRPA1 agonists reduce both the responsiveness of
insulin-secreting cells and the expression of pancreatic and duodenal homeobox 1 (PDX1), which is
a transcription factor for insulin expression [112]. Consequently, the definite contribution of TRPA1 to
glibenclamide-associated effects in type II diabetes patients remains to be clarified. Besides TRPA1,
TRPM5 is also often associated with type II diabetes. Its expression in diabetic patients is negatively
correlated with blood glucose concentrations [113]. TRPM5 is expressed in beta cells mediating
depolarizing currents after glucose stimulation. Additional stimulation with stevioside, one of
the main glycosides of the plant Stevia rebaudiana and used as a sweetener and sugar substitute,
potentiates glucose-induced currents by increasing the frequency of Ca2+-oscillations, which triggers
insulin response [114,115]. In wild type mice, treatment with stevioside reduced blood glucose
significantly, but not in TRPM5-deficient mice. Moreover, stevioside protects mice on high fat diet from
hyperglycemia. Therefore, stevioside, as TRPM5 modulator, is a promising therapeutic option in type
II diabetes patients [114]. Chronic and acute pancreatitis have distinct histopathologies and etiologies,
but are both accompanied by inflammatory events and pain [116]. Pain reflects the sensitization
of pancreatic sensory neurons. The pancreatitis-associated pain was shown to be related to TRPA1
and TRPV1 expression, and it functioned in afferents in an experimental acute pancreatitis model
in mouse [117]. The administration of specific TRP channel antagonists in early phases of recurrent
bouts of acute pancreatitis significantly reduces inflammation. The combined antagonist treatment
even ameliorates morphological changes in the pancreas [118]. Additional behavioral experiments
demonstrated that both antagonists also attenuate pain and signs of discomfort. Therefore, targeting
of TRPA1 and TRPV1 in patients with recurrent bouts of acute pancreatitis may inhibit the progression
to chronic pancreatitis.
3.5. Bladder
TRP channels are widely expressed in the urinary tract, neuronal fibers innervating the bladder,
and urethra and epithelial and mucosal layers of the bladder and urethral walls. Therefore, they are
involved in many effects of toxicants, and are consequently an attractive pharmaceutical target for the
treatment of (chemically-induced) disorders in the urinary tract.
It is reported that patients treated with cyclophosphamide suffer from cystitis accompanied by
inflammation and bleeding. During treatment, the cyclophosphamide metabolite acrolein accumulates
in the bladder and promotes inflammation [119]. In female Wistar rats with cyclophosphamide-induced
bladder inflammation, a considerably high transcriptional plasticity of urinary bladder TRP channels
were demonstrated. Chronic cystitis increased TRPA1 and TRPV4 transcripts in the (sub)urothelium of
female rats, whereas in acute cystitis, TRPV1 and TRPV4 mRNA levels are decreased. However, TRPV1
and TRPV4 protein levels are increased in acute and chronic cystitis [120]. This lack of correlation
between transcript and protein expression may reflect changes in posttranscriptional modifications.
The observed TRPV1 increase is associated with bladder hyperreflexia [121]. In addition, antagonism of
TRPV4 increased functional bladder capacity and reduced micturition frequency in mice and rats with
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acute cystitis, suggesting that chronic cystitis in human patients may improve with TRPV4 antagonist
treatment [122].
In bladder transitional cell carcinoma TRPV1 expression declines with the increase of tumor
grade [123]. Curcumin, a popular Indian food spice, is a very cytotoxic agent in bladder tumor cell
lines. Since curcumin has a vanilloid structure with a vanilloid-like activity via a selective binding
to TRPV1, TRPV1 activation by curcumin could be a possible mechanism to induce cell death and
prevent tumor growth [124].
Patients with bladder overactivity are initially treated with Botulinum neurotoxin A (BoNT/A)
to block the presynaptic release of acetylcholine from the efferent parasynapatic nerves, to paralyze
the bladder temporarily [125]. However, BoNT/A also reduces TRPV1 expression on afferent nerves
while the nerves remain intact. Therefore, BoNT/A affects bladder contractility by modulating the
expression of TRPV1 on peripheral nerve fibers [124].
3.6. Skin
Phtalate esters are widely used as plasticizers for plastics, synthetic leather, vinyl flooring, wall
coverings, paint, adhesive agents, and cosmetics. These esters are also commonly found in house dust
and are associated with allergic diseases in children [126]. Dibutyl phthalate (DBP) directly activates
TRPA1 in dorsal root ganglia isolated from mouse, as well as in cultured TRPA1-overexpressing
cells [127,128]. Thereby both, DBP and also common TRPA1 agonists enhance skin sensitization
to fluorescein isothiocyanate (FITC), which can be completely abrogated with the specific TRPA1
antagonist HC-030031. For TRPV1 a comparable contribution in such sensitization processes was
shown, whereas TRPM8 is not involved in the enhancement of skin sensitization to FITC [129]. It is
speculated that neuropeptides like CGRP are released from peripheral nerve endings via activation
of TRPA1. In this context, it has already been described that CGRP triggers FITC-induced chronic
hypersensitivity, while it suppresses trinitrobenzene-induced hypersensitivity. CGRP differently
regulates the immunological contribution in form of T helper cell (TH1 and TH2) responses [130].
In cutaneous photosensitivity, it is widely accepted that the symptoms like pain and itching
are based on the accumulation of porphyrins, which enhance the production of free radicals [131].
A common feature in patients suffering from porphyria or undergoing photodynamic therapy is
the experience of strong pain from bright light. Classical photosensitizers like protoporphyrin IX,
an intermediate in the heme biosynthesis pathway, transfer an electron to molecular oxygen-producing
ROS. In photodynamic therapy, photosensitization is induced by excess levels of protoporphyrin IX,
generating singlet oxygen to treat precancerous lesions [132]. The formation of ROS upon exposure to
UV light, activates TRPA1 mediating the calcium entry into the cell. Mutation studies revealed that
cysteine C633 and C651 are indispensable for disulfide bonds to mediate this UV-induced calcium
influx. The activation of TRPA1 was abolished by the treatment with antioxidants acting as ROS
scavenger, suggesting that oxidative processes are essential for UV-light-mediated TRPA1 activation.
Protoporphyrin IX enhanced TRPA1 and TRPV1 activation. This activation in pain signaling nerve
endings acts as cellular sensors to detect the oxidative stress produced by near-UV and visible blue
light, which is enhanced in the presence of cellular or exogenous photosensitizers [131]. Therefore,
selective antagonist may provide new therapeutic options for porphyria patients and for unlimited
use of photodynamic therapy.
In the cosmetic industry chemical reagents are applied on the skin for rejuvenation.
These procedures cause protein coagulation and tissue injury in various depth of the skin.
Trichloroacetic acid (TCA), the most-widely used chemical peeler, exerts direct toxic effects on the skin.
TRPV1 was indispensable for the expression of growth factors and cytokines after TCA treatment.
TRPV1-deficient mice showed even more severe ulcerations compared to the wild type mice, suggesting
that the modulation of TRPV1 can support rejuvenation treatments [133].
Clotrimazole (CLT) is a widely used antifungal for topical treatment of yeast infections of the
skin, vagina, and mouth. CLT induced calcium influx in TRPV1-expressing cells, but not in closely
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related heat-activated TRPV2, TRPV3, and TRPV4 channels. In TRPV4-expressing cells, CLT even led
to a reduction of basal calcium levels. HEK293 cells expressing TRPA1 clearly showed an intracellular
calcium increase, though it was significantly slower than the influx in TRPV1 cells. In mouse
experiments, the injection of CLT evokes noci-defensive behavior which could be attenuated by
specific antagonist of TRPV1. Moreover, CLT shifts the voltage dependence towards a more negative
voltage for TRPA1 and TRPV1, whereas for TRPM8 it shifts toward more positive voltages. Thus,
CLT acts more as a gating modifier than a classical antagonist/agonist of these channels [83]. Due to its
different effects on TRPA1 and TRPM8, CLT is a useful tool to discriminate between menthol-induced
TRPA1 and TRPM8 responses in nociceptors, which are either potentiated by CLT in TRPA1-expressing
cells or otherwise heavily repressed in TRPM8-expressing cells. CLT was identified as the most
sensitive inhibitor of TRPM8 known so far. This opens up new possibilities as therapeutic agent
against TRPM8-driven diseases like cold allodynia, and even certain types of malignancies [83].
Skin can itch for various reasons, including bacterial infections, insect bites, allergies, and different
types of dermatitis. Itch is also a common side effect of drug treatment, such as in the case of
the anti-malaria drug chloroquine (QC). In DRG a QC-induced calcium influx was shown to be
TRP channel dependent. Knockout experiments in mice revealed that TRPA1 mediates the calcium
flux, whereas TRPV1 was not involved [134]. In behavioral studies, wild type and TRPV1-deficient
mice showed QC-induced scratching, whereas TRPA1−/− mice did not, which is evidence that
TRPA1-expressing neurons are required for QC-induced non-histaminic itch [134]. Also in acute
contact dermatitis, resembled by an oxazolone-induced model of dermatitis in mice, TRPA1 is the
determining channel to transduce the histamine-independent inflammation and pruritus [135].
3.7. Oral Mucosa
In oral mucosa TRPA1, TRPV1, and TRPM8 channels are predominantly expressed as
chemosensors for irritants contained in food, drinks, and cigarette smoke. Lipophilic irritants
such as mustard oil, capsaicin, and menthol activate TRPA1, TRPV1, and TRPM8, respectively,
in sensory nerves of the buccal mucosa mediating the release of CGRP. Nicotine as a toxic substance, is,
however, completely ineffective to induce CGRP exocytosis when applied in low concentrations [136].
Higher concentrations that may be reached in individuals consuming oral tobacco products evoked
only a low CGRP secretion at pH 7.4. However, when deprotonated, uncharged and lipophilic
nicotine was applied at pH 9, a robust TRPA1- and TRPV1-dependent response was observed.
More physiological relevant experiments with full cigarette smoke containing hydrophilic nicotine,
applied by smoking machines, showed moderate effects that were likely mediated by TRPA1 [136,137].
3.8. Cardiovascular System
There are only a few studies that suggest a role of TRP channels in chemical-induced
cardiovascular toxicity. A single exposure to diesel exhausts was shown to increase the sensitivity of the
heart to triggered arrhythmias [138]. This effect seemed to be mediated via the pulmonary activation
of TRPA1, with subsequent sympathetic modulation, and it could be prevented by pre-incubation
with RR [138]. Administration of TRPA1 or TRPV1 blockers prevented the increase of QRS duration,
and a decrease in ST segment length (both are indicators for beginning cardiac stress), which were
caused by diesel exhaust [138]. The results point to some evidence that activation of pulmonary sensory
TRPA1 channels, which are known to be particularly sensitive to inhaled irritants, are involved in
sympathetic activation [138]. Related results were found after pulmonary exposure of rats to ultrafine
titanium dioxide particles, which resulted in elevated mean and diastolic blood pressure in response to
norepinephrine [102]. RR inhibited substance P synthesis in nodose ganglia and associated functional
and biological changes in the cardiovascular system [102].
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3.9. Eyes
The eyes are one of the most sensitive organs with regard to irritation by chemicals. Most of
the effects have been attributed to neuronal and sensory TRP channels (see section “Neuronal TRP
channels”) like TRPA1. However, it was speculated that TRPV channels may play a role in a variety of
cellular functions directly in the corneal epithelium [139]. TRPV1, V3, V4, and weakly V2 were detected
by polymerase chain reaction (PCR) in a human corneal epithelial cell line [139]. Immunohistochemical
stainings, together with PCR experiments and functional calcium measurements, revealed expression of
TRPV3 in the murine cornea or primary corneal epithelial cells [139]. Carvacrol, the major component
of plants such as oregano, savoy, clove and thyme is known as sensitizer and allergen, activates TRPV3
channels and directly affects cell viability [139]. Unfortunately, cytotoxicity after pre-incubation with
TRP channel blockers and carvacrol exposure was not evaluated. Remarkably, low dose exposures
with carvacrol, that did not result in a significant TRPV3 activation, were found to improve corneal
wound healing in the scratch assay [139].
4. Closing Remarks
TRP channels are important actors in many physiological, but also pathophysiological processes.
Over the last few years, they have come into focus as specific targets to counteract toxicity of certain
chemical compounds. For some chemicals, e.g., acrolein, specific activation of TRP channels has
been explicitly proven in vivo and in vitro, whereas for other compounds, the overall picture is less
clear. As example for the latter, sulfur mustard has been clearly identified to activate TRPA1 channels
in vitro [89]. However, contact to that agent seems not to induce acute pain or irritation symptoms.
There are more examples pointing to a mismatch of in vitro results, and the clinical in vivo picture.
Moreover, results obtained from rodent animal experiments do not necessarily reflect the human
situation. This illustrates the need for further comprehensive investigations. Elucidation of the exact
activation mechanisms, as well as the identification of the biological consequences of TRP channel
activation through chemicals, should be in the focus of upcoming research.
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